U.S. patent application number 16/404385 was filed with the patent office on 2019-11-28 for population pharmacokinetics tools and uses thereof.
The applicant listed for this patent is Bioverativ Therapeutics Inc.. Invention is credited to Haiyan Jiang.
Application Number | 20190362856 16/404385 |
Document ID | / |
Family ID | 53274200 |
Filed Date | 2019-11-28 |
View All Diagrams
United States Patent
Application |
20190362856 |
Kind Code |
A1 |
Jiang; Haiyan |
November 28, 2019 |
POPULATION PHARMACOKINETICS TOOLS AND USES THEREOF
Abstract
The present invention is directed to computer based
pharmacokinetics systems, such as, web-based pharmacokinetics
systems, and their use to predict a dose and a dosing interval for
a patient in need of a clotting factor therapy.
Inventors: |
Jiang; Haiyan; (Belmont,
MA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Bioverativ Therapeutics Inc. |
Waltham |
MA |
US |
|
|
Family ID: |
53274200 |
Appl. No.: |
16/404385 |
Filed: |
May 6, 2019 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
15101756 |
Jun 3, 2016 |
10325687 |
|
|
PCT/US2014/068956 |
Dec 6, 2014 |
|
|
|
16404385 |
|
|
|
|
61944467 |
Feb 25, 2014 |
|
|
|
61934286 |
Jan 31, 2014 |
|
|
|
61913149 |
Dec 6, 2013 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
G16C 20/90 20190201;
A61K 38/4846 20130101; C12N 9/644 20130101; G06F 19/3456 20130101;
G16H 20/10 20180101; G16H 50/50 20180101; C07K 2319/30 20130101;
C12Y 304/21022 20130101; C07K 14/755 20130101; G16C 20/70 20190201;
G06N 7/005 20130101; G16C 20/30 20190201; A61K 38/37 20130101 |
International
Class: |
G16H 50/50 20060101
G16H050/50; G16H 20/10 20060101 G16H020/10; G06N 7/00 20060101
G06N007/00; G16C 20/70 20060101 G16C020/70; C12N 9/64 20060101
C12N009/64; C07K 14/755 20060101 C07K014/755; G16C 20/30 20060101
G16C020/30; A61K 38/48 20060101 A61K038/48; A61K 38/37 20060101
A61K038/37 |
Claims
1-44. (canceled)
45. A web-based method of estimating individual patient
pharmacokinetics (PK) of a long-acting Factor VIII (FVIII), the
method comprising: (a) receiving, by one or more electronic
devices, individual long-acting FVIII PK information, (b)
transmitting, by a processing device, the individual long-acting
FVIII PK information to a web-based application program accessible
through a web server, wherein the application is programmed to
implement a long-acting FVIII population pharmacokinetic (popPK)
model, such as that of Example 9 or 11, and a Bayesian estimation
program, (c) receiving from the web-based server and program,
individualized patient long-acting FVIII PK information using the
popPK model, the Bayesian estimation program, and the transmitted
information of (b), and (d) outputting, by the one or more
electronic devices, the individualized patient PK information.
46. (canceled)
47. A web-based method of estimating individual patient
pharmacokinetics (PK) of a long-acting Factor VIII (FVIII), the
method comprising: (a) receiving, of individual long-acting FVIII
PK information by a web-based application program accessible
through a web server and programmed to implement a long-acting
FVIII population pharmacokinetic (popPK) model, such as that of
Example 9 or 11, and a Bayesian estimation program, wherein the
received information is transmitted by one or more electronic
devices, (b) calculating by the web-based program, individualized
patient PK information of a long-acting FVIII using the FVIII popPK
model, the Bayesian estimation program and the received
information, and (c) transmitting, by a processing device, the
estimated individualized patient long-acting FVIII PK information
of (b) to one or more electronic devices, for output of the
information.
48-52. (canceled)
53. A web-based method of estimating individual patient
pharmacokinetics (PK) of a long-acting Factor VIII (FVIII), the
method comprising: (a) receiving, by one or more electronic
devices, information regarding individual body weight and (i)
desired rise of plasma factor activity level following dosing or
(ii) desired dose or desired dose interval, (b) transmitting, by a
processing device, the information of (a) to a web-based
application program accessible through a web server, wherein the
application is programmed to implement a long-acting FVIII
population pharmacokinetic (popPK) model, such as that of Example 9
or 11, and a Bayesian estimation program, (c) receiving from the
web based server and program, individualized patient PK information
of a long-acting FVIII calculated using the popPK model, the
Bayesian estimation program, and the transmitted information of
(b), and (d) outputting, by the one or more electronic devices, the
estimated patient PK information.
54-56. (canceled)
57. The method of claim 53, further comprising selecting a dosing
regimen based on the output estimated patient PK information of
(d), and administering the long-acting FVIII to the patient
according to the selected regimen.
58-70. (canceled)
71. The method of claim 53, wherein the long-acting FVIII
polypeptide comprises a FVIII portion and a second portion.
72. (canceled)
73. (canceled)
74. The method of claim 71, wherein the second portion comprises a
human Fc.
75. The method of claim 71, wherein the second portion comprises a
mutant Fc.
76. The method of claim 71, wherein the long-acting FVIII
polypeptide is in the form of a hybrid comprising a second
polypeptide which comprises a neonatal Fc receptor (FcRn) binding
partner (BP).
77. (canceled)
78. (canceled)
79. The method of claim 71, wherein said Factor VIII portion is
human Factor VIII.
80. The method of claim 71, wherein said Factor VIII portion has a
full or partial deletion of the B domain.
81-93. (canceled)
94. A web-based method of estimating individual patient
pharmacokinetics (PK) of a long-acting Factor VIII (FVIII), the
method comprising: (a) receiving, by one or more electronic
devices, individual long-acting FVIII PK information, (b)
transmitting, by a processing device, the individual long-acting
FVIII PK information to a web-based application program accessible
through a web server, wherein the application is programmed to
implement a long-acting FVIII population pharmacokinetic (popPK)
model, such as that of Example 16, and a Bayesian estimation
program, (c) receiving from the web-based server and program,
individualized patient long-acting FVIII PK information using the
popPK model, the Bayesian estimation program, and the transmitted
information of (b), and (d) outputting, by the one or more
electronic devices, the individualized patient PK information.
95. A web-based method of estimating individual patient
pharmacokinetics (PK) of a long-acting Factor VIII (FVIII), the
method comprising: (a) receiving, of individual long-acting FVIII
PK information by a web-based application program accessible
through a web server and programmed to implement a long-acting
FVIII population pharmacokinetic (popPK) model, such as that of
Example 16, and a Bayesian estimation program, wherein the received
information is transmitted by one or more electronic devices, (b)
calculating by the web-based program, individualized patient PK
information of a long-acting FVIII using the FVIII popPK model, the
Bayesian estimation program and the received information, and (c)
transmitting, by a processing device, the estimated individualized
patient long-acting FVIII PK information of (b) to one or more one
electronic devices, for output of the information.
96. (canceled)
97. (canceled)
98. A web-based method of estimating individual patient
pharmacokinetics (PK) of a long-acting Factor VIII (FVIII), the
method comprising: (a) receiving, by one or more electronic
devices, information regarding individual body weight and (i)
desired rise of plasma factor activity level following dosing or
(ii) desired dose or desired dose interval, (b) transmitting, by a
processing device, the information of (a) to a web-based
application program accessible through a web server, wherein the
application is programmed to implement a long-acting FVIII
population pharmacokinetic (popPK) model, such as that of Example
16, and a Bayesian estimation program, (c) receiving from the web
based server and program, individualized patient PK information of
a long-acting FVIII calculated using the popPK model, the Bayesian
estimation program, and the transmitted information of (b), and (d)
outputting, by the one or more electronic devices, the estimated
patient PK information.
99. (canceled)
100. The method of claim 98, further comprising selecting a dosing
regimen based on the output estimated patient PK information of
(d), and administering the long-acting FVIII to the patient
according to the selected regimen.
101-109. (canceled)
110. The method of claim 98, wherein the long-acting FVIII
polypeptide comprises a FVIII portion and a second portion.
111. (canceled)
112. (canceled)
113. The method of claim 110, wherein the second portion comprises
a human Fc.
114. The method of claim 110, wherein the second portion comprises
a mutant Fc.
115. The method of claim 110, wherein the long-acting FVIII
polypeptide is in the form of a hybrid comprising a second
polypeptide which comprises a neonatal Fc receptor (FcRn) binding
partner (BP).
116. The method of claim 110, wherein said Factor VIII portion is
human Factor VIII.
117. The method of claim 110, wherein said Factor VIII portion has
a full or partial deletion of the B domain.
118-139. (canceled)
Description
RELATED APPLICATIONS
[0001] This application is a continuation of U.S. patent
application Ser. No. 15/101,756, filed Jun. 3, 2016, which is a 35
U.S.C. .sctn. 371 filing of International Patent Application No.
PCT/US2014/068956, filed Dec. 6, 2014, which claims priority to
U.S. Provisional Patent Application Ser. Nos. 61/944,467, filed
Feb. 25, 2014, 61/934,286, filed Jan. 31, 2014, and 61/913,149,
filed Dec. 6, 2013, the entire disclosures of which are hereby
incorporated herein by reference in their entirety.
FIELD OF THE INVENTION
[0002] The present invention is directed to computer based
pharmacokinetics systems, such as, web-based pharmacokinetics
systems, and their use to predict a dose and a dosing interval for
a patient in need of a clotting factor therapy.
BACKGROUND ART
[0003] While plasma-derived and recombinant clotting factor
products allow hemophilia patients to live longer and healthier,
hemophilia still remains one of the most costly and complex
conditions to manage. The cost of clotting factor products exceeds
$50,000 a year per patient. See Blankenship C. S., Biotechnol.
Healthc. 2008, 5(4): 37-40. According to the National Heart, Lung,
and Blood Institute, National Institute of Health (NIH),
approximately 18,000 people in the U.S. have hemophilia, and 400
babies are born with the disease each year. Morbidity &
Mortality: 2012 Chart Book on Cardiovascular, Lung and Blood
Disease, page 5, National Heart, Lung, and Blood Institute, NIH.
Due to its complexity, this chronic disease requires a special
therapeutic management process for doctors, pharmacies, and
patients. Clinicians often assess lifestyle, psychosocial
requirements, and the home environment when evaluating a patient's
or guardian's ability to provide adequate care.
[0004] In hemophilia, blood clotting is disturbed by a lack of
certain plasma blood clotting factors. Hemophilia A, the most
common form of hemophilia, is caused by Factor VIII deficiency.
Hemophilia B is caused by decreased synthesis of Factor IX protein
or synthesis of defective Factor IX having reduced activity.
Treating hemophilia involves replacing missing or defective
clotting factor with recombinant or plasma-derived FVIII or FIX.
For patients who have developed antibodies against recombinant or
plasma-derived FVIII or FIX, Factor VII can be used as a bypass
therapy. Commercially available clotting factors are usually
administered by peripheral intravenous injection. However, for
patients with small veins or children who require frequent
injections, clotting factors can be administered by a central
venous access device. See Blankenship C. S., Biotechnol. Healthc.
2008, 5(4): 37-40.
[0005] Currently, three FIX products are approved by the Food and
Drug Administration (FDA). The first, BENEFIX.RTM., is a
recombinant FIX product marketed by Pfizer. The second and third
products are plasma-derived FIX products, ALPHANINE.RTM. marketed
by Grifols and MONONINE.RTM. marketed by CSL Behring. According to
their labels, BENEFIX.RTM. is supplied as a lyophilized powder in
five different dosages: 250 IU, 500 IU, 1000 IU, 2000 IU, and 3000
IU. MONONINE.RTM. is supplied as a single dose vial with Sterile
Water for Injection at 500 IU and 1000 IU. ALPHANINE is supplied in
lyophilized form as single doses at 500 IU, 1000 IU, and 1500 IU.
The FIX dose required for each patient is calculated based on the
formula:
Number of factor IX IU required (IU)=Body Weight (kg).times.Desired
Factor IX Increase (% or IU/dL).times.Reciprocal of Observed
Recovery (IU/kg per IU/dL) (A)
[0006] Several Factor VIII products are also commercially
available, which include recombinant FVIII products (ADVATE.RTM.
and RECOMBINATE.RTM. marketed by Baxter, KOGENATE.RTM. FS marketed
by Bayer, HELIXATE.RTM. FS marketed by CSL-Behring, and XYNTHA.RTM.
and REFACTO.RTM. marketed by PFIZER) and Plasma-derived FVIII
products (HEMOFIL-M.RTM. marketed by Baxter, MONARC-M.RTM. by
American Red Cross, and MONOCLATE-P.RTM. marketed by CSL Behring).
The required FVIII dose for each patient is calculated using the
following formula:
Number of factor FVIII IU required (IU)=Body Weight
(kg).times.Desired Factor FVIII Increase (IU/dL or % of
normal).times.0.5(IU/kg per IU/dL) (B)
[0007] However, administering clotting factors can be complicated
and costly for patients. The invention as described herein provides
improved clotting factor-dosing methods.
BRIEF SUMMARY OF THE INVENTION
[0008] The present invention is directed to a method of estimating
long-acting FIX dosing information individualized for a patient,
the method comprising: a) receiving, by a computer-based system
containing (i) the long-acting FIX population pharmacokinetic
(popPK) model of Example 5 or 7 and (ii) a Bayesian estimation
program, at least one of patient information and desired treatment
outcome information, b) calculating, by the computer-based system,
individualized long-acting FIX dosing information using the FIX
popPK model, respectively, the Bayesian estimation program, and the
received information, and c) outputting, by the computer-based
system, the individualized dosing information.
[0009] Also disclosed is a method of estimating long-acting FVIII
dosing information individualized for a patient, the method
comprising: a) receiving, by a computer-based system containing (i)
the long-acting FVIII popPK model of Example 9 or 11 or 16 and (ii)
a Bayesian estimation program, at least one of patient information
and desired treatment outcome information, b) calculating, by the
computer-based system, individualized long-acting FVIII dosing
information using the FVIII popPK model, respectively, the Bayesian
estimation program, and the received information, and c)
outputting, by the computer-based system, the individualized dosing
information. Further disclosed is the method as described herein,
further comprising selecting a dosing regimen based on the output
individualized dosing information of (c) and administering the
long-acting FIX polypeptide to the patient according to the
selected dosing regimen. Also disclosed is the method as described
herein, further comprising selecting a dosing regimen based on the
output individualized dosing information of (c) and administering
the long-acting FVIII polypeptide to the patient according to the
selected dosing regimen.
[0010] Certain embodiments include a computer readable storage
medium having instructions stored thereon that, when executed by a
processor, causes the processor to perform the method as described
herein.
[0011] Also disclosed is a system comprising a processor and a
memory, the memory having instructions stored thereon that, when
executed by the processor, cause the processor to perform the
method as described herein.
[0012] Further disclosed is a method of estimating a long-acting
FIX dosing regimen based on median popPK, the method comprising: a)
receiving, by a computer-based system containing (i) the
long-acting FIX popPK model of Example 5 or 7 and (ii) a Bayesian
estimation program, at least one of patient information and desired
treatment outcome information, b) calculating, by the
computer-based system, median long-acting FIX PK information using
the FIX popPK model, respectively, the Bayesian estimation program,
and the received information, and c) outputting, by the
computer-based system, the median PK information. Also disclosed is
the method as described herein, further comprising selecting a
dosing regimen based on the output median PK information of (c),
and administering the long-acting FIX to a patient according to the
selected dosing regimen.
[0013] Certain embodiments include a method of estimating a
long-acting FVIII dosing regimen based on median popPK, the method
comprising: a) receiving, by a computer-based system containing (i)
the long-acting FVIII popPK model of Example 9 or 11 or 16 and (ii)
a Bayesian estimation program, at least one of patient information
and desired treatment outcome information, b) calculating, by the
computer-based system, median long-acting FVIII PK information
using the FVIII popPK model, respectively, the Bayesian estimation
program, and the received information, and c) outputting, by the
computer-based system, the median PK information. Also disclosed is
the method as described herein, further comprising selecting a
dosing regimen based on the output median PK information of (c),
and administering the long acting FVIII to a patient according to
the selected dosing regimen.
[0014] Certain embodiments include a computer readable storage
medium having instructions stored thereon that, when executed by a
processor, cause the processor to perform the method as described
herein.
[0015] Also disclosed is a system comprising a processor and a
memory, the memory having instructions stored thereon that, when
executed by the processor, causes the processor to perform the
method as described herein.
[0016] Some embodiments include a method of estimating individual
patient PK of a long-acting FIX, the method comprising: (a)
receiving, by a computer-based system containing (i) the
long-acting FIX population pharmacokinetic (popPK) model of Example
5 or 7 and (ii) a Bayesian estimation program, individual
long-acting FIX PK information, b) estimating, by the
computer-based system, individualized patient PK information of a
long-acting FIX using the FIX popPK model, the Bayesian estimation
program, and the received information, and c) outputting, by the
computer-based system, the individualized patient PK information.
Also disclosed is the method as described herein, further
comprising selecting a dosing regimen based on the output
individualized patient PK information of (c), and administering the
long-acting FIX to the patient according to the selected
regimen.
[0017] Certain embodiments include a method of estimating
individual patient PK of a long-acting FVIII, the method
comprising: (a) receiving, by a computer-based system containing
(i) the long-acting FVIII popPK model of Example 9 or 11 or 16 and
a Bayesian estimation program, individual long-acting FVIII PK
information, b) estimating, by the computer-based system,
individualized patient PK information of a long-acting FVIII using
the FVIII popPK model, the Bayesian estimation program, and the
received information, and c) outputting, by the computer-based
system, the individualized patient PK information. Also disclosed
is the method as described herein, further comprising selecting a
dosing regimen based on the output individualized patient PK
information of (c), and administering the long-acting FVIII to the
patient according to the selected regimen.
[0018] Some embodiments include a computer readable storage medium
having instructions stored thereon that, when executed by a
processor, causes the processor to perform the method as described
herein.
[0019] Also disclosed is a system comprising a processor and a
memory, the memory having instructions stored thereon that, when
executed by the processor, cause the processor to perform the
method as described herein.
[0020] Some embodiments include the method as described herein,
wherein the desired treatment outcome information is desired rise
in plasma FIX or FVIII level following dosing and the output
information is dose for acute treatment.
[0021] Also disclosed is the method, wherein the desired treatment
outcome information is desired dosing interval and the output
information is dose for prophylaxis.
[0022] Some embodiments include the method as described herein,
wherein the desired treatment outcome information is desired dose
and the output information is interval for prophylaxis.
[0023] Also disclosed is the method as described herein, wherein
(a) further comprises receiving, by the computer-based system,
additional patient information.
[0024] Some embodiments include the method as described herein,
wherein the patient information is age or body weight.
[0025] Some embodiments include a web-based method of estimating
long-acting FIX dosing information individualized for a patient,
the method comprising: (a) receiving, by one or more electronic
devices, at least one of patient information and desired treatment
outcome information, (b) transmitting, by a processing device, the
at least one of patient information and desired treatment outcome
information to a web-based application program accessible through a
web server, wherein the application is programmed to implement a
long-acting FIX population pharmacokinetic (popPK) model of Example
5 or 7 and a Bayesian estimation program, (c) receiving from the
web based server and program, individualized dosing information
calculated using the popPK model, the Bayesian estimation program,
and the transmitted information of (b), and (d) outputting, by the
one or more electronic devices, the individualized dosing
information.
[0026] Also disclosed is a web-based method of estimating
long-acting FVIII dosing information individualized for a patient,
the method comprising: (a) receiving, by one or more electronic
devices, at least one of patient information and desired treatment
outcome information, (b) transmitting, by a processing device, the
at least one of patient information and desired treatment outcome
information to a web-based application program accessible through a
web server, wherein the application is programmed to implement a
long-acting FVIII popPK model of Example 9 or 11 or 16, and a
Bayesian estimation program, (c) receiving from the web based
server and program, individualized dosing information calculated
using the popPK model, the Bayesian estimation program, and the
transmitted information of (b), and (d) outputting, by the one or
more electronic devices, the individualized dosing information.
[0027] Some embodiments include a web-based method of estimating
long-acting FIX dosing information individualized for a patient,
the method comprising: (a) receiving, by a processing device, at
least one of patient information and desired treatment outcome
information by a web-based application program accessible through a
web server and programmed to implement a long-acting FIX population
pharmacokinetic (popPK) model, and a Bayesian estimation program,
wherein the received information is transmitted by one or more
electronic devices, (b) calculating, by the web-based program,
individualized long-acting FIX dosing information using the FIX
popPK model, the Bayesian estimation program, and the received
information, and (c) transmitting, by a processing device, the
individualized calculated dosing information of (b) to one or more
electronic devices for output of the information.
[0028] Also disclosed is a web-based method of estimating
long-acting FVIII dosing information individualized for a patient,
the method comprising: (a) receiving, by a processing device, at
least one of patient information and desired treatment outcome
information by a web-based application program accessible through a
web server and programmed to implement a long-acting FVIII popPK
model, and a Bayesian estimation program, wherein the received
information is transmitted by one or more electronic devices, (b)
calculating, by the web-based program, individualized long-acting
FVIII dosing information using the FVIII popPK model of Example 9
or 11 or 16, the Bayesian estimation program, and the received
information, and (c) transmitting, by a processing device, the
individualized calculated dosing information of (b) to one or more
electronic devices for output of the information. In some
embodiments, the method as described herein further comprises
selecting a dosing regimen based on the output individualized
dosing information of (e) and administering the long-acting FIX to
the patient according to the selected dosing regimen. In other
embodiments, the method as described herein further comprises
selecting a dosing regimen based on the output individualized
dosing information of (e) and administering the long-acting FVIII
to the patient according to the selected dosing regimen.
[0029] Some embodiments include the method as described herein,
wherein the desired treatment outcome information is desired rise
in plasma FIX activity level following dosing and the dosing output
information is dose for acute treatment.
[0030] Also disclosed is the method as described herein, wherein
the desired treatment outcome information is desired rise in plasma
FVIII activity level following dosing and the dosing output
information is dose for acute treatment.
[0031] Some embodiments include is the method as described herein,
wherein the desired treatment outcome information is desired dosing
interval and the dosing output information is dose for
prophylaxis.
[0032] Also disclosed is the method as described herein, wherein,
the desired treatment outcome information is desired dose and the
dosing output information is interval for prophylaxis.
[0033] Some embodiments include a web-based method of estimating a
long-acting FIX dosing regimen based on median FIX popPK, the
method comprising: (a) receiving, by one or more electronic devices
at least one of patient information and desired treatment outcome
information, (b) transmitting, by a processing device, the at least
one of patient information and desired treatment outcome
information to a web-based application program accessible through a
web server, wherein the application is programmed to implement a
long-acting FIX population pharmacokinetic (popPK) model, such as
that of Example 5 or 7, and a Bayesian estimation program, (c)
receiving from the web based server and program, median long-acting
FIX PK dosing information calculated using the FIX popPK model,
respectively, the Bayesian estimation program, and the received
information, and (d) outputting, by the one or more electronic
devices, the median PK information.
[0034] Also disclosed is a web-based method of estimating a
long-acting FVIII dosing regimen based on median FVIII popPK, the
method comprising: (a) receiving, by one or more electronic devices
at least one of patient information and desired treatment outcome
information, (b) transmitting, by a processing device, the at least
one of patient information and desired treatment outcome
information to a web-based application program accessible through a
web server, wherein the application is programmed to implement a
long-acting FVIII population pharmacokinetic (popPK) model, such as
that of Example 9 or 11 or 16, and a Bayesian estimation program,
(c) receiving from the web based server and program, median
long-acting FVIII PK dosing information calculated using the FVIII
popPK model, respectively, the Bayesian estimation program, and the
received information, and (d) outputting, by the one or more
electronic devices, the median PK information.
[0035] Some embodiments include a web-based method of estimating a
long-acting FIX dosing regimen based on median FIX popPK, the
method comprising: (a) receiving, by a processing device, at least
one of patient information and desired treatment outcome
information by a web-based application program accessible through a
web server and programmed to implement a long-acting FIX popPK
model, and a Bayesian estimation program, wherein the received
information is transmitted by one or more electronic devices, (b)
calculating, by the web-based program, individualized long-acting
FIX dosing information using the FIX popPK model, the Bayesian
estimation program, and the received information, and (c)
transmitting, by a processing device, the individualized calculated
dosing information of (b) to one or more electronic devices for
output of the information.
[0036] Also disclosed is a web-based method of estimating a
long-acting FVIII dosing regimen based on median FVIII popPK, the
method comprising: (a) receiving, by a processing device, at least
one of patient information and desired treatment outcome
information by a web-based application program accessible through a
web server and programmed to implement a long-acting FVIII
population pharmacokinetic (popPK) model, and a Bayesian estimation
program, wherein the received information is transmitted by one or
more electronic devices, (b) calculating, by the web-based program,
individualized long-acting FVIII dosing information using the FVIII
popPK model, the Bayesian estimation program, and the received
information, and (c) transmitting, by a processing device, the
individualized calculated dosing information of (b) to one or more
electronic devices for output of the information. Also disclosed is
the method as described herein, further comprising selecting a
dosing regimen based on the output median PK information of (e),
and (f) administering the long-acting FIX to a patient according to
the selected dosing regimen. Some embodiments include the method as
described herein, further comprising selecting a dosing regimen
based on the output median PK information of (e), and (f)
administering the long-acting FVIII to a patient according to the
selected dosing regimen.
[0037] Some embodiments include the method as described herein,
wherein the desired treatment outcome information is desired rise
in plasma FIX activity level following dosing and the dosing output
information is dose for acute treatment. Some embodiments include
the method as described herein, wherein the desired treatment
outcome information is desired rise in plasma FVIII activity level
following dosing and the dosing output information is dose for
acute treatment. Also disclosed is the method as described herein,
wherein the desired treatment outcome information is desired dosing
interval and the dosing output information is dose for prophylaxis.
Some embodiments include the method as described herein, wherein,
the desired treatment outcome information is desired dose and the
dosing output information is interval for prophylaxis.
[0038] Also disclosed is a web-based method of method of estimating
individual patient PK of a long-acting FIX, the method comprising:
(a) receiving, by one or more electronic devices, individual
long-acting FIX PK information, (b) transmitting, by a processing
device, the individual long-acting FIX PK information to a
web-based application program accessible through a web server,
wherein the application is programmed to implement a long-acting
FIX population pharmacokinetic (popPK) model, such as that of
Example 5 or 7, and a Bayesian estimation program, (c) receiving
from the web-based server and program, individualized patient
long-acting FIX PK information using the popPK model, the Bayesian
estimation program, and the transmitted information of (b) and (d)
outputting, by the one or more electronic devices, the
individualized patient PK information.
[0039] Some embodiments include is a web-based method of estimating
individual patient PK of a long-acting FVIII, the method
comprising: (a) receiving, by one or more electronic devices,
individual long-acting FVIII PK information, (b) transmitting, by a
processing device, the individual long-acting FVIII PK information
to a web-based application program accessible through a web server,
wherein the application is programmed to implement a long-acting
FVIII population pharmacokinetic (popPK) model, such as that of
Example 9 or 11 or 16, and a Bayesian estimation program, (c)
receiving from the web-based server and program, individualized
patient long-acting FVIII PK information using the popPK model, the
Bayesian estimation program, and the transmitted information of (b)
and (d) outputting, by the one or more electronic devices, the
individualized patient PK information.
[0040] Also disclosed is a web-based method of estimating
individual patient PK of a long-acting FIX, the method comprising:
(a) receiving, of individual long-acting FIX PK information by a
web-based application program accessible through a web server and
programmed to implement a long-acting FIX population
pharmacokinetic (popPK) model, such as that of Example 5 or 7, and
a Bayesian estimation program, wherein the received information is
transmitted by one or more electronic devices, (b) calculating by
the web-based program, individualized patient PK information of a
long-acting FIX using the FIX popPK model, the Bayesian estimation
program and the received information, and (c) transmitting, by a
processing device, the estimated individualized patient long-acting
FIX PK information of (b) to one or more one or more electronic
devices, for output of the information.
[0041] Some embodiments include web-based method of estimating
individual patient PK of a long-acting FVIII, the method
comprising: (a) receiving, of individual long-acting FVIII PK
information by a web-based application program accessible through a
web server and programmed to implement a long-acting FVIII popPK
model, such as that of Example 9 or 11 or 16, and a Bayesian
estimation program, wherein the received information is transmitted
by one or more electronic devices, (b) calculating by the web-based
program, individualized patient PK information of a long-acting
FVIII using the FVIII popPK model, the Bayesian estimation program
and the received information, and (c) transmitting, by a processing
device, the estimated individualized patient long-acting FVIII PK
information of (b) to one or more one or more electronic devices,
for output of the information.
[0042] In certain embodiments, the method as described herein
further comprises selecting a dosing regimen based on the output
estimated patient PK information of (e), and administering the
long-acting FIX to the patient according to the selected regimen.
In other embodiments, the method as described herein further
comprises selecting a dosing regimen based on the output estimated
patient PK information of (e), and administering the long-acting
FVIII to the patient according to the selected regimen.
[0043] Some embodiments include the method as described herein,
further comprising selecting a dosing regimen based on the output
estimated patient PK information of (e), and administering the
long-acting FIX to the patient according to the selected
regimen.
[0044] In certain embodiments, the method as described herein
further comprises selecting a dosing regimen based on the output
estimated patient PK information of (e), and administering the
long-acting FVIII to the patient according to the selected
regimen.
[0045] Some embodiments include a web-based method of estimating
individual patient PK of a long-acting FIX, the method comprising:
(a) receiving, by one or more electronic devices, information
regarding individual body weight and (i) desired rise of plasma
factor activity level following the dose or (ii) desired dose or
desired dose interval, (b) transmitting, by a processing device,
the information of (a) to a web-based application program
accessible through a web server, wherein the application is
programmed to implement a long-acting FIX population
pharmacokinetic (popPK) model, such as that of Example 5 or 7, and
a Bayesian estimation program, (c) receiving from the web based
server and program, individualized patient PK information of a
long-acting FIX calculated using the popPK model, the Bayesian
estimation program, and the transmitted information of (b), and (d)
outputting, by the one or more electronic devices, the estimated
patient PK information.
[0046] Also included is a web-based method of estimating individual
patient PK of a long-acting FVIII, the method comprising: (a)
receiving, by one or more electronic devices, information regarding
individual body weight and (i) desired rise of plasma factor
activity level following the dose or (ii) desired dose or desired
dose interval, (b) transmitting, by a processing device, the
information of (a) to a web-based application program accessible
through a web server, wherein the application is programmed to
implement a long-acting FVIII popPK model, such as that of Example
9 or 11 or 16, and a Bayesian estimation program, (c) receiving
from the web based server and program, individualized patient PK
information of a long-acting FVIII calculated using the popPK
model, the Bayesian estimation program, and the transmitted
information of (b), and (d) outputting, by the one or more
electronic devices, the estimated patient PK information.
[0047] Some embodiments include a web-based method of estimating
individual patient PK of a long-acting FIX, the method comprising:
(a) receiving, by one or more electronic devices, information
regarding individual body weight and (i) desired rise of plasma
factor activity level following the dose or (ii) desired dose or
desired dose interval, (b) transmitting, by a processing device,
the information of (a) to a web-based application program
accessible through a web server, wherein the application is
programmed to implement a long-acting FIX population
pharmacokinetic (popPK) model, such as that of Example 5 or 7, and
a Bayesian estimation program, (c) receiving from the web based
server and program, individualized patient PK information of the
long-acting FIX calculated using the popPK model, the Bayesian
estimation program, and the transmitted information of (b), and (d)
outputting, by the one or more electronic devices, the estimated
patient PK information.
[0048] Some embodiments include a web-based method of estimating
individual patient PK of a long-acting FVIII, the method
comprising: (a) receiving, by one or more electronic devices,
information regarding individual body weight and (i) desired rise
of plasma factor activity level following the dose or (ii) desired
dose or desired dose interval, (b) transmitting, by a processing
device, the information of (a) to a web-based application program
accessible through a web server, wherein the application is
programmed to implement a long-acting FVIII popPK model, such as
that of Example 9 or 11 or 16, and a Bayesian estimation program,
(c) receiving from the web based server and program, individualized
patient PK information of the long-acting FVIII calculated using
the popPK model, the Bayesian estimation program, and the
transmitted information of (b), and (d) outputting, by the one or
more electronic devices, the estimated patient PK information.
[0049] In other embodiments, the method as described herein further
comprises selecting a dosing regimen based on the output estimated
patient PK information of (e), and administering the long-acting
FIX to the patient according to the selected regimen. Some
embodiments include the method as described herein, further
comprising selecting a dosing regimen based on the output estimated
patient PK information of (e), and administering the long-acting
FIX to the patient according to the selected regimen. Also included
is the method as described herein, wherein (a) further comprises
receiving, by the electronic device, patient information and (b)
further comprises transmitting, by a processing device, the patient
information to the web-based application program.
[0050] Some embodiments include the method as described herein,
wherein (a) further comprises receiving information by the
electronic device information relating to diagnostic (baseline)
factor level, dosing history, actual dose, actual time of PK
sampling or factor activity level, and (b) further comprises
transmitting, by a processing device, the information to the
web-based application program.
[0051] Also disclosed is the method as described herein, wherein
the individualized patient PK includes a PK curve or a PK parameter
selected from incremental recovery (Cmax/Dose), mean residence
time, terminal t.sub.1/2, clearance, Vss and AUC/Dose.
[0052] Some embodiments include the method as described herein,
wherein the information is desired rise in plasma FIX activity
level following dosing and the dosing output information is dose
for acute treatment.
[0053] Also disclosed is the method as described herein, wherein
the information is desired rise in plasma FVIII activity level
following dosing and the dosing output information is dose for
acute treatment.
[0054] Some embodiments include the method as described herein,
wherein the information is desired dose and the dosing output
information is dose for prophylaxis.
[0055] Also disclosed is the method as described herein, wherein,
the information is desired dose interval and the dosing output
information is interval for prophylaxis.
[0056] Some embodiments include the method as described herein,
wherein, the electronic device is selected from a digital pen, a
smart phone, a tablet computer, a personal digital assistant, a
handheld computer, a laptop computer, a scanner, a camera, and a
fax machine.
[0057] Also disclosed is a computer readable storage medium having
instructions stored thereon that, when executed by a processor,
cause the processor to estimate a long-acting FIX dosing
information individualized for a patient, wherein the
computer-based system comprises (i) a long-acting FIX population
pharmacokinetic (popPK) model of Example 5 or 7 and (ii) a Bayesian
estimation program.
[0058] Some embodiments include a computer readable storage medium
having instructions stored thereon that, when executed by a
processor, cause the processor to estimate a long-acting FVIII
dosing information individualized for a patient, wherein the
computer-based system comprises (i) a long-acting FVIII population
pharmacokinetic (popPK) model of Example 9 or 11 or 16 and (ii) a
Bayesian estimation program.
[0059] Also disclosed is a system comprising a processor and a
memory, the memory having instructions stored thereon that, when
executed by the processor, cause the processor to estimate a
long-acting FIX dosing information individualized for a patient,
wherein the memory comprises (i) a long-acting FIX population
pharmacokinetic (popPK) model of Example 5 or 7 and (ii) a Bayesian
estimation program and wherein the system receives at least one of
patient information and desired treatment outcome information,
calculates individualized long-acting FIX dosing information using
the popPK model, the Bayesian estimation program, and the received
information, and outputting the individualized dosing
information.
[0060] Some embodiments include a system comprising a processor and
a memory, the memory having instructions stored thereon that, when
executed by the processor, cause the processor to estimate a
long-acting FVIII dosing information individualized for a patient,
wherein the memory comprises (i) a long-acting FVIII population
pharmacokinetic (popPK) model of Example 9 or 11 or 16 and (ii) a
Bayesian estimation program and wherein the system receives at
least one of patient information and desired treatment outcome
information, calculates individualized long-acting FVIII dosing
information using the popPK model, the Bayesian estimation program,
and the received information, and outputting the individualized
dosing information.
[0061] Also disclosed is a method of treating a bleeding episode
comprising administering to a subject in need thereof a therapeutic
dose of a clotting factor at a dosing interval, wherein the dose
and dosing interval are calculated using a web-based application
that is accessible through a web server, wherein the application is
programmed to implement a clotting factor population
pharmacokinetic (popPK) model and a Bayesian estimation program to
calculate the dose and dosing interval.
[0062] Also disclosed is a method of treating a bleeding episode
comprising (1) calculating a therapeutic dose of a clotting factor
and a dosing interval of the clotting factor for a subject in need
thereof using a web-based application that is accessible through a
web server, wherein the application is programmed to implement a
clotting factor population pharmacokinetic (popPK) model and a
Bayesian estimation program to calculate the dose and dosing
interval and (2) administering the clotting factor at the
calculated dose and the dosing interval to the subject.
[0063] In some embodiments, the method further comprises entering
individual clotting factor pharmacokinetic information.
[0064] In some embodiments, the method further comprises,
optionally contemporaneously, updating the popPK model based on the
individual clotting factor pharmacokinetic information.
[0065] In some embodiments, the application continuously updates
the popPK model based on newly input clotting factor
pharmacokinetic information.
[0066] In some embodiments, the method further comprises, before
the calculating, inputting a body weight of the subject.
[0067] In some embodiments, the method further comprises inputting
a rise of clotting factor plasma activity level desired following
the administrating ("desired rise of clotting factor plasma
activity level").
[0068] Also disclosed is the method as described herein, wherein
the clotting factor is long-acting. Also disclosed is the method as
described herein, wherein the long-acting clotting factor is
rFVIIIFc or rFIXFc.
[0069] In some embodiments, the method further comprises, before
the calculating, inputting the subject's age. Also disclosed is the
method, as described herein, wherein the subject is less than 6
years old, equal to or greater than 6 years old and less than 12
years old, less than 12 years old, or equal to or greater than 12
years old.
[0070] Also disclosed is the method, as described herein, wherein
the long-acting clotting factor is rFVIIIFc and the method further
comprises, before the calculating, inputting the subject's Von
Willebrand Factor (VWF) level.
[0071] In some embodiments, the method further comprises, before
the calculating, measuring a clotting factor activity level in
plasma at various time points after an initial dose of the clotting
factor, wherein individual subject clotting factor pharmacokinetic
information is, optionally contemporaneously, calculated based on
the clotting factor activity level.
[0072] In some embodiments, the method, further comprises, before
the measuring, administering an initial dose of the clotting
factor.
[0073] Also disclosed is the method, as described herein wherein
the initial dose is a fixed interval dose.
[0074] In some embodiments of the method herein, the clotting
factor popPK model is updated, optionally contemporaneously, and
is, optionally immediately, available through the web server.
[0075] In some embodiments, the clotting factor popPK model is
updated, optionally immediately, after the individual subject
clotting factor pharmacokinetic information is added to the
application and wherein an updated clotting factor popPK model is
available for a next use.
[0076] Some embodiments include a web-based method of, optionally
contemporaneously, improving the predictive accuracy of clotting
factor dosing information, the method comprising: (a) accessing a
web-based application accessible through a web server, the
application comprising a dataset comprising clotting factor
population pharmacokinetic (popPK) information, (b) inputting
individual subject clotting factor pharmacokinetic information into
the application to create a new dataset, and (c) calculating, using
the application, a clotting factor popPK model using the new
dataset.
[0077] Also disclosed is the method as described herein, wherein
the calculating is performed automatically or upon request.
[0078] Also disclosed is the method as described herein, wherein
the popPK model is used to create a dosing regimen for clotting
factor administration to a subject in need thereof.
[0079] In some embodiments, the method further comprises
administering to the subject a clotting factor according to the
regimen.
[0080] Also disclosed is the method as described herein, wherein
the clotting factor is long-acting.
[0081] Also disclosed is the method as described herein, wherein
the long-acting clotting factor is rFVIIIFc or rFIXFc.
[0082] Also disclosed is the method as described herein, wherein
(a) the clotting factor is rFVIIIFc and the popPK model includes
one or more parameters selected from the group consisting of the
parameters in Example 9, 11, and 16 (Table 18, 24, 25, or 33), or
(b) the clotting factor is rFIXFc and the popPK model includes one
or more parameters selected from the group consisting of the
parameters in Example 5 or 7 (Table 10, 13, or 14). Also disclosed
is the method as described herein, wherein the clotting factor is
rFVIIIFc and the popPK model is generated as disclosed in Examples
9, 11, 16, or any combinations thereof. Also disclosed is the
method as described herein, wherein one or more parameters for the
popPK model are selected from the group consisting of the
parameters in Table 18, 24, 25, 33, and any combinations thereof.
Also disclosed is the method as described herein, wherein the
clotting factor is rFIXFc and the popPK model is generated as
disclosed in Example 5, 7, or both. Also disclosed is the method as
described herein, wherein one or more parameters for the popPK
model are selected from the group consisting of the parameters in
Table 10, 13, 14, and any combinations thereof.
[0083] Some embodiments include a system for producing an improved
clotting factor regimen to be administered to a subject in need
thereof, the system comprising a web-based application accessible
through a web server, wherein the application comprises: (a) a
first dataset comprising clotting factor population pharmacokinetic
(popPK) information, (b) a second dataset comprising the first
dataset and individual clotting factor pharmacokinetic information
of a subject, and (c) a first regimen for a subject in need thereof
calculated by the application using the dataset of (b), wherein the
first regimen has improved predictive accuracy in comparison to a
second regimen calculated by the application using the dataset of
(a).
[0084] Also disclosed is the system, as described herein, wherein
the application continuously updates a popPK model based on newly
input clotting factor pharmacokinetic information. 122. Also
disclosed is the system as described herein, wherein the individual
clotting factor pharmacokinetic information of (b) is from the
subject of (c) or is from a subject different from the subject of
(c).
[0085] Some embodiments include a method of producing an improved
clotting factor regimen for administration to a subject in need
thereof, the method comprising: (a) accessing a web-based
application accessible through a web server, the application
comprising a first dataset comprising clotting factor population
pharmacokinetic (popPK) information, (b) inputting individual
clotting factor pharmacokinetic information into the application to
create a second dataset, (c) calculating the regimen for the
subject in need thereof using the dataset of (b), wherein the
calculated regimen has improved predictive accuracy in comparison
to a regimen calculated from the dataset of (a), and (d) recording
the calculated regimen.
[0086] Also disclosed is the method as described herein, which
comprises recording the calculated regimen on a computer readable
storage medium.
[0087] Also disclosed is the method as described herein, wherein
the individual clotting factor pharmacokinetic information of (b)
is from the subject of (c).
[0088] Also disclosed is the method as described herein, wherein
the individual clotting factor pharmacokinetic information of (b)
is from a subject different from the subject of (c).
[0089] The method may further comprises producing the recorded
regimen.
[0090] The method may further comprise administering the regimen to
the subject of (c)
[0091] Also disclosed is the method as described herein, wherein
the calculating is performed automatically or upon request.
[0092] Also disclosed is the system or method described herein,
wherein the dataset includes data from the popPK model in Examples
9, 11, 16, or any combinations thereof. Also disclosed is the
system or method described herein, wherein the data include one or
more parameters for the popPK model selected from the group
consisting of the parameters in Table 18, 24, 25, 33, and any
combinations thereof. Also disclosed is the system or method
described herein, wherein the dataset includes data from the popPK
model in Example 5, 7, or both. Also disclosed is the system or
method described herein, wherein the data include one or more
parameters for the popPK model selected from the group consisting
of the parameters in Table 10, 13, 14, and any combinations
thereof.
[0093] Some embodiments include a method of administering rFVIIIFc
to a subject in need thereof, comprising administering to the
subject a therapeutic dose of rFVIIIFc at a dosing interval greater
than one times longer than the dosing interval required for an
equivalent amount of FVIII, wherein the subject is <6 years old
or 6 to <12 years old, and wherein the therapeutic dose has at
least one pharmacokinetic property, expressed in arithmetic mean
with 95% confidence interval, selected from the group consisting
of: a terminal half-life of 12.67 (11.23, 14.11) hours, a terminal
half-life of 14.88 (11.98, 17.77) hours, a clearance of 3.60 (3.13,
4.07) mL/h/kg, a clearance of 2.78 (2.44, 3.13) mL/h/kg, an
incremental recovery of 1.92 (1.80, 2.04) IU/dL per IU/kg, an
incremental recovery of 2.44 (2.07, 2.80) IU/dL per IU/kg, a mean
recovery time of 17.24 (15.40, 19.07) hours, a recovery time of
20.90 (17.06, 24.74) hours, a volume of distribution at steady
state of 58.58 (54.90, 62.27) mL/kg, a volume of distribution at
steady state of 52.13 (45.25, 59.01) mL/kg, a dose normalized area
under the concentration-time curve of 30.04 (26.45, 33.63) IU*h/dL
per IU/kg, and a dose normalized area under the concentration-time
curve of 41.87 (34.00, 49.75) IU*h/dL per IU/kg for the older
cohort.
[0094] Also disclosed is the method as described herein, the medium
as described herein, or the system as described herein, wherein the
long-acting FIX polypeptide comprises a FIX portion and a second
portion.
[0095] Some embodiments include the method as described herein,
wherein the long-acting FVIII polypeptide comprises a FVIII portion
and a second portion. Also disclosed is the method as described
herein, wherein the second portion is albumin or a fragment thereof
or an immunoglobulin constant region or a portion thereof. Some
embodiments include the method as described herein, wherein the
immunoglobulin constant region or a portion thereof comprises a
neonatal Fc receptor (FcRn) or an Fc domain.
[0096] Some embodiments include the method as described herein,
wherein the second portion comprises a human Fc. Also disclosed is
the method as described herein, wherein the second portion
comprises a mutant Fc.
[0097] Also disclosed is the method as described herein, wherein
the long-acting FIX polypeptide or the long-acting FVIII
polypeptide is in the form of a hybrid comprising a second
polypeptide in association with said chimeric polypeptide, wherein
said second polypeptide comprises a FcRn BP.
[0098] Some embodiments include the method as described herein,
wherein the Factor IX is a human Factor IX. Also disclosed is the
method as described herein, wherein the FIX is a mutant Factor IX.
Some embodiments include the method as described herein, wherein
said Factor VIII is human Factor VIII. Also disclosed is the method
as described herein, wherein said Factor VIII has a full or partial
deletion of the B domain.
BRIEF DESCRIPTION OF DRAWINGS/FIGURES
[0099] FIG. 1 shows FIXFc study design and CONSORT chart. Efficacy
data that were collected outside of the efficacy period were not
included in the efficacy analyses. *PK subgroup dosed with rFIX
followed by PK assessment and washout (greater than or equal to 5
days) prior to rFIXFc dosing for PK evaluation. rFIX sampling was
done as follows: pre-injection, 10 (.+-.2) min, 1 hour (.+-.15
min), 3 hr (.+-.15 min), 6 hr (.+-.15 min), 24 (.+-.2) hr, 48
(.+-.2) hr, 72 (.+-.3) hr, and 96 (.+-.3) hr (4 d) from the start
of the injection. rFIXFc sampling was done as follows:
pre-injection, 10 (.+-.2) min, 1 hour (.+-.15 min), 3 hr (.+-.15
min), 6 hr (.+-.15 min), 24 (.+-.2) hr, 48 (.+-.2) hr, 96 (.+-.3)
hr (4 d), 144 (.+-.3) hr (6 d), 168 (.+-.3) hr (7 d), 192 (.+-.3)
hr (8 d), and 240 (.+-.3) hr (10 d) from the start of the
injection. Infusion was within 10 minutes. Blood samples were
collected over 96 hours for each subject. A repeat PK assessment of
rFIXFc was also performed at Week 26. ED=exposure day;
PK=pharmacokinetics.
[0100] FIGS. 2A-2C show study design for phase 1/2a (B) and phase 3
(C) clinical trials of a long-acting FIXFc polypeptide (i.e.,
rFIXFc). FIG. 2C shows rFIXFc sampling schemes.
[0101] FIG. 3 shows a summary of Arm 1 sequential dosing and PK
sampling of a long-acting FIX polypeptide (i.e., rFIXFc).
[0102] FIG. 4 shows a diagram of three-compartment pharmacokinetic
model of a long-acting FIX polypeptide (i.e., rFIXFc). IV
intravenous V.sub.1 volume of compartment 1, V.sub.2 volume of
compartment 2, V.sub.3 volume of compartment 3, Q.sub.2
inter-compartmental clearance between compartments 1 and 2, Q.sub.3
inter-compartmental clearance between compartments 1 and 2.
[0103] FIG. 5A shows pairwise comparison of baseline and repeat
pharmacokinetics CL estimates for the base model with IOV for a
long-acting FIX polypeptide (i.e., rFIXFc).
[0104] FIG. 5B shows pairwise comparison of baseline and repeat
pharmacokinetics V.sub.1 estimates for the base model with IOV.
Dashed line represents the mean. CL clearance, IOV inter-occasion
variability, PK pharmacokinetic, V.sub.1 volume of compartment
1.
[0105] FIG. 6 shows individual PK parameters versus body weight
(BW) of a long-acting FIX polypeptide (i.e., rFIXFc).
[0106] FIGS. 7A-7D show goodness-of-fit plots of the final model of
FIX activity predicted by the population or individual PK model
compared to observed FIX activity. The solid line is the unit line;
dashed line represents the linear regression line in (FIG. 7A) and
(FIG. 7B) and the LOESS smoother in (FIG. 7C) and (FIG. 7D); DV is
observed FIX activity (adjusted for baseline activity and residual
decay) and unit is IU/dL (%); PRED is the population FIX activity
prediction and unit is IU/dL; IPRED is the individual FIX activity
prediction and unit is IU/dL; CWRES is conditional weighted
residual; TIME is the time after dose and unit is hour. DV is
dependent variable.
[0107] FIGS. 8A-8D show Visual Predictive Check (VPC) plots of the
population PK model for 50 IU/kg or 100 IU/kg doses of a
long-acting FIX polypeptide (i.e., rFIXFc). Visual predictive check
for the final model derived from the modeling dataset (8A and 8B),
and the model derived from the full dataset (8C and 8D). The solid
and dashed lines are 10th, 50th and 90.sup.th percentiles of the
observation (solid) and simulation (dashed), respectively. FIGS. 8A
and 8C represent dose groups of 50 IU/kg. FIGS. 8B and 8D represent
dose groups of 100 IU/kg.
[0108] FIG. 9 shows validation of the population PK model with the
trough/peak records for a long-acting FIX polypeptide (i.e.,
rFIXFc). R2=0.9857, P<0.001.
[0109] FIG. 10 shows a representative plot of observed and
predicted perioperative FIX activity for a long-acting FIX
polypeptide (i.e., rFIXFc).
[0110] FIGS. 11A-11C show a population simulation of steady-state
FIX activity time profile (5th-95th percentile) for a long-acting
FIX polypeptide (i.e., rFIXFc).
[0111] FIG. 12 shows a simulation of steady-state FIX activity vs.
time profile for a long-acting FIX polypeptide (i.e., rFIXFc)
comparing 50 IU/kg vs 4000 IU once weekly and 100 IU/kg vs 8000 IU
every 10 days in 5th to 95th percentile of the population.
[0112] FIG. 13 shows a proposed output for individual PK assessment
of a long-acting FIX polypeptide (i.e., rFIXFc) or a long-acting
FVIII polypeptide (i.e., rFVIIIFc).
[0113] FIG. 14 shows a proposed output for individualized dosing
regimen selection for episodic treatment of a long-acting FIX
polypeptide (i.e., rFIXFc) or a long-acting FVIII polypeptide
(i.e., rFVIIIFc).
[0114] FIG. 15 shows a proposed output for dosing regimen
selections without individualized PK assessment of a long-acting
FIX polypeptide (i.e., rFIXFc) or a long-acting FVIII polypeptide
(i.e., rFVIIIFc).
[0115] FIG. 16 shows another proposed output for dosing regimen
selections without individualized PK assessment of a long-acting
FIX polypeptide (i.e., rFIXFc).
[0116] FIG. 17 shows an example computer system that can be used in
embodiments for a long-acting FIX polypeptide (i.e., rFIXFc) or a
long-acting FVIII polypeptide (i.e., rFVIIIFc).
[0117] FIG. 18 shows a graph plotting the predicted total number of
bleeds vs. time under 1% FIX activity level of a long-acting FIX
polypeptide (i.e., rFIXFc).
[0118] FIG. 19 shows a graph plotting the predicted total number of
bleeds vs. time under 5% FIX activity level of a long-acting FIX
polypeptide (i.e., rFIXFc).
[0119] FIG. 20 shows goodness-of-fit plots for the full dataset
model of a long-acting FIX polypeptide (i.e., rFIXFc). The solid
line is the unit line; dashed line represents the linear regression
line in (A) and (B) and the LOESS smoother in (C) and (D); DV is
observed FIX activity (adjusted for baseline activity and residual
decay) and unit is IU/dL (%); PRED is the prediction by population
PK parameter estimates and unit is IU/dL; IPRED is the prediction
by individual PK parameter estimates and unit is IU/dL; CWRES is
conditional weighted residual; TIME unit is hour; and DV is
dependent variable.
[0120] FIG. 21 shows details on the design of the sequential PK
subgroup (Arm 1) dosing and PK sampling of a long-acting FVIII
polypeptide (i.e., rFVIIIFc).
[0121] FIG. 22 shows patient disposition enrolled in the A-LONG
study (N=165) for a long-acting FVIII polypeptide.
[0122] FIG. 23 shows dose modification in Arm 1 (individualized
prophylaxis) for a long-acting FVIII polypeptide.
[0123] FIGS. 24A-24D show goodness of fit diagnostic plots for the
two-compartment model of pharmacokinetics of long-acting rFVIIIFc.
FIG. 24A shows observed (DV) v. predicted (PRED). FIG. 24B shows
observed (DV) v. individual predicted (IPRE). FIG. 24C shows
conditional weighted residuals (CWRES) v. Predicted (PRED). FIG.
24D shows conditional weighted residuals (CWRES) v. Time
(TIME).
[0124] FIGS. 25A-25C show the predicted steady-state activity
profiles of selected rFVIIIFc prophylaxis dosing regimens. The line
in the middle represents the median; the dark shaded area covers
the 25th to 75th percentiles; the light shaded area covers the 5th
to 95th percentiles. FIG. 25A shows a dosing regimen of 50 IU/kg at
every 3 days. FIG. 25B shows a dosing regimen of 50 IU/kg at every
4 days. FIG. 25C shows a dosing regimen of 50 IU/kg at every 5
days.
[0125] FIG. 26 shows the predicted FVIII activity for the
hypothetical perioperative dosing regimen in Table 21 for a
long-acting FVIII polypeptide (i.e., rFVIIIFc). The middle line
shows the 50 percentile. The light shaded areas represent the 5th
to 25th percentile and 75th to 95th percentile. The dark shaded
areas represent the 25th to 50th percentile and the 50th to 75th
percentile.
[0126] FIG. 27 shows the predicted FVIII activity for the
hypothetical perioperative dosing regimen in Table 22 for a
long-acting FVIII polypeptide (i.e., rFVIIIFc).
[0127] FIG. 28 is a representative plot comparing the simulated and
observed FVIII activities within the first 21 days after the first
rFVIIIFc surgical dose (n=13; 9 major surgeries, 4 minor
surgeries). The upper line represents the line of identity (unity
line); the lower line (linear regression line) is the nonparametric
fit of the data.
[0128] FIG. 29 shows another proposed output for dosing regimen
selections without individualized PK assessment for a long-acting
FVIII polypeptide.
[0129] FIG. 30A-30D show the goodness of fit diagnostics of the
final model for rFVIIIFc. FIG. 30A shows Observed (DV) vs Predicted
(PRED), and FIG. 30B shows Observed (DV) vs Individual Predicted
(IPRE). FIG. 30C shows Conditional Weighted Residuals (CWRES) vs
Predicted (PRED) for a long-acting FVIII polypeptide (i.e.,
rFVIIIFc), and FIG. 30D shows Conditional Weighted Residuals
(CWRES) vs Time (TIME) for a long-acting FVIII polypeptide (i.e.,
rFVIIIFc).
[0130] FIG. 31A shows the visual predictive check (VPC) results
(Baseline PK profiles) of the final model for Arm 1 sequential PK
group.
[0131] FIG. 31B shows the visual predictive check (VPC) results
(Baseline PK profiles) of the final model for Arm 1 non-sequential
PK group. For FIGS. 31A and 31B, the 5th, 50th (median), and 95th
percentiles of simulated data are represented by the dotted lines
and gray shaded area, while the 5th, 50th (median), and 95th
percentiles of the observed data are presented as solid lines and
solid circles.
[0132] FIG. 31C shows VPC results (Baseline PK profiles) of the
final model for Arm 2 (phase 3 study) rFVIIIFc.
[0133] FIG. 31D shows VPC results (Baseline PK profiles) of the
final model for Arm 3 (phase 3 study) rFVIIIFc.
[0134] FIG. 31E shows VPC results (Baseline PK profiles) of the
final model for Cohort A (phase 1/2a study) rFVIIIFc. FIG. 31F
shows VPC results (Baseline PK profiles) of the final model for
Cohort B (phase 1/2a study) rFVIIIFc. For FIGS. 31C-F, the 5th,
50th (median), and 95th percentiles of simulated data are
represented by the dotted lines and gray shaded area, while the
5th, 50.sup.th, and 95th percentiles of the observed data are
presented as solid lines and solid circles.
[0135] FIG. 32 shows the external validation of the rFVIIIFc model.
Observed (DV) vs Individual Predicted (IPRE) values from the
validation set only.
[0136] FIG. 33A-33B shows the goodness of fit diagnostics of the
base model for ADVATE.RTM.. FIG. 33A shows Observed (DV) vs
Individual Predicted (IPRE); FIG. 33B shows Conditional Weighted
Residuals (CWRES) vs Predicted (PRED).
[0137] FIG. 34 shows an ADVATE.RTM. model comparison. The lower
line in the graph is the current model; the upper line is the model
reported by Bjorkman et al. Superimposed are the ADVATE.RTM.
activity data from the Phase 3 study dataset.
[0138] FIG. 35A-35H show steady state activity profiles of selected
rFVIII prophylaxis dosing regimens. FIG. 35A shows 50 IU/dL E3D
without uncertainty; FIG. 35B shows 50 IU/dL E3D with uncertainty;
FIG. 35C shows 50 IU/dL E4D without uncertainty; FIG. 35D shows 50
IU/dL E4D with uncertainty; FIG. 35E shows 50 IU/dL E5D without
uncertainty; FIG. 35F shows 50 IU/dL E5D with uncertainty; FIG. 35G
shows 65 IU/dL QW without uncertainty; FIG. 35 H shows 65 IU/dL QW
with uncertainty. In FIGS. 35A, 35C, 35E, and 35G, the solid line
is the predicted median activity, the dark grey shaded region
covers the 25th to 75th percentiles of the predicted activity and
the light grey shaded region covers the 5th to 95th percentiles of
the predicted activity. In FIGS. 35B, 35D, 35F, and 35H, the middle
line is the predicted median activity with the 90% confidence
interval around the predictions represented by the grey shaded
region. The upper and the lower lines represent the 5th and 95th
percentiles of the predicted activity, respectively, along with the
corresponding 90% confidence intervals represented by the grey
shaded regions.
[0139] FIGS. 36A-36C show a comparison of individual Bayesian
parameter estimates for rFVIII and rFVIIIFc. FIG. 36A: Clearance
(CL)--Each point represents one individual. Both agents were
administered at a nominal dose of 50 IU/kg. FIG. 36B: Central
Volume (V.sub.1)--each point represents one individual. The solid
line is the identity line. Both agents were administered at a
nominal dose of 50 IU/kg. FIG. 36C: Time to 1 IU/dL (Time 1%)--each
point represents one individual. The solid line is the identity
line. Both agents were administered at a nominal dose of 50
IU/kg.
[0140] FIG. 37 shows the predicted annualized bleeding rate (ABR)
correlated with time under the target trough FVIII levels of 1, 3,
and 5 IU/dL.
[0141] FIG. 38 shows A-LONG study design for a long-acting FVIII
polypeptide (i.e., rFVIIIFc).
[0142] FIG. 39 shows comparison of the number of prophylactic
infusions for FVIII (prestudy) and rFVIIIFc (on-study) in Arm-1
subjects.
[0143] FIG. 40 shows comparison of patient-reported, 12 month,
prestudy bleeding events and on-study ABR (last 3 months);
stratified by last on-study dosing interval.
[0144] FIG. 41 shows simulated dosing regiments: predicted
proportion of individuals with steady-state FVIII trough levels
above 5 IU/dL (1%).
[0145] FIG. 42 shows time (days) under target FVIII trough levels
by treatment arm in the A-LONG study.
[0146] FIG. 43 shows predicted ABR versus time under target trough
FVIII levels of 1, 3, and 5 IU/dL, based on (A) the unadjusted NBR
model and (B) the adjusted NBR model.
[0147] FIG. 44 shows probability of bleeding versus the time under
the target trough FVIII levels of 1, 3, and 5 IU/dL for (A) any
bleed, (B) spontaneous bleeds, (C) traumatic bleeds, and (D) joint
bleeds.
[0148] FIG. 45 shows a block diagram of an exemplary network-based
system 2000 for obtaining an estimated patient individualized
dosing information, patient individualized PK information, and
patient median PK information.
[0149] FIGS. 46A to 46J show exemplary screen shots of the
pharmacokinetic tool (e.g., web-based application) for calculating
individual dosing information.
[0150] FIGS. 47A to 47B show exemplary screen shots for inputting
user administration (A) and prior therapy information (B).
DETAILED DESCRIPTION OF THE INVENTION
[0151] The present invention provides a computer-based system,
e.g., web-based system for estimating individual patient PK of a
long-acting FIX protein or a long-acting FVIII protein for
treatment of hemophilia, e.g., Hemophilia B or Hemophilia A or a
method of estimating individual patient PK of a long-acting FIX
protein or a long-acting FVIII protein using the computer-based
system, e.g., web-based system.
I. Definitions
[0152] The term "about" is used herein to mean approximately,
roughly, around, or in the regions of. When the term "about" is
used in conjunction with a numerical range, it modifies that range
by extending the boundaries above and below the numerical values
set forth. In general, the term "about" is used herein to modify a
numerical value above and below the stated value by a variance of
10 percent, up or down (higher or lower).
[0153] The term "polypeptide," "peptide" and "protein" are used
interchangeably and refer to a polymeric compound comprised of
covalently linked amino acid residues.
[0154] The term "polynucleotide" and "nucleic acid" are used
interchangeably and refer to a polymeric compound comprised of
covalently linked nucleotide residues. Polynucleotides can be DNA,
cDNA, RNA, single stranded, or double stranded, vectors, plasmids,
phage, or viruses. Polynucleotides include those in Table 33 or
Table 35, which encode the polypeptides of Table 34 or Table 36,
respectively. Polynucleotides also include fragments of the
polynucleotides of Table 33 or Table 35, e.g., those that encode
fragments of the polypeptides of Table 34 or Table 36, such as the
Factor IX, Factor VIII, Fc, signal sequence, propeptide, 6His and
other fragments of the polypeptides of Table 34 or Table 36.
[0155] The term "administering," as used herein, means to or
prescribe or give a pharmaceutically acceptable a long-acting FIX
polypeptide or a long-acting FVIII polypeptide of the invention to
a subject via a pharmaceutically acceptable route. Examples of
routes of administration include, but are not limited to,
intravenous, e.g., intravenous injection and intravenous infusion,
e.g., via central venous access. Additional routes of
administration include subcutaneous, intramuscular, oral, nasal,
and pulmonary administration, preferably subcutaneous. A
long-acting FIX polypeptide or a long-acting FVIII polypeptide (a
FIX or FVIII chimeric or hybrid proteins) can be administered as
part of a pharmaceutical composition comprising at least one
excipient. Advantages of the present invention include: improved
regimen compliance; reduced break through bleeds; increased
protection of joints from bleeds; prevention of joint damage;
reduced morbidity; reduced mortality; prolonged protection from
bleeding; decreased thrombotic events; and improved quality of
life.
[0156] The term "chimeric polypeptide," as used herein, means a
polypeptide that includes within it at least two polypeptides (or
portions thereof such as subsequences or peptides) from different
sources. Chimeric polypeptides can include two, three, four, five,
six, seven, or more polypeptides or portions thereof from different
sources, such as different genes, different cDNAs, or different
animal or other species. Chimeric polypeptides can include one or
more linkers joining the different polypeptides or portions
thereof. Thus, the polypeptides or portions thereof can be joined
directly or they can be joined indirectly, via linkers, or both,
within a single chimeric polypeptide. Chimeric polypeptides can
include additional peptides such as signal sequences and sequences
such as 6His and FLAG that aid in protein purification or
detection. In addition, chimeric polypeptides can have amino acid
or peptide additions to the N- and/or C-termini. Exemplary chimeric
polypeptides of the invention are Factor IX-FcRn BP chimeric
polypeptides, e.g., FIXFc in SEQ ID NO: 2 (Table 34) or Factor
VIII-FcRn BP chimeric polypeptides, e.g., FVIIIFc in SEQ ID NO: 10
(Table 36).
[0157] Factor IX or Factor VIII coagulant activity is expressed as
International Unit(s) (IU). Several assays are available for
measuring Factor IX activity, including the one stage clotting
assay (activated partial thromboplastin time; aPTT), thrombin
generation time (TGA) and rotational thromboelastometry
(ROTEM.RTM.).
[0158] "Dosing interval," as used herein, means the amount of time
that elapses between multiple doses being administered to a
subject. Dosing interval can thus be indicated as ranges. The
dosing interval in the methods of the invention using a chimeric
FIX-FcRn BP, e.g., a chimeric FIX-Fc can be at least about one and
one-half to eight times longer than the dosing interval required
for an equivalent amount (in IU/kg) of said Factor IX without the
FcRn BP, e.g., Fc portion (i.e., a polypeptide consisting of said
FIX). Dosing interval can thus be indicated as ranges. The dosing
interval in the methods of the invention using a chimeric
FVIII-FcRn BP, e.g., a chimeric FVIII-Fc can be at least about one
and one-half to eight times longer than the dosing interval
required for an equivalent amount (in IU/kg) of said Factor VIII
without the FcRn BP, e.g., Fc portion (i.e., a polypeptide
consisting of said FVIII).
[0159] The term "dosing frequency" as used herein refers to the
frequency of administering doses of a long-acting FIX polypeptide
or a long-acting FVIII polypeptide in a given time. Dosing
frequency can be indicated as the number of doses per a given time,
e.g., once a week or once in two weeks.
[0160] The term "bleeding episode" as used herein is given a
standardized definition: A bleeding episode starts from the first
sign of a bleed, and ends 72 hours after the last treatment for the
bleeding, within which any symptoms of bleeding at the same
location, or injections less than or equal to 72 hours apart, is
considered the same bleeding episode. See Blanchette V. (2006)
Haemophilia 12:124-7. As used herein, any injection to treat the
bleeding episode, taken more than 72 hours after the preceding one,
is considered the first injection to treat a new bleeding episode
at the same location. Likewise, any bleeding at a different
location is considered a separate bleeding episode regardless of
time from the last injection.
[0161] The term "prophylaxis of one or more bleeding episode" or
"prophylactic treatment" as used herein means administering a
long-acting FIX polypeptide or a long-acting FVIII polypeptide in
multiple doses to a subject over a course of time to increase the
level of Factor IX or Factor VIII activity in a subject's plasma.
In one embodiment, "prophylaxis of one or more bleeding episode"
indicates use of a long-acting FIX polypeptide or a long-acting
FVIII polypeptide to prevent or inhibit occurrence of one or more
spontaneous or uncontrollable bleeding or bleeding episodes or to
reduce the frequency of one or more spontaneous or uncontrollable
bleeding or bleeding episodes. In another embodiment, the increased
FIX or FVIII activity level is sufficient to decrease the incidence
of spontaneous bleeding or to prevent bleeding in the event of an
unforeseen injury. Prophylactic treatment decreases or prevents
bleeding episodes, for example, those described under on-demand
treatment. Prophylactic treatment can be individualized, as
discussed under "dosing interval", e.g., to compensate for
inter-subject variability.
[0162] The term "about once a week" as used herein means
approximate number, and "about once a week" can include every seven
days.+-.two days, i.e., every five days to every nine days. The
dosing frequency of "once a week" thus can be every five days,
every six days, every seven days, every eight days, or every nine
days.
[0163] The term "individualized interval prophylaxis" as used
herein means use of a long-acting FIX polypeptide or a long-acting
FVIII polypeptide for an individualized dosing interval or
frequency to prevent or inhibit occurrence of one or more
spontaneous and/or uncontrollable bleeding or bleeding episodes or
to reduce the frequency of one or more spontaneous and/or
uncontrollable bleeding or bleeding episodes. In one embodiment,
the "individualized interval" includes every 10 days.+-.3 days,
i.e. every seven days to every 13 days. The dosing frequency of the
"individualized interval prophylaxis" thus can be ever three days,
every seven days, every eight days, every nine days, every ten
days, every 11 days, every 12 days, or every 13 days.
[0164] The term "on-demand treatment," as used herein, means
treatment that is intended to take place over a short course of
time and is in response to an existing condition, such as a
bleeding episode, or a perceived short term need such as planned
surgery. The "on-demand treatment" is used interchangeably with
"episodic" treatment. Conditions that can require on-demand
treatment include a bleeding episode, hemarthrosis, muscle bleed,
oral bleed, hemorrhage, hemorrhage into muscles, oral hemorrhage,
trauma, trauma capitis, gastrointestinal bleeding, intracranial
hemorrhage, intra-abdominal hemorrhage, intrathoracic hemorrhage,
bone fracture, central nervous system bleeding, bleeding in the
retropharyngeal space, bleeding in the retroperitoneal space, or
bleeding in the illiopsoas sheath. Bleeding episodes other than
these are also included. The subject can be in need of surgical
prophylaxis, peri-operative management, or treatment for surgery.
Such surgeries include minor surgery, major surgery, tooth
extraction, tonsillectomy, other dental/thoraco-facial surgeries,
inguinal herniotomy, synovectomy, total knee replacement, other
joint replacement, craniotomy, osteosynthesis, trauma surgery,
intracranial surgery, intra-abdominal surgery, intrathoracic
surgery. Surgeries other than these are also included.
[0165] Additional conditions that can require on-demand treatment
include minor hemorrhage, hemarthroses, superficial muscle
hemorrhage, soft tissue hemorrhage, moderate hemorrhage,
intramuscle or soft tissue hemorrhage with dissection, mucous
membrane hemorrhage, hematuria, major hemorrhage, hemorrhage of the
pharynx, hemorrhage of the retropharynx, hemorrhage of the
retroperitonium, hemorrhage of the central nervous system, bruises,
cuts, scrapes, joint hemorrhage, nose bleed, mouth bleed, gum
bleed, intracranial bleeding, intraperitoneal bleeding, minor
spontaneous hemorrhage, bleeding after major trauma, moderate skin
bruising, or spontaneous hemorrhage into joints, muscles, internal
organs or the brain. Additional reasons for on-demand treatment
include the need for pen-operative management for surgery or dental
extraction, major surgery, extensive oral surgery, urologic
surgery, hernia surgery, orthopedic surgery such as replacement of
knee, hip, or other major joint.
[0166] The term "treatment" or "treating" as used herein means
amelioration or reduction of one or more symptoms of bleeding
diseases or disorders including, but not limited to, hemophilia B.
In one embodiment, "treatment of" or "treating" a bleeding disease
or disorder includes prevention of one or more symptoms of a
bleeding disease or disorder. In a bleeding disease or disorder
caused by a FIX deficiency (e.g., a low baseline FIX activity) or a
FVIII deficiency, the term "treatment" or "treating" means a FIX or
FVIII replacement therapy. By administering a long-acting FIX
polypeptide or a long-acting FVIII polypeptide to a subject, the
subject can achieve and/or maintain a plasma trough level of a FIX
or FVIII activity at about 1 IU/dl or above 1 IU/dl. In other
embodiments, "treatment" or "treating" means reduction of the
frequency of one or more symptoms of bleeding diseases or
disorders, e.g., spontaneous or uncontrollable bleeding episodes.
"Treatment," however, need not be a cure.
[0167] The term "perioperative management" as used herein means use
of a long-acting FIX polypeptide or a long-acting FVIII polypeptide
before, concurrently with, or after an operative procedure, e.g., a
surgical operation. The use for "perioperative management" of one
or more bleeding episode includes surgical prophylaxis before
(i.e., preoperative), during (i.e., intraoperative), or after
(i.e., postoperative) a surgery to prevent one or more bleeding or
bleeding episode or reducing or inhibiting spontaneous and/or
uncontrollable bleeding episodes before, during, and after a
surgery.
[0168] Pharmacokinetic (PK) parameters include the terms above and
the following terms, which have their ordinary meaning in the art,
unless otherwise indicated. Some of the terms are explained in more
detail in the Examples. PK parameters can be based on FIX or FVIII
antigen level (often denoted parenthetically herein as "antigen")
or FIX or FVIII activity level (often denoted parenthetically
herein as "activity"). In the literature, PK parameters are often
based on FIX or FVIII activity level due to the presence in the
plasma of some subjects of endogenous, inactive FIX or FVIII, which
interferes with the ability to measure administered (i.e.,
exogenous) FIX or FVIII using antibody against FIX or FVIII,
respectively. However, when FIX or FVIII is administered as part of
a fusion or hybrid protein containing a heterologous polypeptide
such as an FcRn BP, administered (i.e., exogenous) FIX or FVIII
antigen can be accurately measured using antibody to the
heterologous polypeptide. In addition, certain PK parameters can be
based on model predicted data (often denoted parenthetically herein
as "model predicted") or on observed data (often denoted
parenthetically herein as "observed"), and preferably are based on
observed data.
[0169] "Baseline," as used herein, is the lowest measured plasma
Factor IX or FVIII level in a subject prior to administering a
dose. The Factor IX or FVIII plasma levels can be measured at two
time points prior to dosing: at a screening visit and immediately
prior to dosing. Alternatively, (a) the baseline in subjects whose
pretreatment FIX or FVIII activity is <1%, who have no
detectable FIX or FVIII antigen, and have nonsense genotypes can be
defined as 0%, (b) the baseline for subjects with pretreatment FIX
or FVIII activity <1% and who have detectable FIX or FVIII
antigen can be set at 0.5%, (c) the baseline for subjects whose
pretreatment FIX or FVIII activity is between 1-2% is Cmin (the
lowest activity throughout the PK study), and (d) the baseline for
subjects whose pretreatment FIX or FVIII activity is .gtoreq.2% can
be set at 2%. Activity above the baseline pre-dosing can be
considered residue drug from prior treatment, and can be decayed to
baseline and subtracted from the PK data following long-acting FIX
polypeptide or long-acting FVIII polypeptide dosing.
[0170] "T.sub.1/2.beta.," or "T.sub.1/2 beta" or "Beta HL," as used
herein, is half-life associated with elimination phase,
t.sub.1/2.beta.=(ln 2)/elimination rate constant associated with
the terminal phase. The T.sub.1/2 beta can be measured by FIX or
FVIII activity or by FIX or FVIII antigen level in plasma. The
T.sub.1/2 beta based on activity is shown as T.sub.1/2 beta
(activity), and the T.sub.1/2 beta based on the FIX or FVIII
antigen level can be shown as T.sub.1/2 beta (antigen). Both
T.sub.1/2 beta (activity) and T.sub.1/2 beta (antigen) can be shown
as ranges or a geometric mean.
[0171] "Trough," as used herein, is the lowest plasma Factor IX or
FVIII activity level reached after administering a dose of chimeric
polypeptide of the invention or another Factor IX or FVIII molecule
and before the next dose is administered, if any. Trough is used
interchangeably herein with "threshold." Baseline Factor IX or
FVIII levels are subtracted from measured Factor IX or FVIII levels
to calculate the trough level.
[0172] The term "annualized bleeding rate" ("ABR) as used herein
refers to the number of bleeding episodes (including spontaneous
and traumatic bleeds) experienced by a subject during a defined
time period, extrapolated to 1 year. For example two bleeds in six
months would indicate an ABR of four. The median ABR provides a
single number to describe all subjects, indicating that half of the
subjects had individual ABRs less than or equal to the median and
half had ABRs greater than or equal to the median. For example, an
ABR can be calculated according to the following formula:
Annualized bleeding rate = Number of bleeding episodes during the
efficacy period Total number of days during the efficacy period
.times. 365.25 ( C ) ##EQU00001##
[0173] The population pharmacokinetic modeling terms used herein
(e.g., model, modeling, validation, dataset) have their ordinary
and customary meaning in the field of pharmacokinetics.
[0174] "Immediately," as used herein in reference to updating a
popPK model, means that the model is updated as soon as the
application performs necessary modeling computations to arrive at
an updated model. Thus, "immediately," may reasonably differ in
duration of time depending on the hardware and software on which
the application is running.
[0175] "Contemporaneously," as used herein in reference to
updating, calculating, and inmproving, means shortly after the user
has input the information needed to update the popPK model or to
calculate the pharmacokinetic information, preferably during the
same session in which the user has input the information.
[0176] "Subject," as used herein means a human. Subject as used
herein includes an individual who is known to have at least one
incidence of uncontrolled bleeding episodes, who has been diagnosed
with a disease or disorder associated with uncontrolled bleeding
episodes, e.g., a bleeding disease or disorder, e.g., hemophilia A
or hemophilia B, who are susceptible to uncontrolled bleeding
episodes, e.g., hemophilia, or any combinations thereof. Subjects
can also include an individual who is in danger of one or more
uncontrollable bleeding episodes prior to a certain activity, e.g.,
a surgery, a sport activity, or any strenuous activities. The
subject can have a baseline FIX or FVIII activity less than 1%,
less than 0.5%, less than 2%, less than 2.5%, less than 3%, or less
than 4%. Subjects also include pediatric humans. Pediatric human
subjects are birth to 20 years, preferably birth to 18 years, birth
to 16 years, birth to 15 years, birth to 12 years, birth to 11
years, birth to 6 years, birth to 5 years, birth to 2 years, and 2
to 11 years of age.
[0177] "Therapeutic dose," "dose," "effective dose," or "dosing
amount" as used herein, means a dose that achieves a plasma trough
level of a FIX or FVIII activity at least about 1 IU/dl or above 1
IU/dl in the subject administered with the long-acting FIX
polypeptide or the long-acting FVIII polypeptide. For the purpose
of this invention, in one embodiment, the "dose" refers to the
amount of the doses that a plasma trough level of a FIX or FVIII
activity is maintained at least about 1 IU/dl or above 1 IU/dl, at
least about 2 IU/dl or above 2 IU/dl, at least about 3 IU/dl or
above 3 IU/dl, at least about 4 IU/dl or above 4 IU/dl, or at least
about 5 IU/dl or above 5 IU/dl throughout the administration of the
long-acting FIX polypeptide or the long-acting FVIII polypeptide.
In another embodiment, the "dose" reduces or decreases frequency of
bleeding or bleeding disorder. In other embodiments, the "dose"
stops on-going, uncontrollable bleeding or bleeding episodes. In
still other embodiments, the "dose" prevents spontaneous bleeding
or bleeding episodes in a subject susceptible to such spontaneous
bleeding or bleeding episodes. The "dose" or "therapeutic dose"
need not cure hemophilia.
[0178] "Variant," as used herein, refers to a polynucleotide or
polypeptide differing from the original polynucleotide or
polypeptide, but retaining essential properties thereof, e.g.,
Factor IX coagulant activity or Fc (FcRn binding) activity.
Generally, variants are overall closely similar, and, in many
regions, identical to the original polynucleotide or polypeptide.
Variants include polypeptide and polynucleotide fragments,
deletions, insertions, and modified versions of original
polypeptides.
II. Methods, Systems, and Storage Medium for Estimating Patient
Individualized Dosing Information, Patient Individualized PK
Information, and Patient Median PK Information--Long-Acting FIX
Polypeptide
[0179] The invention includes a method of estimating a long-acting
FIX dosing information individualized for a patient, the method
comprising: (a) receiving, by a computer-based system containing
the long-acting FIX population pharmacokinetic (popPK) model of
Example 5 or 7, e.g., Table 10, 13, or 14, and, optionally, a
Bayesian estimation program, at least one of patient information
and desired treatment outcome information, (b) calculating, by the
computer-based system, individualized long-acting FIX dosing
information using the popPK model, the optional Bayesian estimation
program, and the received information, and (c) outputting, by the
computer-based system, the individualized dosing information.
[0180] In some embodiments, the method also comprises selecting a
dosing regimen based on the output individualized dosing
information of (c) and administering the long-acting FIX
polypeptide to the patient according to the selected dosing
regimen.
[0181] In some embodiments, the desired treatment outcome
information is desired rise in plasma FIX activity level following
dosing and the output information is dose for acute treatment.
[0182] In some embodiments, the desired treatment outcome
information is desired dosing interval and the output information
is dose for prophylaxis.
[0183] In some embodiments, the desired treatment outcome
information is desired dose and the output information is interval
for prophylaxis.
[0184] The invention also includes a method of estimating a
long-acting FIX dosing regimen based on median popPK, the method
comprising: (a) receiving, by a computer-based system containing
the long-acting FIX popPK model of Example 5 or 7, e.g., Table 10,
13, or 14, and, optionally, a Bayesian estimation program, at least
one of patient information and desired treatment outcome
information, (b) calculating, by the computer-based system, median
long-acting FIX PK information using the popPK model, the optional
Bayesian estimation program, and the received information, and (c)
outputting, by the computer-based system, the median PK
information.
[0185] In some embodiments, the method also comprises selecting a
dosing regimen based on the output median PK information of (c),
and administering the long-acting FIX polypeptide to a patient
according to the selected dosing regimen.
[0186] The invention also includes a method of estimating
individual patient long-acting FIX PK, the method comprising: (a)
receiving, by a computer-based system containing the long-acting
FIX population pharmacokinetic (popPK) model of Example 5 or 7,
e.g., Table 10, 13, or 14, and, optionally, a Bayesian estimation
program, individual long-acting FIX PK information, (b) estimating,
by the computer-based system, individualized patient long-acting
FIX PK information using the popPK model, the optional Bayesian
estimation program, and the received information, and (c)
outputting, by the computer-based system, the individualized
patient PK information.
[0187] In some embodiments, the method also comprises selecting a
dosing regimen based on the output individualized patient PK
information of (c), and administering the long-acting FIX
polypeptide to the patient according to the selected regimen.
[0188] In some embodiments (a) further comprises receiving, by the
computer-based system, patient information.
[0189] In some embodiments the patient information is age, e.g., 12
and older, or body weight. Additional patient information includes
diagnostic (baseline) FIX level, PK determinations, time of PK
sampling, dosing history if PK samples were taken from multiple
doses, actual dose, FIX activity level, etc.
[0190] In some embodiments, desired treatment outcome information
is, e.g., desired PK or desired regimen outcome, e.g., desired rise
in plasma FIX activity level following dose, desired dosing
interval, and desired dose.
[0191] In some embodiments, output information is, e.g., PK curve,
PK parameter such as incremental recovery (Cmax/dose), mean
residence time, terminal t1/2, clearance, Vss, AUC/dose, doses and
associated troughs, and intervals and associated troughs.
[0192] For example, for assessing individualized patient PK, the
system can recommend that the user input 2-3 optimized PK sampling
time points. In this case, system output can include PK curve and
one or more selected PK parameters, e.g., incremental recovery
(Cmax/Dose), mean residence time, terminal t1/2, clearance, Vss,
AUC, and time to 1 or X %, etc. e.g., FIG. 12.
[0193] As additional examples, to select an individualized dosing
regimen using the output individual PK parameters discussed in the
preceding paragraph, (i) the dose selected for acute treatment can
be based on user input of the desired rise in plasma FIX activity
level following the dose, (ii) the dose selected for prophylaxis
can be based on user input of the desired dosing interval, or (iii)
the selected interval for prophylaxis can be based on user input
for the desired dose. In the first case, the system can output the
dose (IU) based in the patient's incremental recovery, e.g., FIG.
14. In the second case, system output can be a table of doses and
associated troughs, e.g., x IU/kg, 1% trough, y IU/kg, 2% trough,
etc. e.g., FIG. 15, top. In the third case, system output can be a
table of intervals and associated troughs, e.g., x days, 1% trough,
y IU/kg, 2% trough, etc., e.g., FIG. 15, bottom.
[0194] The user may wish to use the system without inputting any
individualized PK data. In this case, the dosing output would be
based on the population median rather than being individualized for
the particular patient. E.g., FIG. 15. In this way, the user
inputs, e.g., body weight and age, and (i) the desired rise in
plasma FIX activity level following the dose, (ii) the desired dose
interval for prophylaxis, or (iii) the desired dose for
prophylaxis. In the first case, the system can output the dose. In
the second case, the system can output the dose and associated
trough, e.g., Table 6. In the third case, the system can output the
interval and associated trough, e.g., Table 7.
[0195] In some embodiments, the system is compliant with patient
privacy laws. In some embodiments, the system is encrypted, e.g.,
with SSL. In some embodiments, input patient information is made
anonymous.
[0196] In some embodiments, the system includes a user help
function.
[0197] The method can be carried out by, e.g., a physician, a
nurse, or another healthcare practitioner.
[0198] Additional embodiments include a computer readable storage
medium having instructions stored thereon that, when executed by a
processor, cause the processor to perform any of the methods or
processes described herein.
[0199] Additional embodiments include a system comprising a
processor and a memory, the memory having instructions stored
thereon that, when executed by the processor, cause the processor
to perform any of the above methods.
[0200] The user of the system or computer readable storage medium,
can be, e.g., a physician, a nurse, or another healthcare
practitioner.
[0201] For additional embodiments of these aspects of the
invention, see Examples 5 and 7, and the Figures discussed
therein.
[0202] Additional embodiments include a computer readable storage
medium having instructions stored thereon that, when executed by a
processor, cause the processor to perform any of the methods or
processes described herein.
[0203] In some embodiments, the system is web-based.
[0204] According to one embodiment, the invention includes a
web-based method of estimating a long-acting FIX dosing information
individualized for a patient, the method comprising: (a) receiving,
by one or more electronic devices, at least one of patient
information and desired treatment outcome information, (b)
transmitting, by a processing device, the at least one of patient
information and desired treatment outcome information to a
web-based application program accessible through a web server,
wherein the application is programmed to implement a long-acting
FIX population pharmacokinetic (popPK) model, such as that of
Example 5 or 7, e.g., Table 10, 13, or 14, and, optionally, a
Bayesian estimation program, (c) receiving from the web based
server and program, individualized dosing information calculated
using the popPK model, the optional Bayesian estimation program,
and the transmitted information of (b), and (d) outputting, by the
one or more electronic devices, the individualized dosing
information. In some embodiments, the method also comprises
selecting a dosing regimen based on the output individualized
dosing information of (d) and administering the long-acting FIX
polypeptide to the patient according to the selected dosing
regimen.
[0205] In some embodiments, the patient information includes body
weight. In some embodiments, the desired treatment outcome
information is desired rise in plasma FIX activity level following
dosing and the output information is dose for acute treatment. In
some embodiments, the desired treatment outcome information is
desired dosing interval and the output information is dose for
prophylaxis. In some embodiments, the desired treatment outcome
information is desired dose and the output information is interval
for prophylaxis.
[0206] The invention also includes a web-based method of estimating
a long-acting FIX dosing information individualized for a patient,
wherein the method comprises: (a) receiving, by a processing
device, at least one of patient information and desired treatment
outcome information by a web-based application program accessible
through a web server and programmed to implement a long-acting FIX
population pharmacokinetic (popPK) model, and a Bayesian estimation
program, and the received information, and (c) transmitting, by a
processing device, the individualized calculated dosing information
of (b) to one or more electronic devices for output of the
information. In some embodiments, the method also comprises
selecting a dosing regimen based on the output individualized
dosing information transmitted in (c) and administering the
long-acting FIX to the patient according to the selected dosing
regimen.
[0207] In some embodiments, the patient information includes body
weight. In some embodiments, the desired treatment outcome
information is desired rise in plasma FIX activity level following
dosing and the output information is dose for acute treatment. In
some embodiments, the desired treatment outcome information is
desired dosing interval and the output information is dose for
prophylaxis. In some embodiments, the desired treatment outcome
information is desired dose and the output information is interval
for prophylaxis.
[0208] The invention also includes a web-based method of estimating
a long-acting FIX dosing information individualized for a patient,
the method comprising: (a) receiving, by an electronic device, at
least one of patient information and desired treatment outcome, (b)
transmitting, by a processing device, the individual long-acting
FIX PK information to outcome information to a web-based
application program accessible through a web server, and programmed
to implement a long-acting FIX population pharmacokinetic (popPK)
model, such as that of Example 5 or 7, e.g., Table 10, 13, or 14,
and, optionally, a Bayesian estimation program, (c) calculating, by
the web-based program, individualized long-acting FIX dosing
information using the popPK model, and. Optionally a Bayesian
estimation program, and the received information, (d) transmitting,
by a processing device, the individualized calculated dosing
information of (c) to one or more one or more electronic devices,
and (e) outputting, by the one or more electronic devices, the
individualized dosing information. In some embodiments, the method
also comprises selecting a dosing regimen based on the output
individualized dosing information of (e) and administering the
long-acting FIX polypeptide to the patient according to the
selected dosing regimen. In some embodiments, the method also
comprises selecting a dosing regimen based on the output
individualized dosing information in (e) and administering the
long-acting FIX polypeptide to the patient according to the
selected dosing regimen.
[0209] In some embodiments, the patient information includes body
weight. In some embodiments, the desired treatment outcome
information is desired rise in plasma FIX activity level following
dosing and the output information is dose for acute treatment. In
some embodiments, the desired treatment outcome information is
desired dosing interval and the output information is dose for
prophylaxis. In some embodiments, the desired treatment outcome
information is desired dose and the output information is interval
for prophylaxis.
[0210] The invention also includes a web-based method of estimating
a long-acting FIX dosing regimen based on median popPK, the method
comprising: (a) receiving, by one or more electronic devices at
least one of patient information and desired treatment outcome
information, (b) transmitting, by a processing device, the at least
one of patient information and desired treatment outcome
information to a web-based application program accessible through a
web server, wherein the application is programmed to implement a
long-acting FIX population pharmacokinetic (popPK) model, such as
that of Example 5 or 7, e.g., Table 10, 13, or 14, and a Bayesian
estimation program, (c) receiving from the web based server and
program, median long-acting FIX PK dosing information calculated
using the popPK model, the Bayesian estimation program, and the
received information, and (d) outputting, by the one or more
electronic devices, the median PK information. In some embodiments,
the method also comprises selecting a dosing regimen based on the
output median PK information of (e), and (f) administering the
long-acting FIX polypeptide to a patient according to the selected
dosing regimen. In some embodiments, the method also comprises
selecting a dosing regimen based on the output individualized
dosing information output in (d) and administering the long-acting
FIX polypeptide to the patient according to the selected dosing
regimen.
[0211] In some embodiments, the patient information includes body
weight. In some embodiments, the desired treatment outcome
information is desired rise in plasma FIX activity level following
dosing and the output information is dose for acute treatment. In
some embodiments, the desired treatment outcome information is
desired dosing interval and the output information is dose for
prophylaxis. In some embodiments, the desired treatment outcome
information is desired dose and the output information is interval
for prophylaxis.
[0212] The invention also includes a web-based method of estimating
a long-acting FIX dosing regimen based on median popPK, that
comprises: (a) receiving, by a processing device, at least one of
patient information and desired treatment outcome information by a
web-based application program accessible through a web server and
programmed to implement a long-acting FIX population
pharmacokinetic (popPK) model, and a Bayesian estimation program,
wherein the received information is transmitted by one or more
electronic devices, (b) calculating, by the web-based program,
individualized long-acting FIX dosing information using the popPK
model, the Bayesian estimation program, and the received
information, and (c) transmitting, by a processing device, the
individualized calculated dosing information of (b) to one or more
electronic devices for output of the information. In some
embodiments, the method also comprises selecting a dosing regimen
based on the output individualized dosing information transmitted
in (c) and administering the long-acting FIX polypeptide to the
patient according to the selected dosing regimen.
[0213] In some embodiments, the desired treatment outcome
information is desired rise in plasma FIX activity level following
dosing and the output information is dose for acute treatment. In
some embodiments, the desired treatment outcome information is
desired dosing interval and the output information is dose for
prophylaxis. In some embodiments, the desired treatment outcome
information is desired dose and the output information is interval
for prophylaxis.
[0214] The invention also includes a web-based method of estimating
individual patient long-acting FIX PK, the method comprising: (a)
receiving, by one or more electronic devices, individual
long-acting FIX PK information, (b) transmitting, by a processing
device, the individual long-acting FIX PK information to a
web-based application program accessible through a web server,
wherein the application is programmed to implement a long-acting
FIX population pharmacokinetic (popPK) model, such as that of
Example 5 or 7, e.g., Table 10, 13, or 14, and a Bayesian
estimation program, (c) receiving from the web-based server and
program, individualized patient long-acting FIX PK information
using the popPK model, the Bayesian estimation program, and the
transmitted information of (b) and (d) outputting, by the one or
more electronic devices, the individualized patient PK information.
In some embodiments the patient information is age or body weight.
In some embodiments, the method also comprises selecting a dosing
regimen based on the individualized patient PK information output
in (d) and administering the long-acting FIX polypeptide to the
patient according to the selected dosing regimen.
[0215] The invention also includes a web-based method of estimating
a long-acting FIX dosing regimen based on median popPK, the method
comprising: (a) receiving, by one or more electronic devices at
least one of patient information and desired treatment outcome
information, (b) transmitting, by a processing device, the at least
one of patient information and desired treatment outcome
information to a web-based application program accessible through a
web server, wherein the application is programmed to implement a
long-acting FIX population pharmacokinetic (popPK) model, such as
that of Example 5 or 7, e.g., Table 10, 13, or 14, and, optionally,
a Bayesian estimation program, (c) receiving from the web based
server and program, median long-acting FIX PK dosing information
calculated using the popPK model, the optional Bayesian estimation
program, and the received information, and (d) outputting, by the
one or more electronic devices, the median PK information. In some
embodiments, the method also comprises selecting a dosing regimen
based on the output median PK information of (d), and (f)
administering long-acting FIX to a patient according to the
selected dosing regimen.
[0216] In some embodiments, the desired treatment outcome
information is desired rise in plasma FIX activity level following
dosing and the output information is dose for acute treatment. In
some embodiments, the desired treatment outcome information is
desired dosing interval and the output information is dose for
prophylaxis. In some embodiments, the desired treatment outcome
information is desired dose and the output information is interval
for prophylaxis.
[0217] The invention also includes a web-based method of estimating
individual patient long-acting FIX PK, the method comprising: (a)
receiving, by one or more electronic devices, individual
long-acting FIX PK information, (b) transmitting, by a processing
device, the individual long-acting FIX PK information to a
web-based application program accessible through a web server,
wherein the application is programmed to implement a long-acting
FIX population pharmacokinetic (popPK) model, such as that of
Example 5 or 7, e.g., Table 10, 13, or 14, and, optionally, a
Bayesian estimation program, (c) receiving from the web-based
server and program, individualized patient long-acting FIX PK
information calculated using the popPK model, the optional Bayesian
estimation program, and the transmitted information of (b) and (d)
outputting, by the one or more electronic devices, the calculated
patient PK information. In some embodiments, the method also
comprises selecting a dosing regimen based on the output calculated
patient PK information of (d) and administering the long-acting FIX
polypeptide to the patient according to the selected dosing
regimen.
[0218] In particular embodiments, the individual long-acting FIX PK
information includes 2-3 PK sampling time points. In some
embodiments, the individual long-acting FIX PK information includes
one or more of patient body weight, diagnostic (baseline) factor
level, dosing history if PK samples were taken from multiple doses,
actual dose, actual time of PK sampling, factor activity level and
patient body weight.
[0219] In some embodiments the output individualized patient PK
includes a PK curve or a PK parameter selected from incremental
recovery (Cmax/Dose), mean residence time, terminal t.sub.1/2,
clearance, Vss and AUC/Dose. In some embodiments, the desired
treatment outcome information based on the individual patient's PK
is desired rise in plasma FIX activity level following dosing and
the output information is dose for acute treatment.
[0220] The invention also includes a web-based method of estimating
individual patient long-acting FIX PK, the method comprising: (a)
receiving, of individual long-acting FIX PK information by a
web-based application program accessible through a web server, and
programmed to implement a long-acting FIX population
pharmacokinetic (popPK) model, such as that of Example 5 or 7,
e.g., Table 10, 13, or 14, and, optionally, a Bayesian estimation
program, wherein the received information is transmitted by one or
more electronic devices (b) estimating, by the web-based program,
individualized patient long-acting FIX PK information using the
popPK model, the optional Bayesian estimation program, and the
received information, and (c) transmitting, by a processing device,
the estimated individualized patient long-acting FIX PK information
of (b) to one or more one or more electronic devices for output of
the individualized patient PK information. In some embodiments, the
method also comprises selecting a dosing regimen based on the
transmitted patient PK information in (c) and administering the
long-acting FIX polypeptide to the patient according to the
selected dosing regimen.
[0221] In particular embodiments, the individual long-acting FIX PK
information includes 2-3 PK sampling time points. In some
embodiments, the individual long-acting FIX PK information includes
one or more of patient body weight, diagnostic (baseline) factor
level, dosing history if PK samples were taken from multiple doses,
actual dose, actual time of PK sampling, factor activity level and
patient body weight.
[0222] In some embodiments the output individualized patient PK
includes a PK curve or a PK parameter selected from incremental
recovery (Cmax/Dose), mean residence time, terminal t.sub.1/2,
clearance, Vss and AUC/Dose. In some embodiments, the desired
treatment outcome information based on the individual patient's PK
is desired rise in plasma FIX activity level following dosing and
the output information is dose for acute treatment.
[0223] The invention also includes a web-based method of estimating
individual patient long-acting FIX PK, the method comprising: (a)
receiving, by one or more electronic devices, individual
long-acting FIX PK information, (b) transmitting, by a processing
device, the individual long-acting FIX PK information to a
web-based application program accessible through a web server, and
programmed to implement a long-acting FIX population
pharmacokinetic (popPK) model, such as that of Example 5 or 7,
e.g., Table 10, 13, or 14, and, optionally, a Bayesian estimation
program, (c) estimating, by the web-based program, individualized
patient long-acting FIX PK information using the popPK model, the
optional Bayesian estimation program, and the received information,
(d) transmitting, by a processing device, the estimated
individualized patient long-acting FIX PK information of (c) to one
or more one or more electronic devices, and (e) outputting, by the
one or more electronic devices, the individualized patient PK
information. In some embodiments, the method also comprises
selecting a dosing regimen based on the transmitted patient PK
information of (d) and administering the long-acting FIX
polypeptide to the patient according to the selected dosing
regimen.
[0224] In particular embodiments, the individual long-acting FIX PK
information includes 2-3 PK sampling time points. In some
embodiments, the individual long-acting FIX PK information includes
one or more of patient body weight, diagnostic (baseline) factor
level, dosing history if PK samples were taken from multiple doses,
actual dose, actual time of PK sampling, factor activity level and
patient body weight.
[0225] In some embodiments the output individualized patient PK
includes a PK curve or a PK parameter selected from incremental
recovery (Cmax/Dose), mean residence time, terminal t1/2,
clearance, Vss and AUC/Dose. In some embodiments, the desired
treatment outcome information based on the individual patient's PK
is desired rise in plasma FIX activity level following dosing and
the output information is dose for acute treatment.
[0226] In another embodiment, the invention includes a web-based
method of estimating individual patient long-acting FIX PK, the
method comprising: (a) receiving, by one or more electronic
devices, information regarding individual body weight and (i)
desired rise of plasma factor activity level following the dose or
(ii) desired dose or desired dose interval, (b) transmitting, by a
processing device, the information of (a) to a web-based
application program accessible through a web server, wherein the
application is programmed to implement a long-acting FIX population
pharmacokinetic (popPK) model, such as that of Example 5 or 7,
e.g., Table 10, 13, or 14, and a Bayesian estimation program, (c)
receiving from the web based server and program, individualized
patient long-acting FIX PK information calculated using the popPK
model, the Bayesian estimation program, and the transmitted
information of (b), and (d) outputting, by the one or more
electronic devices, the estimated patient PK information. In some
embodiments, the method also comprises selecting a dosing regimen
based on the output estimated patient PK information output of (d),
and administering the long-acting FIX polypeptide to the patient
according to the selected regimen.
[0227] In some embodiments (a) further comprises receiving, by the
electronic device patient information and (b) further comprises
transmitting, by a processing device, the patient information to
the web-based application program. In some embodiments (a) further
comprises receiving information, by the electronic device
information relating to diagnostic (baseline) factor level, dosing
history (if PK samples were taken from multiple doses), actual
dose, actual time of PK sampling or factor activity level and (b)
further comprises transmitting, by a processing device, the
information to the web-based application program. In some
embodiments the individualized patient PK includes a PK curve or a
PK parameter selected from incremental recovery (Cmax/Dose), mean
residence time, terminal t.sub.1/2, clearance, Vss and
AUC/Dose.
[0228] In another embodiment, the invention includes a web-based
method of estimating individual patient long-acting FIX PK, that
comprises: (a) receiving information regarding individual body
weight and (i) desired rise of plasma factor activity level
following the dose or (ii) desired dose or desired dose interval,
wherein the received information is transmitted by one or more
electronic devices, (c) estimating, by the web-based program,
individualized patient long-acting FIX PK information using the
popPK model, the Bayesian estimation program, and the received
information, based on population median, and (c) transmitting, by a
processing device, the estimated patient PK information of (b) to
one or more electronic devices for output of the information. In
some embodiments, the method also comprises selecting a dosing
regimen based on the estimated patient PK information transmitted
in (c), and administering the long-acting FIX polypeptide to the
patient according to the selected regimen.
[0229] In some embodiments (a) further comprises receiving, by the
electronic device additional patient information and (b) further
comprises transmitting, by a processing device, the additional
patient information to the web-based application program. In some
embodiments (a) further comprises receiving information, by the
electronic device information relating to diagnostic (baseline)
factor level, dosing history (if PK samples were taken from
multiple doses), actual dose, actual time of PK sampling or factor
activity level and (b) further comprises transmitting, by a
processing device, the information to the web-based application
program.
[0230] In another embodiment, the invention includes a web-based
method of estimating individual patient long-acting FIX PK, the
method comprising: (a) receiving, by one or more electronic
devices, patient information regarding individual body weight and
(i) desired rise of plasma factor activity level following the dose
or (ii) desired dose or desired dose interval, (b) transmitting, by
a processing device, the information of (a) to a web-based
application program accessible through a web server, and programmed
to implement a long-acting FIX population pharmacokinetic (popPK)
model, such as that of Example 5 or 7, e.g., Table 10, 13, or 14,
and, optionally, a Bayesian estimation program, (c) estimating, by
the web-based program, individualized patient long-acting FIX PK
information using the popPK model, the optional Bayesian estimation
program, and the received information, based on population medium,
(d) transmitting, by a processing device, the estimated patient PK
information of (c) to one or more electronic devices, and (e)
outputting, by the one or more electronic devices, the estimated
patient PK information. In some embodiments, the method also
comprises selecting a dosing regimen based on the estimated patient
PK information of (c), and administering long-acting FIX to the
patient according to the selected regimen.
[0231] In some embodiments, a processor (processing device) is an
electronic device. In some embodiments, the electronic device is
selected from a digital pen, a smart phone, a tablet computer, a
personal digital assistant, a handheld computer, a laptop computer,
a point-of-sale transaction device, a scanner, a camera, and a fax
machine.
[0232] In some embodiments (a) further comprises receiving, by the
electronic device patient information and (b) further comprises
transmitting, by a processing device, the patient information to
the web-based application program. In some embodiments (a) further
comprises receiving information, by the electronic device
information relating to diagnostic (baseline) factor level, dosing
history (if PK samples were taken from multiple doses), actual
dose, actual time of PK sampling or factor activity level and (b)
further comprises transmitting, by a processing device, the
information to the web-based application program. In some
embodiments the individualized patient PK includes a PK curve or a
PK parameter selected from incremental recovery (Cmax/Dose), mean
residence time, terminal t.sub.1/2, clearance, Vss and
AUC/Dose.
[0233] In some embodiments, the electronic device is selected from
a digital pen, a smart phone, a tablet computer, a personal digital
assistant, a handheld computer, a laptop computer, a point-of-sale
transaction device, a scanner, a camera, and a fax machine.
[0234] The electronic device can be a general-purpose computer with
a processor, local memory, display, and one or more computer input
devices such as a keyboard, a mouse and/or a joystick.
Alternatively, the electronic device can be a specialized computing
device such as, for example, a mobile handset. The electronic
device communicates with one or more network-based (e.g.,
web-based) application programs over one or more networks, such as
the Internet. Similar to the electronic device, the network-based
(e.g., web-based) application program can be implemented using any
general-purpose computer capable of serving data to the electronic
device.
[0235] Each of the client, authority, or transmitter may be
implemented on any electronic device. Such electronic device can
include, but is not limited to, a personal computer, mobile device
such as a mobile phone, workstation, embedded system, game console,
television, set-top box, or any other computing device. Further, an
electronic device can include, but is not limited to, a device
having a processor and memory for executing and storing
instructions. Software may include one or more applications and an
operating system. Hardware can include, but is not limited to, a
processor, memory and graphical user interface display. The
electronic device may also have multiple processors and multiple
shared or separate memory components. For example, the electronic
device may be a clustered computing environment or server farm.
[0236] Network 116 can be any network or combination of networks
that can carry data communication, and may be referred to herein as
a computer network. Such network 116 can include, but is not
limited to, a local area network, medium area network, and/or wide
area network such as the Internet. Network 116 can support
protocols and technology including, but not limited to, World Wide
Web protocols and/or services. Intermediate web servers, gateways,
or other servers may be provided between components of system 100
depending upon a particular application or environment.
III. Method, System, and Storage Medium for Estimating Patient
Individualized Dosing Information, Patient Individualized PK
Information, and Patient Median PK Information--FVIII
[0237] The invention also includes a method of estimating a
long-acting FVIII dosing information individualized for a patient,
the method comprising: (a) receiving, by a computer-based system
containing the long-acting FVIII population pharmacokinetic (popPK)
model of Example 9 or 11 or 16, e.g., Table 18, 24, 25, or 33, and,
optionally, a Bayesian estimation program, at least one of patient
information and desired treatment outcome information, (b)
calculating, by the computer-based system, individualized
long-acting FVIII dosing information using the popPK model, the
optional Bayesian estimation program, and the received information,
and (c) outputting, by the computer-based system, the
individualized dosing information.
[0238] In some embodiments, the method also comprises selecting a
dosing regimen based on the output individualized dosing
information of (c) and administering the long-acting FVIII
polypeptide to the patient according to the selected dosing
regimen.
[0239] In some embodiments, the desired treatment outcome
information is desired rise in plasma FVIII activity level
following dosing and the output information is dose for acute
treatment.
[0240] In some embodiments, the desired treatment outcome
information is desired dosing interval and the output information
is dose for prophylaxis.
[0241] In some embodiments, the desired treatment outcome
information is desired dose and the output information is interval
for prophylaxis.
[0242] The invention also includes a method of estimating a
long-acting FVIII dosing regimen based on median popPK, the method
comprising: (a) receiving, by a computer-based system containing
the long-acting FVIII popPK model of Example 9 or 11 or 16, e.g.,
Table 18, 24, 25, or 33, and, optionally, a Bayesian estimation
program, at least one of patient information and desired treatment
outcome information, (b) calculating, by the computer-based system,
median long-acting FVIII PK information using the popPK model, the
optional Bayesian estimation program, and the received information,
and (c) outputting, by the computer-based system, the median PK
information.
[0243] In some embodiments, the method also comprises selecting a
dosing regimen based on the output median PK information of (c),
and administering the long-acting FVIII polypeptide to a patient
according to the selected dosing regimen.
[0244] The invention also includes a method of estimating
individual patient long-acting FVIII PK, the method comprising: (a)
receiving, by a computer-based system containing the long-acting
FVIII population pharmacokinetic (popPK) model of Example 9 or 11
or 16, e.g., Table 18, 24, 25, or 33, and, optionally, a Bayesian
estimation program, individual long-acting FVIII PK information,
(b) estimating, by the computer-based system, individualized
patient long-acting FVIII PK information using the popPK model, the
optional Bayesian estimation program, and the received information,
and (c) outputting, by the computer-based system, the
individualized patient PK information.
[0245] In some embodiments, the method also comprises selecting a
dosing regimen based on the output individualized patient PK
information of (c), and administering the long-acting FVIII
polypeptide to the patient according to the selected regimen.
[0246] In some embodiments (a) further comprises receiving, by the
computer-based system, patient information.
[0247] In some embodiments the patient information is age, e.g., 12
and older, Von Willebrand Factor, hematocrit, or body weight.
Additional patient information includes diagnostic (baseline) FVIII
level, PK determinations, time of PK sampling, dosing history if PK
samples were taken from multiple doses, actual dose, FVIII activity
level, etc.
[0248] In some embodiments, desired treatment outcome information
is, e.g., desired PK or desired regimen outcome, e.g., desired rise
in plasma FVIII activity level following dose, desired dosing
interval, and desired dose.
[0249] In some embodiments, output information is, e.g., PK curve,
PK parameter such as incremental recovery (Cmax/dose), mean
residence time, terminal t1/2, clearance, Vss, AUC/dose, doses and
associated troughs, and intervals and associated troughs.
[0250] For example, for assessing individualized patient PK, the
system can recommend that the user input 2-3 optimized PK sampling
time points. In this case, system output can include PK curve and
one or more selected PK parameters, e.g., incremental recovery
(Cmax/Dose), mean residence time, terminal t1/2, clearance, Vss,
AUC, and time to 1 or X %, etc., e.g., FIG. 14.
[0251] As additional examples, to select an individualized dosing
regimen using the output individual PK parameters discussed in the
preceding paragraph, (i) the dose selected for acute treatment can
be based on user input of the desired rise in plasma FVIII activity
level following the dose, (ii) the dose selected for prophylaxis
can be based on user input of the desired dosing interval, or (iii)
the selected interval for prophylaxis can be based on user input
for the desired dose. In the first case, the system can output the
dose (IU) based in the patient's incremental recovery, e.g., FIG.
14. In the second case, system output can be a table of doses and
associated troughs, e.g., x IU/kg, 1% trough, y IU/kg, 2% trough,
etc. e.g., FIG. 15, top. In the third case, system output can be a
table of intervals and associated troughs, e.g., x days, 1% trough,
y IU/kg, 2% trough, etc., e.g., FIG. 15, bottom.
[0252] The user may wish to use the system without inputting any
individualized PK data. In this case, the dosing output would be
based on the population median rather than being individualized for
the particular patient. E.g., FIG. 15. In this way, the user
inputs, e.g., body weight and age, and (i) the desired rise in
plasma FVIII activity level following the dose, (ii) the desired
dose interval for prophylaxis, or (iii) the desired dose for
prophylaxis. In the first case, the system can output the dose. In
the second case, the system can output the dose and associated
trough. E.g., Table 19 In the third case, the system can output the
interval and associated trough. E.g., Table 20.
[0253] In some embodiments, the system is compliant with patient
privacy laws. In some embodiments, the system is encrypted, e.g.,
with SSL. In some embodiments, input patient information is made
anonymous.
[0254] In some embodiments, the system includes a user help
function.
[0255] The method can be carried out by, e.g., a physician, a
nurse, or another healthcare practitioner.
[0256] Additional embodiments include a computer readable storage
medium having instructions stored thereon that, when executed by a
processor, cause the processor to perform any of the above
methods.
[0257] Additional embodiments include a system comprising a
processor and a memory, the memory having instructions stored
thereon that, when executed by the processor, cause the processor
to perform any of the above methods.
[0258] The user of the system or computer readable storage medium,
can be, e.g., a physician, a nurse, or another healthcare
practitioner.
[0259] For additional embodiments of these aspects of the
invention, see Examples 9, 10, and 11 and the Figures discussed
therein.
[0260] In some embodiments, the system is web-based.
[0261] According to one embodiment, the invention includes a
web-based method of estimating a long-acting FVIII dosing
information individualized for a patient, the method comprising:
(a) receiving, by one or more electronic devices, at least one of
patient information and desired treatment outcome information, (b)
transmitting, by a processing device, the at least one of patient
information and desired treatment outcome information to a
web-based application program accessible through a web server,
wherein the application is programmed to implement a long-acting
FVIII population pharmacokinetic (popPK) model, such as that of
Example 9 or 11 or 16, e.g., Table 18, 24, 25, or 33, and,
optionally, a Bayesian estimation program, (c) receiving from the
web based server and program, individualized dosing information
calculated using the popPK model, the optional Bayesian estimation
program, and the transmitted information of (b), and (d)
outputting, by the one or more electronic devices, the
individualized dosing information. In some embodiments, the method
also comprises selecting a dosing regimen based on the output
individualized dosing information of (d) and administering the
long-acting FVIII polypeptide to the patient according to the
selected dosing regimen.
[0262] In some embodiments, the patient information includes body
weight. In some embodiments, the desired treatment outcome
information is desired rise in plasma FVIII activity level
following dosing and the output information is dose for acute
treatment. In some embodiments, the desired treatment outcome
information is desired dosing interval and the output information
is dose for prophylaxis. In some embodiments, the desired treatment
outcome information is desired dose and the output information is
interval for prophylaxis.
[0263] The invention also includes a web-based method of estimating
a long-acting FVIII dosing information individualized for a
patient, wherein the method comprises: (a) receiving, by a
processing device, at least one of patient information and desired
treatment outcome information by a web-based application program
accessible through a web server and programmed to implement a
long-acting FVIII population pharmacokinetic (popPK) model, and a
Bayesian estimation program, and the received information, and (c)
transmitting, by a processing device, the individualized calculated
dosing information of (b) to one or more electronic devices for
output of the information. In some embodiments, the method also
comprises selecting a dosing regimen based on the output
individualized dosing information transmitted in (c) and
administering the long-acting FVIII polypeptide to the patient
according to the selected dosing regimen.
[0264] In some embodiments, the patient information includes body
weight. In some embodiments, the desired treatment outcome
information is desired rise in plasma FVIII activity level
following dosing and the output information is dose for acute
treatment. In some embodiments, the desired treatment outcome
information is desired dosing interval and the output information
is dose for prophylaxis. In some embodiments, the desired treatment
outcome information is desired dose and the output information is
interval for prophylaxis.
[0265] The invention also includes a web-based method of estimating
a long-acting FVIII dosing information individualized for a
patient, the method comprising: (a) receiving, by an electronic
device, at least one of patient information and desired treatment
outcome, (b) transmitting, by a processing device, the individual
long-acting FVIII PK information to outcome information to a
web-based application program accessible through a web server, and
programmed to implement a long-acting FVIII population
pharmacokinetic (popPK) model, such as that of Example 9 or 11 or
16, e.g., Table 18, 24, 25, or 33, and, optionally, a Bayesian
estimation program, (c) calculating, by the web-based program,
individualized long-acting FVIII dosing information using the popPK
model, and optionally a Bayesian estimation program, and the
received information, (d) transmitting, by a processing device, the
individualized calculated dosing information of (c) to one or more
one or more electronic devices, and (e) outputting, by the one or
more electronic devices, the individualized dosing information. In
some embodiments, the method also comprises selecting a dosing
regimen based on the output individualized dosing information of
(e) and administering the long-acting FVIII polypeptide to the
patient according to the selected dosing regimen. In some
embodiments, the method also comprises selecting a dosing regimen
based on the output individualized dosing information in (e) and
administering the long-acting FVIII polypeptide to the patient
according to the selected dosing regimen.
[0266] In some embodiments, the patient information includes body
weight. In some embodiments, the desired treatment outcome
information is desired rise in plasma FVIII activity level
following dosing and the output information is dose for acute
treatment. In some embodiments, the desired treatment outcome
information is desired dosing interval and the output information
is dose for prophylaxis. In some embodiments, the desired treatment
outcome information is desired dose and the output information is
interval for prophylaxis
[0267] The invention also includes a web-based method of estimating
a long-acting FVIII dosing regimen based on median popPK, the
method comprising: (a) receiving, by one or more electronic devices
at least one of patient information and desired treatment outcome
information, (b) transmitting, by a processing device, the at least
one of patient information and desired treatment outcome
information to a web-based application program accessible through a
web server, wherein the application is programmed to implement a
long-acting FVIII population pharmacokinetic (popPK) model, such as
that of Example 9 or 11 or 16, e.g., Table 18, 24, 25, or 33, and a
Bayesian estimation program, (c) receiving from the web based
server and program, median long-acting FVIII PK dosing information
calculated using the popPK model, the Bayesian estimation program,
and the received information, and (d) outputting, by the one or
more electronic devices, the median PK information. In some
embodiments, the method also comprises selecting a dosing regimen
based on the output median PK information of (e), and (f)
administering the long-acting FVIII polypeptide to a patient
according to the selected dosing regimen. In some embodiments, the
method also comprises selecting a dosing regimen based on the
output individualized dosing information output in (d) and
administering the long-acting FVIII polypeptide to the patient
according to the selected dosing regimen.
[0268] In some embodiments, the patient information includes body
weight. In some embodiments, the desired treatment outcome
information is desired rise in plasma FVIII activity level
following dosing and the output information is dose for acute
treatment. In some embodiments, the desired treatment outcome
information is desired dosing interval and the output information
is dose for prophylaxis. In some embodiments, the desired treatment
outcome information is desired dose and the output information is
interval for prophylaxis.
[0269] The invention also includes a web-based method of estimating
a long-acting FVIII dosing regimen based on median popPK, that
comprises: (a) receiving, by a processing device, at least one of
patient information and desired treatment outcome information by a
web-based application program accessible through a web server and
programmed to implement a long-acting FVIII population
pharmacokinetic (popPK) model, and a Bayesian estimation program,
wherein the received information is transmitted by one or more
electronic devices, (b) calculating, by the web-based program,
individualized long-acting FVIII dosing information using the popPK
model, the Bayesian estimation program, and the received
information, and (c) transmitting, by a processing device, the
individualized calculated dosing information of (b) to one or more
electronic devices for output of the information. In some
embodiments, the method also comprises selecting a dosing regimen
based on the output individualized dosing information transmitted
in (c) and administering the long-acting FVIII polypeptide to the
patient according to the selected dosing regimen.
[0270] In some embodiments, the desired treatment outcome
information is desired rise in plasma FVIII activity level
following dosing and the output information is dose for acute
treatment. In some embodiments, the desired treatment outcome
information is desired dosing interval and the output information
is dose for prophylaxis. In some embodiments, the desired treatment
outcome information is desired dose and the output information is
interval for prophylaxis.
[0271] The invention also includes a web-based method of estimating
individual patient long-acting FVIII PK, the method comprising: (a)
receiving, by one or more electronic devices, individual
long-acting FVIII PK information, (b) transmitting, by a processing
device, the individual long-acting FVIII PK information to a
web-based application program accessible through a web server,
wherein the application is programmed to implement a long-acting
FVIII population pharmacokinetic (popPK) model, such as that of
Example 9 or 11 or 16, e.g., Table 18, 24, 25, or 33, and a
Bayesian estimation program, (c) receiving from the web-based
server and program, individualized patient long-acting FVIII PK
information using the popPK model, the Bayesian estimation program,
and the transmitted information of (b) and (d) outputting, by the
one or more electronic devices, the individualized patient PK
information. In some embodiments the patient information is age or
body weight. In some embodiments, the method also comprises
selecting a dosing regimen based on the individualized patient PK
information output in (d) and administering the long-acting FVIII
polypeptide to the patient according to the selected dosing
regimen.
[0272] The invention also includes a web-based method of estimating
a long-acting FVIII dosing regimen based on median popPK, the
method comprising: (a) receiving, by one or more electronic devices
at least one of patient information and desired treatment outcome
information, (b) transmitting, by a processing device, the at least
one of patient information and desired treatment outcome
information to a web-based application program accessible through a
web server, wherein the application is programmed to implement a
long-acting FVIII population pharmacokinetic (popPK) model, such as
that of Example 9 or 11 or 16, e.g., Table 18, 24, 25, or 33, and,
optionally, a Bayesian estimation program, (c) receiving from the
web based server and program, median long-acting FVIII PK dosing
information calculated using the popPK model, the optional Bayesian
estimation program, and the received information, and (d)
outputting, by the one or more electronic devices, the median PK
information. In some embodiments, the method also comprises
selecting a dosing regimen based on the output median PK
information of (d), and (f) administering the long-acting FVIII
polypeptide to a patient according to the selected dosing
regimen.
[0273] In some embodiments, the desired treatment outcome
information is desired rise in plasma FVIII activity level
following dosing and the output information is dose for acute
treatment. In some embodiments, the desired treatment outcome
information is desired dosing interval and the output information
is dose for prophylaxis. In some embodiments, the desired treatment
outcome information is desired dose and the output information is
interval for prophylaxis.
[0274] The invention also includes a web-based method of estimating
individual patient long-acting FVIII PK, the method comprising: (a)
receiving, by one or more electronic devices, individual
long-acting FVIII PK information, (b) transmitting, by a processing
device, the individual long-acting FVIII PK information to a
web-based application program accessible through a web server,
wherein the application is programmed to implement a long-acting
FVIII population pharmacokinetic (popPK) model, such as that of
Example 9 or 11 or 16, e.g., Table 18, 24, 25, or 33, and,
optionally, a Bayesian estimation program, (c) receiving from the
web-based server and program, individualized patient long-acting
FVIII PK information calculated using the popPK model, the optional
Bayesian estimation program, and the transmitted information of (b)
and (d) outputting, by the one or more electronic devices, the
calculated patient PK information. In some embodiments, the method
also comprises selecting a dosing regimen based on the output
calculated patient PK information of (d) and administering the
long-acting FVIII polypeptide to the patient according to the
selected dosing regimen.
[0275] In particular embodiments, the individual long-acting FVIII
PK information includes 2-3 PK sampling time points. In some
embodiments, the individual long-acting FVIII PK information
includes one or more of patient body weight, diagnostic (baseline)
factor level, dosing history if PK samples were taken from multiple
doses, actual dose, actual time of PK sampling, factor activity
level and patient body weight.
[0276] In some embodiments the output individualized patient PK
includes a PK curve or a PK parameter selected from incremental
recovery (Cmax/Dose), mean residence time, terminal t1/2,
clearance, Vss and AUC/Dose. In some embodiments, the desired
treatment outcome information based on the individual patient's PK
is desired rise in plasma FIX activity level following dosing and
the output information is dose for acute treatment.
[0277] The invention also includes a web-based method of estimating
individual patient long-acting FVIII PK, the method comprising: (a)
receiving, of individual long-acting FVIII PK information by a
web-based application program accessible through a web server, and
programmed to implement a long-acting FVIII population
pharmacokinetic (popPK) model, such as that of Example 9 or 11 or
16, e.g., Table 18, 24, 25, or 33, and, optionally, a Bayesian
estimation program, wherein the received information is transmitted
by one or more electronic devices (b) estimating, by the web-based
program, individualized patient long-acting FVIII PK information
using the popPK model, the optional Bayesian estimation program,
and the received information, and (c) transmitting, by a processing
device, the estimated individualized patient long-acting FVIII PK
information of (b) to one or more one or more electronic devices
for output of the individualized patient PK information. In some
embodiments, the method also comprises selecting a dosing regimen
based on the transmitted patient PK information in (c) and
administering the long-acting FVIII polypeptide to the patient
according to the selected dosing regimen.
[0278] In particular embodiments, the individual long-acting FVIII
PK information includes 2-3 PK sampling time points. In some
embodiments, the individual long-acting FVIII PK information
includes one or more of patient body weight, diagnostic (baseline)
factor level, dosing history if PK samples were taken from multiple
doses, actual dose, actual time of PK sampling, factor activity
level and patient body weight.
[0279] In some embodiments the output individualized patient PK
includes a PK curve or a PK parameter selected from incremental
recovery (Cmax/Dose), mean residence time, terminal t1/2,
clearance, Vss and AUC/Dose. In some embodiments, the desired
treatment outcome information based on the individual patient's PK
is desired rise in plasma FVIII activity level following dosing and
the output information is dose for acute treatment.
[0280] The invention also includes a web-based method of estimating
individual patient long-acting FVIII PK, the method comprising: (a)
receiving, by one or more electronic devices, individual
long-acting FVIII PK information, (b) transmitting, by a processing
device, the individual long-acting FVIII PK information to a
web-based application program accessible through a web server, and
programmed to implement a long-acting FVIII population
pharmacokinetic (popPK) model, such as that of Example 9 or 11 or
16, e.g., Table 18, 24, 25, or 33, and, optionally, a Bayesian
estimation program, (c) estimating, by the web-based program,
individualized patient long-acting FVIII PK information using the
popPK model, the optional Bayesian estimation program, and the
received information, (d) transmitting, by a processing device, the
estimated individualized patient long-acting FVIII PK information
of (c) to one or more one or more electronic devices, and (e)
outputting, by the one or more electronic devices, the
individualized patient PK information. In some embodiments, the
method also comprises selecting a dosing regimen based on the
transmitted patient PK information of (d) and administering the
long-acting FVIII polypeptide to the patient according to the
selected dosing regimen.
[0281] In particular embodiments, the individual long-acting FVIII
PK information includes 2-3 PK sampling time points. In some
embodiments, the individual long-acting FVIII PK information
includes one or more of patient body weight, diagnostic (baseline)
factor level, dosing history if PK samples were taken from multiple
doses, actual dose, actual time of PK sampling, factor activity
level and patient body weight.
[0282] In some embodiments the output individualized patient PK
includes a PK curve or a PK parameter selected from incremental
recovery (Cmax/Dose), mean residence time, terminal t1/2,
clearance, Vss and AUC/Dose. In some embodiments, the desired
treatment outcome information based on the individual patient's PK
is desired rise in plasma FVIII activity level following dosing and
the output information is dose for acute treatment.
[0283] In another embodiment, the invention includes a web-based
method of estimating individual patient long-acting FVIII PK, the
method comprising: (a) receiving, by one or more electronic
devices, information regarding individual body weight and (i)
desired rise of plasma factor activity level following the dose or
(ii) desired dose or desired dose interval, (b) transmitting, by a
processing device, the information of (a) to a web-based
application program accessible through a web server, wherein the
application is programmed to implement a long-acting FVIII
population pharmacokinetic (popPK) model, such as that of Example 9
or 11 or 16, e.g., Table 18, 24, 25, or 33, and a Bayesian
estimation program, (c) receiving from the web based server and
program, individualized patient long-acting FVIII PK information
calculated using the popPK model, the Bayesian estimation program,
and the transmitted information of (b), and (d) outputting, by the
one or more electronic devices, the estimated patient PK
information. In some embodiments, the method also comprises
selecting a dosing regimen based on the output estimated patient PK
information output of (d), and administering the long-acting FVIII
polypeptide to the patient according to the selected regimen.
[0284] In some embodiments (a) further comprises receiving, by the
electronic device patient information and (b) further comprises
transmitting, by a processing device, the patient information to
the web-based application program. In some embodiments (a) further
comprises receiving information, by the electronic device
information relating to diagnostic (baseline) factor level, dosing
history (if PK samples were taken from multiple doses), actual
dose, actual time of PK sampling or factor activity level and (b)
further comprises transmitting, by a processing device, the
information to the web-based application program. In some
embodiments the individualized patient PK includes a PK curve or a
PK parameter selected from incremental recovery (Cmax/Dose), mean
residence time, terminal t1/2, clearance, Vss and AUC/Dose.
[0285] In another embodiment, the invention includes a web-based
method of estimating individual patient long-acting FVIII PK, that
comprises: (a) receiving information regarding individual body
weight and (i) desired rise of plasma factor activity level
following the dose or (ii) desired dose or desired dose interval,
wherein the received information is transmitted by one or more
electronic devices, (c) estimating, by the web-based program,
individualized patient long-acting FVIII PK information using the
popPK model, the Bayesian estimation program, and the received
information, based on population median, and (c) transmitting, by a
processing device, the estimated patient PK information of (b) to
one or more electronic devices for output of the information. In
some embodiments, the method also comprises selecting a dosing
regimen based on the estimated patient PK information transmitted
in (c), and administering the long-acting FVIII polypeptide to the
patient according to the selected regimen.
[0286] In some embodiments (a) further comprises receiving, by the
electronic device additional patient information and (b) further
comprises transmitting, by a processing device, the additional
patient information to the web-based application program. In some
embodiments (a) further comprises receiving information, by the
electronic device information relating to diagnostic (baseline)
factor level, dosing history (if PK samples were taken from
multiple doses), actual dose, actual time of PK sampling or factor
activity level and (b) further comprises transmitting, by a
processing device, the information to the web-based application
program.
[0287] In another embodiment, the invention includes a web-based
method of estimating individual patient long-acting FVIII PK, the
method comprising: (a) receiving, by one or more electronic
devices, patient information regarding individual body weight and
(i) desired rise of plasma factor activity level following the dose
or (ii) desired dose or desired dose interval, (b) transmitting, by
a processing device, the information of (a) to a web-based
application program accessible through a web server, and programmed
to implement a long-acting FVIII population pharmacokinetic (popPK)
model, such as that of Example 9 or 11 or 16, e.g., Table 18, 24,
25, or 33, and, optionally, a Bayesian estimation program, (c)
estimating, by the web-based program, individualized patient
long-acting FVIII PK information using the popPK model, the
optional Bayesian estimation program, and the received information,
based on population medium, (d) transmitting, by a processing
device, the estimated patient PK information of (c) to one or more
electronic devices, and (e) outputting, by the one or more
electronic devices, the estimated patient PK information. In some
embodiments, the method also comprises selecting a dosing regimen
based on the estimated patient PK information of (c), and
administering the long-acting FVIII polypeptide to the patient
according to the selected regimen.
[0288] In some embodiments, a processor (processing device) is an
electronic device. In some embodiments, the electronic device is
selected from a digital pen, a smart phone, a tablet computer, a
personal digital assistant, a handheld computer, a laptop computer,
a point-of-sale transaction device, a scanner, a camera, and a fax
machine.
[0289] In some embodiments (a) further comprises receiving, by the
electronic device patient information and (b) further comprises
transmitting, by a processing device, the patient information to
the web-based application program. In some embodiments (a) further
comprises receiving information, by the electronic device
information relating to diagnostic (baseline) factor level, dosing
history (if PK samples were taken from multiple doses), actual
dose, actual time of PK sampling or factor activity level and (b)
further comprises transmitting, by a processing device, the
information to the web-based application program. In some
embodiments the individualized patient PK includes a PK curve or a
PK parameter selected from incremental recovery (Cmax/Dose), mean
residence time, terminal t1/2, clearance, Vss and AUC/Dose.
[0290] In some embodiments, the electronic device is selected from
a digital pen, a smart phone, a tablet computer, a personal digital
assistant, a handheld computer, a laptop computer, a point-of-sale
transaction device, a scanner, a camera, and a fax machine.
[0291] The electronic device can be a general-purpose computer with
a processor, local memory, display, and one or more computer input
devices such as a keyboard, a mouse and/or a joystick.
Alternatively, the electronic device can be a specialized computing
device such as, for example, a mobile handset. The electronic
device communicates with one or more network-based (e.g.,
web-based) application programs over one or more networks, such as
the Internet. Similar to the electronic device, the network-based
(e.g., web-based) application program can be implemented using any
general-purpose computer capable of serving data to the electronic
device.
[0292] Each of the client, authority, or transmitter may be
implemented on any electronic device. Such electronic device can
include, but is not limited to, a personal computer, mobile device
such as a mobile phone, workstation, embedded system, game console,
television, set-top box, or any other computing device. Further, an
electronic device can include, but is not limited to, a device
having a processor and memory for executing and storing
instructions. Software may include one or more applications and an
operating system. Hardware can include, but is not limited to, a
processor, memory and graphical user interface display. The
electronic device may also have multiple processors and multiple
shared or separate memory components. For example, the electronic
device may be a clustered computing environment or server farm.
[0293] Network 116 can be any network or combination of networks
that can carry data communication, and may be referred to herein as
a computer network. Such network 116 can include, but is not
limited to, a local area network, medium area network, and/or wide
area network such as the Internet. Network 116 can support
protocols and technology including, but not limited to, World Wide
Web protocols and/or services. Intermediate web servers, gateways,
or other servers may be provided between components of system 100
depending upon a particular application or environment.
[0294] In one embodiment of the present invention, the web-based
application allows contemporaneously updating the popPK model based
on the individual clotting factor pharmacokinetic information. In
another embodiment, the web-based application continuously updates
the popPK model based on newly input clotting factor
pharmacokinetic information. By contemporaneously updating the
popPK model based on the individual clotting factor pharmacokinetic
information and/or by continuously updating the popPK model, the
user of the application can have an access to the most updated
popPK model, thereby obtaining the most accurate dosing information
from the web-based application system. In addition, the web-based
application allows the user to pool a large amount of information
quickly and utilize the information in order to calculate the
dosing information of the subject. This type of pooling and
analyzing a large amount of information quickly and efficiently for
the next user is not available routinely and by human hand.
IV. Exemplary Computing Environments for FVIII and FIX
[0295] Various modeling techniques, dosage calculations, and
estimations described herein can be implemented by software,
firmware, hardware, or a combination thereof. FIG. 17 illustrates
an example computer system 1900 in which the embodiments, or
portions thereof, can be implemented as computer-readable code. In
one embodiment, for long-acting FIX polypeptide, the modeling of
Examples 5 and 7, and/or the patient treatment simulation of
Example 6 can be implemented in system 1900. In another embodiment,
for long-acting FVIII polypeptide, the modeling of Examples 9 and
11, and/or the patient treatment simulation of Example 10 can be
implemented in system 1900.
[0296] Computer system 1900 includes one or more processors, such
as processor 1904. Processor 1904 is connected to a communication
infrastructure 1906 (for example, a bus or network).
[0297] Computer system 1900 also includes a main memory 1908,
preferably random access memory (RAM), and may also include a
secondary memory 1910. In accordance with implementations, user
interface data may be stored, for example and without limitation,
in main memory 1908. Main memory 1908 may include, for example,
cache, and/or static and/or dynamic RAM. Secondary memory 1910 may
include, for example, a hard disk drive and/or a removable storage
drive. Removable storage drive 1914 may include a floppy disk
drive, a magnetic tape drive, an optical disk drive, a flash
memory, or the like. The removable storage drive 1914 reads from
and/or writes to removable storage unit 1916 in a well-known
manner. Removable storage unit 1916 may include a floppy disk,
magnetic tape, optical disk, etc. which is read by and written to
by removable storage drive 1914. As will be appreciated by persons
skilled in the relevant art(s), removable storage unit 1916
includes a computer readable storage medium having stored therein
computer software and/or data.
[0298] Computer system 1900 may also include a display interface
1902. Display interface 1902 may be adapted to communicate with
display unit 1930. Display unit 1930 may include a computer monitor
or similar means for displaying graphics, text, and other data
received from main memory 1908 via communication infrastructure
1906. In alternative implementations, secondary memory 1910 may
include other similar means for allowing computer programs or other
instructions to be loaded into computer system 1900. Such means may
include, for example, a removable storage unit 1922 and an
interface 1920. Examples of such means may include a program
cartridge and cartridge interface (such as that found in video game
devices), a removable memory chip (such as an EPROM, or PROM) and
associated socket, and other removable storage units 1922 and
interfaces 1920 which allow software and data to be transferred
from the removable storage unit 1922 to computer system 1900.
[0299] Computer system 1900 may also include a communications
interface 1924. Communications interface 1924 allows software and
data to be transferred between computer system 1900 and external
devices. Communications interface 1924 may include a modem, a
network interface (such as an Ethernet card), a communications
port, a PCMCIA slot and card, or the like. Software and data
transferred via communications interface 1924 are in the form of
signals which may be electronic, electromagnetic, optical, or other
signals capable of being received by communications interface 1924.
These signals are provided to communications interface 1924 via a
communications path 1926. Communications path 1926 carries signals
and may be implemented using wire or cable, fiber optics, a phone
line, a cellular phone link, an RF link or other communications
channels.
[0300] In this document, the term "computer readable storage
medium" is used to generally refer to non-transitory storage media
such as removable storage unit 1916, removable storage unit 1922,
and a hard disk installed in hard disk drive 1912. Computer
readable storage medium can also refer to one or more memories,
such as main memory 1908 and secondary memory 1910, which can be
memory semiconductors (e.g. DRAMs, etc.). These computer program
products are means for providing software to computer system
1900.
[0301] Computer programs (also called computer control logic) are
stored in main memory 1908 and/or secondary memory 1910. Computer
programs may also be received via communications interface 1924 and
stored on main memory 1908 and/or secondary memory 1910. Such
computer programs, when executed, enable computer system 1900 to
implement embodiments as discussed herein. In particular, the
computer programs, when executed, enable processor 1904 to
implement processes of the present disclosure, such as certain
methods discussed above. Accordingly, such computer programs
represent controllers of the computer system 1900. Where
embodiments use software, the software may be stored in a computer
program product and loaded into computer system 1900 using
removable storage drive 1914, interface 1920, or hard drive
1912.
[0302] Embodiments may be directed to computer program products
comprising software stored on any computer readable medium. Such
software, when executed in one or more data processing device,
causes a data processing device(s) to operate as described herein.
Embodiments may employ any computer useable or readable medium.
Examples of computer readable storage media include, but are not
limited to, non-transitory primary storage devices (e.g., any type
of random access memory), and non-transitory secondary storage
devices (e.g., hard drives, floppy disks, CD ROMS, ZIP disks,
tapes, magnetic storage devices, and optical storage devices, MEMS,
nano-technological storage device, etc.). Other computer readable
media include communication mediums (e.g., wired and wireless
communications networks, local area networks, wide area networks,
intranets, etc.).
[0303] FIG. 45 illustrates an example of a network-based system
2000 for a long-acting FIX polypeptide or a long-acting FVIII
polypeptide, in which the embodiments, or portions thereof, can be
implemented as computer-readable code. In one embodiment, for
long-acting FIX polypeptide, the modeling of Examples 5 and 7,
and/or the patient treatment simulation of Example 6 can be
implemented in system 2000. In another embodiment, for long-acting
FVIII polypeptide, the modeling of Examples 9 and 11, and/or the
patient treatment simulation of Example 10 can be implemented in
system 2000.
[0304] Network-based system 2000 includes network 2004 that can be
any network or combination of networks that can carry data
communication, and may be referred to herein as a computer network.
Such network 2004 can include, but is not limited to, a local area
network, medium area network, and/or wide area network such as the
Internet. Network 2004 can support protocols and technology
including, but not limited to, World Wide Web protocols and/or
services. Intermediate web servers, gateways, or other servers may
be provided between components of system 2000 depending upon a
particular application or environment.
[0305] FIG. 45 shows a block diagram of an exemplary network-based
system 2000 for obtaining an estimated patient individualized
dosing information, patient individualized PK information, and
patient median PK information. System 2000 includes an electronic
device 2008 that can communicate over network 2004. Electronic
device 2008 includes a transmitting engine 2012, and receiving
engine 2016. Transmitting engine 2012 may transmit messages over
network 2004. For example, transmitting engine 2012 may transmit
information associated with dosing information individualized for a
patient. Receiving engine 2016 may receive messages over network
2004 (e.g., from server 2020). For example, receiving engine 2016
may receive a response associated with individualized calculated
dosing information transmitted over network 2004 by server
2020.
[0306] Electronic device 2008 can include computer system 1900 and
can include, but is not limited to, a personal computer, mobile
device such as a mobile phone, workstation, embedded system, game
console, television, set-top box, or any other computing device.
Further, electronic device 2008 can include, but is not limited to,
a device having a processor and memory 2017 for executing and
storing instructions.
[0307] Server 2020 is web-based or fixed (physical) and includes a
receiving engine 2026 and a communications interface 2028.
Receiving engine 2026 may receive messages over network 2004 (e.g.,
from electronic device 2008) and communicate the received message
to application program 2032. In one embodiment, application program
2032 can be web-based or computer-based and is programmed to
implement a long-acting FIX population pharmacokinetic (popPK)
model such as that of Example 5 or 7, and, optionally, a Bayesian
estimation program. In another embodiment, application program 2032
is web-based or computer-based and is programmed to implement a
long-acting FVIII population pharmacokinetic (popPK) model such as
that of Example 9 or 11 or 16, and, optionally, a Bayesian
estimation program. Output of application program 2032 may be
communicated by communications interface 2028 over network 2004.
For example, transmitting engine 2030 may transmit output
information associated with dosing information individualized for a
patient over network 2004 to electronic device 2008.
V. Administering Long-Acting FIX Polypeptide
[0308] The present invention further comprises administering a dose
of a long-acting FIX polypeptide to a human subject in need thereof
at a dosing interval, wherein the dose and/or the dosing interval
is identified by the web-based or computer based program.
Administration of the long-acting FIX polypeptide is a replacement
therapy by adding a recombinant FIX to a subject with FIX
deficiency. Administration of the long-acting FIX polypeptide can
reduce or prevent a number of bleeding or bleeding episodes in the
subject.
[0309] The subject for the methods of the invention includes those
in need of control or prevention of bleeding or bleeding episodes.
The subject can be bleeding at the time of administration or be
expected to be bleeding, or can be susceptible to bleeding in minor
hemorrhage, hemarthroses, superficial muscle hemorrhage, soft
tissue hemorrhage, moderate hemorrhage, intramuscle or soft tissue
hemorrhage with dissection, mucous membrane hemorrhage, hematuria,
major hemorrhage, hemorrhage of the pharynx, hemorrhage of the
retropharynx, hemorrhage of the retroperitonium, hemorrhage of the
central nervous system, bruises, cuts, scrapes, joint hemorrhage,
nose bleed, mouth bleed, gum bleed, intracranial bleeding,
intraperitoneal bleeding, minor spontaneous hemorrhage, bleeding
after major trauma, moderate skin bruising, or spontaneous
hemorrhage into joints, muscles, internal organs or the brain. Such
subjects also include those in need of peri-operative management,
such as management of bleeding associated with surgery or dental
extraction. In one embodiment, the subject is in need of
prophylaxis of one or more bleeding episodes. In another
embodiment, the subject is in need of individualized interval
prophylaxis. In other embodiments, the subject is in need of
on-demand treatment of one or more bleeding episodes. In still
other embodiments, the subject is in need of perioperative
management of one or more bleeding episodes.
[0310] The present invention also identifies the appropriate dosing
amount and the dosing interval that can treat or prevent one or
more bleeding episodes. Administration of the appropriate dosing
amount for the dosing interval can achieve a plasma trough level of
a FIX activity at least about 1 IU/dl or above 1 IU/dl during the
interval in a subject administered with a long-acting FIX
polypeptide. In one embodiment, the invention includes a dosing
amount (or ranges of the dosing amount) and a dosing interval (or
ranges of the dosing interval) that can maintain a plasma trough
level of a FIX activity at least about 1 IU/dl (1%) or above 1
IU/dl (1%), at least about 2 IU/dl (2%) or above 2 IU/dl (2%), at
least about 3 IU/dl (3%) or above 3 IU/dl (3%), at least about 4
IU/dl (4%) or above 4 IU/dl (4%), or at least about 5 IU/dl (5%) or
above 5 IU/dl (5%) throughout the interval. In another embodiment,
a dosing amount (or ranges of the dosing amount) and a dosing
interval (or ranges of the dosing interval) that reduces or
decreases frequency of bleeding or bleeding disorder. In other
embodiments, the dosing amount (or ranges of the dosing amount) and
the dosing interval (or ranges of the dosing interval) of a
long-acting FIX polypeptide stops on-going, uncontrollable bleeding
or bleeding episodes in a subject administered with the dosing
amount during the dosing interval. In still other embodiments, the
dosing amount (or ranges of the dosing amount) and the dosing
interval (or ranges of the dosing interval) of a long-acting FIX
polypeptide prevents spontaneous bleeding or bleeding episodes in a
subject susceptible to such spontaneous bleeding or bleeding
episodes. Various dosing amounts and dosing intervals are described
in International Appl. No. PCT/US2011/043569 filed Jul. 11, 2011
and published as WO 2012/006624 on Jan. 12, 2012, which is
incorporated herein by reference in its entirety.
[0311] The doses that can be used in the methods of the invention
are about 10 IU/kg to about 200 IU/kg, about 10 IU/kg to about 180
IU/kg, or about 25 IU/kg to about 200 IU/kg. In one embodiment, the
dose of a long-acting FIX polypeptide is about 10 IU/kg to about 50
IU/kg, about 10 IU/kg to about 100 IU/kg, about 25 IU/kg to about
75 IU/kg, about 25 IU/kg to about 100 IU/kg, about 25 IU/kg to
about 125 IU/kg, about 25 IU/kg to about 150 IU/kg, about 25 IU/kg
to about 50 IU/kg, about 50 IU/kg to about 100 IU/kg, about 50
IU/kg to about 150 IU/kg, about 100 IU/kg to about 150 IU/kg, about
150 IU/kg to about 200 IU/kg, or any combinations thereof.
[0312] The dosing interval can, alternatively, be an individualized
interval that is determined for each subject based on the
population pharmacokinetic data or other information about that
subject. The individualized dose/dosing interval combination can be
the same as those for fixed interval regimens in the preceding
paragraphs, or can differ. The regimen can initially be at a fixed
dosing interval, and then it can change to an individualized dosing
interval.
[0313] In some embodiments, a dose of a long-acting FIX polypeptide
is an amount sufficient for individualized interval prophylaxis of
a bleeding episode. In one example, the individualized interval is
every nine days, every 10 days, every 11 days, every 12 days, every
13 days, every 14 days, every 15 days, every 16 days, every 17
days, every 18 days, every 19 days or two times monthly.
[0314] In some embodiments, a dose of a long-acting FIX polypeptide
is sufficient for on-demand treatment of one or more bleeding
episodes. The doses for the on-demand treatment can vary depending
on the various factors, e.g., subject's baseline FIX activity,
subject's body weight, subject's likelihood of experiencing
bleeding episode, and etc. In one example, the doses for the
on-demand treatment can be about 10 to about 50, about 15 to about
100, about 20 to about 100, about 20 to about 50, about 50 to about
100, about 10, about 20, about 40, about 50, and about 100
IU/kg.
[0315] In certain embodiments, a dosing amount and a dosing
interval combination for a subject is 20 IU/kg once weekly, 40
IU/kg once weekly, 50 IU/kg once weekly, 100 IU/kg every 10 days,
and 100 IU/kg every two weeks (or twice monthly). In one
embodiment, a dosing frequency for a long-acting FIX polypeptide is
about every two weeks or twice monthly. In another embodiment, the
dosing frequency is every 7 days for 25-50 IU/kg, every 10-13 days
for 50-100 IU/kg, or every 14 days for 100-150 IU/kg. The interval
(or frequency) and dose are determined such that the combination of
interval (or frequency) and dose will result in a trough level of
at least about 1-5 or at least about 1-3, or at least about 1, at
least about 2, at least about 3 IU/dl FIX activity in the
subject.
[0316] In some embodiments of the invention, an annualized bleeding
rate (ABR) of a bleeding episode is controlled by the present
methods. For example, the dosing amount and dosing interval can be
administered to reduce or decrease an annualized bleeding rate to a
certain level. In one embodiment, administration of a long-acting
FIX polypeptide at a dose and a dosing interval for prophylaxis of
a bleeding episode results in an annual bleeding rate of less than
2, less than 2.5, less than 3, less than 3.5, less than 4, less
than 4.5, less than 5, less than 5.5, less than 6, less than 6.5,
less than 7, less than 7.5, less than 8, less than 8.5, less than
9, less than 9.5, or less than 10. For example, ABR of weekly
prophylaxis of a bleeding episode can be 2.95.
[0317] The long-acting FIX polypeptide of the invention can provide
a half-life, e.g., T.sub.1/2beta (activity) or T.sub.1/2beta
(antigen), that is longer than wild-type FIX (e.g., a polypeptide
consisting of amino acids 1 to 415 of SEQ ID NO: 2; BENEFIX.RTM.;
or pdFIX). In one embodiment, a T.sub.1/2beta (activity) of a
long-acting FIX polypeptide is at least about 40 hours, at least
about 45 hours, at least about 50 hours, at least about 55 hours,
at least about 60 hours, at least about 65 hours, at least about 70
hours, at least about 75 hours, at least about 80 hours, at least
about 85 hours, at least about 90 hours, at least about 95 hours,
at least about 100 hours, at least about 105 hours, at least about
110 hours, at least about 115, at least about 120, at least about
125, at least about 130, at least about 135, at least about 140, at
least about 145, at least about 150, at least about 155, at least
about 160, at least about 165, at least about 170, at least about
175, at least about 180, at least about 185, at least about 190, or
at least about 193 hours.
[0318] In some embodiments, the T.sub.1/2 beta (activity) of a
long-acting FIX polypeptide is expressed as a mean. For example, a
mean of the T.sub.1/2 beta (activity) of a long-acting FIX
polypeptide is at least about 76 hours, at least about 77 hours, at
least about 78 hours, at least about 79 hours, at least about 80
hours, at least about 81 hours, at least about 82 hours, at least
about 83 hours, at least about 84 hours, at least about 85 hours,
at least about 86 hours, at least about 87 hours, at least about 88
hours, at least about 89 hours, at least about 90 hours, at least
about 91 hours, or at least about 92 hours. In a specific
embodiment, a mean of the T.sub.1/2 beta (activity) of a
long-acting FIX polypeptide is 82 hours.
[0319] In other embodiments, the T.sub.1/2 beta (activity) of a
long-acting FIX polypeptide is shown as a comparison to a T.sub.1/2
beta (activity) of wild-type mature FIX. In one example, the mean
of the T.sub.1/2 beta (activity) is at least about 2.0 fold higher
than wild-type mature FIX (a polypeptide consisting of amino acids
1 to 415 of SEQ ID NO: 2, BENEFIX.RTM., or pdFIX). In another
example, the mean of the T.sub.1/2 beta (activity) is at least
about 2.0 fold, at least about 2.1 fold, at least about 2.2 fold,
at least about 2.3 fold, at least about 2.4 fold, at least about
2.5 fold, at least about 2.6 fold, at least about 2.7 fold, at
least about 2.8 fold, at least about 2.9 fold, at least about 3.0
fold, at least about 3.1 fold, or at least about 3.2 fold higher
than wild-type mature FIX (a polypeptide consisting of amino acids
1 to 415 of SEQ ID NO: 2, BENEFIX.RTM., or pdFIX).
[0320] In certain embodiments of the invention, the method of the
invention further comprises measuring a baseline FIX activity of a
subject prior to the initial administration of a long-acting FIX
polypeptide. Measuring of a baseline FIX activity can employ any
known clotting assays in the art, e.g., one step aPTT assay, two
step chromogenic assay, ROTEM, TGA, or etc.
[0321] In some embodiments, the method of the invention further
comprises measuring a T.sub.1/2beta (activity) or T.sub.1/2beta
(antigen) of the long-acting FIX polypeptide in the subject after
administration of a long-acting FIX polypeptide.
[0322] Long-Acting FIX Polypeptide
[0323] A long-acting FIX polypeptide useful for the invention is a
chimeric polypeptide comprising a FIX polypeptide and a second
portion. In one embodiment, the second portion comprises albumin or
an FcRn binding partner. Non-limiting examples for the second
portion is described elsewhere herein. In certain embodiments, the
long-acting FIX is a fusion protein comprising a single molecule of
human recombinant coagulation FIX (rFIX) covalently linked to the
dimeric Fc domain of immunoglobulin G1 (IgG1) with no intervening
sequence. The FIX polypeptide of the invention comprises a
functional Factor IX polypeptide in its normal role in coagulation,
unless otherwise specified. Thus, the FIX polypeptide includes
variant polypeptides that are functional and the polynucleotides
that encode such functional variant polypeptides. In one
embodiment, the FIX polypeptides are the human, bovine, porcine,
canine, feline, and murine FIX polypeptides. The full length
polypeptide and polynucleotide sequences of FIX are known, as are
many functional variants, e.g., fragments, mutants and modified
versions. FIX polypeptides include full-length FIX, full-length FIX
minus Met at the N-terminus, full-length FIX minus the signal
sequence, mature FIX (minus the signal sequence and propeptide),
and mature FIX with an additional Met at the N-terminus. FIX can be
made by recombinant means ("recombinant Factor IX" or "rFIX"),
i.e., it is not naturally occurring or derived from plasma.
[0324] A great many functional FIX variants are known.
International publication number WO 02/040544 A3, which is herein
incorporated by reference in its entirety, discloses mutants that
exhibit increased resistance to inhibition by heparin at page 4,
lines 9-30 and page 15, lines 6-31. International publication
number WO 03/020764 A2, which is herein incorporated by reference
in its entirety, discloses FIX mutants with reduced T cell
immunogenicity in Tables 2 and 3 (on pages 14-24), and at page 12,
lines 1-27. International publication number WO 2007/149406 A2,
which is herein incorporated by reference in its entirety,
discloses functional mutant FIX molecules that exhibit increased
protein stability, increased in vivo and in vitro half-life, and
increased resistance to proteases at page 4, line 1 to page 19,
line 11. WO 2007/149406 A2 also discloses chimeric and other
variant FIX molecules at page 19, line 12 to page 20, line 9.
International publication number WO 08/118507 A2, which is herein
incorporated by reference in its entirety, discloses FIX mutants
that exhibit increased clotting activity at page 5, line 14 to page
6, line 5. International publication number WO 09/051717 A2, which
is herein incorporated by reference in its entirety, discloses FIX
mutants having an increased number of N-linked and/or O-linked
glycosylation sites, which results in an increased half-life and/or
recovery at page 9, line 11 to page 20, line 2. International
publication number WO 09/137254 A2, which is herein incorporated by
reference in its entirety, also discloses Factor IX mutants with
increased numbers of glycosylation sites at page 2, paragraph [006]
to page 5, paragraph [011] and page 16, paragraph [044] to page 24,
paragraph [057]. International publication number WO 09/130198 A2,
which is herein incorporated by reference in its entirety,
discloses functional mutant FIX molecules that have an increased
number of glycosylation sites, which result in an increased
half-life, at page 4, line 26 to page 12, line 6. International
publication number WO 09/140015 A2, which is herein incorporated by
reference in its entirety, discloses functional FIX mutants that an
increased number of Cys residues, which can be used for polymer
(e.g., PEG) conjugation, at page 11, paragraph [0043] to page 13,
paragraph [0053]. The FIX polypeptides described in International
Application No. PCT/US2011/043569 filed Jul. 11, 2011 and published
as WO 2012/006624 on Jan. 12, 2012 are also incorporated herein by
reference in its entirety.
[0325] In addition, hundreds of non-functional mutations in FIX
have been identified in hemophilia subjects, many of which are
disclosed in Table 5, at pages 11-14 of International publication
number WO 09/137254 A2, which is herein incorporated by reference
in its entirety. Such non-functional mutations are not included in
the invention, but provide additional guidance for which mutations
are more or less likely to result in a functional FIX
polypeptide.
[0326] In one embodiment, the Factor IX (or Factor IX portion of a
chimeric polypeptide) can be at least 70%, at least 80%, at least
85%, at least 90%, at least 95%, at least 96%, at least 97%, at
least 98%, at least 99%, or 100% identical to a FIX amino acid
sequence shown in Table 34A without a signal sequence and
propeptide sequence (amino acids 1 to 415 of SEQ ID NO: 2), or
alternatively, with a propeptide sequence, or with a propeptide and
signal sequence (full length FIX).
[0327] A long-acting FIX polypeptide can be a hybrid FIX
polypeptide. Hybrid FIX polypeptide means a combination of a FIX
chimeric polypeptide with a second polypeptide. The chimeric
polypeptide and the second polypeptide in a hybrid can be
associated with each other via non-covalent protein-protein
interactions, such as charge-charge or hydrophobic interactions.
The chimeric polypeptide and the second polypeptide in a hybrid can
be associated with each other via covalent bond(s) such as
disulfide bonds. The chimeric peptide and the second peptide can be
associated with each other via more than one type of bond, such as
non-covalent and disulfide bonds. Hybrids are described in WO
2004/101740, WO 2005/001025, U.S. Pat. Nos. 7,404,956, 7,348,004,
and WO 2006/074199, each of which is incorporated herein by
reference in its entirety. The second polypeptide can be a second
copy of the same chimeric polypeptide or it can be a non-identical
chimeric polypeptide. In other embodiments, the second polypeptide
is a polypeptide comprising an FcRn BP, e.g., Fc. In some
embodiments, the chimeric polypeptide is a Factor IX-FcRn BP, e.g.,
Factor IX-Fc chimeric polypeptide, and the second polypeptide
consists essentially of Fc. See, e.g., Table 34 (SEQ ID NOs: 2 and
4). See, e.g., U.S. Pat. No. 7,404,956, which is incorporated
herein by reference in its entirety.
VI. Administering Long-Acting FVIII Polypeptide
[0328] The present invention further comprises administering a dose
of a long-acting FVIII polypeptide to a human subject in need
thereof at a dosing interval, wherein the dose and/or the dosing
interval is identified by the web-based or computer based program.
Administration of the long-acting FVIII polypeptide is a
replacement therapy by adding a recombinant FVIII to a subject with
FVIII deficiency. Administration of the long-acting FVIII
polypeptide can reduce or prevent a number of bleeding or bleeding
episodes in the subject.
[0329] Treatment of hemophilia A is a replacement therapy targeting
restoration of FVIII activity to 1 to 5% of normal levels to
prevent spontaneous bleeding (Mannucci, P. M. et al., N. Engl. J.
Med. 344:1773-9 (2001), herein incorporated by reference in its
entirety).
[0330] In one embodiment, the long-acting FVIII polypeptide is
administered at a dosing interval of every three days or longer. In
another embodiment, the effective dose is between about 20 IU/kg
and about 90 IU/kg. In other embodiments, the effective dose is
20-30 IU/kg, 30-40 IU/kg, 40-50 IU/kg, 50-60 IU/kg, 60-70 IU/kg,
70-80 IU/kg, or 80-90 IU/kg.
[0331] In certain embodiments, administration of a long-acting
FVIII polypeptide is for individualized (tailored) prophylaxis and
results in an ABR of less than about 5.5, less than about 5.4, less
than about 5.3, less than about 5.2, less than about 5.1, less than
about 5.0, less than about 4.9, less than about 4.8, less than
about 4.7, less than about 4.6, or less than about 4.5.
[0332] In some embodiments, administration of a long-acting FVIII
polypeptide is for weekly prophylaxis and results in an ABR of less
than about 9.0, less than about 8.9, less than about 8.8, less than
about 8.7, less than about 8.6, less than about 8.5, or less than
about 8.4.
[0333] In other embodiments, administration of a long-acting FVIII
polypeptide is for episodic or on-demand treatment and results in
an ABR of less than about 55, less than about 54, less than about
53, less than about 52, less than about 51, less than about 50,
less than about 49, less than about 48, or less than about 47.
[0334] In some embodiments, the effective dose for individualized
prophylaxis, weekly prophylaxis, or episodic treatment is a fixed
dose or a stratified dose. In one aspect, the fixed dose is about
2,000 IU per dose, about 2,500 IU per dose, about 3,000 IU per
dose, about 3,500 IU per dose, or about 4,000 IU per dose.
[0335] The dosing interval suitable for administration of a
long-acting FVIII polypeptide can be at least about one and
one-half times longer than the dosing interval required for an
equivalent dose of the Factor VIII without the non-Factor VIII
portion (a polypeptide consisting of the Factor VIII portion).
[0336] The dosing interval can be at least about one and one-half
to six times longer, one and one-half to five times longer, one and
one-half to four times longer, one and one-half to three times
longer, or one and one-half to two times longer, than the dosing
interval required for an equivalent dose of the Factor VIII without
the non-Factor VIII portion (a polypeptide consisting of the Factor
VIII portion), e.g., without the Fc portion. The dosing interval
can be at least about one and one-half, two, two and one-half,
three, three and one-half, four, four and one-half, five, five and
one-half or six times longer than the dosing interval required for
an equivalent dose of the Factor VIII without the non-Factor VIII
portion (a polypeptide consisting of the Factor VIII portion),
e.g., without the Fc portion. The dosing interval can be about
every three, four, five, six, seven, eight, nine, ten, eleven,
twelve, thirteen, or fourteen days or longer.
[0337] The dosing interval can be at least about one and one-half
to 5, one and one-half, 2, 3, 4, or 5 days or longer.
[0338] The methods of the invention can be practiced on a subject
in need of prophylactic treatment or on-demand treatment.
[0339] The bleeding condition can be caused by a blood coagulation
disorder. A blood coagulation disorder can also be referred to as a
coagulopathy. In one example, the blood coagulation disorder, which
can be treated with a pharmaceutical composition of the current
disclosure, is hemophilia. In another example, the blood
coagulation disorder that can be treated with a pharmaceutical
composition of the present disclosure is hemophilia A.
[0340] In some embodiments, the type of bleeding associated with
the bleeding condition is selected from hemarthrosis, muscle bleed,
oral bleed, hemorrhage, hemorrhage into muscles, oral hemorrhage,
trauma, trauma capitis, gastrointestinal bleeding, intracranial
hemorrhage, intra-abdominal hemorrhage, intrathoracic hemorrhage,
bone fracture, central nervous system bleeding, bleeding in the
retropharyngeal space, bleeding in the retroperitoneal space, and
bleeding in the illiopsoas sheath.
[0341] In other embodiments, the subject suffering from bleeding
condition is in need of treatment for surgery, including, e.g.,
surgical prophylaxis or pen-operative management. In one example,
the surgery is selected from minor surgery and major surgery.
Exemplary surgical procedures include tooth extraction,
tonsillectomy, inguinal herniotomy, synovectomy, craniotomy,
osteosynthesis, trauma surgery, intracranial surgery,
intra-abdominal surgery, intrathoracic surgery, joint replacement
surgery (e.g., total knee replacement, hip replacement, and the
like), heart surgery, and caesarean section.
[0342] Long-Acting FVIII Polypeptide
[0343] A "B domain" of Factor VIII, as used herein, is the same as
the B domain known in the art that is defined by internal amino
acid sequence identity and sites of proteolytic cleavage by
thrombin, e.g., residues Ser741-Arg1648 of full length mature human
factor VIII. The other human factor VIII domains are defined by the
following amino acid residues: A1, residues Ala1-Arg372; A2,
residues Ser373-Arg740; A3, residues Ser1690-Ile2032; C1, residues
Arg2033-Asn2172; C2, residues Ser2173-Tyr2332. The A3-C1-C2
sequence includes residues Ser1690-Tyr2332. The remaining sequence,
residues Glu1649-Arg1689, is usually referred to as the factor VIII
light chain activation peptide. The locations of the boundaries for
all of the domains, including the B domains, for porcine, mouse and
canine factor VIII are also known in the art. In one embodiment,
the B domain of Factor VIII is deleted ("B domain deleted factor
VIII" or "BDD FVIII"). An example of a BDD FVIII is REFACTO.RTM.
(recombinant BDD FVIII), which has the same sequence as the Factor
VIII portion of the sequence in Table 36A(i) (amino acids 1 to 1457
of SEQ ID NO: 6 or 20 to 1457 of SEQ ID NO: 10). In another
embodiment, the B domain deleted Factor VIII contains an intact
intracellular processing site, which corresponds to Arginine at
residue 754 of B domain deleted Factor VIII, which corresponds to
Arginine residue 773 of SEQ ID NO: 6, or residue 1648 of
full-length Factor VIII, which corresponds to Arginine residue 1667
of SEQ ID NO: 10. The sequence residue numbers used herein without
referring to any SEQ ID Numbers correspond to the Factor VIII
sequence without the signal peptide sequence (19 amino acids)
unless otherwise indicated. For example, 5743/Q1638 of full-length
Factor VIII corresponds to 5762/Q1657 of SEQ ID NO: 10 due to the
19 amino acid signal peptide sequence. In other embodiments, the B
domain deleted FVIII comprises a substitution or mutation at an
amino acid position corresponding to Arginine 1645, a substitution
or mutation at an amino acid position corresponding to Arginine
1648, or a substitution or mutation at amino acid positions
corresponding to Arginine 1645 and Arginine 1648 in full-length
Factor VIII. In some embodiments, the amino acid substituted at the
amino acid position corresponding to Arginine 1645 is a different
amino acid from the amino acid substituted at the amino acid
position corresponding to Arginine 1648. In certain embodiments,
the substitution or mutation is an amino acid other than arginine,
e.g., alanine.
[0344] A "B domain deleted factor VIII" can have the full or
partial deletions disclosed in U.S. Pat. Nos. 6,316,226, 6,346,513,
7,041,635, 5,789,203, 6,060,447, 5,595,886, 6,228,620, 5,972,885,
6,048,720, 5,543,502, 5,610,278, 5,171,844, 5,112,950, 4,868,112,
and 6,458,563, each of which is incorporated herein by reference in
its entirety. In some embodiments, a B domain deleted factor VIII
sequence of the present invention comprises any one of the
deletions disclosed at col. 4, line 4 to col. 5, line 28 and
examples 1-5 of U.S. Pat. No. 6,316,226 (also in U.S. Pat. No.
6,346,513). In some embodiments, a B domain deleted factor VIII of
the present invention has a deletion disclosed at col. 2, lines
26-51 and examples 5-8 of U.S. Pat. No. 5,789,203 (also U.S. Pat.
Nos. 6,060,447, 5,595,886, and 6,228,620). In some embodiments, a B
domain deleted factor VIII has a deletion described in col. 1,
lines 25 to col. 2, line 40 of U.S. Pat. No. 5,972,885; col. 6,
lines 1-22 and example 1 of U.S. Pat. No. 6,048,720; col. 2, lines
17-46 of U.S. Pat. No. 5,543,502; col. 4, line 22 to col. 5, line
36 of U.S. Pat. No. 5,171,844; col. 2, lines 55-68, FIG. 2, and
example 1 of U.S. Pat. No. 5,112,950; col. 2, line 2 to col. 19,
line 21 and Table 2 of U.S. Pat. No. 4,868,112; col. 2, line 1 to
col. 3, line 19, col. 3, line 40 to col. 4, line 67, col. 7, line
43 to col. 8, line 26, and col. 11, line 5 to col. 13, line 39 of
U.S. Pat. No. 7,041,635; or col. 4, lines 25-53, of U.S. Pat. No.
6,458,563. In some embodiments, a B domain deleted factor VIII has
a deletion of most of the B domain, but still contains
amino-terminal sequences of the B domain that are essential for in
vivo proteolytic processing of the primary translation product into
two polypeptide chain (i.e., intracellular processing site), as
disclosed in WO 91/09122, which is incorporated herein by reference
in its entirety. In some embodiments, a B domain deleted factor
VIII is constructed with a deletion of amino acids 747-1638, i.e.,
virtually a complete deletion of the B domain. Hoeben R. C., et al.
J. Biol. Chem. 265 (13): 7318-7323 (1990), incorporated herein by
reference in its entirety. A B domain deleted factor VIII can also
contain a deletion of amino acids 771-1666 or amino acids 868-1562
of factor VIII. Meulien P., et al. Protein Eng. 2(4): 301-6 (1988),
incorporated herein by reference in its entirety. Additional B
domain deletions that are part of the invention include, e.g.,
deletion of amino acids 982 through 1562 or 760 through 1639 (Toole
et al., Proc. Natl. Acad. Sci. U.S.A. 83:5939-5942 (1986)), 797
through 1562 (Eaton et al., Biochemistry 25:8343-8347 (1986)), 741
through 1646 (Kaufman (PCT published application No. WO 87/04187)),
747-1560 (Sarver et al., DNA 6:553-564 (1987)), 741 through 1648
(Pasek (PCT application No. 88/00831)), 816 through 1598 or 741
through 1689 (Lagner (Behring Inst. Mitt. (1988) No 82:16-25, EP
295597)), each of which is incorporated herein by reference in its
entirety. In some embodiments, B domain deleted FVIII comprises a
partial deletion in B domain, i.e., having 21 amino acids from B
domain (i.e., SFSQNSRHPSQNPPVLKRHQR, which is SEQ ID NO: 11)
disclosed in US Publication No. 20100286067 and US Publication No.
US 20120093840, both of which are incorporated herein by reference
in their entireties. Each of the foregoing deletions can be made in
any Factor VIII sequence. Each of the foregoing deletions can be
made in any Factor VIII sequence.
[0345] In one embodiment, the B domain deleted Factor VIII portion
in the long-acting FVIII polypeptide is processed into two chains
connected (or associated) by a metal bond, the first chain
comprising a heavy chain (A1-A2-partial B) and a second chain
comprising a light chain (A3-C1-C2). In another embodiment, the B
domain deleted Factor VIII portion is a single chain Factor VIII.
The single chain Factor VIII can comprise an intracellular
processing site, which corresponds to Arginine at residue 754 of B
domain deleted Factor VIII (residue 773 of SEQ ID NO: 6) or at
residue 1648 of full-length Factor VIII (residue 1657 of SEQ ID NO:
10).
[0346] The metal bond between the heavy chain and the light chain
can be any metal known in the art. For example, the metals useful
for the invention can be a divalent metal ion. The metals that can
be used to associate the heavy chain and light chain include, but
not limited to, Ca.sup.2+, Mn.sup.2+, or Cu.sup.2+. Fatouros et
al., Intern. J. Pharm. 155(1): 121-131 (1997); Wakabayashi et al.,
JBC. 279(13): 12677-12684 (2004).
[0347] The long-acting FVIII polypeptide can comprise a sequence at
least 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, or 100%
identical to the Factor VIII and Fc amino acid sequence shown in
Table 36A(i) without a signal sequence (amino acids 20 to 1684 of
SEQ ID NO: 6) or at least 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%,
99%, or 100% identical to the Factor VIII and Fc amino acid
sequence shown in Table 36A(i) with a signal sequence (amino acids
1 to 1684 of SEQ ID NO: 6), wherein the sequence has Factor VIII
activity. The Factor VIII activity can be measured by activated
Partial Thromboplastin Time (aPPT) assay, chromogenic assay, or
other known methods. The chimeric polypeptide can comprise a
sequence identical to the Factor VIII and Fc amino acid sequence
shown in Table 36A(i) without a signal sequence (amino acids 20 to
1684 of SEQ ID NO: 6) or identical to the Factor VIII and Fc amino
acid sequence shown in Table 36A(i) with a signal sequence (amino
acids 1 to 1684 of SEQ ID NO: 6).
[0348] The Factor VIII polypeptide as used herein is functional
factor VIII polypeptide in its normal role in coagulation, unless
otherwise specified. Thus, the term Factor VIII includes variant
polypeptides that are functional. Factor VIII proteins can be the
human, porcine, canine, and murine factor VIII proteins. As
described in the Background Art section, the full length
polypeptide and polynucleotide sequences are known, as are many
functional fragments, mutants and modified versions. Examples of
human factor VIII sequences are shown as subsequences in SEQ ID
NOs: 6 or 10 (Table 36). Factor VIII polypeptides include, e.g.,
full-length factor VIII, full-length factor VIII minus Met at the
N-terminus, mature factor VIII (minus the signal sequence), mature
factor VIII with an additional Met at the N-terminus, and/or factor
VIII with a full or partial deletion of the B domain. Factor VIII
variants include B domain deletions, whether partial or full
deletions.
[0349] A great many functional factor VIII variants are known, as
is discussed above and below. In addition, hundreds of
nonfunctional mutations in factor VIII have been identified in
hemophilia patients, and it has been determined that the effect of
these mutations on factor VIII function is due more to where they
lie within the 3-dimensional structure of factor VIII than on the
nature of the substitution (Cutler et al., Hum. Mutat. 19:274-8
(2002)), incorporated herein by reference in its entirety. In
addition, comparisons between factor VIII from humans and other
species have identified conserved residues that are likely to be
required for function (Cameron et al., Thromb. Haemost. 79:317-22
(1998); U.S. Pat. No. 6,251,632), incorporated herein by reference
in its entirety.
[0350] The human factor VIII gene was isolated and expressed in
mammalian cells (Toole, J. J., et al., Nature 312:342-347 (1984);
Gitschier, J., et al., Nature 312:326-330 (1984); Wood, W. I., et
al., Nature 312:330-337 (1984); Vehar, G. A., et al., Nature
312:337-342 (1984); WO 87/04187; WO 88/08035; WO 88/03558; U.S.
Pat. No. 4,757,006), each of which is incorporated herein by
reference in its entirety, and the amino acid sequence was deduced
from cDNA. Capon et al., U.S. Pat. No. 4,965,199, incorporated
herein by reference in its entirety, discloses a recombinant DNA
method for producing factor VIII in mammalian host cells and
purification of human factor VIII. Human factor VIII expression in
CHO (Chinese hamster ovary) cells and BHK (baby hamster kidney
cells) has been reported. Human factor VIII has been modified to
delete part or all of the B domain (U.S. Pat. Nos. 4,994,371 and
4,868,112, each of which is incorporated herein by reference in its
entirety), and replacement of the human factor VIII B domain with
the human factor V B domain has been performed (U.S. Pat. No.
5,004,803, incorporated herein by reference in its entirety). The
cDNA sequence encoding human factor VIII and predicted amino acid
sequence are shown in SEQ ID NOs: 1 and 2, respectively, of US
Application Publ. No. 2005/0100990, incorporated herein by
reference in its entirety.
[0351] U.S. Pat. No. 5,859,204, Lollar, J. S., incorporated herein
by reference in its entirety, reports functional mutants of factor
VIII having reduced antigenicity and reduced immunoreactivity. U.S.
Pat. No. 6,376,463, Lollar, J. S., incorporated herein by reference
in its entirety, also reports mutants of factor VIII having reduced
immunoreactivity. US Application Publ. No. 2005/0100990, Saenko et
al., incorporated herein by reference in its entirety, reports
functional mutations in the A2 domain of factor VIII.
[0352] A number of functional factor VIII molecules, including
B-domain deletions, are disclosed in the following patents U.S.
Pat. Nos. 6,316,226 and 6,346,513, both assigned to Baxter; U.S.
Pat. No. 7,041,635 assigned to In2Gen; U.S. Pat. Nos. 5,789,203,
6,060,447, 5,595,886, and 6,228,620 assigned to Chiron; U.S. Pat.
Nos. 5,972,885 and 6,048,720 assigned to Biovitrum, U.S. Pat. Nos.
5,543,502 and 5,610,278 assigned to Novo Nordisk; U.S. Pat. No.
5,171,844 assigned to Immuno Ag; U.S. Pat. No. 5,112,950 assigned
to Transgene S. A.; U.S. Pat. No. 4,868,112 assigned to Genetics
Institute, each of which is incorporated herein by reference in its
entirety.
[0353] The porcine factor VIII sequence is published, (Toole, J.
J., et al., Proc. Natl. Acad. Sci. USA 83:5939-5942 (1986)),
incorporated herein by reference in its entirety, and the complete
porcine cDNA sequence obtained from PCR amplification of factor
VIII sequences from a pig spleen cDNA library has been reported
(Healey, J. F. et al., Blood 88:4209-4214 (1996), incorporated
herein by reference in its entirety). Hybrid human/porcine factor
VIII having substitutions of all domains, all subunits, and
specific amino acid sequences were disclosed in U.S. Pat. No.
5,364,771 by Lollar and Runge, and in WO 93/20093, incorporated
herein by reference in its entirety. More recently, the nucleotide
and corresponding amino acid sequences of the A1 and A2 domains of
porcine factor VIII and a chimeric factor VIII with porcine A1
and/or A2 domains substituted for the corresponding human domains
were reported in WO 94/11503, incorporated herein by reference in
its entirety. U.S. Pat. No. 5,859,204, Lollar, J. S., also
discloses the porcine cDNA and deduced amino acid sequences. U.S.
Pat. No. 6,458,563, incorporated herein by reference in its
entirety assigned to Emory discloses a B-domain deleted porcine
Factor VIII.
[0354] The Factor VIII (or Factor VIII portion of a chimeric
polypeptide) can be at least 60%, 70%, 80%, 90%, 95%, 96%, 97%,
98%, 99%, or 100% identical to a Factor VIII amino acid sequence
shown in Table 36 without a signal sequence (amino acids 20 to 1457
of SEQ ID NO: 6; and amino acids 20 to 2351 of SEQ ID NO: 10),
wherein the Factor VIII portion has Factor VIII activity. The
Factor VIII (or Factor VIII portion of a chimeric polypeptide) can
be identical to a Factor VIII amino acid sequence shown in Table 36
without a signal sequence (amino acids 20 to 1457 of SEQ ID NO: 6;
and amino acids 20 to 2351 of SEQ ID NO: 10).
[0355] The Factor VIII (or Factor VIII portion of a chimeric
polypeptide) can be at least 60%, 70%, 80%, 90%, 95%, 96%, 97%,
98%, 99%, or 100% identical to a Factor VIII amino acid sequence
shown in Table 36 with a signal sequence (amino acids 1 to 1457 of
SEQ ID NO: 6 and amino acids 1 to 2351 of SEQ ID NO: 10), wherein
the Factor VIII portion has Factor VIII activity. The Factor VIII
(or Factor VIII portion of a chimeric polypeptide) can be identical
to a Factor VIII amino acid sequence shown in Table 36 with a
signal sequence (amino acids 1 to 1457 of SEQ ID NO: 6 and amino
acids 1 to 2351 of SEQ ID NO: 10).
[0356] As stated above, polypeptide variants include, e.g.,
modified polypeptides. Modifications include, e.g., acetylation,
acylation, ADP-ribosylation, amidation, covalent attachment of
flavin, covalent attachment of a heme moiety, covalent attachment
of a nucleotide or nucleotide derivative, covalent attachment of a
lipid or lipid derivative, covalent attachment of
phosphotidylinositol, cross-linking, cyclization, disulfide bond
formation, demethylation, formation of covalent cross-links,
formation of cysteine, formation of pyroglutamate, formylation,
gamma-carboxylation, glycosylation, GPI anchor formation,
hydroxylation, iodination, methylation, myristoylation, oxidation,
pegylation (Mei et al., Blood 116:270-79 (2010), which is
incorporated herein by reference in its entirety), proteolytic
processing, phosphorylation, prenylation, racemization,
selenoylation, sulfation, transfer-RNA mediated addition of amino
acids to proteins such as arginylation, and ubiquitination. In some
embodiments, Factor VIII is modified, e.g., pegylated, at any
convenient location. In some embodiments, Factor VIII is pegylated
at a surface exposed amino acid of Factor VIII, e.g., a surface
exposed cysteine, which can be an engineered cysteine. Id.
[0357] The long-acting FVIII polypeptide used herein can comprise
processed Factor VIII or single chain Factor VIII or a combination
thereof "Processed Factor VIII," as used herein means Factor VIII
that has been cleaved at Arginine 1648 (for full-length Factor
VIII) or Arginine 754 (for B-domain deleted Factor VIII), i.e.,
intracellular processing site. Due to the cleavage at the
intracellular processing site, processed Factor VIII comprises two
polypeptide chains, the first chain being a heavy chain and the
second chain being a light chain. For example, the processed Factor
VIII-Fc fusion protein (i.e., Heavy chain and Light chain fused to
Fc) run at approximately 90 kDa and 130 kDa on a non-reducing
SDS-PAGE, respectively, and 90 kDa and 105 kDa on a reducing
SDS-PAGE, respectively. Therefore, in one embodiment, at least
about 50%, about 60%, about 70%, about 75%, about 80%, about 85%,
about 90%, about 95%, about 96%, about 97%, about 98%, about 99%,
or about 100% of the Factor VIII portion in the long-acting FVIII
polypeptide is processed Factor VIII. In another embodiment, about
50%, about 60%, about 70%, about 75%, about 80%, about 85%, about
90%, about 95%, about 96%, about 97%, about 98%, about 99%, or
about 100% of the Factor VIII portion in the long-acting FVIII
polypeptide is processed Factor VIII. In a particular embodiment,
the long-acting FVIII polypeptide comprising processed Factor VIII
is purified (or isolated) from the chimeric polypeptide comprising
single chain Factor VIII, and at least about 75%, about 80%, about
85%, about 90%, about 95%, about 96%, about 97%, about 98%, about
99%, or about 100% of the Factor VIII portion in the long-acting
FVIII polypeptide is processed Factor VIII. In some embodiments,
the long-acting FVIII polypeptide comprises about 15% to 25% of
single chain FVIII polypeptide and about 75% to about 85% of
processed FVIII polypeptide.
[0358] "Single chain Factor VIII," "SC Factor VIII," or "SCFVIII"
as used herein means Factor VIII that has not been cleaved at the
Arginine site (residue 1648 for full-length Factor VIII (i.e.,
residue 1667 of SEQ ID NO: 10) or residue 754 for B-domain deleted
Factor VIII (i.e., residue 773 of SEQ ID NO: 6). Therefore, single
chain Factor VIII in the long-acting FVIII polypeptide used herein
comprises a single chain. In one embodiment, the single chain
Factor VIII contains an intact intracellular processing site. In
another embodiment, the single chain Factor VIII of the invention
comprises a substitution or mutation at an amino acid position
corresponding to Arginine 1645, a substitution or mutation at an
amino acid position corresponding to Arginine 1648, or a
substitution or mutation at amino acid positions corresponding to
Arginine 1645 and Arginine 1648 in full-length Factor VIII. In
other embodiments, the amino acid substituted at the amino acid
position corresponding to Arginine 1645 is a different amino acid
from the amino acid substituted at the amino acid position
corresponding to Arginine 1648. In certain embodiments, the
substitution or mutation is an amino acid other than arginine,
e.g., isoleucine, leucine, lysine, methionine, phenylalanine,
threonine, tryptophan, valine, alanine, asparagine, aspartic acid,
cysteine, glutamic acid, glutamine, glycine, proline,
selenocysteine, serine, tyrosine, histidine, ornithine,
pyrrolysine, or taurine. The single chain Factor VIII-Fc fusion
protein can run at approximately 220 kDa on a non-reducing SDS-PAGE
and at approximately 195 kDa on a reducing SDS-PAGE.
[0359] The Factor VIII portion in the long-acting FVIII polypeptide
used herein has Factor VIII activity. Factor VIII activity can be
measured by any known methods in the art. For example, one of those
methods can be a chromogenic assay. The chromogenic assay mechanism
is based on the principles of the blood coagulation cascade, where
activated Factor VIII accelerates the conversion of Factor X into
Factor Xa in the presence of activated Factor IX, phospholipids and
calcium ions. The Factor Xa activity is assessed by hydrolysis of a
p-nitroanilide (pNA) substrate specific to Factor Xa. The initial
rate of release of p-nitroaniline measured at 405 nM is directly
proportional to the Factor Xa activity and thus to the Factor VIII
activity in the sample. The chromogenic assay is recommended by the
Factor VIII and Factor IX Subcommittee of the Scientific and
Standardization Committee (SSC) of the International Society on
Thrombosis and Hemostasis (ISTH). Since 1994, the chromogenic assay
has also been the reference method of the European Pharmacopoeia
for the assignment of FVIII concentrate potency. Thus, in one
embodiment, the long-acting FVIII polypeptide comprising single
chain Factor VIII has Factor VIII activity comparable to a
long-acting FVIII polypeptide comprising processed Factor VIII
(e.g., a chimeric polypeptide consisting essentially of or
consisting of two Fc portions and processed Factor VIII, wherein
said processed Factor VIII is fused to one of the two Fc portions),
when the Factor VIII activity is measured in vitro by a chromogenic
assay.
[0360] Second Portion
[0361] In some embodiments, the long-acting FIX or FVIII
polypeptide comprises a FIX or FVIII portion and a non-FIX portion
or a non-Factor VIII portion, respectively, e.g., a heterologous
moiety. In one embodiment, the heterologous moiety is capable of
extending in vivo or in vitro half-life of the FIX or FVIII
polypeptide. Exemplary non-FIX or FVIII portions include, e.g., Fc,
albumin, a PAS sequence, transferrin, CTP (28 amino acid C-terminal
peptide (CTP) of human chorionic gonadotropin (hCG) with its 4
O-glycans), polyethylene glycol (PEG), hydroxyethyl starch (HES),
albumin binding polypeptide, albumin-binding small molecules, or
any combination thereof. Exemplary long-acting FVIII polypeptides
of the invention include, e.g., Factor VIII-Fc polypeptides, Factor
VIII-albumin polypeptides, Factor VIII-PAS polypeptides, Factor
VIII-transferrin polypeptides, Factor VIII-CTP polypeptides, Factor
VIII-PEG polypeptides, Factor VIII-HES polypeptides, Factor
VIII-albumin binding polypeptide polypeptides, or Factor
VIII-albumin-binding small molecule polypeptides. Exemplary
long-acting FIX polypeptides of the invention include, e.g., Factor
IX-Fc polypeptides, Factor IX-albumin polypeptides, Factor IX-PAS
polypeptides, Factor IX-transferrin polypeptides, Factor IX-CTP
polypeptides, Factor IX-PEG polypeptides, Factor IX-HES
polypeptides, Factor IX-albumin binding polypeptide polypeptides,
or Factor IX-albumin-binding small molecule polypeptides.
[0362] In one embodiment, the second portion fused to FIX or FVIII
is an FcRn binding partner. In another embodiment, an FcRn binding
partner fused to FIX or FVIII is an Fc fragment. An FcRn binding
partner is any molecule that can be specifically bound by the FcRn
receptor with consequent active transport by the FcRn receptor of
the FcRn binding partner. Thus, the term Fc includes any variants
of IgG Fc that are functional. The region of the Fc portion of IgG
that binds to the FcRn receptor has been described based on X-ray
crystallography (Burmeister et al., Nature 372:379 (1994),
incorporated herein by reference in its entirety). The major
contact area of the Fc with the FcRn is near the junction of the
CH2 and CH3 domains. Fc-FcRn contacts are all within a single Ig
heavy chain. The FcRn binding partners include, e.g., whole IgG,
the Fc fragment of IgG, and other fragments of IgG that include the
complete binding region of FcRn. The major contact sites include
amino acid residues 248, 250-257, 272, 285, 288, 290-291, 308-311,
and 314 of the CH2 domain and amino acid residues 385-387, 428, and
433-436 of the CH3 domain. References made to amino acid numbering
of immunoglobulins or immunoglobulin fragments, or regions, are all
based on Kabat et al. 1991, Sequences of Proteins of Immunological
Interest, U. S. Department of Public Health, Bethesda; MD,
incorporated herein by reference in its entirety. (The FcRn
receptor has been isolated from several mammalian species including
humans. The sequences of the human FcRn, rat FcRn, and mouse FcRn
are known (Story et al., J. Exp. Med. 180: 2377 (1994),
incorporated herein by reference in its entirety.) An Fc can
comprise the CH2 and CH3 domains of an immunoglobulin with or
without the hinge region of the immunoglobulin. Exemplary Fc
variants are provided in WO 2004/101740 and WO 2006/074199,
incorporated herein by reference in its entirety.
[0363] Fc (or Fc portion of a chimeric polypeptide) can contain one
or more mutations, and combinations of mutations.
[0364] Fc (or Fc portion of a chimeric polypeptide) can contain
mutations conferring increased half-life such as M252Y, S254T,
T256E, and combinations thereof, as disclosed in Oganesyan et al.,
Mol. Immunol. 46:1750 (2009), which is incorporated herein by
reference in its entirety; H433K, N434F, and combinations thereof,
as disclosed in Vaccaro et al., Nat. Biotechnol. 23:1283 (2005),
which is incorporated herein by reference in its entirety; the
mutants disclosed at pages 1-2, paragraph [0012], and Examples 9
and 10 of US 2009/0264627 A1, which is incorporated herein by
reference in its entirety; and the mutants disclosed at page 2,
paragraphs [0014] to [0021] of US 20090163699 A1, which is
incorporated herein by reference in its entirety.
[0365] Fc (or Fc portion of a chimeric polypeptide) can also
include, e.g., the following mutations: The Fc region of IgG can be
modified according to well recognized procedures such as site
directed mutagenesis and the like to yield modified IgG or Fc
fragments or portions thereof that will be bound by FcRn. Such
modifications include, e.g., modifications remote from the FcRn
contact sites as well as modifications within the contact sites
that preserve or even enhance binding to the FcRn. For example the
following single amino acid residues in human IgG1 Fc (Fcy1) can be
substituted without significant loss of Fc binding affinity for
FcRn: P238A, S239A, K246A, K248A, D249A, M252A, T256A, E258A,
T260A, D265A, S267A, H268A, E269A, D270A, E272A, L274A, N276A,
Y278A, D280A, V282A, E283A, H285A, N286A, T289A, K290A, R292A,
E293A, E294A, Q295A, Y296F, N297A, S298A, Y300F, R301A, V303A,
V305A, T307A, L309A, Q311A, D312A, N315A, K317A, E318A, K320A,
K322A, S324A, K326A, A327Q, P329A, A330Q, A330S, P331A, P331S,
E333A, K334A, T335A, S337A, K338A, K340A, Q342A, R344A, E345A,
Q347A, R355A, E356A, M358A, T359A, K360A, N361A, Q362A, Y373A,
S375A D376A, A378Q, E380A, E382A, S383A, N384A, Q386A, E388A,
N389A, N390A, Y391F, K392A, L398A, S400A, D401A, D413A, K414A,
R416A, Q418A, Q419A, N421A, V422A, S424A, E430A, N434A, T437A,
Q438A, K439A, S440A, S444A, and K447A, where for example P238A
represents wildtype proline substituted by alanine at position
number 238. In addition to alanine other amino acids can be
substituted for the wildtype amino acids at the positions specified
above. Mutations can be introduced singly into Fc giving rise to
more than one hundred FcRn binding partners distinct from native
Fc. Additionally, combinations of two, three, or more of these
individual mutations can be introduced together, giving rise to
hundreds more FcRn binding partners. Certain of these mutations can
confer new functionality upon the FcRn binding partner. For
example, one embodiment incorporates N297A, removing a highly
conserved N-glycosylation site. The effect of this mutation is to
reduce immunogenicity, thereby enhancing circulating half-life of
the FcRn binding partner, and to render the FcRn binding partner
incapable of binding to FcyRI, FcyRIIA, FcyRIIB, and FcyRIIIA,
without compromising affinity for FcRn (Routledge et al. 1995,
Transplantation 60:847, which is incorporated herein by reference
in its entirety; Friend et al. 1999, Transplantation 68:1632, which
is incorporated herein by reference in its entirety; Shields et al.
1995, J. Biol. Chem. 276:6591, which is incorporated herein by
reference in its entirety). Additionally, at least three human Fc
gamma receptors appear to recognize a binding site on IgG within
the lower hinge region, generally amino acids 234-237. Therefore,
another example of new functionality and potential decreased
immunogenicity can arise from mutations of this region, as for
example by replacing amino acids 233-236 of human IgG1 "ELLG" to
the corresponding sequence from IgG2 "PVA" (with one amino acid
deletion). It has been shown that FcyRI, FcyRII, and FcyRIII which
mediate various effector functions will not bind to IgG1 when such
mutations have been introduced (Ward and Ghetie, Therapeutic
Immunology 2:77 (1995), which is incorporated herein by reference
in its entirety; and Armour et al., Eur. J. Immunol. 29:2613
(1999), which is incorporated herein by reference in its entirety).
As a further example of new functionality arising from mutations
described above affinity for FcRn can be increased beyond that of
wild type in some instances. This increased affinity can reflect an
increased "on" rate, a decreased "off" rate or both an increased
"on" rate and a decreased "off" rate. Mutations believed to impart
an increased affinity for FcRn include, e.g., T256A, T307A, E380A,
and N434A (Shields et al., J. Biol. Chem. 276:6591 (2001), which is
incorporated herein by reference in its entirety).
[0366] The Fc (or Fc portion of a chimeric polypeptide) can be at
least 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, or 100%
identical to the Fc amino acid sequence shown in Table 36 (amino
acids 1458 to 1684 of SEQ ID NO: 6 or amino acids 2352 to 2578 of
SEQ ID NO: 10). The Fc (or Fc portion of a chimeric polypeptide)
can be identical to the Fc amino acid sequence shown in Table 36
(amino acids 1458 to 1684 of SEQ ID NO: 6 and amino acids 2352 to
2578 of SEQ ID NO: 10).
[0367] As discussed above, exemplary long-acting polypeptides also
include FIX or FVIII fused to one or more albumin polypeptides,
albumin binding polypeptides, or albumin-binding small molecules.
In one embodiment, the albumin is human albumin. The albumin or
albumin binding protein can be fused to either the N-terminal end
of FIX or FVIII or to the C-terminal end of FIX or FVIII or
inserted between two amino acids in FIX or FVIII. Examples of
albumin, e.g., fragments thereof, that can be used in the present
invention are known. e.g., U.S. Pat. Nos. 7,592,010; 6,686,179; and
Schulte, Thrombosis Res. 124 Suppl. 2:S6-S8 (2009), each of which
is incorporated herein by reference in its entirety.
[0368] The albumin binding polypeptides can compromise, without
limitation, bacterial albumin-binding domains, albumin-binding
peptides, or albumin-binding antibody fragments that can bind to
albumin. Domain 3 from streptococcal protein G, as disclosed by
Kraulis et al., FEBS Lett. 378:190-194 (1996) and Linhult et al.,
Protein Sci. 11:206-213 (2002) is an example of a bacterial
albumin-binding domain. Examples of albumin-binding peptides
include a series of peptides having the core sequence DICLPRWGCLW
(SEQ ID NO: 12). See, e.g., Dennis et al., J. Biol. Chem. 2002,
277: 35035-35043 (2002). Examples of albumin-binding antibody
fragments are disclosed in Muller and Kontermann, Curr. Opin. Mol.
Ther. 9:319-326 (2007); Rooverset et al., Cancer Immunol.
Immunother. 56:303-317 (2007), and Holt et al., Prot. Eng. Design
Sci., 21:283-288 (2008), which are incorporated herein by reference
in their entireties.
[0369] In certain aspects, a recombinant FIX or FVIII polypeptide
of the invention comprises at least one attachment site for a
non-polypeptide small molecule, variant, or derivative that can
bind to albumin thereof. An example of such albumin binding
moieties is
2-(3-maleimidopropanamido)-6-(4-(4-iodophenyl)butanamido)hexanoate
("Albu" tag) as disclosed by Trusselet et al., Bioconjugate Chem.
20:2286-2292 (2009).
[0370] As discussed above, exemplary long-acting polypeptides also
include FIX or FVIII fused to at least one C-terminal peptide (CTP)
of the .beta. subunit of human chorionic gonadotropin or fragment,
variant, or derivative thereof. The CTP can be fused to FIX or
FVIII either the N-terminal end of FIX or FVIII or to the
C-terminal end of FIX or FVIII or inserted between two amino acids
in FIX or FVIII. One or more CTP peptides fused to or inserted into
a recombinant protein is known to increase the in vivo half-life of
that protein. See, e.g., U.S. Pat. No. 5,712,122, incorporated by
reference herein in its entirety. Exemplary CTP peptides include
DPRFQDSSSSKAPPPSLPSPSRLPGPSDTPIL (SEQ ID NO: 13) or
SSSSKAPPPSLPSPSRLPGPSDTPILPQ. (SEQ ID NO: 14). See, e.g., U.S.
Patent Application Publication No. US 2009/0087411 A1, incorporated
by reference.
[0371] As discussed above, exemplary long-acting polypeptides also
include FIX or FVIII fused to at least one PAS sequence or
fragment, variant, or derivative thereof. The PAS sequence can be
fused to either the N-terminal end of FIX or FVIII or to the
C-terminal end of FIX or FVIII or inserted between two amino acids
in FVIII. A PAS peptide or PAS sequence, as used herein, means an
amino acid sequence comprising mainly alanine and serine residues
or comprising mainly alanine, serine, and proline residues, the
amino acid sequence forming random coil conformation under
physiological conditions. Accordingly, the PAS sequence is a
building block, an amino acid polymer, or a sequence cassette
comprising, consisting essentially of, or consisting of alanine,
serine, and proline which can be used as a part of the heterologous
moiety in the chimeric protein. An amino acid polymer also can form
random coil conformation when residues other than alanine, serine,
and proline are added as a minor constituent in the PAS sequence.
By "minor constituent" is meant that that amino acids other than
alanine, serine, and proline can be added in the PAS sequence to a
certain degree, e.g., up to about 12%, i.e., about 12 of 100 amino
acids of the PAS sequence, up to about 10%, up to about 9%, up to
about 8%, about 6%, about 5%, about 4%, about 3%, i.e. about 2%, or
about 1%, of the amino acids. The amino acids different from
alanine, serine and proline can be selected from the group
consisting of Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu,
Lys, Met, Phe, Thr, Trp, Tyr, and Val. Under physiological
conditions, a PAS peptide forms a random coil conformation and
thereby can mediate an increased in vivo and/or in vitro stability
to a recombinant protein of the invention, and has procoagulant
activity.
[0372] Non-limiting examples of the PAS peptides include
ASPAAPAPASPAAPAPSAPA (SEQ ID NO: 15), AAPASPAPAAPSAPAPAAPS (SEQ ID
NO: 16), APSSPSPSAPSSPSPASPSS (SEQ ID NO: 17), APSSPSPSAPSSPSPASPS
(SEQ ID NO: 18), SSPSAPSPSSPASPSPSSPA (SEQ ID NO: 19),
AASPAAPSAPPAAASPAAPSAPPA (SEQ ID NO: 20), ASAAAPAAASAAASAPSAAA (SEQ
ID NO: 21) or any variants, derivatives, fragments, or combinations
thereof. Additional examples of PAS sequences are known from, e.g.,
US Pat. Publ. No. 2010/0292130 A1 and PCT Appl. Publ. No. WO
2008/155134 A1. European issued patent EP2173890.
[0373] As discussed above, exemplary long-acting polypeptides also
include FIX or FVIII fused to at least one transferrin peptide or
fragment, variant, or derivative thereof. At least one transferrin
peptide can be fused to either the N-terminal end of FIX or FVIII
or to the C-terminal end of FIX or FVIII or inserted between two
amino acids in FIX or FVIII. Any transferrin can be fused to or
inserted into a recombinant FIX or FVIII protein of the invention.
As an example, wild-type human Tf (Tf) is a 679 amino acid protein,
of approximately 75 KDa (not accounting for glycosylation), with
two main domains, N (about 330 amino acids) and C (about 340 amino
acids), which appear to originate from a gene duplication. See
GenBank accession numbers NM001063, XM002793, M12530, XM039845, XM
039847 and S95936 (www.ncbi.nlm.nih.gov), all of which are herein
incorporated by reference in their entirety.
[0374] Transferrin transports iron through transferrin receptor
(TfR)-mediated endocytosis. After the iron is released into an
endosomal compartment and Tf-TfR complex is recycled to cell
surface, the Tf is released back extracellular space for next cycle
of iron transporting. Tf possesses a long half-life that is in
excess of 14-17 days (Li et al., Trends Pharmacol. Sci. 23:206-209
(2002)). Transferrin fusion proteins have been studied for
half-life extension, targeted deliver for cancer therapies, oral
delivery and sustained activation of proinsulin (Brandsma et al.,
Biotechnol. Adv., 29: 230-238 (2011); Bai et al., Proc. Natl. Acad.
Sci. USA 102:7292-7296 (2005); Kim et al., J. Pharmacol. Exp.
Ther., 334:682-692 (2010); Wang et al., J. Controlled Release
155:386-392 (2011)).
[0375] As discussed above, exemplary long-acting polypeptides also
include FIX or FVIII fused to at least one polyethylene glycol
(PEG) moieties.
[0376] PEGylated FVIII can refer to a conjugate formed between FIX
or FVIII and at least one polyethylene glycol (PEG) molecule. PEG
is commercially available in a large variety of molecular weights
and average molecular weight ranges. Typical examples of PEG
average molecular weight ranges include, but are not limited to,
about 200, about 300, about 400, about 600, about 1000, about
1300-1600, about 1450, about 2000, about 3000, about 3000-3750,
about 3350, about 3000-7000, about 3500-4500, about 5000-7000,
about 7000-9000, about 8000, about 10000, about 8500-11500, about
16000-24000, about 35000, about 40000, about 60000, and about 80000
daltons. These average molecular weights are provided merely as
examples and are not meant to be limiting in any way.
[0377] A recombinant long-acting FIX or FVIII protein of the
invention can be PEGylated to include mono- or poly (e.g., 2-4) PEG
moieties. PEGylation can be carried out by any of the PEGylation
reactions known in the art. Methods for preparing a PEGylated
protein product will generally include (i) reacting a polypeptide
with polyethylene glycol (such as a reactive ester or aldehyde
derivative of PEG) under conditions whereby the peptide of the
invention becomes attached to one or more PEG groups; and (ii)
obtaining the reaction product(s). In general, the optimal reaction
conditions for the reactions will be determined case by case based
on known parameters and the desired result.
[0378] There are a number of PEG attachment methods available to
those skilled in the art, for example Malik F et al., Exp. Hematol.
20:1028-35 (1992); Francis, Focus on Growth Factors 3(2):4-10
(1992); European Pat. Pub. Nos. EP0401384, EP0154316, and
EP0401384; and International Pat. Appl. Pub. Nos. WO92/16221 and
WO95/34326. As a non-limiting example, FIX or FVIII variants can
contain cysteine substitutions in one or more insertion sites in
FIX or FVIII, and the cysteines can be further conjugated to PEG
polymer. See Mei et al., Blood 116:270-279 (2010) and U.S. Pat. No.
7,632,921, which are incorporated herein by reference in their
entireties.
[0379] As discussed above, exemplary long-acting polypeptides also
include FIX or FVIII fused to at least one hydroxyethyl starch
(HES) polymer. HES is a derivative of naturally occurring
amylopectin and is degraded by alpha-amylase in the body. HES
exhibits advantageous biological properties and is used as a blood
volume replacement agent and in hemodilution therapy in the
clinics. See, e.g., Sommermeyer et al., Krankenhauspharmazie
8:271-278 (1987); and Weidler et al., Arzneim.-Forschung/Drug Res.
41: 494-498 (1991).
[0380] HES is mainly characterized by the molecular weight
distribution and the degree of substitution. HES has a mean
molecular weight (weight mean) of from 1 to 300 kD, from 2 to 200
kD, from 3 to 100 kD, or from 4 to 70 kD. Hydroxyethyl starch can
further exhibit a molar degree of substitution of from 0.1 to 3,
from 0.1 to 2, from 0.1 to 0.9, or from 0.1 to 0.8, and a ratio
between C2:C6 substitution in the range of from 2 to 20 with
respect to the hydroxyethyl groups. HES with a mean molecular
weight of about 130 kD is VOLUVEN.RTM. from Fresenius. VOLUVEN.RTM.
is an artificial colloid, employed, e.g., for volume replacement
used in the therapeutic indication for therapy and prophylaxis of
hypovolaemia. There are a number of HES attachment methods
available to those skilled in the art, e.g., the same PEG
attachment methods described above.
[0381] Pharmaceutical Composition
[0382] A long-acting FIX polypeptide or a long-acting FVIII
polypeptide can be formulated as a pharmaceutical composition. The
pharmaceutical composition can be formulated for administration to
humans. The pharmaceutical compositions used in the methods of this
invention comprise pharmaceutically acceptable carriers, including,
e.g., ion exchangers, alumina, aluminum stearate, lecithin, serum
proteins, such as human serum albumin, buffer substances such as
phosphates, glycine, sorbic acid, potassium sorbate, partial
glyceride mixtures of saturated vegetable fatty acids, water, salts
or electrolytes, such as protamine sulfate, disodium hydrogen
phosphate, potassium hydrogen phosphate, sodium chloride, zinc
salts, colloidal silica, magnesium trisilicate, polyvinyl
pyrrolidone, cellulose-based substances, polyethylene glycol,
sodium carboxymethylcellulose, polyacrylates, waxes,
polyethylene-polyoxypropylene-block polymers, polyethylene glycol
and wool fat. Various methods of formulating the invention is well
known in the art.
[0383] A long-acting FIX polypeptide or a long-acting FVIII
polypeptide can be formulated as a pharmaceutical composition or
formulation. In certain formulations provided herein, a long-acting
FIX polypeptide or a long-acting FVIII polypeptide is formulated as
a sterile, preservative-free, non-pyrogenic, lyophilized, white to
off-white powder to cake, for intravenous (IV) administration. The
formulation can be provided in a single-use vial.
[0384] In certain embodiments the first container of a
pharmaceutical kit provided herein is a glass vial comprising a
rubber stopper. In certain embodiments, the second container a
pharmaceutical kit provided herein is a syringe body, associated
with a plunger. In certain embodiments, the syringe is a pre-filled
syringe containing the diluent. In certain embodiments, a
pharmaceutical kit provided herein further comprises an adaptor to
connect the glass vial to the syringe body. In certain embodiments
a pharmaceutical kit provided herein further comprises infusion
tubing associated with a needle to be connected to the syringe,
suitable for intravenous infusion.
[0385] In certain embodiments, a desired dose of a long-acting FIX
polypeptide or a long-acting FVIII polypeptide can be achieved
through the use of one pharmaceutical kit as provided herein. In
certain embodiments, more than one pharmaceutical kit can be used
to achieve a desired dose. Provided herein is a method of combining
or pooling the formulations contained in two or more pharmaceutical
kits as provided herein in order to achieve a desired dose.
[0386] The pharmaceutical composition of the invention can be
formulated as a liquid formulation, lyophilized powder, or
suspension. A container comprising the pharmaceutical compositions
can be a vial, a cartridge, or a syringe. In a particular
embodiment, a syringe comprising the pharmaceutical composition is
a dual chamber syringe.
[0387] In certain embodiments, the pharmaceutical composition of
the invention or the reconstitution solution for the lyophilized
powder comprises a preservative in an amount sufficient to provide
antimicrobial activity. Pharmaceutically acceptable preservatives
that are useful for pharmaceutical composition are well known in
the art. For example, examples of the pharmaceutically acceptable
preservatives include, but are not limited to, phenol, m-cresol,
benzyl alcohol, chlorobutanol, methyl paraben, propylparaben,
phenoxyethanol, any other pharmaceutically acceptable preservative,
and any combinations thereof. In a particular embodiment, the
preservative is benzyl alcohol. In some embodiments, the
pharmaceutical composition comprises benzyl alcohol at a
concentration between 0.5% and 0.9%.
[0388] Having now described the present invention in detail, the
same will be more clearly understood by reference to the following
examples, which are included herewith for purposes of illustration
only and are not intended to be limiting of the invention. All
patents and publications referred to herein are expressly
incorporated by reference.
EXAMPLES
Example 1. Product Description
[0389] rFIXFc is a long-acting, fully recombinant fusion protein
consisting of human coagulation Factor IX (FIX) covalently linked
to the Fc domain of human immunoglobulin G1 (IgG1). The Factor IX
portion of rFIXFc has a primary amino acid sequence that is
identical to the Thr.sup.148 allelic form of plasma derived Factor
IX and has structural and functional characteristics similar to
endogenous Factor IX. The Fc domain of rFIXFc contains the hinge,
CH2 and CH3 regions of IgG1. rFIXFc contains 869 amino acids with a
molecular weight of approximately 98 kilodaltons.
[0390] rFIXFc is produced by recombinant DNA technology in a human
embryonic kidney (HEK) cell line, which has been extensively
characterized. The cell line expresses rFIXFc into a defined cell
culture medium that does not contain any proteins derived from
animal or human sources. rFIXFc is purified by a series of
chromatography steps that does not require use of a monoclonal
antibody. The process includes multiple viral clearance steps
including 15 nm virus-retaining nano-filtration. No human or animal
additives are used in the cell culture, purification, and
formulation processes.
Example 2: Dosage and Method of Administration/Method of
Calculating Initial Estimated Dose
[0391] rFIXFc is long-acting anti-hemophilic factor (recombinant)
indicated in adults and children (.gtoreq.12 years) with hemophilia
B (congenital Factor IX deficiency) for, e.g., control and
prevention of bleeding episodes, routine prophylaxis to prevent or
reduce the frequency of bleeding episodes, and perioperative
management (surgical prophylaxis).
[0392] Dosing of rFIXFc, formulated as described in Example 1, can
be estimated as described in this example, but can also be
determined by standard tests such as FIX activity assays described
elsewhere herein.
[0393] 1 IU of rFIXFc per kg body weight is expected to increase
the circulating level of Factor IX by 1% [IU/dL]. rFIXFc has been
shown to have a prolonged circulating half-life.
[0394] No dose adjustment for recovery is generally required. Since
subjects can vary in their pharmacokinetic (e.g., half-life, in
vivo recovery) and clinical responses to rFIXFc, the expected in
vivo peak increase in Factor IX level expressed as IU/dL (or % of
normal) or the required dose can be estimated using the following
formulas:
IU/dL (or % of normal)=[Total Dose (IU)/body weight
(kg)].times.recovery (IU/dL per IU/kg) (D)
OR
Dose (IU)=body weight (kg).times.Desired Factor IX Rise (IU/dL or %
of normal).times.reciprocal of recovery (IU/kg per IU/dL) (E)
[0395] The following table (Table 1) can be used to guide dosing in
bleeding episodes:
TABLE-US-00001 TABLE 1 Guide to rFIXFc Dosing for Treatment of
Bleeding Factor IX Level Required Dose (IU/dL or %
(IU/kg)/Frequency Severity of Bleed of normal) of Doses (hrs) Minor
and Moderate 30-60 30-60 IU/kg For example: joint, Repeat every 48
hours if superficial muscle/no there is further evidence of
neurovascular compromise bleeding (except iliopsoas), superficial
soft tissue, mucous membranes Major 80-120 For repeat dosing,
follow For example: iliopsoas and guidelines for major deep muscle
with surgery [see Table 2] neurovascular injury, or substantial
blood loss, retroperitoneum, CNS Adapted from: Roberts and Eberst,
WFH 2008, and WFH 2012
[0396] Subsequent dosage and duration of treatment depends on the
individual clinical response, the severity of the Factor IX
deficiency, and the location and extent of bleeding.
[0397] The following table (Table 2) can be used to guide dosing
for and perioperative management (surgical prophylaxis):
TABLE-US-00002 TABLE 2 Guide to rFIXFc Dosing for Perioperative
Management (Surgical Prophylaxis)* Initial Factor IX Level Required
Dose (IU/dL or % (IU/kg)/Frequency Type of Surgery of normal) of
Doses (hrs) Minor 50 to 80 50-80 IU/kg Minor operations A single
infusion may be including sufficient. Repeat as needed
uncomplicated after 24-48 hours. dental extraction Major 60 to 120
100 IU/kg (initial dose) (initial level) A repeat dose at 80 IU/kg
Days 1-3: should be considered after 6-10 maintain level hours and
then every 24 hours 40-60% for the first 3 days. Days 4-6: Based on
the long half-life of maintain level rFIXFc, the dose may be 30-50%
reduced and frequency of Days 7-14: dosing in the post-surgical
maintain level setting may be extended after 20-40% day 3 to every
48 hours. Adapted from: Roberts and Eberst, WFH 2008, and WFH 2012
*See Pharmacokinetics (Example 5 below)
[0398] For routine prophylaxis, the recommended starting regimens
are either: 50 IU/kg once weekly, or 100 IU/kg once every 10-14
days. Either regimen can be adjusted based on subject response.
[0399] rFIXFc is contraindicated in subjects who have manifested
severe hypersensitivity reactions, including anaphylaxis, to the
product or its components.
[0400] The clinical response to rFIXFc may vary. If bleeding is not
controlled with the recommended dose, the plasma level of Factor IX
can be determined, and a sufficient dose of rFIXFc can be
administered to achieve a satisfactory clinical response. If the
subject's plasma Factor IX level fails to increase as expected or
if bleeding is not controlled after rFIXFc administration, the
subject's plasma can be tested for the presence of an inhibitor,
e.g., neutralizing antibodies. Subjects using rFIXFc can be
monitored for the development of Factor IX inhibitors by
appropriate clinical observations and laboratory tests known to
those of ordinary skill in the art.
[0401] Subject's plasma can be monitored for Factor IX activity
levels by performing, e.g., the one-stage clotting assay to confirm
adequate Factor IX levels have been achieved and maintained, when
clinically indicated. Subject's plasma can further be monitored for
the development of Factor IX inhibitors.
Example 3. The Clinical Implications of Population Pharmacokinetics
of rFIXFc in Routine Prophylaxis, Control of Bleeding and
Perioperative Management for Hemophilia B Subjects
[0402] BACKGROUND: Clinical dosing of factor IX (FIX) in treatment
of hemophilia B is well established based on empirical practice and
clinical outcomes. Since pharmacokinetics (PK) of FIX activity is
the surrogate efficacy marker, we utilized population PK (popPK)
modeling and simulation to evaluate dosing regimens of long-acting
recombinant FIX Fc fusion protein (rFIXFc). The PK of rFIXFc, from
135 single-dose and 21 repeat-dose profiles in subjects .gtoreq.12
years old (body weight (BW): 45-186.7 kg), was best described by a
3-compartmental model, which showed modest inter-individual
variability (IIV) of 17.7% for clearance (CL) and 21.7% for volume
of central compartment (V1). The proportional residue error of
10.6% approximates the variability of the one-stage clotting assay
for FIX activity. The only covariate that showed a weak association
with rFIXFc PK is BW, which accounted for .about.3% of IIV for CL
and V1, suggesting that BW-independent flat dosing of rFIXFc may be
feasible for treating adult hemophilia B subjects.
[0403] AIMS: To simulate the BW-based and flat dosing regimens for
routine prophylaxis, control of bleeding and perioperative
management in the hemophilia B population.
[0404] METHOD: The validated 3-compartmental popPK model, including
inter-occasion variability and BW as the covariate on CL and V1,
was used for dosing simulations. For BW-based dosing regimen, PK
profiles were simulated for 1000 subjects with BW distribution
representative of the phase 3 study. BW distribution was simulated
using a power function Z=BW-0.5. The generated BW (1000 values)
distribution has a median of 74.9 kg and a range of 38.9 to 172.6
kg, which is similar to our studies (median, 73.3 kg; min and max,
45 and 186.7 kg). For fixed dosing regimen, three populations
(n=1000 each) were stratified based on low (.ltoreq.10th
percentile), typical (10th-90th percentile) and high (.gtoreq.90th
percentile) BW. Variability of exposure parameters, percentage of
population maintaining target Cmax and trough, and deviations of
median exposure parameters in extreme BW groups were compared with
BW-based and flat dosing regimens. To simulate steady-state in
prophylaxis regimen, six doses were applied for all dosing regimens
(once weekly, every 10 days, or every 14 days), with each dosing
interval assigned as one occasion. To simulate the PK profile
following an episodic treatment, a single dose was applied.
[0405] RESULT: Consistent with the observations from the phase 3
study, popPK simulation of 50 IU/kg once weekly or 100 IU/kg every
10-14 days predicted peak FIX activity within the physiologic range
(Cmax <150%) and trough .gtoreq.1% in majority of the
population. All simulated regimens predicted that the majority of
the population will maintain trough activity at or above 1% (Table
3).
TABLE-US-00003 TABLE 3 Predicted percentage of population with
steady-state trough at or above 1% for various prophylaxis dosing
regimens % of population Regimen Total weekly dose with trough
.gtoreq.1% 50 IU/kg weekly 50 95.4 100 IU/kg weekly 100 99.6 100
IU/kg every 10 days 70 89.2 100 IU/kg every 14 days 50 52.8
[0406] A plot showing a population simulation of steady-state FIX
activity vs. time is shown in FIG. 11. Table 4 shows the predicted
steady state FIX activity over the course of 14 days for two dosing
regimens: 50 IU/kg weekly and 100 IU/kg every 14 days.
TABLE-US-00004 TABLE 4 Predicted steady state FIX activity EOI Day
1 Day 3 Day 5 Day 7 Day 10 Day 14 median median median median
median median median [5th, [5th, [5th, [5th, [5th, [5th, [5th,
Dose, IU/kg 95th] 95th] 95th] 95th] 95th] 95th] 95th] 50 IU/kg
weekly 52.6 16.9 7.17 4.16 2.67 NA NA [32.1, [11.2, [3.85, [1.93,
[1.02, 89.3] 26.1] 12.3] 7.83] 5.49] 100 102 30.0 12.0 6.78 4.28
2.29 1.07 100 IU/kg [60.0, [19.6, [6.62, [3.24, [1.82, [0.688,
[0.0758, every 14 days 166] 46.7] 19.9] 12.2] 8.06] 5.33] 3.23]
[0407] Furthermore, BW-based and flat dosing resulted in comparable
PK profiles with comparable exposure parameters, e.g., 50 IU/kg and
4000 IU once weekly predicted a median (5th, 95th percentile) Cmax
of 52.6 (32.1, 89.3) IU/dL and 56.1 (36.2, 90.9) IU/dL,
respectively. Both dosing regimens predicted that >95% of the
population maintains Cmax <150% and trough .gtoreq.1% (FIG. 12).
However, BW-based and flat dosing showed differential effects on
the exposure parameters in extreme (.ltoreq.10th or .gtoreq.90th
percentile) BW populations. This suggests that BW-independent flat
dosing may be feasible for patients 12 years and older.
[0408] The popPK model was used to simulate dosing regimens for
episodic treatment. The model predicts that for the control of
bleeding episodes, a single dose of 50 or 100 IU/kg of rFIXFc is
sufficient to maintain the plasma FIX peak activity levels at 40 to
80 IU/dL (Table 5) as recommended by the World Federation of
Hemophilia (WFH) guidelines.
TABLE-US-00005 TABLE 5 Predicted FIX activity profile after a
single dose of rFIXFc in the 5th to 95th percentile of the
population rFIXFc dose, median [5th, 95th] 50 IU/kg 100 IU/kg End
of infusion 50.8 [30.4, 84.5] 102 [60.8, 169] 12 hours 21.1 [13.5,
33.6] 42.3 [26.8, 67.3] 24 hours (day 1) 14.8 [9.78, 22.7] 29.5
[19.6, 45.5] 36 hours 10.9 [6.79, 17.1] 21.8 [13.7, 34.1] 48 hours
(day 2) 8.51 [5.14, 13.2] 17.0 [10.5, 26.6] 72 hours (day 3) 5.57
[3.05, 9.27] 11.1 [6.22, 18.5] Day 5 3.07 [1.44, 5.62] 6.14 [3.05,
11.0] Day 7 1.93 [0.795, 3.71] 3.88 [1.82, 7.28] Day 10 1.1 [0.277,
2.33] 2.19 [0.775, 4.56] Day 14 0.559 [0, 1.38] 1.08 [0.125,
2.58]
[0409] Analysis of 12 major surgeries and 2 minor surgeries found
that the FIX activities measured during the perioperative period
were largely consistent with the prediction by popPK based on
subjects' pre-surgery baseline PK, indicating no substantial factor
consumption in these surgeries. A representative plot of observed
and predicted perioperative FIX activity is shown in FIG. 10.
Simulated and observed FIX activities were compared within the
first 21 days after the first rFIXFc surgical dose (n=14; 12 major
surgeries, 2 minor surgeries). There was good correlation between
the observed FIX activity data and that predicted by the PK model
(relative prediction error [95% CI], 0.332% [-2.08%, 1.42%]).
[0410] CONCLUSION: PopPK provides a robust and effective means to
evaluate potential dosing regimens. The predictions by popPK
simulation for rFIXFc corroborate the results from the phase 3
study. The simulations of BW-based and flat dosing of rFIXFc
achieved similar PK profiles. Considering the wide therapeutic
range for factor replacement therapy, flat dosing of rFIXFc and
rFIX products may be a potentially viable approach in adult
hemophilia B subjects that warrants further clinical investigation.
Furthermore, using a population PK model, it is feasible to develop
a general dosing guidance to achieve target FIX levels recommended
for perioperative management in patients with hemophilia B.
Example 4. Population Pharmacokinetic Analysis of a Long-Acting
Recombinant Factor IX-Fc Fusion Protein (rFIXFc) in Subjects with
Severe Hemophilia B
[0411] BACKGROUND: Clinical dosing of factor IX (FIX) in treatment
of hemophilia B is well established based on empirical practice and
clinical outcomes. Since pharmacokinetics (PK) of FIX activity is
the surrogate efficacy marker, we utilized population PK (popPK)
modeling and simulation to evaluate dosing regimens of long-acting
recombinant FIX Fc fusion protein (rFIXFc). The PK of rFIXFc, from
135 single-dose and 21 repeat-dose profiles in subjects .gtoreq.12
years old (body weight (BW): 45-186.7 kg), was best described by a
3-compartmental model, which showed modest inter-individual
variability (IIV) of 17.7% for clearance (CL) and 21.7% for volume
of central compartment (V1). The proportional residue error of
10.6% approximates the variability of the one-stage clotting assay
for FIX activity. The only covariate that showed a weak association
with rFIXFc PK is BW, which accounted for .about.3% of IIV for CL
and V1, suggesting that BW-independent flat dosing of rFIXFc may be
feasible for treating adult hemophilia B subjects.
[0412] AIMS: To simulate the BW-based and flat dosing regimens for
routine prophylaxis, control of bleeding and perioperative
management in the hemophilia B population.
[0413] METHOD: The validated 3-compartmental popPK model, including
inter-occasion variability and BW as the covariate on CL and V1,
was used for dosing simulations. For BW-based dosing regimen, PK
profiles were simulated for 1000 subjects with BW distribution
representative of the phase 3 study. BW distribution was simulated
using a power function Z=BW-0.5. The generated BW (1000 values)
distribution has a median of 74.9 kg and a range of 38.9 to 172.6
kg, which is similar to our studies (median, 73.3 kg; min and max,
45 and 186.7 kg). For fixed dosing regimen, three populations
(n=1000 each) were stratified based on low (.ltoreq.10th
percentile), typical (10th-90th percentile) and high (>90th
percentile) BW. Variability of exposure parameters, percentage of
population maintaining target Cmax and trough, and deviations of
median exposure parameters in extreme BW groups were compared with
BW-based and flat dosing regimens. To simulate steady-state in
prophylaxis regimen, six doses were applied for all dosing regimens
(once weekly, every 10 days, or every 14 days), with each dosing
interval assigned as one occasion. To simulate the PK profile
following an episodic treatment, a single dose was applied.
[0414] RESULT: Consistent with the observations from the phase 3
study, popPK simulation of 50 IU/kg once weekly or 100 IU/kg every
10-14 days predicted peak FIX activity within the physiologic range
(Cmax <150%) and trough .gtoreq.1% in majority of the
population. All simulated regimens predicted that the majority of
the population will maintain trough activity at or above 1% (Table
6).
TABLE-US-00006 TABLE 6 Predicted percentage of population with
steady-state trough at or above 1% for various prophylaxis dosing
regimens % of population Regimen Total weekly dose with trough
.gtoreq.1% 50 IU/kg weekly 50 95.4 100 IU/kg weekly 100 99.6 100
IU/kg every 10 days 70 89.2 100 IU/kg every 14 days 50 52.8
[0415] A plot showing a population simulation of steady-state FIX
activity vs. time is shown in FIG. 11. Table 7 shows the predicted
steady state FIX activity over the course of 14 days for two dosing
regimens: 50 IU/kg weekly and 100 IU/kg every 14 days.
TABLE-US-00007 TABLE 7 Predicted steady state FIX activity EOI Day
1 Day 3 Day 5 Day 7 Day 10 Day 14 median median median median
median median median [5th, [5th, [5th, [5th, [5th, [5th, [5th,
Dose, IU/kg 95th] 95th] 95th] 95th] 95th] 95th] 95th] 50 IU/kg
weekly 52.6 16.9 7.17 4.16 2.67 NA NA [32.1, [11.2, [3.85, [1.93,
[1.02, 89.3] 26.1] 12.3] 7.83] 5.49] 100 102 30.0 12.0 6.78 4.28
2.29 1.07 100 IU/kg [60.0, [19.6, [6.62, [3.24, [1.82, [0.688,
[0.0758, every 14 days 166] 46.7] 19.9] 12.2] 8.06] 5.33] 3.23]
[0416] Furthermore, BW-based and flat dosing resulted in comparable
PK profiles with comparable exposure parameters, e.g., 50 IU/kg and
4000 IU once weekly predicted a median (5th, 95th percentile) Cmax
of 52.6 (32.1, 89.3) IU/dL and 56.1 (36.2, 90.9) IU/dL,
respectively. Both dosing regimens predicted that >95% of the
population maintains Cmax <150% and trough .gtoreq.1% (FIG. 12).
However, BW-based and flat dosing showed differential effects on
the exposure parameters in extreme (.ltoreq.10th or 90th
percentile) BW populations. This suggests that BW-independent flat
dosing may be feasible for patients 12 years and older.
[0417] The popPK model was used to simulate dosing regimens for
episodic treatment. The model predicts that for the control of
bleeding episodes, a single dose of 50 or 100 IU/kg of rFIXFc is
sufficient to maintain the plasma FIX peak activity levels at 40 to
80 IU/dL (Table 8) as recommended by the World Federation of
Hemophilia (WFH) guidelines.
TABLE-US-00008 TABLE 8 Predicted FIX activity profile after a
single dose of rFIXFc in the 5th to 95th percentile of the
population rFIXFc dose, median [5th, 95th] 50 IU/kg 100 IU/kg End
of infusion 50.8 [30.4, 84.5] 102 [60.8, 169] 12 hours 21.1 [13.5,
33.6] 42.3 [26.8, 67.3] 24 hours (day 1) 14.8 [9.78, 22.7] 29.5
[19.6, 45.5] 36 hours 10.9 [6.79, 17.1] 21.8 [13.7, 34.1] 48 hours
(day 2) 8.51 [5.14, 13.2] 17.0 [10.5, 26.6] 72 hours (day 3) 5.57
[3.05, 9.27] 11.1 [6.22, 18.5] Day 5 3.07 [1.44, 5.62] 6.14 [3.05,
11.0] Day 7 1.93 [0.795, 3.71] 3.88 [1.82, 7.28] Day 10 1.1 [0.277,
2.33] 2.19 [0.775, 4.56] Day 14 0.559 [0, 1.38] 1.08 [0.125,
2.58]
[0418] Analysis of 12 major surgeries and 2 minor surgeries found
that the FIX activities measured during the perioperative period
were largely consistent with the prediction by popPK based on
subjects' pre-surgery baseline PK, indicating no substantial factor
consumption in these surgeries. A representative plot of observed
and predicted perioperative FIX activity is shown in FIG. 10.
Simulated and observed FIX activities were compared within the
first 21 days after the first rFIXFc surgical dose (n=14; 12 major
surgeries, 2 minor surgeries). There was good correlation between
the observed FIX activity data and that predicted by the PK model
(relative prediction error [95% CI], 0.332% [-2.08%, 1.42%]).
[0419] CONCLUSION: PopPK provides a robust and effective means to
evaluate potential dosing regimens. The predictions by popPK
simulation for rFIXFc corroborate the results from the phase 3
study. The simulations of BW-based and flat dosing of rFIXFc
achieved similar PK profiles. Considering the wide therapeutic
range for factor replacement therapy, flat dosing of rFIXFc and
rFIX products may be a potentially viable approach in adult
hemophilia B subjects that warrants further clinical investigation.
Furthermore, using a population PK model, it is feasible to develop
a general dosing guidance to achieve target FIX levels recommended
for perioperative management in patients with hemophilia B.
Example 5. Population Pharmacokinetic Analysis of a Long-Acting
Recombinant Factor IX-Fc Fusion Protein (rFIXFc) in Subjects with
Severe Hemophilia B
[0420] BACKGROUND: Population pharmacokinetic (PK) models are
developed to understand the sources of variability in dose
requirements (covariates) and to help individualize dosing regimens
if necessary. Dosing histories and subject-specific data are used
to gain an understanding of drug disposition in order to discern
specific demographic and/or clinical factors that may be predictors
of PK parameters. By characterizing the population PK (popPK) of
long-acting FIX-Fc (rFIXFc) in subjects with severe hemophilia B
(.ltoreq.2 IU/dL plasma FIX activity), a model of estimated
population PK parameters of rFIXFc can be established. This model
may assist physicians who wish to tailor dosing for individual
subjects with sparse PK samples.
[0421] METHODS: Male subjects with severe hemophilia B were
included from a phase 1/2a study (n=12) and the phase 3 study
(B-LONG, n=123) described above. The subjects ranged in age from 12
to 76 years and in body weight from 45 to 186 kg. The modeling
dataset included 135 baseline PK profiles at Week 1, as well as 21
repeat PK profiles at Week 26, with a total of 1400 measured FIX
activity records. The final population PK model was validated using
1027 trough/peak FIX activity records from 119 subjects.
[0422] In the popPK analysis, plasma FIX activity was measured by
the one-stage (activated partial thromboplastin time) clotting
assay. Corrected FIX activity was calculated using the formula:
Corrected FIX activity=Measured FIX activity-Baseline-Residual
decay. (F)
[0423] Baseline FIX activity was defined as the lowest level of
activity (LLACT) recorded at screening, predose, postdose, or from
historical clinical records. When the baseline is equal to 0, the
LLACT is less than 1% (lower limit of quantification). When the
baseline FIX activity is equal to LLACT, LLACT is greater than or
equal to 1% and less than or equal to 2%.
[0424] Prestudy residual decay was performed using terminal
half-life obtained from a noncompartmental analysis of the
individual data by the following formula:
Residual decay=(predose-baseline).times.e.sup.-decay
rate.times.time. (G)
[0425] For the popPK model development, NONMEM VII version 1.0
(ICON Development Solutions, Ellicott City, Md.) was used. The
modeling and qualification steps are presented below in Table
9.
TABLE-US-00009 TABLE 9 Modeling and Qualification Steps Steps Model
selection Base model and Inter-individual Base Model, IIV on
CL/V1/Q2/V2/Q3 variability (IIV) evaluation Inter-occasion
variability Base Model with IOV on CL and V1 (IOV) evaluation
Covariate Modelling Final model, body weight as covariate on CL and
V1 Internal qualification (bootstrap and VPC) External
qualification using trough/peak records CL, clearance; V, volume of
distribution; Q, inter-compartmental clearance; VPC, visual
predictive check
[0426] A first order conditional estimation with interaction method
(FOCEI) was used to estimate the popPK parameters. Residual errors
were modeled as combined proportional and additive errors. Stepwise
forward addition (p<0.005) and backward elimination (p<0.001)
covariate modeling was performed. Potential covariates assessed in
this analysis included: body weight (BW), Age, Race, Blood type,
Human Immunodeficiency Virus status, Hepatitis C Virus status,
haematocrit, IgG.sub.1 and albumin concentration, and FIX
genotype.
[0427] Model qualifications included bootstrap, visual predictive
check (VPC) and validation with trough/peak records. The mean
relative prediction error (an indicator of accuracy) was calculated
as:
1 N i = 1 i = N [ DV - IPRED ] DV ( H ) ##EQU00002##
[0428] RESULTS: The rFIXFc disposition was best described by a
three-compartment base model (FIG. 4). The model was further
improved by including intra-subject random changes at different
occasions (i.e., inter-occasion variability, IOV) for CL and V1
(FIG. 5). IOV was smaller than inter-individual variability (IIV),
indicating that individual PK was more accurate than the mean popPK
for individual PK prediction.
[0429] Body weight was found to be a significant covariate for
rFIXFc disposition (FIG. 6), although the impact of BW was limited.
For example, the BW exponent on CL and V1 was 0.436 and 0.396,
respectively, and inclusion of BW reduced inter-individual
variability (IIV) for both CL and V1 only by 3.4% and 2.5%,
respectively. None of the other covariates assessed, including age,
race, blood type or genotype, were significant covariates in this
model.
[0430] The final popPK model is summarized below in Table 10.
TABLE-US-00010 TABLE 10 Summary of the final rFIXFc population
pharmacokinetic model. Population 95% non-parametric IIV.sup.b IOV
Parameter Estimate CI from bootstrap.sup.a (%) (%) CL = Typical CL
.times. (BW/73).sup.0.436 Typical CL for a 73 kg 2.39 2.29, 2.49
17.7 15.1 subject (dL/h) BW exponent on CL 0.436 0.272, 0.584 V1 =
Typical V1 .times. (BW/73).sup.0.396 Typical V1 for a 73 kg 71.4
58.5, 76.0 21.7 17.4 subject (dL) BW exponent on V1 0.396 0.169,
0.580 Q2 (dL/h) 1.67 1.35, 1.89 35.8 -- V2 (dL) 87.0 79.0, 95.5
46.2 -- Q3 (dL/h) 39.3 16.6, 141 -- -- V3 (dL) 39.9 36.6, 52.4 37.7
-- Residual Error: Proportional 10.6% Additive 0.24 IU/dL CI,
confidence interval; IIV, inter-individual variability; IOV, inter
occasion variability; CL, clearance; BW, body weight; V, volume of
distribution; Q, inter-compartmental clearance
[0431] For a typical 73 kg subject, the predicted popPK values for
clearance, volume of central compartment, and volume of
distribution at steady state are 2.39 dL/h, 71.4 dL, and 198 dL,
respectively. Goodness-of-fit plots show that the predicted popPK
data generated by the model closely mimic the observed FIX activity
data (FIG. 7).
[0432] The results of the popPK model were validated using the
observed FIX activity data. The median and 80% interval for
observed and predicted FIX activity time profiles nearly
overlapped, indicating that the final model was able to reproduce
both the central tendency and variability of the observed FIX
activity data on the time scale (FIG. 8). The strong correlation
between observed and predicted FIX activities in the trough/peak
dataset suggested that the final popPK model is predictive (FIG.
9).
[0433] Finally, the overall relative prediction error was -3.23%
with a 95% confidence interval of -5.27% to -1.23%. Post hoc
estimates from this popPK analysis were very similar to the results
from the conventional PK analysis shown below in Table 11.
TABLE-US-00011 TABLE 11 Post hoc empirical Bayesian estimates of
key PK parameters. Phase 3 Phase 1/2a Parameter Mean (SD) Mean (SD)
Clearance (CL), mL/h/kg 3.42 (0.89) 2.82 (0.58) Volume of central
compartment 102 (29.6) 96.2 (24.7) (V1), mL Incremental in vivo
recovery, 1.02 (0.45) 1.04 (0.19) IU/dL per IU/kg Volume of
distribution at 297 (90.5) 234 (70.8) steady-state (Vss), mL/kg
Terminal Half-life, h 86.7 (27.9) 70.9 (13.9) Mean residence time
(MRT), h 89.4 (25.9) 82.5 (15.5) SD, standard deviation
[0434] CONCLUSIONS: The three-compartment popPK model predicted
disposition of rFIXFc with modest inter-individual variability
(IIV). Individual PK parameters derived from the three-compartment
popPK model were similar to those derived from the two-compartment
conventional PK analysis, indicating a limited 3rd compartment
contribution. For a typical 73 kg subject, the popPK model
predicted a clearance of 2.39 dL/h; volume of central compartment
of 71.4 dL; and volume of distribution at steady state of 198 dL.
The only significant covariate assessed in the popPK model was BW,
although its impact on rFIXFc PK variability was limited.
[0435] The final popPK model can be used to simulate dosing
regimens and intervals for routine prophylaxis, control and
prevention of bleeding episodes, and peri-operative management.
This model may assist physicians who wish to tailor dosing for
individual subjects with sparse PK samples.
Example 6. Use of the Population Pharmacokinetic Model of rFIXFc to
Simulate or Estimate Individualized and Median Patient Treatment
Information
[0436] As is discussed in Examples 5 and 7, a model of estimated
population PK parameters of rFIXFc has been established that can
assist physicians and other healthcare practitioners who wish to
tailor dosing for individual subjects with, e.g., sparse PK
samples. Alternatively, the model can be used to determine dosing
based on PK data for the whole population (median PK).
[0437] Thus, individualized patient treatment, e.g.,
pharmacokinetics (PK) and dosing regimens, can be selected using
Bayesian estimation (or similar machine learning algorithm) based
on the population pharmacokinetic (popPK) model described in
Example 5 and 7, above (e.g., Table 10, 13, or 14). In this way,
one can determine alternative prophylactic dosing regimens and
optimized dosing regimens for pen-operative management that have
not previously been studied in the B-LONG trials. Alternatively,
the selected dosing regimen is based on population PK (median PK)
rather than making an individualized selection.
[0438] In some embodiments, the rFIXFc popPK model of Example 5 and
7 (e.g., Table 10, 13, or 14) is used without the Bayesian or
similar machine learning algorithm.
[0439] In some embodiments of this aspect of the invention, the
method is carried out on a computer-based system, e.g., a server, a
desk top computer, a lap top computer, a tablet, a hand held
device, or a smart phone. In some embodiments, the computer-based
system is a computer application. The computer-based system
includes a storage medium for the rFIXFc popPK model discussed in
Example 5 and 7, e.g., the parameters of Table 10, 13, or 14. In
some embodiments, the storage medium can also contain a Bayesian
estimating program, e.g., NONMEM or Phoenix NLME. E.g., Example 5
and 7 (e.g., Table 10, 13, or 14); Kiang et al., Clin.
Pharmacokinet 51:515-525 (2012).
[0440] In some embodiments, the system comprises two or more
computer-based systems. In some embodiments, the user can input
information into a first computer-based system that communicates
with a second computer-based system, and the second computer-based
system carries out calculations and communicates output information
to the first computer-based system. This output information can
include recommendations about individualized or non-individualized
dosing regimens.
[0441] In some embodiments, the user inputs information into the
system and the system calculates and outputs one or more PK or
dosing regimens. In some embodiments, the system uses the received
information to calculate and output individualized or median PK
information. In some embodiments, the system calculates
individualized dosing or interval information.
[0442] Information that can be input by a user and received by the
system includes patient information and desired treatment outcome
information. Based on the type and value of the received
information, the computer-based system calculates output
information based on the rFIXFc popPK model and optional machine
learning algorithm on the storage medium.
[0443] Patient information includes, e.g., age, body weight,
diagnostic (baseline) FIX level, PK determinations, time of PK
sampling, dosing history if PK samples were taken from multiple
doses, actual dose, FIX activity level, etc.
[0444] Desired treatment outcome information includes desired PK or
desired regimen outcome, e.g., desired rise in plasma FIX activity
level following dose, desired dosing interval, and desired
dose.
[0445] Based on the information that was input and received by the
system, the system can output various information, e.g., PK curve,
PK parameter such as incremental recovery (Cmax/dose), mean
residence time, terminal t1/2, clearance, Vss, AUC/dose, doses and
associated troughs, and intervals and associated troughs.
[0446] For example, for assessing individualized patient PK, the
system can recommend that the user input 2-3 optimized PK sampling
time points. In this case, system output can include PK curve and
one or more selected PK parameters, e.g., incremental recovery
(Cmax/Dose), mean residence time, terminal t1/2, clearance, Vss,
AUC, and time to 1 or X %, etc. E.g., FIG. 13.
[0447] As additional examples, to select an individualized dosing
regimen using the output individual PK parameters discussed in the
preceding paragraph, (i) the dose selected for acute treatment can
be based on user input of the desired rise in plasma FIX activity
level following the dose, (ii) the dose selected for prophylaxis
can be based on user input of the desired dosing interval, or (iii)
the selected interval for prophylaxis can be based on user input
for the desired dose. In the first case, the system can output the
dose (IU) based in the patient's incremental recovery. E.g., FIG.
14. In the second case, system output can be a table of doses and
associated troughs, e.g., x IU/kg, 1% trough, y IU/kg, 2% trough,
etc. e.g., FIG. 15, top. In the third case, system output can be a
table of intervals and associated troughs, e.g., x days, 1% trough,
y IU/kg, 2% trough, etc., E.g., FIG. 15, bottom.
[0448] The user may wish to use the system without inputting any
individualized PK data. In this case, the dosing output would be
based on the population median rather than being individualized for
the particular patient. E.g., FIG. 16. In this way, the user
inputs, e.g., body weight and age, and (i) the desired rise in
plasma FIX activity level following the dose, (ii) the desired dose
interval for prophylaxis, or (iii) the desired dose for
prophylaxis. In the first case, the system can output the dose. In
the second case, the system can output the dose and associated
trough, e.g., Table 16. In the third case, the system can output
the interval and associated trough, e.g., Table 16.
[0449] Age can be input to determine if the system is suitable for
the patient because the current version of the popPK model was
built for patients 12 years and older.
[0450] In some embodiments, the system is compliant with patient
privacy laws. In some embodiments, the system is encrypted, e.g.,
with SSL. In some embodiments, input patient information is made
anonymous.
[0451] In some embodiments, the system includes a user help
function.
[0452] The user can be, e.g., a physician, a nurse, or another
healthcare practitioner.
[0453] In some embodiments, the method further includes selecting a
dosing regimen based on the system's output information and
administering rFIXFc to the patient according to the selected
regimen.
Example 7. Population Pharmacokinetic Modeling of Long-Acting
Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Patients with
Hemophilia B
[0454] Background and Objectives: Recombinant factor IX Fc fusion
protein (rFIXFc) is a clotting factor developed using monomeric Fc
fusion technology resulting in a longer circulating half-life. The
objective of this analysis is to elucidate the pharmacokinetic
characteristics of recombinant factor IX Fc fusion protein (rFIXFc)
in patients with hemophilia B and identify covariates that affect
rFIXFc disposition.
[0455] Methods: Population pharmacokinetic analysis using
NONMEM.RTM. was performed with clinical data from two completed
trials in previously treated patients with severe to moderate
hemophilia B. Twelve patients from a phase 1/2a study and 123
patients from a registrational phase 3 study were included in this
population pharmacokinetic analysis.
[0456] Results: A three-compartmental model was found to best
describe the pharmacokinetics of rFIXFc. For a typical 73-kg
patient, population predicted clearance (CL), volume of central
compartment (V.sub.1), and volume of distribution at steady state
(V.sub.ss) were 2.39 dL/h, 71.4 dL and 198 dL, respectively.
Because of repeat pharmacokinetic profiles at week 26 for patients
in a subgroup, inclusion of inter-occasion variability (IOV) on CL
and V.sub.1 were evaluated and significantly improved the model.
The magnitude of IOV on CL and V.sub.1 were both low to moderate
(<20%) and less than the corresponding inter-individual
variability. Body weight (BW) was found to be the only significant
covariate for rFIXFc disposition. However, the impact of BW was
limited, as the BW power exponents on CL and V.sub.1 were 0.436 and
0.396, respectively.
[0457] Conclusions: This is the first population pharmacokinetic
analysis that systematically characterized the pharmacokinetics of
long-acting rFIXFc in patients with hemophilia B. The population
pharmacokinetic model for rFIXFc can be utilized to evaluate and
optimize dosing regimens for the treatment of patients with
hemophilia B.
[0458] 1. Background
[0459] Hemophilia B is a rare bleeding disorder caused by a
deficiency of coagulation factor IX (FIX). The disease is caused by
a mutation on the X chromosome and affects approximately 1 in
30,000 males. Hemophilia B results in abnormal clot formation,
causing prolonged and abnormal bleeding, including bleeding into
joints, soft tissue, muscle and body cavities. Bleeding episodes
may be associated with trauma or occur in the absence of trauma
(spontaneous bleeding). If not treated appropriately, bleeding can
be life-threatening or result in significant morbidity. The current
mainstay of treatment is FIX replacement therapy.
[0460] Recombinant factor IX Fc fusion protein (rFIXFc) is a
recombinant protein consisting of a single molecule of FIX
covalently fused to the Fc domain of human immunoglobulin G1 (IgG1)
with no intervening sequence. The Fc domain is responsible for the
long circulating half-life of IgG1 through interaction with the
neonatal Fc receptor (FcRn) that is expressed in many different
cell types. rFIXFc was therefore designed as a long-acting version
of recombinant FIX. rFIXFc has the potential to fulfill an unmet
medical need by providing a long-acting therapy for control and
prevention of bleeding episodes, routine prophylaxis and
perioperative management in patients with hemophilia B. Two
clinical trials with rFIXFc have been completed in previously
treated patients with severe to moderate hemophilia B (with
.ltoreq.2 IU/dL [%] endogenous FIX): one single dose phase 1/2a
study in 14 patients (12 of them who received doses .gtoreq.12.5
IU/kg had pharmacokinetic assessment) [6], and one registrational
phase 3 study in 123 patients [8]. rFIXFc was shown to be well
tolerated and efficacious in the treatment of bleeding, routine
prophylaxis and perioperative management.
[0461] The purpose of this analysis is to characterize the
population pharmacokinetics of rFIXFc in patients with hemophilia B
and to identify demographic and clinical factors that are potential
determinants of rFIXFc pharmacokinetic variability. The population
pharmacokinetic model of rFIXFc can be used to evaluate and guide
dosing regimens of rFIXFc in the treatment of patients with
hemophilia B.
[0462] 2 Methods
[0463] 2.1 Clinical Studies
[0464] FIX activity data were obtained from two completed clinical
trials in previously treated patients with severe to moderate
hemophilia B. Twelve evaluable patients from the phase 1/2a study
and 123 patients from the phase 3 study (B-LONG) who had measurable
FIX activities were included in this population pharmacokinetic
analysis. The clinical studies are summarized in FIGS. 2A and 2B.
All subjects were patients with severe to moderate hemophilia B
previously treated with FIX products, from 12.1 to 76.8 years of
age. All patients, or patient guardians, gave informed written
consent. The studies were approved by the Ethics committee and
conducted in accordance with the International Conference on
Harmonisation guidelines for Good Clinical Practice.
[0465] 2.2 Pharmacokinetic Sampling and Bioanalytical Methods
[0466] In the phase 1/2a study, 12 patients underwent rFIXFc
pharmacokinetic sampling up to 14 days. In the phase 3 study,
pharmacokinetic samples were collected for rFIXFc in all patients
according to the schedule in FIG. 2C. Pharmacokinetic profiles of
rFIXFc were assessed at week 1 (baseline) for all patients and at
week 26 for the Arm 1 sequential pharmacokinetic subgroup. For
patients on prophylaxis in Arms 1 and 2, additional trough and peak
samples were collected at clinical visits throughout the study.
[0467] The population pharmacokinetic modeling was performed using
plasma FIX activity data as measured by the one-stage activated
partial thromboplastin time (aPTT) clotting assay using
commercially available aPTT reagents (Trinity Biotech) and normal
reference plasma (Precision BioLogic). Lower limit of quantitation
(LLOQ) was 1 IU/dL (%). The accuracy of the assay was within
95-104%, and the intra- and inter-assay precision was approximately
10%.
[0468] 2.3 Data Handling
[0469] A total of 11 data post-infusion were below the limit of
quantification (BLQ, below LLOQ of 1%). Since those post-infusion
BLQ values represent <0.5% of the observations, they were
excluded from the analysis as the first step of data handling.
[0470] The one-stage clotting assay does not distinguish between
FIX activities resulting from endogenous baseline residual activity
and incomplete washout of the pre-study FIX product or the input
study drug, rFIXFc. Therefore, the baseline and residual activity
corrections were applied to the observed FIX activity data
(formulas (I) and (J)). The corrected FIX activities were recorded
as the dependent variable (DV) in the population pharmacokinetic
dataset. Similar baseline and residual activity corrections were
reported previously for the pharmacokinetic analyses of other FIX
products [12-15]. See Bjorkman et al., Eur J Clin Pharmacol. 2012;
68(6):969-77; Bjorkman et al., Eur J Clin Pharmacol. 1994;
46(4):325-32; Bjorkman et al., Haemophilia. 2001; 7(2):133-9; and
Carlsson et al., Haemophilia. 1998; 4(2):83-8.
Residual decay correction=(Predose-baseline).times.e.sup.decay
rate.times.time (I)
Corrected FIX activity=Measured FIX activity-baseline-residual
decay correction (J)
[0471] The endogenous baseline FIX activity level is dictated by
the defective FIX genotype and thus is stable in each individual
subject, yet could be overestimated in patients receiving FIX
replacement therapy who underwent incomplete washout. Therefore the
baseline FIX activity was defined as the lowest FIX activity
observed throughout the study, including all the screening,
pre-dose, and post-dose records. For patients whose lowest observed
FIX activity was <1% (LLOQ), the baseline FIX activity was set
at 0; for patients whose lowest observed FIX activity was between
1-2%, the baseline FIX activity was set at the lowest observed FIX
activity. The study enrollment was limited to subjects with
baseline FIX activity .ltoreq.2%.
[0472] For each individual subject, baseline activity was first
subtracted from observed FIX activity and then residual activity,
if any, was decayed from baseline-corrected FIX activity to obtain
the corrected FIX activity. Residual activity was defined as
pre-dose activity minus baseline FIX activity. For subjects in the
Arm 1 sequential pharmacokinetic subgroup who underwent
pharmacokinetic assessment with the comparator FIX product
(BENEFIX.RTM., Pfizer Inc, New York, N.Y.) prior to rFIXFc
pharmacokinetic assessment, the residual activity was decayed using
the individual subject's BENEFIX.RTM. terminal first-order decay
rate estimated by the non-compartmental analysis in PHOENIX.TM.
WinNonlin 6.2 (Pharsight, Sunnyvale, Calif.). For any subjects who
did not have a BENEFIX.RTM. pharmacokinetic assessment, the
residual activity was decayed from the rFIXFc pharmacokinetic
profiles using the average BENEFIX.RTM. terminal first-order decay
rate from the Arm 1 sequential pharmacokinetic subgroup.
[0473] 2.4 Modeling Strategy and Datasets
[0474] Demographic and clinical factors collected and examined in
the analysis included age, body weight (BW), race, height, human
immunodeficiency virus (HIV) and hepatitis C virus (HCV) status,
IgG1 and albumin concentration, hematocrit (HCT) level, FIX
genotype and blood type.
[0475] The pharmacokinetic dataset was split into the modeling
dataset, which was used to build the population pharmacokinetic
model and validation dataset, which was used to qualify the final
model. The modeling dataset for rFIXFc included 1400 FIX activity
records from 135 baseline pharmacokinetic profiles in both phase
1/2a and 3 studies, as well as 21 repeat pharmacokinetic profiles
that were collected at week 26 from the Arm 1 sequential
pharmacokinetic subgroup in the phase 3 study. The validation
dataset included 1027 trough/peak FIX activity records from the
phase 3 study, excluding the records during and after surgeries.
Peak/trough collection times were recorded by patients
retrospectively into their electronic diary following the clinic
visit. A summary of the modeling and validation datasets is listed
in Table 12.
TABLE-US-00012 TABLE 12 Summary of modeling and validation datasets
No. of FIX Median age Median body weight Dataset No. of patients
activity records (year [range]) (kg [range]) Modeling dataset 12
(Phase 1/2a) 1,400 31.3 (12.1-76.8) 73.3 (45.0-186.7) 123 (Phase 3)
Validation dataset 100 (Phase 3) 1,027 30.7 (12.1-71.6) 72.5
(45.2-186.7)
FIX Factor IX
[0476] The modeling strategy was a two-step approach. The first
step was to build the population pharmacokinetic model using the
modeling dataset and the second step was to validate the model with
goodness-of-fit plots, bootstrapping, visual prediction check (VPC)
and the trough/peak validation dataset. As a comparison, the rFIXFc
model using the full dataset, which combined the modeling and
validation dataset, was also developed.
[0477] 2.5 Population Pharmacokinetic Modeling
[0478] NONMEM.RTM. 7 version 1.0 (ICON Development Solutions,
Ellicott City, Md., USA) with an Intel Fortran compiler (version
12) was used for the population pharmacokinetic model development.
Statistical program R (version 2.15.0, R Foundation for Statistical
Computing, Vienna, Austria) was used to compile NONMEM datasets and
generate graphics. Perl Speaks NONMEM (PsN, version 3.5.3) (Lindbom
et al., Comput Methods Programs Biomed. 2004; 75(2): 85-94) was
used to conduct bootstrapping. PsN and Xpose 4 (Jonsson et al.,
Comput Methods Programs Biomed. 1999; 58(1): 51-64) were used to
perform VPC.
[0479] A first-order conditional estimation with interaction method
(FOCEI) was used to estimate population pharmacokinetic parameters.
Inter-individual variability (IIV) was modeled using exponential
function. The inclusion of IIV terms on pharmacokinetic parameters
was tested sequentially, with the most significant objective
function value (OFV) reduction (P<0.005) entering the model
first. Inter-occasion variability (IOV) (Karlsson et al., J.
Pharmacokinet-Biopharm. 1993: 21(6): 735-50) was also evaluated.
For the modeling dataset, two occasions were defined including
baseline pharmacokinetic profiling at week 1 and repeat
pharmacokinetic profiling at week 26. For the full dataset, six
occasions were defined according to the data density. Residual
errors were modeled as combined proportional and additive
errors.
[0480] Plots of IIV versus covariates were used to screen for
potential demographic and clinical factors that affect rFIXFc
pharmacokinetics. For continuous covariates, scatter plots of ETA
(IIV code used in NONMEM) versus covariates were overlaid with a
non-parametric locally weighted smoother LOESS line to determine
functional relationships; for categorical covariates, box and
whisker plots were used to identify potential differences between
groups (data not shown). A clear trend of positive or negative
slopes and noteworthy correlation coefficients (data not shown)
would suggest a possible influence by the continuous covariates;
pronounced differences among the groups would suggest a possible
influence by the categorical covariates. After identifying
potential covariates, a full stepwise forward addition (P<0.005)
and backward elimination (P<0.001) procedure was conducted for
covariate modeling.
[0481] Besides statistical considerations, model selection was also
aided by goodness-of-fit plots, including DV (observed FIX activity
adjusted for baseline activity and residual decay) versus
population prediction (PRED), DV versus individual prediction
(IPRED), conditional weighted residual (CWRES) versus TIME and PRED
plots. See Wade et al., AAPS J. 2005; 7(2): 45; and Ette et al.,
Pharm Res. 1995; 12(12); 1845-55. Other diagnostics also helped to
select the proper model, including parameter precision, ETA, and
CWRES distribution and shrinkage. See Savic et al., AAPS J. 2009;
11(3): 558-69; and Xu et al., AAPS J. 2012; 14(4); 927-36.
[0482] 2.6 Model Qualification
[0483] Bootstrapping was conducted with 1,000 datasets generated by
random sampling through replacement. Non-parametric median and 95%
(2.5.sup.th and 97.5.sup.th percentiles) confidence intervals (CIs)
of pharmacokinetic parameters were obtained and compared with final
model estimates.
[0484] To check the predictive performance of the model, VPC was
performed to obtain 1,000 simulated pharmacokinetic profiles.
Median, 10th, and 90th percentile of simulated and observed FIX
activities, stratified by dose (50 and 100 IU/kg), were
plotted.
[0485] The trough/peak validation dataset was used to check the
predictability of the model. Specifically, the model was used to
derive Bayesian feedback predictions of FIX activities at
trough/peak time points by setting MAXEVAL=0 in NONMEM control
stream. The mean relative prediction error (an indicator of
accuracy) was calculated using formula:
1 N i = 1 i = N DV - IPRED DV ( K ) ##EQU00003##
[0486] 3. Results
[0487] 3.1 Structural Model and Evaluation of IIV
[0488] Based on previous conventional pharmacokinetic analyses of
rFIXFc, a two-compartment model appropriately described individual
pharmacokinetics, hence a two-compartment model was evaluated first
followed by a three-compartment model. IIV (ETA, values) was
assumed for clearance (CL) and volume of compartment 1 (V.sub.1). A
covariance between CL and V.sub.1 was also included. The
three-compartment model resulted in a reduction of OFV by over 400
units (for additional four parameters) compared with the
two-compartment model, thus was selected as the base model (FIG.
4). Primary pharmacokinetic parameters included CL, V.sub.1, volume
of compartment 2 (V.sub.2) and 3 (V.sub.3), inter-compartmental
clearance between compartments 1 and 2 (Q.sub.2), as well as
between 1 and 3 (Q.sub.3). The inclusion of IIV for the rest of the
pharmacokinetic parameters (V.sub.2, V.sub.3, Q.sub.2 and Q.sub.3)
led to further improvement in the model fitting. However, IIV on
Q.sub.3 was associated with a high standard error (87%), indicating
that the data cannot support a precise estimation of IIV on
Q.sub.3, which was thus not included in the model. No additional
covariance between IIV of pharmacokinetic parameters could be
estimated with precision, thus the only covariance between IIV
retained in the model was the covariance between IIV on CL and
V.sub.1.
[0489] 3.2 Evaluation of IOV
[0490] Since the Arm 1 sequential pharmacokinetic subgroup had
repeat pharmacokinetic profiles at week 26 in addition to baseline
pharmacokinetic profiles at week 1, IOV was evaluated with baseline
pharmacokinetics as occasion 1 and repeat pharmacokinetics as
occasion 2. The inclusion of IOV on CL significantly improved the
model with a reduction of OFV by 171.6 units. The inclusion of IOV
on both CL and V.sub.1 achieved an additional OFV drop of 41.6
units, whereas IOV on V.sub.2 or Q.sub.2 did not improve the model
fit (P>0.05). The IOV on V.sub.3 improved the model fit at
P<0.005 but with a large percentage of relative standard error
(78.4%); Therefore, IOV was only included for CL and V.sub.1.
[0491] Pairwise comparisons of CL and V.sub.1 estimates for
baseline and repeat pharmacokinetics, derived from the base model
with IOV, were plotted in FIG. 5. The changes of either CL or
V.sub.1 between the two occasions were random and small with only
one exception, and the mean CL or V.sub.1 for the two occasions
were similar.
[0492] Overall, the inclusion of IOV reduced the corresponding IIV
on CL and V.sub.1 from 24.0% and 29.6% to 21.1% and 24.2%,
respectively. The inclusion of IOV also reduced proportional and
additive residual errors from 12.1% and 0.30 IU/dL, to 10.5% and
0.24 IU/dL, respectively. The base model with IOV provided a
reasonable fit to the data, and explained the random as well as
small pharmacokinetic changes between occasions studied in the
trial, therefore was chosen for further covariate modeling.
[0493] 3.3 Covariate Modeling
[0494] Based on ETA versus covariate plots, BW, albumin and race on
CL, and "study" on V.sub.2 were speculated to be potential
covariates. Covariate modeling included BW on all pharmacokinetic
parameters, albumin on CL, and "study" on V.sub.2 and CL. BW was
assessed for all pharmacokinetic parameters because it is an
important physiology factor. "Study" was assessed on CL because of
the importance of CL.
[0495] A full stepwise forward addition and backward elimination
procedure was performed. Following the forward covariate inclusion,
the full covariate model was identified with BW on CL and V.sub.1,
and "study" on V.sub.2. However, "study" on V.sub.2 was removed
following the backward elimination procedure (P>0.001).
[0496] Further, the potential residual variability difference
between the phase 1/2a and 3 studies was tested by including two
sets of proportional and additive errors for two studies in the
residual error model. No significant reduction in OFV was observed
(13.7 units, df=2).
[0497] Therefore, although the phase 1/2a and phase 3 studies have
different dosing and sampling schemes, the population
pharmacokinetic modeling did not suggest a PK difference between
the two studies.
[0498] 3.4 Final Model
[0499] The final model of rFIXFc had IIV on
CL/V.sub.1/Q.sub.2/V.sub.2/V.sub.3 but not Q.sub.3, IOV on CL and
V.sub.1 and BW as a covariate on CL and V.sub.1. The model
described the data well (FIG. 4). There were no outstanding trends
observed in the CWRES plots and most CWRES were randomly
distributed between -2 and 2, indicating overall small
discrepancies between measured FIX activities and population
predictions (FIGS. 7C and 7D). Population pharmacokinetic parameter
estimates, IIV and IOV, as well as residual errors were estimated
with precision, evidenced by narrow 95% CIs for each
pharmacokinetic parameter (Table 3). The IIV for CL and V.sub.1
were 17.7 and 21.7%, respectively, which are low to moderate, and
IOV for CL and V.sub.1 were low at 15.1 and 17.4%,
respectively.
[0500] The magnitude of ETA shrinkage on the IIVs was moderate
(<30% for all pharmacokinetic parameters with IIV terms), while
the magnitude of ETA shrinkage on the IOV was occasion-specific,
moderate at first occasion (around 30% on CL and V.sub.1) and
higher at occasion 2 (around 70%) because there were fewer
pharmacokinetic profiles for the second occasion (21 for occasion 2
repeat pharmacokinetics vs. 135 for occasion 1 baseline
pharmacokinetics). The distributions of ETAs and CWRES showed
approximate normal distribution centered around zero without
apparent skewness (data not shown). This was consistent with the
ETABAR P values, all of which were non-significant (P>0.05).
[0501] 3.5 Model Qualification
[0502] Non-parametric bootstrapping was applied to the final model
to assess the model stability. Bootstrapping generated medians and
CIs for the pharmacokinetic parameters, IIV and IOV estimates
(Table 13). The median values from the bootstrapping were very
similar to the model estimates for all the pharmacokinetic
parameters.
TABLE-US-00013 TABLE 13 Summary of rFIXFc population
pharmacokinetic final model Model Bootstrap median Parameter
estimate (95% CI.sup.a) CL = Typical CL .times. ( BW 73 ) 0.436
##EQU00004## Typical CL for a 73-kg patient 2.39 2.39 (2.29, 2.49)
(dL/h) BW exponent on CL 0.436 0.437 (0.272, 0.584) V 1 = Typical V
1 .times. ( BW 73 ) 0.396 ##EQU00005## Typical V.sub.1 = for a
73-kg 71.4 71.2 (58.5, 76.0) patient (dL) BW exponent on V.sub.1
0.396 0.390 (0.169, 0.580) Q.sub.2 (dL/h) 1.67 1.66 (1.35, 1.89)
V.sub.2 (dL) 87.0 87.0 (79.0, 95.5) Q.sub.3 (dL/h) 39.3 39.0 (16.6,
141) V.sub.3 (dL) 39.9 41.2 (36.6, 52.4) IIV.sup.b on CL, % 17.7
17.5 (11.8, 22.4) IOV.sup.c on CL, % 15.1 15.0 (10.7, 19.1) IIV on
V.sub.1, % 21.7 22.4 (15.5, 32.1) IOV on V.sub.1, % 17.4 16.5 (8.7,
22.8) IIV on Q.sub.2, % 35.8 35.0 (22.6, 45.8) IIV on V.sub.2, %
46.2 45.9 (38.0, 55.3) IIV on V.sub.3, % 37.7 37.9 (30.2, 54.3)
Correlation between IIV on 75.6 74.8 CL and V.sub.1, %.
Proportional residual error, % 10.6 10.4 (8.64, 12.0) Additive
residual error, IU/dL 0.24 0.24 (0.17, 0.31) .sup.a95% CI:
Non-parametric 95% CI from bootstrap results with 1,000 datasets
.sup.bIIV calculated as {square root over (variance)} .times. 100
.sup.cIOV calculated as {square root over (variance)} .times. 100
BW body weight, CI confidence interval, CL clearance, IIV
inter-individual variability, IOV inter-occasion variability,
Q.sub.2 inter-compartmental clearance of compartment 2, Q.sub.3
inter-compartmental clearance of compartment 3, rFIXFc recombinant
factor IX Fc, V.sub.1 volume of compartment 1, V.sub.2 volume of
compartment 2, V.sub.3 volume of compartment 3
[0503] The graphic results of the VPC of the final model stratified
by the dose are presented in FIG. 8. The median and 80% interval
(10.sup.th to 90.sup.th percentile) time-activity observed and
predicted profiles nearly overlapped, indicating that the final
model was able to reproduce both the central tendency and
variability of the observed FIX activity time profiles.
[0504] The predictive capability of the final model was further
evaluated using a validation dataset, which contains the
trough/peak FIX activity records that were not included in the
modeling dataset. The final model was used to derive the individual
predictions for the trough and peak observations. Individual
predictions showed good correlation (R.sup.2=0.9857, P<0.001)
with the observations (FIG. 9). The mean relative prediction error
was low at -3.23%, indicating that the final model was qualified to
predict rFIXFc pharmacokinetics in the hemophilia B patient
population.
[0505] 3.6 Full Dataset Model
[0506] Further, a population pharmacokinetic model of rFIXFc was
also built based on the full dataset, including both
pharmacokinetic profile and trough/peak data. The population
parameter estimates of the resulting model, as well as IIV and IOV
(Table 14 below), were comparable with those of the final model
derived from the modeling dataset (Table 13 above). The
goodness-of-fit plots indicated that the model also described the
data adequately (FIG. 20). A slightly greater over-prediction of
FIX activity in the lower range (<10 IU/dL) was observed for the
VPC of the full dataset model. (FIGS. 8C and 8D).
TABLE-US-00014 TABLE 14 Summary of rFIXFc population
pharmacokinetic model derived from the full dataset Parameter
Population estimate (95% CI).sup.a CL = Typical CL .times. ( BW 73
) 0.432 ##EQU00006## Typical CL for a 73-kg patient (dL/h) 2.21
(2.10, 2.32) BW exponent on CL 0.432 (0.251, 0.613) V 1 = Typical V
1 .times. ( BW 73 ) 0.517 ##EQU00007## Typical V.sub.1 = for a
73-kg patient (dL) 70.6 (66.3, 74.9) BW exponent on V.sub.1 0.517
(0.282, 0.752) Q.sub.2 (dL/h) 163.(1.39, 1.87) V.sub.2 (dL) 991.
(84.6, 114) Q.sub.3 (dL/h) 45.6 (35.6, 55.6) V.sub.3 (dL) 40.7
(38.3, 43.1) IIV.sup.b on CL, % 19.7 (16.6, 22.8) IOV.sup.c on CL,
% 17.8 (17.0, 18.7) IIV on V.sub.1, % 21.7 (17.9, 25.6) IOV on
V.sub.1, % 13.8 (12.3, 15.3) IIV on Q.sub.2, % 48.1 (38.5, 57.6)
IIV on V.sub.2, % 51.0 (40.6, 61.3) Correlation between IIV on CL
and V.sub.1, % 60.7 Proportional residual error, % 14.8 (9.56,
20.1) Additive residual error, IU/dL 0.279 (0.112, 0.445) .sup.a95%
CI: The lower and upper limits for 95% CI were calculated
asymptotically using the standard errors estimated by the
covariance step in NONMEM .sup.bIIV calculated as {square root over
(variance)} .times. 100 .sup.cIOV calculated as {square root over
(variance)} .times. 100 BW body weight, CI confidence interval, CL
clearance, IIV inter-individual variability, IOV inter-occasion
variability, rFIXFc recombinant factor IX FC, RSE relative standard
error, Q.sub.2 inter-compartmental clearance of compartment 2,
Q.sub.3 inter-compartmental clearance of compartment 3, V.sub.1
volume of compartment 1, V.sub.2 volume of compartment 2, V.sub.3
volume of compartment 3.
[0507] 4 Discussion
[0508] This is the first systematic population pharmacokinetic
modeling of rFIXFc in patients with hemophilia B. A
three-compartment model described the pharmacokinetics of rFIXFc
well. For a typical 73-kg patient, V.sub.1 for rFIXFc at 71.4 dL is
larger than the plasma volume, which is around 30 dL for a typical
adult, indicating that rFIXFc is not limited in the plasma for the
initial distribution phase after intravenous administration,
similar to that of FIX which is known to bind to collagen IV in the
subendothelium. The IIV for CL and V.sub.1 were low to moderate at
17.7% and 21.7%, respectively, which are consistent with those
reported for plasma-derived FIX (23% for CL and 19% for V.sub.1).
Residual errors were small with a proportional error of 10.6% and
additive error of 0.24 IU/dL. The proportional residual error is
similar to the inter-assay variability of the one-stage aPTT
clotting assay. The small IIV and residual errors indicate that the
model described the data adequately and rFIXFc pharmacokinetics do
not vary substantially among patients. The estimated IOVs for CL
and V.sub.1 were 15.1% and 17.4%, respectively, similar to those
reported for plasma-derived FIX (15% for CL and 12% for V.sub.1).
The small and randomly distributed IOV on CL and V.sub.1 indicate
that rFIXFc pharmacokinetics is relatively stable at different
occasions.
[0509] The approach of using the model to estimate baseline and
differentiate baseline from pre-dose residual activity for each
individual was investigated. However, population modeling cannot
reliably separate baseline from residual activity because not every
FIX activity profile returned to baseline at the last sampling time
point (i.e., the baseline [endogenous] and exogenous signals were
confounded). We also investigated setting baseline activity at 0,
0.5, or an individualized baseline. The individualized baseline
resulted in relatively conservative pharmacokinetic estimates and
more accurate prediction of the trough levels in individual
subjects. Therefore, an individualized baseline was chosen to
handle the activity data in the population pharmacokinetic
modeling, which was also utilized in the conventional
pharmacokinetic analysis.
[0510] BW on CL and V.sub.1 was the only covariate that showed a
statistically significant impact on rFIXFc pharmacokinetics. It was
suggested that the exponent of a physiological or pharmacokinetic
parameter shall not revolve around a fixed number. Hence, the
exponents of BW on CL and V.sub.1 were estimated during the
modeling instead of fixed at presumed values, e.g., 0.75 for CL and
1 for V.sub.1. The estimated BW exponents for CL and V.sub.1 in the
final model were markedly lower at 0.436 and 0.396, respectively.
Furthermore, inclusion of BW as a covariate decreased IIV for CL by
only 3.4% and for V.sub.1 by only 2.5%, suggesting that a
considerable portion of the variability was not explained by
BW.
[0511] The limited impact of BW was not unique to rFIXFc
pharmacokinetics, which was also observed for BENEFIX.RTM. in the
phase 3 study (data not shown). The weak correlation between BW and
pharmacokinetics in our studies differs from a previous report,
which showed that BW, with an exponent of 0.7 on CL, accounted for
a significant portion of the variability in BENEFIX.RTM.
pharmacokinetics in a two-compartment population pharmacokinetic
model. The discrepancy probably can be explained by the different
populations studied, i.e., the adult patients (>19 years) in our
study versus pooled data from 111 children (.ltoreq.15 years),
including 53 infants (<2 years) and 80 adults (>15 years).
This previous report represents a wider range for age and BW than
in our study. See Bjorkman et al., Haemophilia. 2013; 19(5): 753-7.
A recently published paper reported that BeneFIX pharmacokinetics
in 56 patients aged 4-56 years and weighing 18-133 kg, described
also by a three-compartment model, had allometric exponent of CL
terms of 0.66 and volume terms of 0.64. See Id. The slightly
reduced allometric exponent of CL compared with the previous report
might also be explained by the difference of age and BW range
studied. See Udata et al., Blood. 2008; 112(11): 443-4.
[0512] Data splitting is a useful internal model validation
approach in population pharmacokinetic modeling. See Sherwin et
al., Clin. Pharmacokinet. 2012; 51(9); 573-90. Because in the
clinic intensive pharmacokinetic profile data are used to predict
subsequent trough/peak sparse data, the data were split into a
modeling dataset including the intensive pharmacokinetic profile
data from all subjects at week 1 and week 26 and a validation
dataset including the sparse peak and trough data throughout the
phase 3 study. To verify that our modeling strategy was robust,
i.e., building the model with the baseline/repeat pharmacokinetic
profiles without additional trough/peak FIX activity records, we
also built the model using the full dataset consisting of all the
FIX activity records from both the modeling and validation
datasets. The two models were highly comparable with <10%
difference in the pharmacokinetic parameters, IIV and IOV estimates
(Table 13 and Table 14). The comparability between the two models
was also demonstrated by the similar VPC plots for the two models
(FIG. 8). FIX activities in the lower range (<10 IU/dL) were
slightly more over-predicted by the full dataset model. This
difference might be attributed to the imprecise recordings of the
peak/trough collection time in the full dataset, which was recorded
by patients retrospectively into their electronic diary following
the clinic visit. The final model derived from the modeling dataset
is slightly more accurate in predicting trough levels, which is
essential for maintenance of the therapeutic efficacy. Therefore,
the final model derived from the modeling dataset is robust and
predictive to be used for simulation of the dosing regimens for
rFIXFc.
[0513] Finally, the population pharmacokinetic predictions were
largely consistent with the results derived from the conventional
two-stage pharmacokinetic analysis, which used a two-compartment
model, despite a minority (.about.14%) of the pharmacokinetic
profiles could also be described by a three-compartmental model.
The ambiguity in the model selection in the conventional
pharmacokinetic analysis was at least partially due to the
different sampling schemes in different study arms. Such ambiguity
was avoided using population pharmacokinetic modeling. The post-hoc
estimates from this population pharmacokinetic analysis were very
similar to the results from the conventional pharmacokinetic
analysis (Table 15).
TABLE-US-00015 TABLE 15 Comparison of pharmacokinetic parameters
derived from population pharmacokinetic post hoc analysis and
conventional pharmacokinetic analysis for phase III study
Population Conventional pharmacokinetics post hoc pharmacokinetics
analysis Parameter (n = 123) (n = 22).sup.a (units) Geometric mean
(95% CI) Geometric mean (95% CI) CL (mL/h/kg) 3.3 (3.2, 3.5) 3.2
(2.8, 3.6) V.sub.ss (mL/kg) 280.8 (266.4, 296) 314.8 (277.8, 356.8)
Terminal 81.1 (76.5, 86.1) 82.1 (71.4, 94.5) half-life (h) MRT (h)
84.1 (79.8, 88.6) 98.6 (88.2, 110.3) .sup.aPharmacokinetic
parameters derived from 22 patients with intensive sampling
schedule in Arm 1 sequential pharmacokinetic subgroup CI confidence
interval, CL clearance, MRT mean residual time, V.sub.ss volume of
distribution at steady state
[0514] For example, the geometric mean t.sub.1/2 estimated in
population pharmacokinetic and conventional pharmacokinetic are
81.1 h and 82.1 h, respectively. The highly comparable
pharmacokinetic parameters derived from a two-compartment
conventional pharmacokinetic analysis and a three-compartment
population pharmacokinetic analysis suggests that the contribution
of the third compartment to rFIXFc PK was probably limited, but
nevertheless provided better profile definition for the more
complex population modeling. The advantage of developing a
population pharmacokinetic model for rFIXFc is that the model can
be utilized for dosing regimen simulation taking into account IIV
and IOV, because FIX activity is considered as a surrogate for
efficacy; Further, the population pharmacokinetic model combined
with individual sparse pharmacokinetic data can be used to derive
an individualized dosing regimen through Bayesian estimation, which
can alleviate the requirement for extensive sampling. Since
hemophilia is a lifelong disease impacting children as well as
adults, the benefit of pharmacokinetics-tailored dosing regimens
based on data from limited blood sampling is of great interest to
the hemophilia community.
[0515] 5 Conclusion
[0516] This is the first population pharmacokinetic analysis that
systematically characterized the pharmacokinetics of the
long-acting rFIXFc in patients with hemophilia B. The disposition
of rFIXFc was well described by a three-compartment model with low
to moderate IIV and IOV. Body weight was found to be the only
statistically significant but weak covariate on CL and with limited
impact. The qualified population pharmacokinetic model for rFIXFc
is appropriate and predictive, providing a valuable tool to
evaluate and optimize dosing regimens of rFIXFc for the treatment
of patients with hemophilia B.
Example 8. Dosage and Method of Administration/Method of
Calculating Initial Estimated Dose
[0517] rFVIIIFc is long-acting anti-hemophilic factor (recombinant)
indicated in adults and children (.gtoreq.12 years) with hemophilia
A (congenital Factor FVIII deficiency) for, e.g., control and
prevention of bleeding episodes, routine prophylaxis to prevent or
reduce the frequency of bleeding episodes, and perioperative
management (surgical prophylaxis).
[0518] Dosing of rFVIIIFc can be estimated as described in this
example, but can also be determined by standard tests such as FVIII
activity assays described elsewhere herein.
[0519] 1 IU of rFVIIIFc per kg body weight is expected to increase
the circulating level of Factor VIII by 2 [IU/dL]. rFVIIIFc has
been shown to have a prolonged circulating half-life.
[0520] Since patients can vary in their pharmacokinetic (e.g.,
half-life, in vivo recovery) and clinical responses to rFVIIIFc,
the expected in vivo peak increase in Factor VIII level expressed
as IU/dL (or % of normal) or the required dose can be estimated
using the following formulas:
IU/dL (or % of normal)=[Total Dose (IU)/body weight (kg)].times.2
(IU/dL per IU/kg) (L)
OR
Dose (IU)=body weight (kg).times.Desired Factor VIII Rise (IU/dL or
% of normal).times.0.5 (IU/kg per IU/dL) (M)
[0521] The following table (Table 16) can be used to guide dosing
in bleeding episodes:
TABLE-US-00016 TABLE 16 Guide to rFVIIIFc Dosing for Treatment of
Bleeding Desired Factor VIII Level Dose (IU/dL or %
(IU/kg)/Frequency Severity of Bleed of normal) of Doses (hrs) Minor
and Moderate 40-60 20-30 IU/kg For example: joint, Repeat every
24-48 hours superficial muscle/no until bleeding is resolved
neurovascular compromise (except iliopsoas), deep laceration and
renal, superficial soft tissue, mucous membranes Major 80-100 40-50
IU/kg For example: iliopsoas Repeat every 12-24 hours and deep
muscle with until bleeding is resolved neurovascular injury, or
substantial blood loss, retroperitoneum, CNS, throat and neck,
gastrointestinal. Adapted from WFH 2012
[0522] Subsequent dosage and duration of treatment depends on the
individual clinical response, the severity of the Factor VIII
deficiency, and the location and extent of bleeding.
[0523] The following table (Table 17) can be used to guide dosing
for perioperative management (surgical prophylaxis):
TABLE-US-00017 TABLE 17 Guide to rFVIIIFc Dosing for Perioperative
Management (Surgical Prophylaxis) Target Factor VIII Level Dose
(IU/dL or % (IU/kg)/Frequency Type of Surgery of normal) of Doses
(hrs) Minor 50 to 80 25-40 IU/kg Minor operations A single infusion
can be including uncomplicated sufficient. Repeat every dental
extraction 24 hours as needed to control bleeding. Major 80 to 120
An initial preoperative Major operations dose of 40-60 IU/kg
including intra- followed by a repeat dose abdominal, joint of
40-50 IU/kg after 8-24 replacement surgery hours and then every 24
hours to maintain FVIII activity within the target range. rFVIIIFc
has a longer half-life than plasma and recombinant FVIII
products
[0524] For routine prophylaxis, the recommended regimen is 50 IU/kg
every 3-5 days. The dose can be adjusted based on patient response
in the range of 25-65 IU/kg.
[0525] For weekly prophylaxis, the recommended dose is 65
IU/kg.
[0526] rFVIIIFc is contraindicated in patients who have manifested
severe hypersensitivity reactions, including anaphylaxis, to the
product or its components. Severe hypersensitivity reactions were
not observed in clinical trials; however, these have been known to
occur with use of other factor VIII replacement factors.
[0527] The clinical response to rFVIIIFc can vary. If bleeding is
not controlled with the recommended dose, the plasma level of
Factor VIII can be determined, and a sufficient dose of rFVIIIFc
can be administered to achieve a satisfactory clinical response. If
the patient's plasma Factor VIII level fails to increase as
expected or if bleeding is not controlled after rFVIIIFc
administration, the presence of an inhibitor (neutralizing
antibodies) should be suspected, and appropriate testing performed.
Patients using rFVIIIFc can be monitored for the development of
Factor VIII inhibitors by appropriate clinical observations and
laboratory tests known to those of ordinary skill in the art.
[0528] Patient's plasma can be monitored for Factor VIII activity
levels, e.g., the one-stage clotting assay to confirm adequate
Factor VIII levels have been achieved and maintained, when
clinically indicated. Patient's plasma can further be monitored for
the development of Factor VIII inhibitors.
Example 9. Population Pharmacokinetic Analysis of Long-Acting
Recombinant Factor VIII-Fc Fusion Protein (rFVIIIFc) in Patients
with Severe Haemophilia A
[0529] Introduction: In a recently completed Phase 3 clinical study
(A-LONG), rFVIIIFc, a recombinant fusion protein composed of a
single molecule of B domain deleted human coagulation factor VIII
(FVIII) attached to the Fc domain of human immunoglobulin G1
(IgG1), was well-tolerated and effective in the treatment of
bleeding, routine prophylaxis, and perioperative management. The
duration of activity of rFVIIIFc was prolonged, compared to another
recombinant FVIII product (ADVATE.RTM.).
[0530] Objectives: To characterize the activity-time profiles of
rFVIIIFc in hemophilia A patients as measured by the one-stage
clotting assay by population PK analysis; to identify intrinsic and
extrinsic covariates that can affect the variability of rFVIIIFc
PK; and to simulate the rFVIIIFc dosing scenarios of interest using
the model developed.
[0531] Methods: The modeling dataset included activity-time
profiles in a total of 180 subjects (16 from a Phase 1/2a study and
164 from A-LONG) taken over up to 52 weeks of treatment.
[0532] The Phase 1/2a study was an open-label, multicenter,
dose-escalation study that included 2 dose levels. A total of 16
subjects received either 25 IU/kg (n=6) or 65 IU/kg (n=10) of
ADVATE.RTM. followed 3 or 4 days later, respectively, by an equal
dose of rFVIIIFc with an extensive PK sampling scheme following
each dose administration.
[0533] A-LONG was an open-label, multinational, multicenter study
that included 3 treatment arms.
[0534] Subjects were 12 to 65 years old and weighing between 41 kg
and 132 kg. The analysis was done with NONMEM 7 software, and
included model building, covariate search, and model qualification
steps. The data were analyzed using mixed-effects modeling with
maximal likelihood parameter estimation methods.
Covariate-parameter relationships were explored for parameters with
inter-individual variability (IIV) terms, and model diagnostics
were performed to guide model selection. rFVIIIFc dosing regimens
of therapeutic interest were simulated using the current model.
[0535] Results: A 2-compartmental model was found to describe
adequately the activity of rFVIIIFc, described by the formulas (M),
(N), and (O) below:
CL = TVCL [ VWF 118 ] .THETA. 10 ##EQU00008## V 1 = TVV 1 [ WT 73 ]
.THETA. 5 [ HCT 45 ] .THETA. 3 ##EQU00008.2## add = STUD .THETA. 5
+ ( 1 - STUD ) .THETA. 6 ##EQU00008.3## STUD = { 1 for Phase 1 0
for Phase 3 ##EQU00008.4##
[0536] The tight confidence intervals (Cis) indicate that the
parameters are estimated with very good precision (Table 18).
TABLE-US-00018 TABLE 18 rFVIIIFc Population PK parameters and
bootstrap- derived 95% Confidence Intervals Population
Nonparametric Parameter Symbol Estimate 95% CI Clearance, CL,
[dL/h] .THETA.1 1.65 1.57-1.74 Exponent on VWF .THETA.10 -0.343
-0.439--0.247 Central Volume, V1, [dL] .THETA.2 37.5 36.5-38.4
Allometric exponent on V1 .THETA.8 0.382 0.271-0.499 Exponent on
HCT .THETA.9 -0.419 -0.656--0.208 Intercompartmental .THETA.3
0.0746 0.0594-0.184 Clearance, Q, [dL/h] Peripheral Volume, V2,
.THETA.4 6.92 3.80-13.8 [dL] IIV on CL, [%] .eta.1 24.3 20.5-27.7
IIV on V1, [%] .eta.2 13.4 11.0-15.5 Correlation between IIV on
.eta.12 0.548 Not calculated CL and V1 IOV on CL, [%] .eta.3 20.6
16.7-25.1 IOV on V1, [%] .eta.4 12.0 7.46-16.3 Correlation between
IOV .eta.34 0.639 Not calculated on CL and V1 Additive error, Phase
.THETA.5 0.421 0.172-0.612 1/2A study, [IU/dL] Additive error,
Phase 3 .THETA.6 0.208 0.126-0.275 study, [IU/dL] Proportional
error, [%] .THETA.7 13.6 12.0-15.3
[0537] The IIV and the residual errors are very low. The goodness
of fit diagnostics (FIG. 24) indicate that the model adequately
describes the data.
[0538] The population estimate for the clearance (CL) is 1.65 dL/h,
and Vss is 44.4 dL. The inter-individual variability (IIV) of CL is
moderate (CV=24.3%) and of central volume of distribution (V1) is
low (CV=13.4%). The inter-occasional variability (IOV) of both CL
and V1 is low (20.6 and 12.0% respectively). The additive residual
error is very low (0.208 IU/dL), and so is the proportional
residual error (13.6%), approximating the precision of the
one-stage clotting assay for FVIII activity. Von Willebrand Factor
(VWF) level was identified as the major covariate for CL.
Consistent with mechanistic knowledge (Lillicrap 2008), higher
levels of VWF yielded lower clearance values, reflecting the
protective role that VWF has on FVIII activity. This is reflected
in the negative exponent on VWF. Body Weight (BW) and Hematocrit
(HCT) were identified as weak covariates on V1. This is the first
population PK analysis that systematically describes and
characterizes the prolonged activity profile of the long-acting
rFVIIIFc.
[0539] Conclusion: The population PK model of rFVIII activity
adequately describes the observed activity-time profiles after long
term administration. The clearance of rFVIIIFc activity is lower
than the clearance reported for ADVATE.RTM., resulting in longer
duration of activity. The low IIV underlines the consistency and
homogeneity of the activity profiles. The low IOV indicates that
rFVIIIFc maintains stable and predictable activity with long term
administration over time. The set of covariates identified is
physiologically relevant. Therefore, the population model developed
can be used to simulate various dosing scenarios in support of
dosing regimen selection and other decision making related to
rFVIIIFc therapy.
[0540] The model was used to predict the activity time profile
following a single dose of rFVIIIFc in patients with severe
hemophilia A. In addition the model was used to predict trough
activity for three different prophylaxis regimens.
[0541] Table 19 presents the model-predicted steady state peaks and
troughs of the rFVIIIFc activity-time profiles with 50 IU/kg dose
administered every 3, 4, or 5 days. The simulated steady-state
activity profiles are presented in FIG. 25.
TABLE-US-00019 TABLE 19 Predicted Steady-State Peaks and Troughs of
rFVIIIFc Activity-Time Profiles with 50 IU/kg Dose Administered
Every 3, 4, or 5 Days Dosing Frequency Percentile of Every 3 Days
Every 4 Days Every 5 Days Subjects Peak Trough Peak Trough Peak
Trough Median (5.sup.th, 95.sup.th 102 5.27 100 2.32 98.5 1.10
prediction (70.4, (0.774, (69.9, (<0.5a, (69.1, (<0.5,
interval) 149) 20.4) 141) 11.4) 139) 6.17)
[0542] A dosing regimen of 50 IU/kg every 5 days is predicted to
yield troughs above 1 IU/dL in 53.4% of individuals and a dosing
regimen of 65 IU/kg administered weekly is predicted to yield
troughs above 1 IU/dL in 26.6% of the individuals treated.
[0543] The population PK models for rFVIIIFc and ADVATE.RTM.
adequately described the combined activity data from the two
clinical studies. The major covariate for rFVIIIFc activity
identified by the population PK analysis was VWF level on CL.
Weight and hematocrit were identified as minor covariates on the
central volume of distribution. The results from the simulations
support the dosing recommendations derived from the Phase 3 study
results and can be used to aid dosing regimen selection and
adjustment.
[0544] Simulation of Regimens for Perioperative Management
[0545] According to the WFH Guidelines, minor surgical procedures
may require the attainment of target factor levels of 50 to 80
IU/dL, which can be achieved with a single rFVIIIFc infusion of 25
to 40 IU/kg. If a finer adjustment of the target is desirable, the
required rFVIIIFc dose can be determined based on the predicted
activity profiles in Table 20, below:
TABLE-US-00020 TABLE 20 Predicted rFVIIIFc Activity-Time Profiles
(in IU/dL) After a Single Administration Time (h) Dose EOI 12 24 36
48 72 96 (IU/kg) Median (5.sup.th, 95.sup.th Prediction Interval)
20 38.7 22.7 13.4 7.92 4.72 1.79 0.763 (27.3, 54.5) (13.5, 35.0)
(5.79, 23.8) (2.44, 16.7) (1.06, 12.0) (<0.5*-6.52)
(<0.5*-3.63) 25 48.4 28.3 16.8 9.90 5.90 2.24 0.953 (34.2, 68.1)
(16.9, 43.7) (7.24, 29.8) (3.05, 20.8) (1.32, 15.0) (<0.5*-8.15)
(<0.5*-4.54) 30 58.1 34.0 20.2 11.9 7.07 2.69 1.14 (41.0, 81.7)
(20.2, 52.5) (8.69, 35.8) (3.66, 25.0) (1.59, 18.0) (<0.5*-9.78)
(<0.5*-5.44) 40 77.5 45.3 26.9 15.8 9.43 3.58 1.53 (54.7, 109)
(27.0, 70.0) (11.6, 47.7) (4.88, 33.3) (2.11, 24.0) (<0.5*-13.0)
(<0.5*-7.26) 50 96.8 56.6 33.6 19.8 11.8 4.48 1.91 (68.3, 136)
(33.7, 87.5) (14.5, 59.6) (6.10, 41.7) (2.64, 30.0) (0.615-16.3)
(<0.5*-9.07) 65 126 73.6 43.7 25.7 15.3 5.82 2.48 (88.9, 177)
(43.8, 114) (18.8, 77.5) (7.94, 54.2) (3.44, 38.9) (0.800-21.2)
(<0.5*-11.8) EOI = end of infusion. *BLQ values were set at
<0.5.
[0546] For major surgery, WFH recommends a stricter control of
Factor VIII dosing, with high activity levels attained in the
pre-operative period and during surgery, followed by stepwise
decrease of the activity levels during the post-operative period,
e.g., within 1 to 3 days, 4 to 6 days, and as long as needed. The
population PK model developed can be used as a tool to design such
complicated activity profiles.
[0547] An evaluation of the population PK model, similar to
external model validation, indicated that the population PK model
is in good concordance with the activity observed during the
surgical period. The correlation coefficient between the observed
and individual predicted activity during surgery is high (R=0.742).
The minimal discrepancies between observed and model-predicted
activities during surgery are not more than 10% and point to a
modest over-prediction associated with peak activity. This may be
due to minimal loss of rFVIIIFc during surgery, associated with
blood loss. For the surgeries performed in this study, the average
blood loss was less than 200 mL.
[0548] Table 21 presents the dosing times, doses, and predicted
FVIII activity for a hypothetical perioperative dosing regimen, to
achieve levels recommended by WFH Guidelines. The doses, times, and
administration as well as the predicted activities are listed for
each subsequent dose. All doses after the second one are
administered at 24-hour intervals. The resulting activity time
profile is presented in FIG. 26.
TABLE-US-00021 TABLE 21 Dosing Times, Doses and Predicted FVIII
Activity for a Hypothetical Perioperative Dosing Regimen for
rFVIIIFc Dosing Dosing Time Dose Trough (IU/dL) Day (h) (IU/kg)
Median (5.sup.th, 95.sup.th Prediction Interval) 0 0 60 0 12 50
67.3 (39.6, 105) 1 24 50 95.4 (50.7, 159) 2 48 50 67.0 (23.6, 140)
3 72 40 57.9 (19.0, 132) 4 96 40 48.1 (15.4, 119) 5 120 40 45.0
(14.8, 112) 6 144 40 44.0 (14.7, 109) 7 168 30 43.6 (14.7, 108) 8
192 30 36.9 (11.9, 95.6) 9 216 30 34.5 (11.3, 88.9) 10 240 30 33.6
(11.2, 85.6) 11 264 30 33.2 (11.2, 83.6) 12 288 30 33.0 (11.2,
82.4) 13 312 30 32.9 (11.1, 81.7)
[0549] Table 21 presents the dosing times, doses and predicted
FVIII activity for a simpler hypothetical perioperative dosing
regimen. All doses after the fourth dose are administered at 48 h
intervals. FIG. 27 shows the predicted FVIII activity for the
hypothetical perioperative dosing regimen in Table 22.
TABLE-US-00022 TABLE 22 Dosing times, Doses and Predicted FVIII
Activity for a Sample Perioperative Dosing Regimen II Dosing Dosing
Time Dose Trough (IU/dL) Day (hr) (IU/kg) Median [5.sup.th,
95.sup.th PI] 0 0 60 0 12 50 68.2 [39.8, 105] 1 24 50 97.7 [50.8,
160] 2 48 50 68.6 [23.7, 144] 4 96 50 22.0 [3.96, 75.1] 6 144 50
16.4 [3.32, 57.6] 8 192 50 15.6 [3.25, 52.7] 10 240 50 15.4 [3.23,
51.0] 12 288 50 15.3 [3.22, 50.4]
[0550] The model was used to predict FVIII activity in patients
during the post-operative period based on subjects' presurgery
baseline PK. In the Phase 3 study, there were 13 subjects who
underwent major and minor surgeries and also had their rFVIIIFc
activity measured during the perioperative period. These subjects
had variable dosing regimens and time intervals in perioperative
management. To check whether the observed FVIII activity during
this period (coded as OCC=0 in the database) are in agreement with
the population PK model, an evaluation, similar to external model
validation, was performed.
[0551] Predicted FVIII activity was largely consistent with
observed FVIII activity. FIG. 28 is a representative plot comparing
the predicted and observed FVIII activities within the first 21
days after the first rFVIIIFc surgical dose (n=13; 9 major
surgeries, 4 minor surgeries). There was good correlation between
the observed FVIII activity data and that predicted by the PK model
(relative prediction error 95% CI). The resulting Goodness of Fit
(observed DV, versus individual predicted, IPRED) diagnostics,
shown in FIG. 28, indicates that the population PK model is in
concordance with the activity observed during the surgical period.
The correlation coefficient between the observed and individual
predicted activity is high (R=0.742).
[0552] The nonparametric fit of the data, represented by the lower
line in FIG. 28, diverges only slightly from the identity line
(upper line). This divergence is not more than 10% and points to a
modest over-prediction in the region of high activity. This may be
due to minimal loss of rFVIIIFc during surgery, associated with
blood loss. For the surgeries performed in this study, the average
blood loss was less than 200 mL. These results indicate that the
surgical procedures that have been studied in the Phase 3 study had
no significant impact on the PK properties of rFVIIIFc.
[0553] In conclusion, it is feasible to develop a general dosing
guidance to achieve target FVIII levels recommended for
perioperative management in patients with haemophilia A using a
population PK model.
Example 10. Use of the Population Pharmacokinetic Model of rFVIIIFc
to Simulate or Estimate Individualized and Median Patient
Treatment
[0554] As is discussed in Example 9 or 11 or 16, the rFVIIIFc
population model that has now been developed can be used to
simulate (estimate) various dosing scenarios in support of dosing
regimen selection and other decision making related to rFVIIIFc
therapy.
[0555] For example, individualized patient treatment, e.g.,
pharmacokinetics (PK) and dosing regimens, can be selected using
Bayesian estimation (or similar machine learning algorithm) based
on the population pharmacokinetic (popPK) model described in
Example 9 or 11 or 16, (e.g., Table 18, 24, 25, or 33). In this
way, one can determine alternative prophylactic dosing regimens and
optimized dosing regimens for pen-operative management that have
not previously been studied in the A-LONG trials. Alternatively,
the selected dosing regimen is based on population PK (median PK)
rather than making an individualized selection.
[0556] In some embodiments, the rFVIIIFc popPK model of Example 9
or 11 or 16 (e.g., Table 18, 24, 25, or 33) is used without the
Bayesian or similar machine learning algorithm.
[0557] In some embodiments of this aspect of the invention, the
method is carried out on a computer-based system, e.g., a server, a
desk top computer, a lap top computer, a tablet, a hand held
device, or a smart phone. In some embodiments, the computer-based
system is a computer application. The computer-based system
includes a storage medium for the rFVIIIFc popPK model discussed in
Example 9 or 11 or 16, e.g., the parameters of Table 18, 24, 25, or
33. In some embodiments, the storage medium can also contain a
Bayesian estimating program, e.g., NONMEM or Phoenix NLME. E.g.,
Example 9 or 11 or 16; Kiang et al., Clin. Pharmacokinet 51:515-525
(2012).
[0558] In some embodiments, the system comprises two or more
computer-based systems. In some embodiments, the user can input
information into a first computer-based system that communicates
with a second computer-based system, and the second computer-based
system carries out calculations and communicates output information
to the first computer-based system. This output information can
include recommendations about individualized or non-individualized
dosing regimens.
[0559] In some embodiments, the user inputs information into the
system and the system calculates and outputs one or more PK or
dosing regimens. In some embodiments, the system uses the received
information to calculate and output individualized or median PK
information. In some embodiments, the system calculates
individualized dosing or interval information.
[0560] Information that can be input by a user and received by the
system includes patient information and desired treatment outcome
information. Based on the type and value of the received
information, the computer-based system calculates output
information based on the rFVIIIFc popPK model and optional machine
learning algorithm on the storage medium.
[0561] Patient information includes, e.g., age, Von Willebrand
Factor (VWF) level, hematocrit (HCT), body weight (BW), diagnostic
(baseline) FVIII level, PK determinations, time of PK sampling,
dosing history if PK samples were taken from multiple doses, actual
dose, FVIII activity level, etc.
[0562] Desired treatment outcome information includes desired PK or
desired regimen outcome, e.g., desired rise in plasma FVIII
activity level following dose, desired dosing interval, and desired
dose.
[0563] Based on the information that was input and received by the
system, the system can output various information, e.g., PK curve,
PK parameter such as incremental recovery (Cmax/dose), mean
residence time, terminal t1/2, clearance, Vss, AUC/dose, doses and
associated troughs, and intervals and associated troughs.
[0564] For example, for assessing individualized patient PK, the
system can recommend that the user input 2-3 optimized PK sampling
time points. In this case, system output can include PK curve and
one or more selected PK parameters, e.g., incremental recovery
(Cmax/Dose), mean residence time, terminal t1/2, clearance, Vss,
AUC, and time to 1 or X %, etc. E.g., FIG. 13.
[0565] As additional examples, to select an individualized dosing
regimen using the output individual PK parameters discussed in the
preceding paragraph, (i) the dose selected for acute treatment can
be based on user input of the desired rise in plasma FVIII activity
level following the dose, (ii) the dose selected for prophylaxis
can be based on user input of the desired dosing interval, or (iii)
the selected interval for prophylaxis can be based on user input
for the desired dose. In the first case, the system can output the
dose (IU) based in the patient's incremental recovery. E.g., FIG.
14. In the second case, system output can be a table of doses and
associated troughs, e.g., x IU/kg, 1% trough, y IU/kg, 2% trough,
etc. E.g., FIG. 15, top. In the third case, system output can be a
table of intervals and associated troughs, e.g., x days, 1% trough,
y IU/kg, 2% trough, etc., E.g., FIG. 15, bottom.
[0566] The user may wish to use the system without inputting any
individualized PK data. In this case, the dosing output would be
based on the population median rather than being individualized for
the particular patient. E.g., FIG. 29. In this way, the user
inputs, e.g., body weight and age, and (i) the desired rise in
plasma FVIII activity level following the dose, (ii) the desired
dose interval for prophylaxis, or (iii) the desired dose for
prophylaxis. In the first case, the system can output the dose. In
the second case, the system can output the dose and associated
trough. E.g., Table 20 In the third case, the system can output the
interval and associated trough. E.g., Table 19.
[0567] Age can be input to determine if the system is suitable for
the patient because the current version of the popPK model was
built for patients 12 years and older.
[0568] In some embodiments, the system is compliant with patient
privacy laws. In some embodiments, the system is encrypted, e.g.,
with SSL. In some embodiments, input patient information is made
anonymous.
[0569] In some embodiments, the system includes a user help
function.
[0570] The user can be, e.g., a physician, a nurse, or another
healthcare practitioner.
[0571] In some embodiments, the method further includes selecting a
dosing regimen based on the system's output information and
administering rFVIIIFc to the patient according to the selected
regimen.
Example 11. Population Pharmacokinetics of Recombinant Factor
VIII:Fc
[0572] Abstract
[0573] Population pharmacokinetics (PK) of FVIII activity-time
profiles following recombinant factor VIII Fc fusion protein
(rFVIIIFc) and recombinant factor VIII (rFVIII) dosing were
evaluated in treated patients with severe hemophilia A (from two
clinical trials). Potential covariates were determined. A
2-compartment model adequately described the PK of both compounds.
Von Willebrand Factor (vWF) concentration was the major covariate
for rFVIIIFc clearance, reflecting its protective role in FVIII
activity clearance. The effect of body weight and hematocrit on the
central volume of distribution (V1) of rFVIIIFc was minor. The
population PK for rFVIII demonstrated similar behavior to that in
the published literature. The results of these analyses confirmed
that rFVIIIFc clearance (1.65 dL/h) is much lower than that of
rFVIII (2.53 dL/h), while V.sub.1 at steady state was similar. The
strong positive correlations between the PK parameters of rFVIIIFc
and rFVIII suggest that individuals who have high time-related PK
characteristics with rFVIII are likely to have comparable
characteristics with rFVIIIFc. Steady-state activity-time profiles
for selected rFVIIIFc dosing regimens were simulated accounting for
model prediction uncertainty. These population PK analyses and
simulations provide a comprehensive characterization of the PK of
rFVIIIFc and rFVIII and may be useful for designing dosing
regimens.
Introduction
[0574] Hemophilia A is an X-chromosome-linked coagulation disorder
that primarily affects males, and occurs in approximately 1-2 per
10,000 live births. It is caused by mutations and/or deletions in
the F8 gene, resulting in a deficiency of factor VIII (FVIII)
activity. Severe hemophilia A is defined as a coagulation activity
of FVIII in plasma (FVIII:C) level <1% (<1 IU/dL), and
individuals with this severe form of the disease experience
recurrent spontaneous bleeding, primarily into the muscles and
joints, leading to joint damage and severe disability. This is
associated with a negative impact on psychosocial well-being and
quality of life.
[0575] Modern FVIII replacement therapy for hemophilia A relies on
the infusion of specific concentrates to substitute the deficient
or inactive endogenous FVIII. Such infusions are performed either
episodically (e.g., for on-demand treatment of bleeding or
before/during and after surgery) or prophylactically. Target factor
activity levels may vary depending on the dosing paradigm; for
acute bleeding such as during major surgeries, this may be as high
as 80 to 100 IU/dL, while the goal for prophylaxis is to maintain
trough activity levels >1 IU/dL.
[0576] Recombinant factor VIII Fc fusion protein (rFVIIIFc) is a
novel protein composed of a single B-domain-deleted human
coagulation FVIII molecule attached to the Fc domain of human
immunoglobulin G1 (IgG1), designed to offer a longer circulating
half-life (t.sub.1/2) than currently available FVIII products.
Clinical studies have confirmed this increase in t112 relative to
recombinant FVIII (rFVIII) and demonstrated the safety and efficacy
of rFVIIIFc for the prevention and treatment of bleeding episodes
in patients with hemophilia A.
[0577] The quantitative characterization of FVIII activity-time
profiles (referred to as pharmacokinetics [PK]) provides critical
information for determining dose levels and dosing frequencies to
achieve target therapeutic levels. Traditionally, the PK of most
marketed agents have been characterized by non-compartmental or
compartmental 2-stage methods. More recently, a number of
population PK models and model implementations for several FVIII
products have been published.
[0578] The objective of this example is to present the development
of a population PK model based on rFVIIIFc activity data in
individuals with severe hemophilia. The PK parameters of the model
were estimated and significant determinants (covariates) of
variability in rFVIIIFc PK in subjects with hemophilia A were
identified. The population PK model was then used to simulate
rFVIIIFc dosing regimens of interest. A population PK model for
antihemophilic factor ([recombinant], plasma albumin-free method),
a rFVIII product used as comparator in the clinical studies
performed, was also developed.
[0579] Methods: Clinical Studies
[0580] The clinical data that served as a basis for the population
PK model development originated from two studies--a phase 1/2a
(n=16) and a phase 3 study (n=164). These protocols were approved
by local institutional review boards/ethics committees, and the
studies were conducted in accordance with the International
Conference on Harmonization guidelines for Good Clinical
Practice.
[0581] The Phase 1/2a study was an open-label, crossover,
dose-escalation, multicenter study to determine the safety,
tolerability, and PK of a single intravenous (IV) injection of
rFVIIIFc in previously treated patients with severe hemophilia A.
(Powell J S, Josephson N. c, Quon D, et al, Safety and prolonged
activity of recombinant factor VIII Fc fusion protein in hemophilia
A patients. Blood, 2012, 119 (13), 3031-7). The study included two
cohorts dosed at the 25 IU/kg (Cohort A) and 65 IU/kg (Cohort B)
level. After screening and a minimum of 4 days initial washout
period, subjects from both cohorts received a single 25 IU/kg
(Cohort A) or 65 IU/kg (Cohort B) dose of rFVIII followed by a
3-day (Cohort A) or 4-day (Cohort B) blood sampling regimen for PK
assessment (see upper panel of Table 23 for the Phase 1/2a sampling
schedule). These patients then received a 25 IU/kg (Cohort A) or 65
IU/kg (Cohort B) single dose of rFVIIIFc followed by a 7-day
(Cohort A) or 10-day (Cohort B) blood sampling regimen for PK
assessment.
TABLE-US-00023 TABLE 23 Intensive sampling schedules in the Phase
1/2a and Phase 3 studies Study Arm/Cohort Agent Dose Sampling
Schedule Phase Cohort A rFVIII 25 IU/kg 0, 0.167, 0.5, 1, 3, 6, 9,
1/2a 24, 48, 72 h rFVIIIFc 25 IU/kg 0, 0.167, 0.5, 1, 3, 6, 9, 24,
48, 72, 96, 120, 168 h Cohort B rFVIII 65 IU/kg 0, 0.167, 0.5, 1,
3, 6, 9, 24, 48, 72, 96 h rFVIIIFc 65 IU/kg 0, 0.167, 0.5, 1, 3, 6,
9, 24, 48, 72, 96, 120, 168, 192, 216, 240 h Phase Arm 1 PK rFVIII
50 IU/kg 0, 0.5, 1, 6, 24, 48, 72 h 3 Arm 1 PK rFVIIIFc 50 IU/kg 0,
0.5, 1, 6, 24, 72, 96 and 120 h Arm 1 rFVIIIFc 50 IU/kg 0, 0.5, 3,
72, 96 h Non-PK Arm 2 rFVIIIFc 65 IU/kg 0, 0.5, 3, 72, 96 h Arm 3
rFVIIIFc 50 IU/kg 0, 0.5, 3, 72, 96 h
[0582] The Phase 3 study was an open-label, multinational,
multicenter study to evaluate the safety, PK, and efficacy of
rFVIIIFc administered as an IV injection to subjects with severe
hemophilia A, at least 12 years of age (Mahlangu J. et al. Phase 3
study of recombinant factor VIII Fc fusion protein in haemophilia
A, Lancet, submitted 2013). At study start, all subjects underwent
a washout of FVIII products for 72-96 hours followed by an initial
PK sampling. The study comprises 3 treatment arms:
[0583] In Arm 1 (n=118) patients received individualized
prophylaxis regimen, consisting of two subgroups--a Sequential PK
Subgroup and a Non-sequential PK Subgroup. Subjects assigned to the
Arm 1 Sequential PK subgroup received a single dose of rFVIII 50
IU/kg on Day 0 followed by semi-sparse blood sampling for PK
assessment over a 72-hour period (7 timepoints) according to the
schedules shown in Table 23 (lower panel). Following a washout
period, these subjects then received a single dose of rFVIIIFc 50
IU/kg followed by a semi-sparse PK sampling at 8 timepoints over a
120-hour period. PK profiling of rFVIIIFc 50 IU/kg was reassessed
12-24 weeks later. Subjects in Arm 1 non-sequential PK subgroup
received a single rFVIIIFc dose of 50 IU/kg of rFVIIIFc, on Day 0
followed by a semi-sparse PK blood sampling performed at 5
timepoints. Upon completion of the rFVIIIFc PK assessment, an
individualized prophylaxis regimen was established for each
individual in Arm 1 (both subgroups) based on their PK, in which
the dose (25-65 IU/kg) and dosing interval (3-5 days) were
determined to maintain a trough level of 1% to 3% rFVIIIFc
activity.
[0584] In Arm 2 (n=24) patients received a weekly prophylaxis
regimen. Subjects received a single rFVIIIFc dose of 65 IU/kg of
rFVIIIFc on Day 0 followed by a semi-sparse PK blood sampling
performed at 5 timepoints. After the PK assessment, subjects in Arm
2 were administered a fixed weekly prophylaxis rFVIIIFc dose of 65
IU/kg.
[0585] In Arm 3 (N=23) patients received episodic dosing regimen
with a single rFVIIIFc dose of 50 IU/kg of rFVIIIFc on Day 0
followed by a semi-sparse PK blood sampling performed at 5
timepoints. During the study, subjects in Arm 3 were treated
episodically at rFVIIIFc doses of 10-50 IU/kg depending on the
severity of the bleed.
[0586] In addition to the PK profiling, peak and trough
measurements were carried out periodically, at nominal times spread
over the whole course of study participation (e.g., peak/trough
collections at week 7, 14, 28, 38, 52, etc.) for subjects in Arms 1
and 2.
[0587] Assay Methodology
[0588] For the Phase 1/2a study, the FVIII activity was measured by
one-stage clotting (activated partial thromboplastin time [aPTT])
assay with a Siemens BCS-XP analyzer (Siemens AG, Erlangen,
Germany) with the use of commercial reagents (Dade Actin FSL;
Siemens Healthcare Diagnostics, Inc., Newark, Del., USA) and
calibration against a normal reference plasma (CRYOCHECK.TM.;
Precision Biologics, Dartmouth, Nova Scotia, Canada) traceable to
the World Health Organization (WHO) Fifth International Standard
for human plasma. In addition, FVIII activity was also measured by
a chromogenic substrate assay with the use of a commercially
available kit (Aniara BIOPHEN.TM. FVIII:C; Aniara, West Chester,
Ohio, USA) that complies with European Pharmacopoeia
recommendations. This assay was calibrated against normal human
reference plasma (ORKE45; Instrumentation Laboratory, Bedford,
Mass., USA), which also had a potency assigned against the human
plasma standard from the WHO Fifth International Standard. The
lower limits of quantification (LLOQ) for the aPTT and chromogenic
assays were 0.5 IU/dL and 0.4 IU/dL, respectively. In the phase 3
study, FVIII activity was measured using the one-stage aPTT assay
as outlined above.
[0589] Data Assembly and Manipulation
[0590] Datasets generated from both studies were merged together to
form the population PK analysis dataset. An occasion (OCC) variable
was added to the rFVIIIFc dataset to enable the inclusion of
inter-occasional variability (IOV) in the models. Occasions are
defined within each individual, as clusters of observations,
separated from previous observations by at least 1 week of dosing.
Occasions 1 and 2 are reserved for the Baseline (first) and Repeat
(second) intensive PK sampling period. The rest of the occasions
are allocated to trough and peak measurements, and as such,
represent sparse observation periods.
[0591] Some missing covariate values were imputed by substituting
with a typical (median) value. Where missing covariate values could
not be imputed, these were replaced by negative values and ignored.
Where only a fraction of the covariate values for a given
individual were missing, they were imputed from the remaining
values by a LOCF (Last Observation Carried Forward) technique--this
was the case for von Willebrand Factor (VWF) antigen levels, IgG1
levels (IGG1), and hematocrit (HCT).
[0592] Baseline Correction and Residual Decay
[0593] Activity levels observed before administration of a rFVIII
product represent a combination of endogenous activity (baseline)
and residual activity from pre-study drug. To account for that,
baseline and residual drug corrections were performed on the
observed FVIII activity results for both rFVIIIFc and rFVIII.
Similar corrections are typical for PK analyses of other FVIII and
factor IX products (Bjorkman S, C. M., Berntop E, Pharmacokinetics
of Factor IX in patients with hemophilia B. Eur J Clin Pharmacol,
1994. 46: p. 325-332; Carlsson M, B. S., Berntop E, Multidose
pharmacokinetics of factor IX: Implications for dosing in
prophylaxis. Hemophilia, 1998. 4: p. 83-88; Bjorkman S, S. A.,
Berntop E, Pharmacokinetics of recombinant factor IX in relation to
age of the patients: Implications for dosing in prophylaxis.
Hemophilia, 2001. 7: p. 133-139; Bjorkman S, O. M., Spotts G, et
al., Population pharmacokinetics of recombinant factor VIII--the
relationships of pharmacokinetics to age and body weight. Blood,
2012. 119: p. 612-618 ("Bjorkman 2012 A"); Bjorkman S, A. V.,
Population pharmacokinetics of plasma-derived factor IX in adult
patients with hemophilia B: Implications for dosing in prophylaxis.
Eur J Clin Pharmacol, 2012. 68(6): p. 969-77). These corrected
activity-time profiles were included in the population PK datasets.
It should be noted that only the first (baseline) rFVIII and
rFVIIIFc activity-time profiles were corrected for residual
decay.
[0594] Residual decay was performed using the terminal half-life
(t.sub.1/2) obtained from noncompartmental analysis (NCA) of the
raw, observed activity data. For the Arm 1 PK subgroup, rFVIII and
Baseline rFVIIIFc PK profiles were decayed using the respective
subject's rFVIII t.sub.1/2. For the Arm 1 non PK subgroup, Arm 2,
and Arm 3, rFVIIIFc PK profiles were decayed using the average
rFVIII t.sub.1/1 obtained from the Arm 1 PK subgroup.
[0595] The pre-dose FVIII activity levels are a combination of
endogenous activity (baseline) and the residual activity from
previous pre-study drug administration(s). Therefore, the baseline
and residual drug corrections were performed on the observed FVIII
activity results prior to data analysis.
[0596] The baseline- and residual-corrected activity (FVIII:Ccorr)
is calculated from the actual observed activity (FVIII:Cobs) based
on the formula given below:
FVIII:Ccorr=FVIII:Cobs-Baseline Activity-Residual decay (Eq. X)
[0597] where the Residual decay=(Pre-dose Activity-Baseline
Activity)*e.sup.-.lamda.*time
[0598] Residual decay, to account for activity as a result of
previous administration of a FVIII product, was performed using the
terminal first-order decay rate (.lamda.) obtained from
noncompartmental analysis (NCA) of the raw, observed activity data.
The endogenous or baseline activity was set to zero for all
subjects in the above equation.
[0599] For the Arm 1 sequential PK subgroup, the FVIII activities
following Advate and Baseline rFVIIIFc PK administrations were
decayed using the respective subject's Advate .lamda.. The FVIII
activity-time profiles resulting from rFVIIIFc infusions for the
subjects in Arm 1 non-sequential PK subgroup, Arm 2, and Arm 3 were
decayed using the average Advate .lamda. obtained from the Arm 1
sequential PK subgroup.
[0600] Population Analysis Methodology
[0601] Two population PK models were developed independently of
each other--one for rFVIIIFc, based on the rFVIIIFc data, and one
for rFVIII, based on the rFVIII data alone.
[0602] Mixed-effects modeling with maximum likelihood parameter
estimation methods were used to evaluate the population
characteristics of rFVIIIFc and rFVIII in hemophilia A patients.
For the description of random inter-individual variability (IIV), a
log-normal distribution of the random effects, with a block
covariance matrix was used. Various random residual error
configurations were tested by combinations of additive and
proportional variance terms. Inclusion of IOV to account for the
change in the system properties with time was evaluated. First
order conditional estimation with interaction (FOCEI) method was
implemented for parameter estimation.
[0603] Diagnostic plots, minimum value of the objective function
(OFV), and the evaluation of shrinkage were used to guide model
building and assess goodness-of-fit. The Likelihood Ratio Test was
used to compare hierarchical models.
[0604] The base pharmacokinetic model was developed by exploring
typical structural models, including one- and two-compartment
linear models. Models were compared by goodness-of-fit diagnostics
including the Likelihood Ratio Test (significance level of 0.01,
change in objective function value (OFV)=6.64 for 1 degree of
freedom [df]), diagnostic plots, and estimates and standard errors
of model parameters. The statistical model was built by testing and
discriminating between various IIV and IOV structures and between
different combinations of additive and proportional residual error
terms. Candidate models were run from a number (usually 25-50) of
different randomly generated initial estimates to assess the model
stability and convergence.
[0605] Weight (WT) and Study (STUD), although technically assumed
covariates, are sometimes considered as intrinsic to the basic
model as their inclusion can be postulated a priori. For this
reason the base models developed included these covariates.
[0606] The following factors were considered as potential
covariates: height, age, race, blood type, hematocrit, von
Willebrand factor antigen levels, IgG1 levels, albumin levels,
non-neutralizing antibody (ADA) presence, HCV status, HIV
status.
[0607] The continuous covariates were centered around a standard
value--usually the median of the study population. For the forward
covariate inclusion procedure, the Likelihood Ratio Test was used
to compare hierarchical models with a significance level of 0.01.
Decrease in the respective IIV term and other Goodness of Fit
measures were also considered for inclusion. Once the full
population covariate model was constructed a stepwise backwards
deletion method with a significance level of 0.001 (change in
objective function value=10.8 for 1 degree of freedom) was used to
determine the final model. In all cases, physiological relevance of
the covariates was considered before accepting a covariate.
[0608] A bootstrap procedure (nominally 1000 bootstraps),
implemented by the bootstrap function of the Perl speaks NONMEN
software package (PsN) was used to characterize the uncertainty in
the model parameter estimates. Nonparametric 95% confidence
intervals (CI) of all parameters were constructed based on the
bootstrap results.
[0609] The predictive ability of the final model(s) was evaluated
using simulation in a visual predictive check (vpc) using the vpc
function of PsN. Outliers with |CWRES (Conditional Weighted
RESiduals)|>5 were evaluated for impact on the qualified models
by sensitivity analysis. Atypical drug activity data (such as very
low or very high activity levels, or data not compliant with the
trough-dose-peak sequence) were excluded from the analysis if no
apparent explanation for these observations was provided. Activity
data were excluded from the analysis if corresponding dosing or
sampling times were missing or could not be reconstructed.
[0610] In order to evaluate the impact of values below the level of
quantitation (BLQ), the analysis was performed using various
approaches, either (i) excluding the BLQ values or (ii) using
method(s) outlined in the literature to handle BLQ values (Beal,
S., Ways to fit a PK model with some data below the quantification
limit. J Pharmacokin Pharmacodyn, 2001. 28: p. 481-504; Jae Eun
Ahn, M. O. K., Adrian Dunne and Thomas M. Ludden, Likelihood based
approaches to handling data below the quantification limit using
NONMEM VI J Pharmacokin Pharmacodyn, 2008. 35(4): p. 401-21).
[0611] Simulations
[0612] A number of rFVIIIFc dosing regimens were simulated. During
the simulations, the activity-time profiles at Steady State (SS)
for 2000 individuals were generated. Weight characteristics of the
population simulated were derived from the Phase 3 study data.
Where IOV was part of the model, the SS dosing interval or period
simulated was set up as a single occasion. All dosing regimens were
simulated using the same value of the random seed(s) to ensure
comparability of the results. Simulation results are represented as
the median as well as the 5th, 25th, 75th, and 95th percentiles
activity-time curves.
[0613] Two types of simulation exercises were performed. In the
first type, simulations were performed with models without
including uncertainty in the model parameters. These simulations
were used to illustrate the dosing regimen of interest and to
derive parameters of therapeutic relevance (such as the percentage
of individuals with FVIII activity levels >1 IU/dL). In the
second type of simulation, univariate uncertainty distributions
were reconstructed from the bootstrap results and used to explore
the impact of modeling uncertainties on model predictions. The
uncertainty distributions were sampled 1,000 times and 2,000
individuals were simulated with each set of parameter values. The
90% CIs of the activity percentile profiles were calculated from
the simulated curves.
[0614] Software and Hardware
[0615] NONMEM (ICON plc, Dublin, Ireland, versions 7.1.2, and 7.2)
was used for population PK analysis with Intel Fortran compiler
(Intel Corporation, Santa Clara, Calif., version 11.1.048 and
version 12.1).
[0616] Most of the model development was done on a workstation with
a Quad Xeon Intel Processor and 8 GB of RAM. The computer intensive
procedures such as bootstraps, visual predictive checks, etc. were
run with up to 24 parallel cores on an HP 20-node cluster, each
node with 2 quad-core Intel Xeon E5630 (160 cores in total) at 2.53
GHz and 24 to 60 GB of RAM.
[0617] Results: Base Model for rFVIIIFc
[0618] The base model for rFVIIIFc is a two compartment model with
covariate WT on the central volume of distribution (V.sub.1); IOV,
and BLOCK(2) IIV on clearance (CL) and V.sub.1; common proportional
error, and separate additive residual error for the Phase 1/2a and
Phase 3 data (TVV.sub.1: typical apparent value for central volume
of distribution):
V 1 = TVV 1 [ WT 73 ] .THETA. 8 ( P ) add = STUD .THETA. 5 + ( 1 -
STUD ) .THETA. 6 , where STUD = { 1 for Phase 1 0 for Phase 3 . ( Q
) ##EQU00009## [0619] The population parameters and the
bootstrap-derived nonparametric 95% CIs are given in Table 24:
TABLE-US-00024 [0619] TABLE 24 Population parameters of the base
model for rFVIIIFc Method BLQ values commented out M3 Method
Population Nonparametric Population Parameter Symbol Estimate 95%
CI Estimate Clearance, CL, [dL/h] .THETA..sub.1 1.63 1.54-1.73 1.72
Central Volume, V.sub.1, [dL] .THETA..sub.2 37.9 36.9-38.8 36.4
Allometric exponent on V.sub.1 .THETA..sub.8 0.448 0.341-0.552
0.498 Intercompartmental Clearance, Q, [dL/h] .THETA..sub.3 0.0742
0.0581-0.187 1.15 Peripheral Volume, V.sub.2, [dL] .THETA..sub.4
6.77 3.83-12.7 5.79 IIV on CL, [%] .eta..sub.1 29.3 24.9-33.5 31.1
IIV on V1, [%] .eta..sub.2 13.5 11.3-15.5 13.8 Correlation between
IIV on CL and V.sub.1 .eta..sub.12 0.464 N.C. .sup.a 0.461 IOV on
CL, [%] .eta..sub.3 20.7 16.5-25.1 21.9 IOV on V.sub.1, [%]
.eta..sub.4 12.2 7.81-16.2 10.5 Correlation between IOV on CL and
V.sub.1 .eta..sub.34 0.643 N.C. .sup.b 0.558 Additive error, Phase
1/2a study, [IU/dL] .THETA..sub.5 0.419 0.150-0.634 0.469 Additive
error, Phase 3 study, [IU/dL] .THETA..sub.6 0.207 0.112-0.270 0.264
Proportional error, [%] .THETA..sub.7 13.7 12.1-15.5 14.6 .sup.a
Nonparametric 95% CI of 0.00972-0.0281 for a population mean of the
covariance .omega. 12 of 0.0184 .sup.b Nonparametric 95% CI of
0.00637-0.0310 for a population mean of the covariance .omega.34 of
0.0163
[0620] The observation records containing BLQ activity values were
excluded while developing the base model. In order to assess the
influence of the BLQ values on the population estimates, these data
records were re-introduced and the estimation was re-run using the
M3 and M4 methods. Those runs experienced some instability in both
the estimation and covariance steps; M4 was more unstable than M3.
When an Importance Sampling estimation step (METHOD=IMP) was
implemented following the FOCEI estimation, both the minimization
and covariance step converged with the M3 method. Despite the
inherent estimation instability with the inclusion of the BLQ
values, whenever the estimation converged, the parameter estimates
were very close to the estimates obtained in the same model that
excluded BLQ values (see Table 24, last column).
[0621] Covariate Model Building and Final Model for rFVIIIFc
[0622] As a result of the forward covariate inclusion, the full
covariate model was identified, with VWF, AGE, and Hepatitis C
virus (HCV, binary) as covariates on CL, and hematocrit (HCT), in
addition to the base model WT and STUD as covariates on the central
volume of distribution (V.sub.1).
[0623] According to the accepted mechanistic hypothesis about the
influence of antibodies on protein kinetics, the presence of
antibodies usually increases the clearance of the target proteins
by speeding up their rate of elimination. The incidence of
antibodies in the dataset was low--5 individuals had antibodies at
baseline, while 6 individuals acquired antibodies during the course
of the clinical trial. It should be noted also that the antibody
detection was transient within the same individual.
[0624] Testing the antibody presence (ADA) as a binary covariate on
V.sub.1 unexpectedly led to a statistically significant drop in the
OFV, while the influence on ADA on clearance was negligible. A
closer inspection of the model revealed that although the drop in
the OFV was statistically significant, the IIV term on V.sub.1
decreased only marginally (from 0.018 in to 0.0173) following the
covariate inclusion. The V.sub.1 in the presence of antibodies
increased by 18%, which is unlikely to be clinically meaningful. A
possible explanation for the assignment of the ADA covariate to the
V.sub.1, rather than to the clearance, is the dominant influence of
those individuals who are antibody-positive at baseline over the
individuals who acquire antibodies during therapy.
[0625] Due to the small number of those individuals as well as the
transient character of the antibody response, the antibody
covariate (ADA) on V.sub.1 was rejected. Thus, no definitive effect
of the presence of non-neutralizing antibodies on the PK of
rFVIIIFc activity could be detected by this analysis.
[0626] As a result of the backward elimination procedure, STUD
covariate on V.sub.1 as well as HCV and AGE covariates on clearance
were removed from the full covariate model without a significant
impact on the OFV. The removal of the HCT on V.sub.1, however, led
to a significant increase in the OFV, therefore HCT was
retained.
[0627] The final population PK model for rFVIIIFc was a two
compartment model with covariates VWF on CL, WT and HCT on V.sub.1,
IOV (7 occasions), BLOCK(2) variance-covariance matrix on CL and
V.sub.1, and separate additive residual error for the Phase 1/2a
and Phase 3 with a common proportional error term, as follows
(TVCL: typical apparent value for clearance):
CL = TVCL [ VWF 118 ] .THETA. 10 ( R ) V 1 = TVV 1 [ WT 73 ]
.THETA. 8 [ HCT 45 ] .THETA. 9 ( S ) add = STUD .THETA. 5 + ( 1 -
STUD ) .THETA. 6 , where STUD = { 1 for Phase 1 0 for Phase 3 ( T )
##EQU00010##
[0628] The population parameters of the final model and the
bootstrap-derived nonparametric 95% CIs are given in Table 25:
TABLE-US-00025 TABLE 25 Population parameters of the final model
for rFVIIIFc Method BLQ values commented out M3 Method Population
Nonparametric Population Parameter Symbol Estimate 95% CI Estimate
Clearance, CL, [dL/h] .THETA..sub.1 1.65 1.57 to 1.74 1.73 Exponent
on VWF .THETA..sub.10 -0.343 -0.439 to -0.247 -0.391 Central
Volume, V.sub.1, [dL] .THETA..sub.2 37.5 36.5 to 38.4 36.8
Allometric exponent on V.sub.1 .THETA..sub.8 0.382 0.271 to 0.499
0.423 Exponent on HCT .THETA..sub.9 -0.419 -0.656 to -0.208 -0.412
Intercompartmental Clearance, Q, [dL/h] .THETA..sub.3 0.0746 0.0594
to 0.184 0.279 Peripheral Volume, V.sub.2, [dL] .THETA..sub.4 6.92
3.80 to 13.8 4.09 IIV on CL, [%] .eta..sub.1 24.3 20.5 to 27.7 25.1
IIV on V.sub.1, [%] .eta..sub.2 13.4 11.0 to 15.5 13.6 Correlation
between IIV on CL and V.sub.1 .eta..sub.12 0.548 N.C. .sup.a 0.563
IOV on CL, [%] .eta..sub.3 20.6 16.7 to 25.1 22.0 IOV on V.sub.1,
[%] .eta..sub.4 12.0 7.46 to 16.3 9.27 Correlation between IOV on
CL and V.sub.1 .eta..sub.34 0.639 N.C. .sup.b 0.526 Additive error,
Phase 1/2a study, [IU/dL] .THETA..sub.5 0.421 0.172 to 0.612 0.416
Additive error, Phase 3 study, [IU/dL] .THETA..sub.6 0.208 0.126 to
0.275 0.240 Proportional error, [%] .THETA..sub.7 13.6 12.0 to 15.3
15.4 .sup.b Nonparametric 95% CI of 0.00956-0.0264 for a population
mean of the covariance .omega.12 of 0.0179 .sup.c Nonparametric 95%
CI of 0.00579-0.0312 for a population mean of the covariance
.omega. 34 of 0.0158
[0629] As with the base model case, the influence of the BLQ values
on the population estimates was assessed by running the M3 method
on the final model with the BLQ values re-included in the dataset.
The run completed with a successful minimization, but the
covariance step was aborted, confirming the inherent instability
introduced by the inclusion of BLQ values. There are minimal
differences between the two sets of parameter estimates (Table 25);
all M3 method parameters, except the intercompartmental clearance
and the proportional error terms, lie within the nonparametric 95%
CI identified for the final model.
[0630] The Goodness of Fit (GoF) diagnostics of the final model are
shown in FIG. 30A-D; the results of a Visual Predictive Check are
presented in FIG. 31A-F.
[0631] The IIV of the activity was low to moderate. Typically, as
with other FVIII products (Bjorkman S, Blanchette V S, Fischer K,
et al., J Thromb Haemost., 8(4):730-736 (2010); Bjorkman S, Oh M,
Spotts G, et al., Blood, 119(2):612-618 (2010)) the CL had higher
IIV while the IIV of the volume of distribution, characterized by a
coefficient of variation (CV) of 13.4%, was very low. Similarly,
the IOV was low, which was in line with observations from other
FVIII products (Bjorkman S, Blanchette V S, Fischer K, et al., J
Thromb Haemost., 8(4):730-736 (2010); Bjorkman S, Oh M, Spotts G,
et al., Blood, 119(2):612-618 (2010)). As with the IIV, the IOV of
the clearance was higher than the IOV of the volume of
distribution.
[0632] The GoF plots indicate that the model fitted the
experimental data very well, specifically at the lower end of the
activities (which is the range of interest with respect to
therapeutic effects). There were no systematic deviations or shapes
detectable in the residual plots and no notable deviations from the
symmetry distribution assumption for most of the exponential
inter-individual variability (ETA) terms.
[0633] The residual error values for both the base and the final
models were very low. The additive error was less than the LLOQ.
The proportional error was of the same magnitude as the precision
of the assay (CV <10%). This showed that the final model had
almost completely extracted the information contained in the data;
the unexplained variance was almost exclusively due to the inherent
activity assay variability.
[0634] The ETA shrinkage of the IIV terms was moderate, whereas the
ETA shrinkage on the IOV terms was higher (>25%) and was
especially high for occasions containing sparse data.
[0635] The results from both the base and the final models indicate
that the activity of rFVIIIFc does not display strong dependence on
weight. CL did not accept a WT covariate, while the retained WT
covariate on the V.sub.1 had a low value exponent (0.382 with 95%
CI of 0.271-0.499). This opens the opportunity of exploring fixed
(weight-independent) dosing regimens for rFVIIIFc if such are of
benefit to the patients.
[0636] AGE was included in the full covariate model as a very weak
covariate, which was cancelled during the backward elimination of
covariates. The dataset did not include individuals <12 years of
age. Therefore, the activity of rFVIIIFc is not impacted by age for
individuals aged >12 years.
[0637] External Validation of the rFVIIIFc Model
[0638] In order to further qualify the predictive performance of
the PK model, an external validation procedure was performed. A
model development (training) dataset was constructed, containing
the intensive sampled profiles from the two studies (a total of
1162 observation records in the training set). In addition, a model
validation set included all of the remaining observed data
(predominantly peak and trough observations, a total of 888
observation records in the validation set). As the first step of
the external validation, a model development procedure, similar to
the base model development, was carried out with the training
dataset. The parameters estimated from the whole dataset and from
the training dataset only were very similar (results not
shown).
[0639] At the validation step, the validation data (peak and trough
data for occasions 3 through 7) were re-introduced. The model was
run with parameter estimates set to the population means from the
training set model with the NONMEM option MAXEVAL=0. The GoF
diagnostics for the validation set only (troughs and peaks) are
shown in FIG. 32. There was a very good agreement between the
observed data in the validation dataset and the predicted data by
the model developed on the training set.
[0640] Base Model for rFVIII
[0641] The base model for rFVIII (model Adv0D) is a two compartment
model with covariates WT on V.sub.1 and study (STUD) on the
peripheral volume (V2), BLOCK(2) IIV on CL, V.sub.1, common
additive error and separated proportional residual error by
study:
V 1 = TVV 1 [ WT 73 ] .THETA. 8 ( U ) V 2 = TVV 2 [ .THETA. 9 ]
STUD ( V ) prop = STUD .THETA. 6 + ( 1 - STUD ) .THETA. 7 , where
STUD = { 1 for Phase 1 0 for Phase 3 ( W ) ##EQU00011##
[0642] The population parameters of model Adv0D and the
bootstrap-derived nonparametric 95% CIs are given in Table 26. No
IOV was included in Adv0D as only single dose data were available
for this agent. No covariate model was built in this case as
developing a full rFVIII model was outside the scope of this
modeling exercise.
[0643] The GoF diagnostics of model Adv0D are shown in FIG. 33.
TABLE-US-00026 TABLE 26 Population parameters and bootstrap-derived
nonparametric 95% CI's for the base ADVATE .RTM. model Population
Nonparametric Parameter Symbol Estimate 95% CI.sup.a Clearance, CL,
[dL/h] .THETA..sub.1 2.53 2.32-2.78 Central Volume, V.sub.1, [dL]
.THETA..sub.2 34.6 32.5-36.2 Allometric exponent on V.sub.1
.THETA..sub.8 0.508 0.277-0.762 Intercompartmental .THETA..sub.3
0.548 0.401-0.929 Clearance, Q, [dL/h] Peripheral Volume for Phase
3, .THETA..sub.4 4.94 3.82-6.51 V.sub.2, [dL] V.sub.2 Correcting
Coefficient for .THETA..sub.9 2.17 1.64-3.00 Phase 1/2a IIV on CL,
[%] .eta..sub.1 30.4 24.4-35.8 IIV on V.sub.1, [%] .eta..sub.2 16.2
11.4-19.3 Correlation between IIV on CL .eta..sub.12 0.532 N.C.
.sup.b and V.sub.1 IIV on V.sub.2, [%] .eta..sub.4 30.6 0.31-42.4
Additive error, [IU/dL] .THETA..sub.5 0.110 0.00110-0.256
Proportional error, Phase 1/2a .THETA..sub.6 10.9 8.42-12.6 study,
[%] Proportional error, Phase 3 study .THETA..sub.7 16.8 10.0-22.4
[%] .sup.aOut of 1000 bootstraps, 23 runs with minimization
terminated were skipped when calculating the bootstrap results.
.sup.b Nonparametric 95% CI of 0.00773-0.0442 for a population mean
of the covariance .quadrature..sub.12 of 0.0263
[0644] The narrow CIs of the rFVIII model parameter estimates
indicate that they were estimated with very good precision. V.sub.1
approximates the plasma volume, and the IIV of the activity was low
to moderate. The residual errors of Adv0D were very low, and the
additive error was less than one-quarter of the LLOQ. The
proportional errors for both studies were of the same magnitude as
the precision of the aPTT assay (CV <10%). This shows that Adv0D
almost completely captured the information contained in the data;
the unexplained variance was almost exclusively due to the
measurement errors. The model diagnostics suggest that the model
described the data adequately. There were no systematic deviations
or shapes detectable in the residual plots. The lower end of the
activities (which is the range of interest with respect to
therapeutic effects) was approximated very well.
[0645] Model Implementation: Simulations of Prospective Dosing
Regimens
[0646] The population PK models adequately describe the time course
of both rFVIII and rFVIIIFc activity. Therefore, they can be used
to simulate various dosing scenarios in the target population with
the aim to explore and compare the resulting activity profiles.
Such model based simulations have been widely used, especially in
recent years, and have become a valuable tool in support of
operational, regulatory, and therapeutic decision making.
[0647] In patients with hemophilia, it is widely accepted that 1
IU/dL (or 1% activity) is a threshold value under which the risk of
bleeding increases (Collins P W, B. V., Fischer K, et al.,
Break-through bleeding in relation to predicted factor VIII levels
in patients receiving prophylactic treatment for severe hemophilia
A. J Thromb Haemost., 2009. 7(3): p. 413-20; MASAC, Recommendation
#190 Concerning Products Licensed for the Treatment of Hemophilia
and Other Bleeding Disorders. March 2009 (Replaced by
Recommendation #215, November 2012). New York, N.Y.: National
Hemophilia Foundation). It should be noted, however, that the
threshold cannot be considered an "absolute criterion" by itself;
other factors, such as duration of time with low activity levels,
patient characteristics, etc. are likely also involved.
[0648] For the simulation of rFVIIIFc activity, the base model (Eq.
Q) was used. This was preferred to the final model as: (i) the base
model and the final model provided the same approximation of the
data; the final model only assigned part of the IIV to the
covariates selected, and (ii) no covariate model was developed for
rFVIII, so it is meaningful to compare simulations from base models
when FVIIIFc is referenced to rFVIII. In addition to that, at this
moment, the course of the time-variant covariates, VWF and HCT, has
not qualitatively characterized. In any case, the parameter values
of the base and final models from Tables 24 and 25 indicate that
the base model is adequate and can be used for simulations.
[0649] The simulations without uncertainty were performed with both
the base model without BLQ data (considered to be mildly
optimistic, see the Discussion section) and with the base model
with BLQ data included (considered to be conservative, see the
Discussion section). The simulations with uncertainty were based
upon the base model without BLQ values.
[0650] Several rFVIIIFc prophylaxis dosing regimens that are of
therapeutic interest have been simulated. Table 28 presents the
predicted SS peaks and troughs of the rFVIIIFc activity-time
profiles (5.sup.th, 25.sup.th, 50.sup.th [median], 75.sup.th, and
95.sup.th percentiles) at various dose levels administered every 3,
4, or 5 days (E3D, E4D, and E5D administration, respectively). The
top section of Table 28 displays the simulation results with the
base model with no BLQ data included and no uncertainty. The bottom
section of Table 28 displays the simulation results with the base
model with BLQ included and no uncertainty. The middle section of
Table 28 displays the simulation results with uncertainty in the
model parameters. The simulated SS activity profiles of selected
rFVIIIFc prophylaxis dosing regimens are given in FIG. 35 for
illustrative purposes. Panels A, C, E, and G display the
simulations without uncertainty; panels B, D, F, and H display the
90% confidence regions around the 5%, 50%, and 95% percentile
curves calculated from the uncertainty simulations.
[0651] These simulation results can be considered when determining
long-term prophylaxis dosing regimens. It should be noted also that
a dosing regimen of 65 IU/kg administered weekly (QW) is predicted
to yield troughs >1 IU/dL in 26.6% of the individuals treated
(also shown in FIG. 35, using the base model with no BLQ data), or
16.8% of the individuals treated (using the base model with BLQ
data). The 90% confidence region of these predictions is 14.6% to
35.8%. The dosing regimens simulated include dose levels and dosing
intervals that have been tested in the phase 1/2a and phase 3
studies. Therefore, the simulations can be considered to
interpolate within the existing clinical experience, increasing the
credibility of the predictions.
TABLE-US-00027 TABLE 27 Comparison of ADVATE .RTM. population PK
parameters from the current analysis and the analysis published in
Bjorkman 2012 A This Analysis Estimates from Parameter Estimates
[Bjorkman 2012a] Clearance, CL, [dL/h] 2.53 2.30* Allometric
exponent on CL Not estimated 0.8 Central Volume, V.sub.1, [dL] 34.6
28.6* Allometric exponent on V.sub.1 0.508 0.905 Intercompartmental
Clearance, 0.548 1.47 Q, [dL/h] Peripheral Volume, V.sub.2, [dL]
4.94 8.92* Allometric exponent on V.sub.2 Not estimated 0.76
V.sub.2 Correcting Coefficient for 2.17 Not estimated Phase 1/2a
IIV on CL, [%] 30.4 30.0 IIV on V.sub.1, [%] 16.2 21.0 Correlation
between IIV on 0.532 0.45 CL and V.sub.1 IIV on V.sub.2, [%] 30.6
Not estimated Additive error, [IU/dL] 0.110 8.90 Proportional
error, Phase 10.9 Not estimated 1/2a study, [%] Proportional error,
Phase 16.8 Not estimated 3 study [%] *CL, V1 and V2 calculated for
an average 73 kg, 30 yr old subject from equations 4-7 (Bjorkman
2012 A)
[0652] The dosing regimens simulated include dose levels (20-65
IU/kg) and dosing intervals that have been tested in the Phase 1/2a
and Phase 3 studies. Therefore, the simulations can be considered
to interpolate within the existing clinical experience, increasing
the credibility of the predictions.
TABLE-US-00028 TABLE 28 Predicted SS peaks and troughs of the
rFVIIIFc activity-time profiles with various dose regimens Unit
Percentile Dosing Frequency Dose of Every 3 Days Every 4 Days Level
Subjects Peak Trough Peak Trough 25 IU/kg 5% 35.2 <0.5.sup.a
34.9 <0.5.sup.a 50% 51.2 2.64 50.0 1.16 95% 74.5 10.2 70.7 5.69
40 IU/kg 5% 56.3 0.619 55.9 <0.5.sup.a 50% 82.0 4.22 80.0 1.85
95% 119 16.3 113 9.11 50 IU/kg 5% 70.4 0.774 69.9 <0.5.sup.a 50%
102 5.27 100 2.32 95% 149 20.4 141 11.4 25 IU/kg 5% 35.2 (33.8,
36.7) <0.5.sup.a (<0.5.sup.a, 0.545) 34.9 (33.7, 36.3)
<0.5.sup.a (<0.5.sup.a, <0.5.sup.a) 50% 51.5 (50.5, 52.5)
2.63 (2.23, 3.05) 50.0 (49.0, 51.0) 1.16 (0.895, 1.45) 95% 74.5
(72.0, 77.0) 10.3 (8.60, 12.2) 71.0 (68.5, 73.5) 5.80 (4.60, 7.05)
40 IU/kg 5% 56.3 (54.1, 58.6) 0.591 (<0.5.sup.a, 0.872) 55.8
(53.8, 58.0) <0.5.sup.a (<0.5.sup.a, <0.5.sup.a) 50% 82.4
(80.8, 84.0) 4.21 (3.57, 4.88) 80.0 (78.4, 81.6) 1.85 (1.43, 2.31)
95% 119 (115, 123) 16.5 (13.8, 19.4) 114 (110, 118) 9.28 (7.35,
11.3) 50 IU/kg 5% 70.4 (67.6, 73.3) 0.739 (<0.5.sup.a, 1.09)
69.8 (67.3, 72.5) <0.5.sup.a (<0.5.sup.a, 0.521) 50% 103
(101, 105) 5.26 (4.46, 6.10) 100 (98.0, 102) 2.31 (1.79, 2.89) 95%
149 (144, 154) 20.6 (17.2, 24.3) 142 (137, 147) 11.6 (9.19, 14.1)
25 IU/kg 5% 37.2 <0.5.sup.a 37.0 <0.5.sup.a 50% 52.9 2.54
51.6 1.01 95% 75.6 10.8 71.8 5.92 40 IU/kg 5% 59.5 <0.5.sup.a
59.2 <0.5.sup.a 50% 84.7 4.06 82.5 1.61 95% 121 17.2 115 9.47 50
IU/kg 5% 74.3 0.509 74.1 <0.5.sup.a 50% 106 5.07 103 2.01 95%
151 21.5 144 11.8 Unit Percentile Dosing Frequency Dose of Every 5
Days Level Subjects Peak Trough Model 25 IU/kg 5% 34.6
<0.5.sup.a Base model 50% 49.2 0.549 with 95% 69.6 3.08 BLQ
values 40 IU/kg 5% 55.3 <0.5.sup.a commented 50% 78.8 0.878 out
95% 111 4.94 50 IU/kg 5% 69.1 <0.5.sup.a 50% 98.5 1.10 95% 139
6.17 25 IU/kg 5% 34.3 (33.0, 35.9) <0.5.sup.a (<0.5.sup.a,
<0.5.sup.a) Base model 50% 49.3 (48.2, 50.5) 0.535 (0.5.sup.a,
0.69) with 95% 69.5 (66.5, 72.5) 3.1 (2.27, 3.96) BLQ values 40
IU/kg 5% 54.8 (52.7, 57.4) <0.5.sup.a (<0.5.sup.a,
<0.5.sup.a) commented 50% 78.8 (77.1, 80.8) 0.856 (0.560, 1.10)
out 95% 111 (106, 116) 4.96 (3.63, 6.34) (with 50 IU/kg 5% 68.5
(65.9, 71.7) <0.5.sup.a (<0.5.sup.a, <0.5.sup.a)
uncertainty)* 50% 98.5 (96.4, 101) 1.07 (0.700, 1.38) 95% 139 (133,
145) 6.20 (4.54, 7.92) 25 IU/kg 5% 35.8 <0.5.sup.a Base model
50% 51.0 <0.5.sup.a with 95% 70.9 3.27 BLQ (M3 40 IU/kg 5% 57.2
<0.5.sup.a method) 50% 81.5 0.619 95% 113 5.23 50 IU/kg 5% 71.5
<0.5.sup.a 50% 102 0.774 95% 142 6.54 .sup.aBelow the level of
quantification. *Simulation results shown as median and 90% CI
[0653] Other Implementations
[0654] Although the rFVIIIFc and rFVIII population PK models were
developed separately, a comparative evaluation of the individual
Bayesian PK parameter estimates of the subjects (from the Phase 1
study and the Arm 1 PK Subgroup of the Phase 3 study) who received
both rFVIII and rFVIIIFc indicates that they are highly correlated.
FIG. 36A-C presents the individual Bayesian CL, V.sub.1, and Time
to 1 IU/dL (Time 1%) estimates for rFVIII and rFVIIIFc, where each
point represents one individual. The correlation coefficients are
uniformly high: R=0.839 (R2=0.7043) for CL, R=0.862 (R2=0.7437) for
V.sub.1, and R=0.865 (R2=0.7481) for Time 1%.
Discussion
[0655] The generally narrow CIs of the parameter value estimates of
both the base and final rFVIIIFc models indicate that the
population PK parameters were estimated with good precision. The PK
behavior of the activity profiles as assessed by population
analysis is typical for a FVIII product (Bjorkman S, Oh M, Spotts
G, et al., Blood., 119(2):612-618 (2012)) with a peripheral
compartment much smaller than the central volume (V.sub.2 is >5
times lower than V.sub.1). The V.sub.1 approximates the plasma
volume.
[0656] By far the strongest covariate for rFVIIIFc identified in
this analysis was vWF on CL. As a result of the inclusion of the
vWF covariate on CL, the CV of the IIV on this parameter decreased
by approximately 20%. These results are expected, as the vast
majority of circulating FVIII (>95%) is in complex with vWF and
is protected from proteolytic degradation, premature binding to its
receptors, and rapid CL from the blood. The negative exponent on
vWF indicates that the higher the measured level of vWF, the lower
the rFVIII CL, which is in line with the above mechanistic
hypothesis.
[0657] The (across and within) individual range of vWF in the model
development dataset was in the range of 10-495%. The 10% value was
repeated and found to be erroneous (after database lock). This
would result in a variation of the rFVIIIFc CL from 3.85-1.10
dL/hr, the population mean being 1.65 dL/hr. It should be noted
that VWF is a time-varying parameter within the same individual.
The exact mechanisms and relationships governing this
within-individual variation are not well elucidated or
quantitatively characterized. A quantitative framework for the vWF
level IIVs needs to be combined with the current population PK
model to permit further investigation of the possible dosing
implications of the VWF covariate. Another time-varying covariate
that was identified was HCT on V.sub.1; however, the influence of
HCT was rather weak. Such a relationship has not been reported for
FVIII products previously and a mechanistic hypothesis linking HCT
with FVIII activity has not been proposed.
[0658] Although no definitive effect of non-neutralizing antibodies
on the observed activity was detected as a result of the population
PK analysis, due to the small number of subjects with antibodies
and the transient character of the antibody response, such an
effect cannot be totally excluded.
[0659] The results from the VPC and the simulations indicate that
both the full and the base model without the BLQ values (not shown)
in the dataset mildly overestimate the trough activity. For
example, with 65 IU QW dosing, the base model predicts that more
than one-quarter of the individuals will have trough values above
the 1 IU/dL threshold. This prediction can be compared with the
results from Arm 2 (weekly dosing with 65 IU/kg) of the phase 3
study, where 9 of 21 (42.9%) had troughs above 1 IU/dL at Week 7; 6
of 19 (31.6%) had troughs above 1 IU/dL at Week 14, and 1 of 6
(16.7%) had troughs above 1 IU/dL at Week 18. On the other hand,
both the full and base model with the BLQ values included seem to
underestimate the trough activity--using the base version of this
model predicts that 16.8% of the Arm 2 individuals will have
troughs >1 IU/dL. This apparent discrepancy is reconciled in the
simulations with uncertainty, where the predicted 90% CI include
any of the respective predicted troughs and peaks using either the
base model with or without BLQ values in the dataset (compare the
middle section with the top and bottom sections of Table 28). These
simulation results confirm the power of population PK model-based
simulations with uncertainty, which can be seen as a generalization
of the two alternative base models.
[0660] Evidence from the published literature (Bjorkman S,
Folkesson A, Jonsson S., A. Eur J Clin Pharmacol; 65(10):989-998
2009), Bjorkman S, Oh M, Spotts G, et al., Blood., 119(2):612-618
(2012)), as well as from the current research, indicates that FVIII
displays a 2-compartment disposition; however, the peripheral
compartment has a small V.sub.1 and its impact on the activity
profiles is very subtle. The weak influence of the second
compartment on the observed activity profiles has led to the
inability to fit a 2-compartment model to clinical data in at least
one instance (Karafoulidou A, Suarez E, Anastasopoulou I, et al.,
Eur J Clin Pharmacol.; 65(11):1121-1130 (2009)).
[0661] The mechanisms determining the observed shapes are not well
elucidated--as stated in Bjorkman S, Folkesson A, Jonsson S. A.,
Eur J Clin Pharmacol.; 65(10):989-998 (2009): " . . . It is still
not clear whether the 2-compartment characteristic reflects
distribution of FVIII from the circulation or rapid initial
elimination of some of the injected protein." In the absence of
well-defined mechanistic understanding, the information contained
in the clinical data available remains critical for model
selection.
[0662] The observed variation in the intercompartmental clearance
(Tables 24 and 25) leads to the effect that for the models (either
base or final) developed without BLQ data, the estimator captures a
curvature in the profiles due to the second compartment close to
the limit of detection. This behavior of the estimator is the
source of the apparent terminal t.sub.1/2 value. It should be
pointed out that: (i) such an overestimation occurs at very low
activities, close to the LLOQ; (ii) such an overestimation is not
likely to affect meaningfully the predictive performance of the
model within the time window of interest (up to 5-7 days); and
(iii) such an overestimation affects only a very small portion
(less than 2-3%) of the overall area under the curve associated
with the activities close to the LLOQ, where the divergence between
the models begins.
[0663] When the BLQ values were reintroduced into the dataset and
the M3 method was applied in NONMEM, the estimator seemed to move
the curvature due to the second compartment toward the initial
portion of the profile. It should be kept in mind that the M3
method treats the BLQ values as categorical variables and what
happens under the LLOQ is quantitatively unknown.
[0664] A similar effect was observed for the 2 variants of the
rFVIII base model (Table 26), where the model derived from phase
1/2a data overestimated terminal t.sub.1/2, whereas the model from
the phase 3 data provided a terminal t112 value in line with the
conventional analyses results. Similar to the rFVIIIFc models, the
mean residence time (MRT) and the Time to 1% were largely
unaffected. Based on this discussion, the rFVIIIFc models developed
from data without the BLQ values as well as the rFVIII model
reflective of the phase 1/2a data have the potential to
over-predict the activity during simulation. Such an
over-prediction within the time window of interest (up to 5-7 days)
is expected to be low. On the other hand, the models developed from
data with the BLQ values as well as the rFVIII model reflective of
the phase 3 data have the potential to under-predict the activity
during simulation. The impact of the model variation on the model
predictions were quantified by the simulations performed.
[0665] The results from the uncertainty simulations demonstrate
that any of the developed pivotal models (with and without BLQ
values, base and final, etc.) can be used for simulations without
an impact on the overall PK conclusions, provided that the random
nature of the predictions is acknowledged. The selection of the
simulation model should be determined by the objectives and/or the
context (eg, risk tolerance) of the simulation exercise. When risk
tolerance is low, the more conservative models (with the BLQ data
included) may be the best simulation option. For
population-oriented simulations (such as those shown in Table 28)
the base model simulation is adequate, whereas for
individual-oriented simulations, when the individual covariate
values are of interest, the final covariate model may be more
appropriate. It is suggested that simulations with uncertainty
should be the preferred option, accounting for the inherent
randomness of the simulations. It is also important to note that
when referencing between rFVIII and rFVIIIFc dosing regimens, it is
meaningful to use either the optimistic models for both agents, or
the conservative models for both agents to avoid the potential of
bias.
[0666] Although the external validation exercise was not conducted
in a random manner, the results emphasize the strong predictive
potential of the current population PK model and indicate that the
peak and troughs in the long term can be predicted by a model
developed on a semi-sparse sampling schedule. This represents one
possible treatment scenario, when the physician adjusts the dosing
regimen (initially or during the course of therapy) based on PK
information derived from more or less intensive sampling scheme.
Due to the low IOV, this adjustment is likely to be valid for
extended periods in the absence of abrupt changes in the system
state (such as illness, trauma, etc.).
[0667] There is a subtle difference between the rFVIII models
derived from the phase 3 data and the one identified from the phase
1/2a data--the peripheral volume of distribution V.sub.2 is 4.94 dL
from phase 3 and 2.17 times higher, when identified from phase 1/2a
data. This difference may originate from the difference in the
sampling schemes between the two studies (10-11 sampling points in
phase 1/2a and fewer sampling points in phase 3) and makes the
rFVIII phase 3 model more conservative with respect to predicting
trough values (predicts lower trough values) than the rFVIII phase
1/2a model. This subtle difference is built into the STUD covariate
(Table 26) and may account for any differences in design, assays,
execution, and other conditions across the 2 studies. No BLQ model
has been developed for rFVIII due to the very low number of BLQ
values in the rFVIII dataset as a result of the shorter sampling
window for this agent (see Table 23).
[0668] Table 27 shows that the FVIII population PK parameters from
the current analysis and the analysis published by Bjorkman S, Oh
M, Spotts G, et al., Blood, 119(2):612-618 (2010) are comparable,
although there are differences in the analysis methodology.
Bjorkman's model identified a weight dependence of CL and V.sub.2,
which was not substantiated by our data. Additionally, age was not
identified by our modeling as a covariate of rFVIIIFc clearance. It
is worth mentioning that the data used by Bjorkman S, Oh M, Spotts
G, et al., Blood, 119(2):612-618 (2010) include PK profiles from
subjects as young as 1 year; hence the, age and weight range in
this dataset may be considerably wider. The latter would facilitate
the identification of WT/AGE covariates from such data.
[0669] The high positive correlations between the PK parameters of
rFVIII and rFVIIIFc, illustrated in FIG. 36 A-C, suggest that
individuals who had high CL values for rFVIII are very likely to
have had high CL values for rFVIIIFc as well, and vice-versa. The
population PK models predicted that the average population CL for
rFVIIIFc (1.65 dL/hr) is about 35% lower than that of rFVIII (2.53
dL/hr). This is consistent with the geometric mean (95% CI) for the
intraindividual CL ratio of rFVIIIFc to rFVIII (0.64 [0.60-0.69])
derived from the conventional 2-stage compartmental analysis. At
the same time, the V.sub.1 panel of FIG. 36 A-C indicates that
individuals had similar V.sub.1 values for rFVIII and for rFVIIIFc.
These two relationships rise the hypothesis that individuals who
had high time-related characteristics (such as t.sub.1/2, MRT, Time
to 1%, and Time to 3%) for rFVIII are very likely to have had high
characteristics for rFVIIIFc, and vice-versa. This hypothesis was
confirmed in the Time 1% panel of FIG. 36 A-C, where the individual
Times to 1%, calculated based on the Bayesian estimates from the
rFVIII and rFVIIIFc model, are plotted.
[0670] Time to 1% activity is a PK outcome parameter that is
directly related to frequency of dosing under the paradigm of
maintaining target activity above this threshold. Therefore, based
on the relationship identified, a conclusion can be made, that
individuals who were on less frequent rFVIII dosing would require
less frequent rFVIIIFc dosing, and vice-versa. Such a relationship
could be useful when transition between the two products is
considered.
[0671] Conclusions
[0672] The population PK analysis and simulations presented provide
a comprehensive quantitative characterization of the activity-time
profiles for rFVIIIFc and rFVIII. These confirm that the CL of
rFVIIIFc is much lower than the CL of rFVIII, while the volumes of
distribution at steady state are similar. This was first observed
following noncompartmental analysis and conventional 2-stage
analysis of the same data and explain the extended duration of
activity achieved by rFVIIIFc relative to rFVIII.
[0673] The population PK model for rFVIIIFc was used for simulation
of various dosing scenarios to aid dosing regimen selection and
adjustment. Based on this, it was concluded that individuals on a
less frequent rFVIII dosing regimen would require less frequent
rFVIIIFc dosing, and vice-versa. Such a relationship could be
useful when transitioning from one agent to the other.
[0674] The population PK models are useful tools for predicting
peak, trough, and average activity of various dosing scenarios, and
can be further extended to develop aids and methods for
individualizing treatment. Many efforts have been made to correlate
activity levels with bleeding risk, although a definitive
quantitative relationship to calculate bleeding probability based
on activity has not yet been identified. These population PK models
may serve as a basis for the development of a population
PK/pharmacodynamics model to better understand the relationship
between FVIII activity and bleeding.
Example 12. Association of Bleeding Tendency with Time Under Target
FIX Activity Levels in Severe Hemophilia B Patients Treated with
Recombinant Factor IX-Fc Fusion Protein (rFIXFc)
[0675] The objective of this post hoc analysis was to evaluate the
relationship between the annualized time spent under target 1, 3,
and 5 IU/dL FIX activity levels and clinical outcomes (overall,
spontaneous, traumatic, and joint bleeds), as well as the
probability of experiencing bleeding episodes given time spent
under the target trough.
[0676] Subjects
[0677] Subjects enrolled in the B-LONG study with available
efficacy data were used for this analysis. This study included male
subjects (.gtoreq.12 years of age) with hemophilia B (FIX levels
.ltoreq.2 IU/dL), no history of FIX inhibitors, and .gtoreq.100
exposure days to FIX.
[0678] Design
[0679] B-LONG was a phase 3 interventional, nonrandomized,
open-label, multicenter study of rFIXFc in subjects with hemophilia
B.
[0680] Subjects were assigned by the investigator based on the
clinical site's standard of care to 1 of 4 treatment arms: Arm 1,
weekly prophylaxis (50 IU/kg every 7 days; dose adjusted to
maintain factor levels); Arm 2, individualized interval prophylaxis
(100 IU/kg dose, every 10 days; interval adjusted to maintain
factor levels); Arm 3, episodic (on-demand) treatment as needed for
bleeding episodes (20-100 IU/kg, depending on bleeding severity);
Arm 4, perioperative management.
[0681] The dose (in Arm 1) and the interval (in Arm 2) were
adjusted during the study to maintain a trough level of 1 to 3
IU/dL above baseline, or higher if clinically necessary. The end of
the study was defined as the point in time when pre-specified
criteria were reached (e.g., 53 subjects completed .gtoreq.50
rFIXFc exposure days, in conjunction with additional criteria).
[0682] Statistical Analysis
[0683] Data from the B-LONG study were used to evaluate the
relationship between bleeding tendency and FIX activity in
individuals with severe hemophilia B. A 3-compartment population
pharmacokinetics model of rFIXFc was developed based on the
activity-time profiles of 12 subjects from a phase 1/2a study 7 of
rFIXFc and 123 subjects from the B-LONG study.
[0684] Individual post hoc pharmacokinetic parameters were used to
construct continuous FIX activity-time profiles for each dose of
rFIXFc administered over the course of the study for all individual
subjects in the B-LONG study.
[0685] The cumulative time spent under the target trough FIX levels
of 1, 3, and 5 IU/dL for each individual on-study was calculated
and normalized to obtain an annualized time under the respective
target trough level, expressed in days. The time spent under the
target trough level (1, 3, or 5 IU/dL) is summarized by treatment
arm (individualized weekly prophylaxis, individualized interval
prophylaxis, and episodic treatment).
[0686] Negative binomial regression models, unadjusted and adjusted
for the number of pre-study bleeding episodes and pre-treatment
switch (i.e., switching from on-demand to prophylaxis), were used
to evaluate the association between the annualized time spent under
the target trough FIX activity levels of 1, 3, or 5 IU/dL and the
number of bleeding episodes experienced on-study Subjects.
Results
[0687] Of the 123 subjects in the study, 117 subjects in the
prophylactic and episodic arms had available information for
calculating time spent under target trough levels; 106 subjects had
available efficacy data for inclusion in multivariable models. Of
the 117 subjects evaluated for time under the target trough, 2
declined to switch to study drug, 1 did not participate in the
efficacy period, 7 were missing information regarding pre-study
bleeding episodes, and 1 was missing information regarding
pre-study treatment. Demographic and baseline characteristics for
these 106 subjects were consistent with that expected in the severe
hemophilia B population.
[0688] The median time under the target trough level is summarized
by treatment arm in Table 29. The annualized median time spent
under the 1 IU/dL target trough level in both prophylaxis arms was
0 days, while the annualized median time spent under the 1 IU/dL
target trough level in the episodic arm was 146.28 days.
TABLE-US-00029 TABLE 29 Annualized Time (Days) Under Target FIX
Trough Levels by Treatment Arm in the B-LONG Study.sup.a Weekly
Individualized Episodic Target prophylaxis interval prophylaxis
treatment trough level (N = 62) (n = 28) (n = 27) 1 IU/dL Mean (SD)
0.1 (0.81) 0.00 (0.00) 140.12 (95.79) Median 0.00 0.00 146.28 IQR
0.00, 0.00 0.00, 0.00 65.5, 214.2 3 IU/dL Mean (SD) 37.67 (43.47)
35.01 (32.39) 248.70 (76.33) Median 19.86 34.12 270.47 IQR 3.61,
64.92 8.87, 50.75 207.9, 298.6 5 IU/dL Mean (SD) 121.22 (73.28)
118.46 (52.84) 293.19 (43.06) Median 140.48 129.32 308.54 IQR
51.49, 178.5 78.74, 162.4 257.1, 302.6 FIX, factor IX; SD, standard
deviation, IQR, interquartile range. .sup.aThe median (IQR)
on-study weekly dose among subjects with time under target trough
information in Arm 1 was 45.2 IU/kg (38.1, 53.7 IU/kg; n = 61) and
in Arm 2 was 57.1 IU/kg (53.5, 68.9 IU/kg; n = 26).
[0689] The predicted ABRs by annualized time (in days) under the
targeting trough FIX levels of 1, 3, and 5 IU/dL based on the
adjusted negative binomial regression model are shown in FIG.
37.
[0690] Based on the unadjusted negative binomial regression model,
for every additional day spent under the target troughs of 1, 3,
and 5 IU/dL, there was an estimated increase in the overall ABR of
0.8%, 0.5%, and 0.5%, respectively (P <0.0001 for all
comparisons). Based on the adjusted negative binomial regression
model, for every additional day spent under the target troughs of
1, 3, and 5 IU/dL, there was an estimated increase in the overall
ABR of 0.5%, 0.3%, and 0.2%, respectively (P <0.05 for all
comparisons).
[0691] This is the first report to demonstrate a relationship
between bleeding tendency and time spent under 1, 3, and 5 IU/dL
FIX activity in hemophilia B subjects. The majority of subjects in
the prophylaxis arms (60%) did not spend any time under 1 IU/dL FIX
activity during the trial. Results of this study demonstrated a
significant association between increased duration of time spent
under a target therapeutic FIX activity level (1, 3, or 5 IU/dL)
and an increased bleeding tendency, after adjusting for baseline
bleeding tendency in the past 12 months and switching from an
on-demand therapy at baseline to a prophylaxis regimen on-study.
Although all trough levels were associated with changes in ABR, a
steeper slope was seen with a target trough of 1 IU/dL; hence, that
trough is more sensitive to change and potentially more meaningful
to subjects compared with troughs of 3 and 5 IU/dL. The statistical
power to determine a change in bleeding probability under a target
trough of 1 IU/dL was limited due to the relatively small number of
subjects spending time under this activity level. These results
confirm the importance of a minimum therapeutic threshold of 1
IU/dL for prophylactic FIX replacement therapy and provide
additional support for the use of 1% as the minimal trough level in
the population pharmacokinetic simulations for establishing
effective rFIXFc prophylaxis regimens.
Example 13. Dosing Long-Lasting Recombinant Factor VIII-Fc Fusion
Protein (rFVIIIFc)Clotting Factors
[0692] A-LONG Study Design
[0693] A-LONG is a phase 3, open-label, multicenter, partially
randomized study of the PK, efficacy, and safety of rFVIIIFc in
patients with severe hemophilia A.
[0694] METHODS: The study enrolled 165 subjects into 1 of 3
treatment arms (FIG. 38). In Arm 1, dosing recommendations were
based on individual subject PK evaluations to target a steady-state
FVIII activity trough of 1% to 3% (1-3 IU/dL) or higher, with
additional regimen adjustments made if the subject experienced
.gtoreq.2 spontaneous bleeding episodes over a rolling 8-week
period.
[0695] Study Population: Previously treated males aged .gtoreq.12
years with severe hemophilia A (<1 IU/dL [1%] endogenous FVIII
activity or severe genotype) and treated prophylactically, or
treated episodically and with a history of .gtoreq.12 bleeding
events in the 12 months prior to the study. Exclusion criteria:
history of inhibitors (neutralizing antibodies), history of
hypersensitivity associated with any FVIII concentrate or
intravenous immunoglobulin, or other coagulation disorders.
[0696] Prophylactic Dosing Subgroup Analysis: The subgroup of
subjects with .gtoreq.6 months on-study who were (1) previously on
prophylactic therapy (.gtoreq.2 injections/week) and assigned to
the individualized prophylaxis arm (Arm 1), or (2) previously
treated episodically and assigned to the weekly prophylaxis arm
(Arm 2; FIG. 38) was analyzed. Self-reported information collected
at the time of study enrollment from patient logs and/or hospital
records included prestudy prophylactic dose and dosing frequency
(infusions per week), and the number of bleeding episodes in the
prior 12 months. On-study parameters recorded included rFVIIIFc
dose and dosing interval (number of days), and the median ABR for
the last 3 months on-study, once subjects' treatment regimens had
stabilized. Subjects were stratified according to their final
on-study rFVIIIFc dose and dosing interval, and the corresponding
self-reported prestudy FVIII dose and infusion frequency were
analyzed. Subjects were also stratified according to their prestudy
FVIII infusion frequency, and their final on-study dosing interval
was examined. Population PK models for rFVIIIFc and ADVATE.RTM.
were developed based on A-LONG PK data (collected in 164 subjects
over .ltoreq.52 weeks of treatment, and in 30 subjects
participating in the sequential PK analysis, respectively), and
factors that may be determinants of variability in FVIII activity
were identified. Subjects were monitored for the development of
inhibitors and adverse events. The presence of inhibitors was
assessed by the Nijmegen-modified Bethesda assay. Descriptive
statistics included the median and interquartile range (IQR) values
for demographic characteristics, estimated number of prestudy
bleeding events, and on-study ABR for the prophylactic dosing
subgroups of Arms 1 and 2.
[0697] RESULTS: Study Participants--Baseline characteristics of the
subjects in the prophylactic dosing subgroups were consistent with
the overall A-LONG study population and were representative of a
population with severe hemophilia A (FIG. 38). Among Arm 1 subjects
previously treated prophylactically, >80% were on their prestudy
regimen for 12 months; the most common products used for
prophylaxis prior to study entry were Kogenate/Helixate (25/80
subjects; 31.3%) and rFVIII (22/80 subjects; 27.5%).
[0698] Dosing Interval Analysis: Nearly all subjects (79/80; 98.8%)
had a decrease in the number of prophylactic infusions administered
per week on-study compared with their self-reported prestudy
infusion frequency, as shown in FIG. 39. Prior to entering the
study, most subjects (65/80; 81.3%) reported a FVIII prophylactic
regimen of 3 times per week. On-study, the most common rFVIIIFc
prophylactic dosing intervals were every 3 days (29/80 subjects;
36.3%), twice weekly (23/80 subjects; 28.8%), and every 5 days
(24/80 subjects; 30.0%).
[0699] On-study rFVIIIFc Dosing: The median on-study rFVIIIFc dose
was 50 IU/kg, most commonly administered every 5 days (19/37
subjects; 51.4%), or every 3 days (16/37 subjects; 43.2% [Table 30,
solid box]). At study end, 22/80 subjects (27.5%) were taking the
twice-weekly starting regimen of 25 IU/kg on Day 1 and 50 IU/kg on
Day 4 (Table 30, dashed box). Comparison of individual subject
half-lives for rFVIII and rFVIIIFc in subjects from the A-LONG
sequential PK subgroup indicates a longer half-life for rFVIIIFc
compared with rFVIII (1.53-fold longer; P <0.0001), 5 which
supports the increased dosing intervals for rFVIIIFc observed in
the trial.
TABLE-US-00030 TABLE 30 Prescribed Prophylactic Dose and Dosing
Interval (End of Study) in Arm 1 Subjects Last on-study dosing
frequency Every Twice Every Every Dose per injection (IU/kg).sup.a
3 days weekly 4 days 5 days Total, n 25-35 4 -- -- -- 4 25/50.sup.b
-- ##STR00001## -- -- 22 40-45 2 1 -- -- 3 50 ##STR00002## -- 2
##STR00003## 37 60-65 7 -- 2 5 14 Total 29 23 4 24 80 .sup.aBlack
boxes indicate most common dose at study end (50 IU/kg); dashed box
indicates second most common regimen at study end (25 IU/kg (Day
1); 50 IU/kg (Day 4)). .sup.bInitial dosing regimen of 25 IU/kg on
Day 1, followed by 50 IU/kg on Day 4.
[0700] Factor Consumption: Overall, weekly factor consumption for
prophylaxis remained consistent for the majority of patients; the
median difference in weekly dose (last on-study minus prestudy) was
4.4 (data not shown) Prestudy median (IQR) weekly dose: 78.0 IU/kg
(60.0, 102.5). On-study (last 3 months) median (IQR) weekly dose:
79.2 IU/kg (72.1, 111.5).
[0701] Prior Episodic/Weekly Prophylaxis Subgroup (Arm 2): Per
protocol, dose and dosing interval were unchanged in Arm 2 during
the course of the study. The median (min, max) dose of rFVIIIFc was
65.9 (51.2, 76.5) IU/kg per week.
[0702] Efficacy Outcome: ABR: Median ABR in the last 3 months
on-study was lower than the self-reported prestudy median number of
bleeding episodes across all rFVIIIFc dosing interval subgroups, as
shown in FIG. 40. Overall, subjects in the prior
prophylaxis/individualized prophylaxis subgroup (Arm 1) reported a
median of 6.0 bleeding episodes in the 12 months prior to study; in
the last 3 months on-study they had a median ABR of 0.0. Subjects
in the prior episodic/weekly prophylaxis subgroup (Arm 2) reported
a median of 29.0 bleeding episodes in the 12 months prior to study;
in the last 3 months on-study they had a median ABR of 4.0.
[0703] Simulation of FVIII Activity (Population PK Modeling):
Dosing regimen simulations using population PK models of
ADVATE.RTM. and rFVIIIFc predicted the proportion of subjects who
would maintain a trough FVIII activity level at steady-state above
1 IU/dL (1%; FIG. 41). The values reported are the lowest and
highest predicted proportions of subjects, respectively, who would
remain protected (e.g., >1%) during the shortest and longest
portions of the dosing period, respectively.
Example 14. The Bleeding Tendency in Relation to Predicted FVIII
Activity Levels in Severe Hemophilia a Patients Treated with
Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc)
[0704] The objective of this post hoc analysis was to evaluate the
relationship between the annualized time spent under target 1
IU/dL, 3 IU/dL, and 5 IU/dL FVIII activity levels and clinical
outcomes (e.g., overall, spontaneous, traumatic, and joint bleeds),
as well as the probability of experiencing .gtoreq.1 bleed given
time spent under the target trough level.
[0705] METHODS: Subjects enrolled in the A-LONG study who had
available efficacy data were used in this analysis. The study
included previously-treated male subjects (.gtoreq.12 years of age)
with severe hemophilia A and no history of FVIII inhibitors.
Subjects on prophylaxis prior to study entry were assigned to
treatment in Arm 1, individualized prophylaxis (twice-weekly
dosing; 25 IU/kg on Day 1 and 50 IU/kg on Day 4 during the first
week, followed by 25-65 IU/kg every 3-5 days; dose and interval
adjusted to maintain factor trough levels of 1 to 3 IU/dL above
baseline, or higher if clinically necessary). Subjects on prior
episodic treatment were randomized to Arm 2, weekly prophylaxis (65
IU/kg), or Arm 3, episodic (on-demand) treatment as needed for
bleeding episodes (10-50 IU/kg, depending on bleeding severity).
The end of the study was defined as the point in time when
prespecified criteria were reached (e.g., 104 subjects completed
.gtoreq.50 rFVIIIFc exposure days, in conjunction with additional
criteria).
[0706] Data from the A-LONG study were used to evaluate the
relationship between bleeding tendency and FVIII activity in
individuals with severe hemophilia A. A two-compartment population
pharmacokinetics (PK) model of rFVIIIFc was developed based on
FVIII activity data collected from a total of 180 subjects (16
subjects from a phase 1 study and 164 subjects from the phase 3
A-LONG study). Individual post hoc PK parameters were used to
construct continuous FVIII activity-over-time profiles for each
dose of rFVIIIFc administered over the course of the study for all
individual subjects in the A-LONG study.
[0707] The cumulative annualized time spent under the target trough
FVIII levels of 1 IU/dL, 3 IU/dL, and 5 IU/dL, for each individual
on-study, was calculated and normalized to obtain an annualized
time under the respective target trough level, expressed in days.
The time spent under the target trough level (1 IU/dL, 3 IU/dL, and
5 IU/dL) is summarized by treatment arm (i.e., individualized
prophylaxis, weekly prophylaxis, and episodic treatment). Negative
binomial regression models, unadjusted and adjusted for the
annualized number of pre-study bleeding episodes and pre-treatment
switch (i.e., switching from on-demand to prophylaxis), were used
to evaluate the association between the annualized time under the
target trough FVIII levels of 1 IU/dL, 3 IU/dL, and 5 IU/dL and the
numbers of spontaneous, traumatic, and joint bleeds, and bleeds
overall. Logistic regression models, unadjusted and adjusted for
the number of pre-study bleeding episodes and pre-treatment switch,
were used to evaluate the association between the time spent under
the target trough level of 1 IU/kg, 3 IU/kg, and 5 IU/kg and the
probability of experiencing bleeding. Data were also stratified by
the type of bleed (e.g., spontaneous, traumatic, or joint
bleeds).
[0708] RESULTS: Of the 165 subjects who enrolled in the A-LONG
study, the time spent under the target troughs was calculated for
163 subjects; 162 subjects had available data for inclusion in
multivariable models. Demographic and baseline characteristics of
subjects enrolled in A-LONG were consistent with that expected in a
severe hemophilia A population (Table 31).
TABLE-US-00031 TALE 31 Baseline Demographic and Clinical
Characteristics Total A-LONG population Characteristic (n = 165)
Median (min, max) age, y 30.0 (12, 65) Median (min, max) weight, kg
71.60 (42.0, 127.4) Median (min, max) BMI, kg/m.sup.2 23.90 (15.3,
37.4) Race, n (%) White 107 (64.8) Asian 43 (26.1) Black 10 (6.1)
Other 5 (3.0) Geographic location, n (%) North America 56 (33.9)
Europe 41 (24.8) Other 68 (41.2) Received pre-study episodic
treatment, 78/165 (47.3) n/N (%) Estimated median (min, max) number
of 16 (0, 120) bleeding episodes during the 12 months prior to the
start of the study BMI, body mass index.
[0709] The annualized median time under the target trough level is
summarized by treatment group in Table 32 and FIG. 42. The
annualized median time spent under the 1 IU/dL target trough level
was 2.17 days in the individualized prophylaxis arm, 51.55 days in
the weekly prophylaxis arm, and 224.8 days in the episodic
treatment arm.
TABLE-US-00032 TABLE 32 Annualized Time (Days) Under Target FVIII
Trough Levels by Treatment Arm in the A-LONG Study.sup.a
Individualized Weekly Episodic Target prophylaxis prophylaxis
treatment trough level (n = 117) (n = 23) (n = 23) 1 IU/dL Mean
(SD) 9.5 (20.2) 54.81 (55.9) 200.7 (77.0) Median 2.17 51.55 244.8
IQR 0.00, 8.49 0.84, 98.81 140.3, 260.6 3 IU/dL Mean (SD) 50.19
(40.8) 126.2 (61.5) 246.3 (60.5) Median 43.72 130.3 266.6 IQR
21.75, 66.57 74.58, 176.7 195.2, 292.5 5 IU/dL Mean (SD) 91.36
(46.9) 159.6 (59.5) 267.1 (51.4) Median 92.39 167.3 284.0 IQR
66.44, 117.0 123.0, 205.8 225.8, 305.2 FVIII, factor VIII; SD,
standard deviation, IQR, interquartile range. .sup.aThe median
(IQR) on-study weekly dose among subjects with time under target
trough information in Arm 1 was 77.9 IU/kg (72.3, 91.2 IU/kg; n =
117) and in Arm 2 was 65.6 IU/kg (64.2, 68.2 IU/kg; n = 23).
[0710] The predicted ABRs by annualized time (in days) under the
target trough FVIII levels of 1 IU/dL, 3 IU/dL, and 5 IU/dL based
on the unadjusted and adjusted negative binomial regression models
are shown in FIGS. 43A and B, respectively. Based on both the
unadjusted and adjusted negative binomial regression models, a
significant increase was observed in the predicted overall ABR for
each additional annualized day under the target troughs of 1 IU/dL,
3 IU/dL, and 5 IU/dL (FIG. 43). Based on the unadjusted negative
binomial regression model, for every additional day spent under the
target troughs of 1 IU/dL, 3 IU/dL, and 5 IU/dL, there was an
estimated increase in the overall ABR of 1%, 0.9%, and 0.9%,
respectively (P <0.0001 for all comparisons). Based on the
adjusted negative binomial regression model, for every additional
day spent under the target troughs of 1 IU/dL, 3 IU/dL, and 5
IU/dL, there was an estimated increase in the overall ABR of 0.9%,
0.8%, and 0.8%, respectively (P <0.0001 for all comparisons).
For spontaneous bleeds, traumatic bleeds, and joint bleeds, a
significant increase was also observed in the predicted ABR for
each additional day under the target trough (1 IU/dL, 3 IU/dL, and
5 IU/dL), based on both the unadjusted and adjusted negative
binomial regression models (P.ltoreq.0.0003).
[0711] The adjusted probability of experiencing any bleed according
to the time (in days) under target trough FVIII levels of 1 IU/dL,
3 IU/dL, and 5 IU/dL is shown in FIG. 44. Results for the adjusted
probability of experiencing spontaneous, traumatic, or joint bleeds
according to time (in days) under target trough FVIII levels of 1
IU/dL, 3 IU/dL, and 5 IU/dL are also shown in FIG. 44. As the time
spent under the target trough FVIII levels of 1 IU/dL, 3 IU/dL, and
5 IU/dL increased, the adjusted probability of experiencing all
types of bleeding episodes increased.
Example 15. Pharmacokinetics of Recombinant Factor VIII Fc Fusion
Protein (rFVIIIFc) in Previously-Treated Children with Severe
Hemophilia A (Kids-ALONG)
[0712] Kids A-LONG was a phase 3 open-label study evaluating the
safety, efficacy, and pharmacokinetics of recombinant factor VIII
Fc fusion protein (rFVIIIFc), in previously treated children with
severe hemophilia A (endogenous FVIII level <1 IU/dL
[<1%]).
[0713] Methods: The study enrolled 71 subjects. The starting
rFVIIIFc regimen was twice-weekly prophylaxis (Day 1, 25 IU/kg; Day
4, 50 IU/kg); dose (.ltoreq.80 IU/kg) and dosing interval
(.gtoreq.2 days) were adjusted as needed. A subset of subjects had
sequential pharmacokinetic evaluations of FVIII and rFVIIIFc. The
primary endpoint was development of inhibitors (neutralizing
antibodies). Secondary endpoints included pharmacokinetics,
annualized bleeding rate (ABR) and number of infusions required to
control a bleed.
[0714] Results: No subject developed an inhibitor to rFVIIIFc.
Adverse events were typical of a pediatric hemophilia population.
rFVIIIFc half-life was prolonged relative to FVIII, consistent with
observations in adults and adolescents. The median ABR was 1.96
overall, and 0.00 for spontaneous bleeds; 46.4% of subjects
reported no bleeding episodes on study. 93.0% of bleeding episodes
were controlled with 1-2 infusions. The median average weekly
rFVIIIFc prophylactic dose was 88.1 IU/kg. At study end, 62/69 of
subjects (90%) were infusing twice-weekly. Among subjects
previously on FVIII prophylaxis, 74% reduced their dosing frequency
with rFVIIIFc.
[0715] Pharmacokinetics: Of the 60 subjects dosed with rFVIIIFc in
the pharmacokinetics subgroup, 54 (<6 years of age, n=23; 6 to
<12 years of age, n=31) had evaluable pharmacokinetic data by
the one-stage clotting assay. The activity-time profiles in both
age cohorts, adjusted for baseline and residual prestudy FVIII
activity, were adequately characterized by noncompartmental
analysis with moderate inter-subject variability. All numbers are
given in arithmetic mean (95% confidence interval). The terminal
half-life of rFVIIIFc in subjects aged <6 years of age and 6 to
<12 years of age was 12.67 (11.23, 14.11) hours and 14.88
(11.98, 17.77) hours, respectively. An age-dependent effect on
clearance was observed, with mean clearance higher in the younger
cohort of 3.60 (3.13, 4.07) mL/h/kg than in the older cohort of
2.78 (2.44, 3.13) mL/h/kg. Incremental recovery of rFVIIIFc was
consistent between the age cohorts (mean of approximately 2 IU/dL
per IU/kg) (with the younger cohort having 1.92 (1.80, 2.04) IU/dL
per IU/kg and the older cohort having 2.44 (2.07, 2.80) IU/dL per
IU/kg. The mean recovery time was 17.24 (15.40, 19.07) hours in the
younger cohort and 20.90 (17.06, 24.74) in the older cohort. The
volume of distribution at steady state was 58.58 (54.90, 62.27)
mL/kg for the younger cohort and 52.13 (45.25, 59.01) mL/kg for the
older cohort. The dose normalized area under the concentration-time
curve was 30.04 (26.45, 33.63) IU*h/dL per IU/kg for the younger
cohort and 41.87 (34.00, 49.75) IU*h/dL per IU/kg for the older
cohort.
Example 16. Population Pharmacokinetic Analysis of Long-Acting
Recombinant Factor VIII-Fc Fusion Protein (rFVIIIFc) in Adult,
Adolescent, and Pediatric Patients with Severe Haemophilia A
[0716] The population pharmacokinetic (popPK) data for the
adult/adolescent (.gtoreq.12 years) and pediatric studies discussed
above were combined to develop a new rFVIIIFc popPK model. As
before (see Examples 9 and 11; Tables 18, 24, and 25), a final
model (Table 33) was developed from base and covariate models.
TABLE-US-00033 TABLE 33 Final Model Population Parameter Estimates
and Bootstrap-derived Nonparametric 95% CI's Population %
Nonparametric Parameter Estimate RSE 95% CI.sup.a Clearance, CL,
[dL/h] 1.56 2.01 1.49, 1.64 Central Volume, V1, [dL] 32.8 1.22
31.5, 33.6 Intercompartmental Clearance, Q, [dL/h] 0.157 77.1
0.0468, 1.18 Peripheral Volume, V2, [dL] 2.93 19.9 2.41, 5.43
Allometric exponent on CL/Q 0.704 4.47 0.640, 0.760 Allometric
exponent on V1/V2 0.945 2.17 0.908, 0.987 Exponent on VWF~CL -0.413
10.1 -0.497, -0.330 .omega..sup.2.sub.CL (IIV; inter-individual
variability) 0.0585 12.4 0.0432, 0.0741 .omega..sup.2.sub.V1 (IIV)
0.0265 13.8 0.0198, 0.0337 Covariance.sub.CL:V1 (IIV) 0.0185 23.5
0.0109, 0.0266 .omega.2CL (IOV; inter-occasion variability) 0.0470
13.9 0.0342, 0.0604 .omega..sup.2.sub.V1 (IOV) 0.00987 41.9
0.00323, 0.0197 Covariance.sub.CL:V1 (IOV) 0.0110 40.2 0.00444,
0.0228 Additive error, Phase 1/2a study, [IU/dL] 0.402 20.3 0.172,
0.600 Additive error, Phase 3 and Pediatric study, [IU/dL] 0.217
14.6 0.161, 0.285 Proportional error, Phase 1/2a and Phase 3 study
[%] 15.4 8.44 12.7, 17.7 Proportional error, Pediatric study [%]
21.2 6.70 18.1, 24.3
[0717] The model-predicted steady state (SS) peaks and troughs of
the rFVIIIFc activity-time profiles for various rFVIIIFc dosing
regimens are presented in Table 34 (for adult/adolescents
(.gtoreq.12 years)), Table 35 (6 to <1 2 year) and Table 36
(<6 year age cohorts). These results can be considered when
determining the chronic dosing regimens for prophylaxis.
TABLE-US-00034 TABLE 34 Predicted steady state (SS) peaks and
troughs of the rFVIIIFc activity-time profiles with 50 IU/kg dose
administered every 3, 4, or 5 days for .gtoreq.12 years. Unit
Percentile Dosing Frequency Dose Of Every 3 Days Every 4 Days Every
5 Days Every 7 Days Level Subjects Peak Trough Peak Trough Peak
Trough Peak Trough 25 IU/kg 5% 37.8 <0.5.sup.a 37.0
<0.5.sup.a 36.7 <0.5.sup.a -- -- 25% 46.4 1.07 45.0
<0.5.sup.a 44.1 <0.5.sup.a -- -- 50% 53.1 2.39 51.1 0.922
50.1 <0.5.sup.a -- -- 75% 60.2 4.71 58.2 2.10 56.7 0.932 -- --
95% 73.3 10.6 69.9 5.49 68.5 2.79 -- -- 40 IU/kg 5% 60.5 0.522 59.2
<0.5.sup.a 58.7 <0.5.sup.a -- -- 25% 74.3 1.71 71.9 0.589
70.6 <0.5.sup.a -- -- 50% 85.0 3.83 81.7 1.48 80.2 0.613 -- --
75% 96.3 7.53 93.1 3.35 90.8 1.49 -- -- 95% 117 16.9 112 8.78 110
4.47 -- -- 50 IU/kg 5% 75.7 0.654 73.9 <0.5.sup.a 73.4
<0.5.sup.a -- -- 25% 92.9 2.14 89.9 0.737 88.3 <0.5.sup.a --
-- 50% 106 4.78 102 1.84 100 0.766 -- -- 75% 120 9.41 116 4.19 113
1.86 -- -- 95% 147 21.1 140 11.0 137 5.59 -- -- 65 IU/kg 5% 98.3
0.850 96.1 <0.5.sup.a 95.4 <0.5.sup.a 94.2 <0.5.sup.a 25%
121 2.78 117 0.958 115 <0.5.sup.a 114 <0.5.sup.a 50% 138 6.22
133 2.40 130 0.995 130 <0.5.sup.a 75% 157 12.2 151 5.45 148 2.42
146 0.586 95% 191 27.5 182 14.3 178 7.27 177 2.63 .sup.aBelow the
level of quantitation of 0.5 IU/dL.
TABLE-US-00035 TABLE 35 Predicted steady state (SS) peaks and
troughs of the rFVIIIFc activity-time profiles with various dose
levels administered every 3, 4, or 5 days for 6 to <12 years.
Unit Percentile Dosing Frequency Dose Of Every 2 Days Every 3 Days
Every 4 Days Every 5 Days Level Subjects Peak Trough Peak Trough
Peak Trough Peak Trough 25 IU/kg 5% 37.7 0.868 35.3 <0.5.sup.a
35.2 <0.5.sup.a 34.2 <0.5.sup.a 25% 45.6 2.29 43.1 0.586 42.3
<0.5.sup.a 41.6 <0.5.sup.a 50% 52.1 3.97 49.3 1.25 48.4
<0.5.sup.a 47.5 <0.5.sup.a 75% 59.7 6.40 56.3 2.35 54.7 0.921
54.0 <0.5.sup.a 95% 72.5 12.9 67.7 5.07 66.1 2.43 65.7 1.15 40
IU/kg 5% 60.3 1.39 56.5 <0.5.sup.a 56.3 <0.5.sup.a 54.7
<0.5.sup.a 25% 73.0 3.67 69.0 0.937 67.6 <0.5.sup.a 66.5
<0.5.sup.a 50% 83.3 6.34 78.9 2.00 77.5 0.638 76.0 <0.5.sup.a
75% 95.5 10.2 90.1 3.76 87.6 1.47 86.4 0.585 95% 116 20.6 108 8.12
106 3.88 105 1.85 50 IU/kg 5% 75.4 1.74 70.6 <0.5.sup.a 70.3
<0.5.sup.a 68.4 <0.5.sup.a 25% 91.3 4.58 86.2 1.17 84.5
<0.5.sup.a 83.1 <0.5.sup.a 50% 104 7.93 98.6 2.49 96.8 0.797
95.0 <0.5.sup.a 75% 119 12.8 113 4.70 109 1.84 108 0.731 95% 145
25.7 135 10.1 132 4.86 131 2.31 65 IU/kg 5% 98.0 2.26 91.8
<0.5.sup.a 91.4 <0.5.sup.a 88.9 <0.5.sup.a 25% 119 5.96
112 1.52 110 <0.5.sup.a 108 <0.5.sup.a 50% 135 10.3 128 3.24
126 1.04 123 <0.5.sup.a 75% 155 16.6 146 6.10 142 2.39 140 0.950
95% 189 33.4 176 13.2 172 6.31 171 3.00 80 IU/kg 5% 121 2.78 113
0.599 113 <0.5.sup.a 109 <0.5.sup.a 25% 146 7.33 138 1.87 135
0.552 133 <0.5.sup.a 50% 167 12.7 158 3.99 155 1.28 152
<0.5.sup.a 75% 191 20.5 180 7.51 175 2.95 173 1.17 95% 232 41.1
217 16.2 212 7.77 210 3.69 .sup.aBelow the level of quantitation of
0.5 IU/dL.
TABLE-US-00036 TABLE 36 Predicted steady state (SS) peaks and
troughs of the rFVIIIFc activity-time profiles with various dose
levels administered every 3, 4, or 5 days for <6 years. Unit
Percentile Dosing Frequency Dose Of Every 2 Days Every 3 Days Every
4 Days Every 5 Days Level Subjects Peak Trough Peak Trough Peak
Trough Peak Trough 25 IU/kg 5% 35.6 0.512 33.7 <0.5.sup.a 33.8
<0.5.sup.a 32.9 <0.5.sup.a 25% 42.9 1.43 41.1 <0.5.sup.a
40.6 <0.5.sup.a 40.1 <0.5.sup.a 50% 48.8 2.54 47.0 0.700 46.5
<0.5.sup.a 45.8 <0.5.sup.a 75% 55.9 4.22 53.5 1.39 52.4
<0.5.sup.a 51.8 <0.5.sup.a 95% 67.3 8.75 64.2 3.13 63.3 1.42
63.2 0.586 40 IU/kg 5% 57.0 0.820 54.0 <0.5.sup.a 54.0
<0.5.sup.a 52.6 <0.5.sup.a 25% 68.7 2.28 65.8 <0.5.sup.a
65.0 <0.5.sup.a 64.2 <0.5.sup.a 50% 78.1 4.06 75.3 1.12 74.3
<0.5.sup.a 73.2 <0.5.sup.a 75% 89.5 6.75 85.5 2.22 83.8 0.738
82.8 <0.5.sup.a 95% 108 14.0 103 5.01 101 2.27 101 0.938 50
IU/kg 5% 71.2 1.03 67.4 <0.5.sup.a 67.5 <0.5.sup.a 65.8
<0.5.sup.a 25% 85.8 2.85 82.2 0.613 81.2 <0.5.sup.a 80.2
<0.5.sup.a 50% 97.7 5.07 94.1 1.40 92.9 <0.5.sup.a 91.5
<0.5.sup.a 75% 112 8.44 107 2.78 105 0.922 104 <0.5.sup.a 95%
135 17.5 128 6.26 127 2.84 126 1.17 65 IU/kg 5% 92.6 1.33 87.7
<0.5.sup.a 87.8 <0.5.sup.a 85.5 <0.5.sup.a 25% 112 3.71
107 0.797 106 <0.5.sup.a 104 <0.5.sup.a 50% 127 6.59 122 1.81
121 0.505 119 <0.5.sup.a 75% 145 11.0 139 3.61 136 1.20 135
<0.5.sup.a 95% 175 22.7 167 8.14 165 3.69 164 1.52 80 IU/kg 5%
114 1.64 108 <0.5.sup.a 108 <0.5.sup.a 105 <0.5.sup.a 25%
137 4.56 132 0.981 130 <0.5.sup.a 128 <0.5.sup.a 50% 156 8.12
151 2.32 149 0.621 146 <0.5.sup.a 75% 179 13.5 171 4.44 168 1.48
166 0.542 95% 215 28.0 206 10.0 203 4.54 202 1.88 .sup.aBelow the
level of quantitation of 0.5 IU/dL.
[0718] The foregoing description of the specific embodiments will
so fully reveal the general nature of the invention that others
can, by applying knowledge within the skill of the art, readily
modify and/or adapt for various applications such specific
embodiments, without undue experimentation, without departing from
the general concept of the present invention. Therefore, such
adaptations and modifications are intended to be within the meaning
and range of equivalents of the disclosed embodiments, based on the
teaching and guidance presented herein. It is to be understood that
the phraseology or terminology herein is for the purpose of
description and not of limitation, such that the terminology or
phraseology of the present specification is to be interpreted by
the skilled artisan in light of the teachings and guidance.
TABLE-US-00037 TABLE 37 Polynucleotide Sequences: FIX-Fc A. FIX-Fc
Chain DNA Sequence (SEQ ID NO: 1, which encodes SEQ ID NO: 2)
pSYN-FIX-030 Nucleotide sequence (nt 1 to 7583): FIX exon 1 (signal
peptide, 1st amino acid propeptide): nt 690-777 FIX mini intron: nt
778-1076 FIX propeptide sequence: nt 1077-1126 Mature FIX sequence:
nt 1127-2371 Fc: nt 2372-3052
gcgcgcgttgacattgattattgactagttattaatagtaatcaattacggggtcattagttcatagcccatat-
atgg
agttccgcgttacataacttacggtaaatggcccgcctggctgaccgcccaacgacccccgcccattgacgtca-
ataa
tgacgtatgttcccatagtaacgccaatagggactttccattgacgtcaatgggtggagtatttacggtaaact-
gccc
acttggcagtacatcaagtgtatcatatgccaagtacgccccctattgacgtcaatgacggtaaatggcccgcc-
tggc
attatgcccagtacatgaccttatgggactttcctacttggcagtacatctacgtattagtcatcgctattacc-
atgg
tgatgcggttttggcagtacatcaatgggcgtggatagcggtttgactcacggggatttccaagtctccacccc-
attg
acgtcaatgggagtttgttttggcaccaaaatcaacgggactttccaaaatgtcgtaacaactccgccccattg-
acgc
aaatgggcggtaggcgtgtacggtgggaggtctatataagcagagctctctggctaactagagaacccactgct-
tact
ggcttatcgaaattaatacgactcactatagggagacccaagcttcgcgacgtacggccgccaccatgcagcgc-
gtga
acatgatcatggcagaatcaccaggcctcatcaccatctgccttttaggatatctactcagtgctgaatgtaca-
ggtt
tgtttccttttttaaaatacattgagtatgcttgccttttagatatagaaatatctgatgctgtcttcttcact-
aaat
tttgattacatgatttgacagcaatattgaagagtctaacagccagcacgcaggttggtaagtactgtgggaac-
atca
cagattttggctccatgccctaaagagaaattggctttcagattatttggattaaaaacaaagactttcttaag-
agat
gtaaaattttcatgatgttttcttttttgctaaaactaaagaattattcttttacatttcagtttttcttgatc-
atga
aaacgccaacaaaattctgaatcggccaaagaggtataattcaggtaaattggaagagtttgttcaagggaatc-
taga
gagagaatgtatggaagaaaagtgtagttttgaagaagcacgagaagtttttgaaaacactgaaagaacaactg-
aatt
ttggaagcagtatgttgatggagatcagtgtgagtccaatccatgtttaaatggcggcagttgcaaggatgaca-
ttaa
ttcctatgaatgttggtgtccctttggatttgaaggaaagaactgtgaattagatgtaacatgtaacattaaga-
atgg
cagatgcgagcagttttgtaaaaatagtgctgataacaaggtggtttgctcctgtactgagggatatcgacttg-
caga
aaaccagaagtcctgtgaaccagcagtgccatttccatgtggaagagtttctgtttcacaaacttctaagctca-
cccg
tgctgagactgtttttcctgatgtggactatgtaaattctactgaagctgaaaccattttggataacatcactc-
aaag
cacccaatcatttaatgacttcactcgggttgttggtggagaagatgccaaaccaggtcaattcccttggcagg-
ttgt
tttgaatggtaaagttgatgcattctgtggaggctctatcgttaatgaaaaatggattgtaactgctgcccact-
gtgt
tgaaactggtgttaaaattacagttgtcgcaggtgaacataatattgaggagacagaacatacagagcaaaagc-
gaaa
tgtgattcgaattattcctcaccacaactacaatgcagctattaataagtacaaccatgacattgcccttctgg-
aact
ggacgaacccttagtgctaaacagctacgttacacctatttgcattgctgacaaggaatacacgaacatcttcc-
tcaa
atttggatctggctatgtaagtggctggggaagagtcttccacaaagggagatcagctttagttcttcagtacc-
ttag
agttccacttgttgaccgagccacatgtcttcgatctacaaagttcaccatctataacaacatgttctgtgctg-
gctt
ccatgaaggaggtagagattcatgtcaaggagatagtgggggaccccatgttactgaagtggaagggaccagtt-
tctt
aactggaattattagctggggtgaagagtgtgcaatgaaaggcaaatatggaatatataccaaggtgtcccggt-
atgt
caactggattaaggaaaaaacaaagctcactgacaaaactcacacatgcccaccgtgcccagctccggaactcc-
tggg
cggaccgtcagtcttcctcttccccccaaaacccaaggacaccctcatgatctcccggacccctgaggtcacat-
gcgt
ggtggtggacgtgagccacgaagaccctgaggtcaagttcaactggtacgtggacggcgtggaggtgcataatg-
ccaa
gacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcctcaccgtcctgcaccaggact-
ggct
gaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcgagaaaaccatctccaaag-
ccaa
agggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccaggtcagcc-
tgac
ctgcctggtcaaaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaact-
acaa
gaccacgcctcccgtgttggactccgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggt-
ggca
gcaggggaacgtcttctcatgctccgtgatgcatgaggctctgcacaaccactacacgcagaagagcctctccc-
tgtc
tccgggtaaatgagaattcagacatgataagatacattgatgagtttggacaaaccacaactagaatgcagtga-
aaaa
aatgctttatttgtgaaatttgtgatgctattgctttatttgtaaccattataagctgcaataaacaagttggg-
gtgg
gcgaagaactccagcatgagatccccgcgctggaggatcatccagccggcgtcccggaaaacgattccgaagcc-
caac
ctttcatagaaggcggcggtggaatcgaaatctcgtagcacgtgtcagtcctgctcctcggccacgaagtgcac-
gcag
ttgccggccgggtcgcgcagggcgaactcccgcccccacggctgctcgccgatctcggtcatggccggcccgga-
ggcg
tcccggaagttcgtggacacgacctccgaccactcggcgtacagctcgtccaggccgcgcacccacacccaggc-
cagg
gtgttgtccggcaccacctggtcctggaccgcgctgatgaacagggtcacgtcgtcccggaccacaccggcgaa-
gtcg
tcctccacgaagtcccgggagaacccgagccggtcggtccagaactcgaccgctccggcgacgtcgcgcgcggt-
gagc
accggaacggcactggtcaacttggccatggtttagttcctcaccttgtcgtattatactatgccgatatacta-
tgcc
gatgattaattgtcaacacgtgctgatcagatccgaaaatggatatacaagctcccgggagctttttgcaaaag-
ccta
ggcctccaaaaaagcctcctcactacttctggaatagctcagaggcagaggcggcctcggcctctgcataaata-
aaaa
aaattagtcagccatggggcggagaatgggcggaactgggcggagttaggggcgggatgggcggagttaggggc-
ggga
ctatggttgctgactaattgagatgcatgctttgcatacttctgcctgctggggagcctggggactttccacac-
ctgg
ttgctgactaattgagatgcatgctttgcatacttctgcctgctggggagcctggggactttccacaccctcgt-
cgag
ctagcttcgtgaggctccggtgcccgtcagtgggcagagcgcacatcgcccacagtccccgagaagttgggggg-
aggg
gtcggcaattgaaccggtgcctagagaaggtggcgcggggtaaactgggaaagtgatgtcgtgtactggctccg-
cctt
tttcccgagggtgggggagaaccgtatataagtgcagtagtcgccgtgaacgttctttttcgcaacgggtttgc-
cgcc
agaacacaggtaagtgccgtgtgtggttcccgcgggcctggcctctttacgggttatggcccttgcgtgccttg-
aatt
acttccacctggctccagtacgtgattcttgatcccgagctggagccaggggcgggccttgcgctttaggagcc-
cctt
cgcctcgtgcttgagttgaggcctggcctgggcgctggggccgccgcgtgcgaatctggtggcaccttcgcgcc-
tgtc
tcgctgctttcgataagtctctagccatttaaaatttttgatgacctgctgcgacgctttttttctggcaagat-
agtc
ttgtaaatgcgggccaggatctgcacactggtatttcggtttttggggccgcgggcggcgacggggcccgtgcg-
tccc
agcgcacatgttcggcgaggcggggcctgcgagcgcggccaccgagaatcggacgggggtagtctcaagctggc-
cggc
ctgctctggtgcctggcctcgcgccgccgtgtatcgccccgccctgggcggcaaggctggcccggtcggcacca-
gttg
cgtgagcggaaagatggccgcttcccggccctgctccagggggctcaaaatggaggacgcggcgctcgggagag-
cggg
cgggtgagtcacccacacaaaggaaaggggcctttccgtcctcagccgtcgcttcatgtgactccacggagtac-
cggg
cgccgtccaggcacctcgattagttctggagcttttggagtacgtcgtctttaggttggggggaggggttttat-
gcga
tggagtttccccacactgagtgggtggagactgaagttaggccagcttggcacttgatgtaattctccttggaa-
tttg
ccctttttgagtttggatcttggttcattctcaagcctcagacagtggttcaaagtttttttcttccatttcag-
gtgt
cgtgaacacgtggtcgcggccgcgccgccaccatggagacagacacactcctgctatgggtactgctgctctgg-
gttc
caggttccactggtgacaaaactcacacatgcccaccgtgcccagcacctgaactcctgggaggaccgtcagtc-
ttcc
tcttccccccaaaacccaaggacaccctcatgatctcccggacccctgaggtcacatgcgtggtggtggacgtg-
agcc
acgaagaccctgaggtcaagttcaactggtacgtggacggcgtggaggtgcataatgccaagacaaagccgcgg-
gagg
agcagtacaacagcacgtaccgtgtggtcagcgtcctcaccgtcctgcaccaggactggctgaatggcaaggag-
taca
agtgcaaggtctccaacaaagccctcccagcccccatcgagaaaaccatctccaaagccaaagggcagccccga-
gaac
cacaggtgtacaccctgcccccatcccgcgatgagctgaccaagaaccaggtcagcctgacctgcctggtcaaa-
ggct
tctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaagaccacgcctccc-
gtgt
tggactccgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtc-
ttct
catgctccgtgatgcatgaggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaatga-
ctcg
agagatctggccggctgggcccgtttcgaaggtaagcctatccctaaccctctcctcggtctcgattctacgcg-
tacc
ggtcatcatcaccatcaccattgagtttaaacccgctgatcagcctcgactgtgccttctagttgccagccatc-
tgtt
gtttgcccctcccccgtgccttccttgaccctggaaggtgccactcccactgtcctttcctaataaaatgagga-
aatt
gcatcgcattgtctgagtaggtgtcattctattctggggggtggggtggggcaggacagcaagggggaggattg-
ggaa
gacaatagcaggcatgctggggatgcggtgggctctatggcttctgaggcggaaagaaccagtggcggtaatac-
ggtt
atccacagaatcaggggataacgcaggaaagaacatgtgagcaaaaggccagcaaaaggccaggaaccgtaaaa-
aggc
cgcgttgctggcgtttttccataggctccgcccccctgacgagcatcacaaaaatcgacgctcaagtcagaggt-
ggcg
aaacccgacaggactataaagataccaggcgtttccccctagaagctccctcgtgcgctctcctgttccgaccc-
tgcc
gcttaccggatacctgtccgcctttctcccttcgggaagcgtggcgctttctcatagctcacgctgtaggtatc-
tcag
ttcggtgtaggtcgttcgctccaagctgggctgtgtgcacgaaccccccgttcagcccgaccgctgcgccttat-
ccgg
taactatcgtcttgagtccaacccggtaagacacgacttatcgccactggcagcagccactggtaacaggatta-
gcag
agcgaggtatgtaggcggtgctacagagttcttgaagtggtggcctaactacggctacactagaagaacagtat-
ttgg
tatctgcgctctgctgaagccagttaccttcggaaaaagagttggtagctcttgatccggcaaacaaaccaccg-
ctgg
tagcggtggtttttttgtttgcaagcagcagattacgcgcagaaaaaaaggatctcaagaagatcctttgatct-
tttc
tacggggtctgacgctcagtggaacgaaaactcacgttaagggattttggtcatgacattaacctataaaaata-
ggcg
tatcacgaggccctttcgtctcgcgcgtttcggtgatgacggtgaaaacctctgacacatgcagctcccggaga-
cggt
cacagcttgtctgtaagcggatgccgggagcagacaagcccgtcagggcgcgtcagcgggtgttggcgggtgtc-
gggg
ctggcttaactatgcggcatcagagcagattgtactgagagtgcaccatatatgcggtgtgaaataccgcacag-
atgc
gtaaggagaaaataccgcatcaggcgccattcgccattcaggctgcgcaactgttgggaagggcgatcggtgcg-
ggcc tcttcgctattacgcca B. Fc DNA sequence (mouse ID( signal peptide
underlined) (SEQ ID NO: 3, which encodes SEQ ID NO: 4) This is the
Fc cassette from pSYN-FIX-030. In addition, there is a separate Fc
expression cassette that was transfected into the cell line in
plasmid pSYN-Fc-015 that encodes the same amino acid sequence, but
contains a few noncoding changes. The second copy of Fc encoding
sequence enables a better monomer: dimer ratio.
Atggagacagacacactcctgctatgggtactgctgctctgggttccaggttccactggtgacaaaactcacac-
atgcc
caccgtgcccagcacctgaactcctgggaggaccgtcagtcttcctcttccccccaaaacccaaggacaccctc-
atgat
ctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaagttcaactggt-
acg
tggacggcgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtc-
a
gcgtcctcaccgtcctgcaccaggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctc-
cca
gcccccatcgagaaaaccatctccaaagccaaagggcagccccgagaaccacaggtgtacaccctgcccccatc-
cc
gcgatgagctgaccaagaaccaggtcagcctgacctgcctggtcaaaggcttctatcccagcgacatcgccgtg-
gagt
gggagagcaatgggcagccggagaacaactacaagaccacgcctcccgtgttggactccgacggctccttcttc-
ctct
acagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttctcatgctccgtgatgcatgaggct-
ctg cacaaccactacacgcagaagagcctctccctgtctccgggtaaa
TABLE-US-00038 TABLE 38 Polypeptide Sequences FIX-Fc Monomer
Hybrid: created by coexpressing FIX-Fc and Fc chains. A. FIX-Fc
chain (SEQ ID NO: 2): (28 amino acid signal sequence underlined, 18
amino acid propeptide double underlined, Fc portion in italics.)
The C-terminal lysine is not present in either subunit; this
Processing is often observed in recombinant proteins produced in
mammalian cell culture, as well as with plasma derived proteins.
FIXFC-SC SUBUNIT: FIX Signal Peptide: -46 MQRVNMIMAE SPGLITICLL
GYLLSAEC FIX Propeptide: -18 TVFLDHENAN KILNRPKR 1 YNSGKLEEFV
QGNLERECME EKCSFEEARE VFENTERTTE FWKQYVDGDQ 51 CESNPCLNGG
SCKDDINSYE CWCPFGFEGK NCELDVTCNI KNGRCEQFCK 101 NSADNKVVCS
CTEGYRLAEN QKSCEPAVPF PCGRVSVSQT SKLTRAETVF 151 PDVDYVNSTE
AETILDNITQ STQSFNDFTR VVGGEDAKPG QFPWQVVLNG 201 KVDAFCGGSI
VNEKWIVTAA HCVETGVKIT VVAGEHNIEE TEHTEQKRNV 251 IRIIPHHNYN
AAINKYNHDI ALLELDEPLV LNSYVTPICI ADKEYTNIFL 301 KFGSGYVSGW
GRVFHKGRSA LVLQYLRVPL VDRATCLRST KFTIYNNMFC 351 AGFHEGGRDS
CQGDSGGPHV TEVEGTSFLT GIISWGEECA MKGKYGIYTK 401 VSRYVNWIKE
KTKLTDKTHT CPPCPAPELL GGPSVFLFPP KPKDTLMISR 451 TPEVTCVVVD
VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ YNSTYRVVSV 501 LTVLHQDWLN
GKEYKCKVSN KALPAPIEKT ISKAKGQPRE PQVYTLPPSR 551 DELTKNQVSL
TCLVKGFYPS DIAVEWESNG QPENNYKTTP PVLDSDGSFF 601 LYSKLTVDKS
RWQQGNVFSC SVMHEALHNH YTQKSLSLSP GK B. Fc chain (SEQ ID NO: 4) 20
amino acid heterologous mouse ID( light chain signal peptide
(underlined): -20 METDTLLLWV LLLWVPGSTG Mature Fc sequence
(corresponding to human IgG1 amino acids 221 to 447, EU numbering)
1 DKTHTCPPCP APELLGGPSV FLFPPKPKDT LMISRTPEVT CVVVDVSHED 51
PEVKFNWYVD GVEVHNAKTK PREEQYNSTY RVVSVLTVLH QDWLNGKEYK 101
CKVSNKALPA PIEKTISKAK GQPREPQVYT LPPSRDELTK NQVSLTCLVK 151
GFYPSDIAVE WESNGQPENN YKTTPPVLDS DGSFFLYSKL TVDKSRWQQG 201
NVFSCSVMHE ALHNHYTQKS LSLSPGK
TABLE-US-00039 TABLE 39 FVIIIFc Polynucleotide Sequences A.
B-Domain Deleted FVIIIFc (i) B-Domain Deleted FVIIIFc Chain DNA
Sequence (FVIII signal peptide underlined. Fc region in bold) (SEQ
ID NO: 5, which encodes SEQ ID NO: 6) A TGCAAATAGA GCTCTCCACC
TGCTTCTTTC TGTGCCTTTT GCGATTCTGC TTTAGTGCCA CCAGAAGATA CTACCTGGGT
GCAGTGGAAC TGTCATGGGA CTATATGCAA AGTGATCTCG GTGAGCTGCC TGTGGACGCA
AGATTTCCTC CTAGAGTGCC AAAATCTTTT CCATTCAACA CCTCAGTCGT GTACAAAAAG
ACTCTGTTTG TAGAATTCAC GGATCACCTT TTCAACATCG CTAAGCCAAG GCCACCCTGG
ATGGGTCTGC TAGGTCCTAC CATCCAGGCT GAGGTTTATG ATACAGTGGT CATTACACTT
AAGAACATGG CTTCCCATCC TGTCAGTCTT CATGCTGTTG GTGTATCCTA CTGGAAAGCT
TCTGAGGGAG CTGAATATGA TGATCAGACC AGTCAAAGGG AGAAAGAAGA TGATAAAGTC
TTCCCTGGTG GAAGCCATAC ATATGTCTGG CAGGTCCTGA AAGAGAATGG TCCAATGGCC
TCTGACCCAC TGTGCCTTAC CTACTCATAT CTTTCTCATG TGGACCTGGT AAAAGACTTG
AATTCAGGCC TCATTGGAGC CCTACTAGTA TGTAGAGAAG GGAGTCTGGC CAAGGAAAAG
ACACAGACCT TGCACAAATT TATACTACTT TTTGCTGTAT TTGATGAAGG GAAAAGTTGG
CACTCAGAAA CAAAGAACTC CTTGATGCAG GATAGGGATG CTGCATCTGC TCGGGCCTGG
CCTAAAATGC ACACAGTCAA TGGTTATGTA AACAGGTCTC TGCCAGGTCT GATTGGATGC
CACAGGAAAT CAGTCTATTG GCATGTGATT GGAATGGGCA CCACTCCTGA AGTGCACTCA
ATATTCCTCG AAGGTCACAC ATTTCTTGTG AGGAACCATC GCCAGGCGTC CTTGGAAATC
TCGCCAATAA CTTTCCTTAC TGCTCAAACA CTCTTGATGG ACCTTGGACA GTTTCTACTG
TTTTGTCATA TCTCTTCCCA CCAACATGAT GGCATGGAAG CTTATGTCAA AGTAGACAGC
TGTCCAGAGG AACCCCAACT ACGAATGAAA AATAATGAAG AAGCGGAAGA CTATGATGAT
GATCTTACTG ATTCTGAAAT GGATGTGGTC AGGTTTGATG ATGACAACTC TCCTTCCTTT
ATCCAAATTC GCTCAGTTGC CAAGAAGCAT CCTAAAACTT GGGTACATTA CATTGCTGCT
GAAGAGGAGG ACTGGGACTA TGCTCCCTTA GTCCTCGCCC CCGATGACAG AAGTTATAAA
AGTCAATATT TGAACAATGG CCCTCAGCGG ATTGGTAGGA AGTACAAAAA AGTCCGATTT
ATGGCATACA CAGATGAAAC CTTTAAGACT CGTGAAGCTA TTCAGCATGA ATCAGGAATC
TTGGGACCTT TACTTTATGG GGAAGTTGGA GACACACTGT TGATTATATT TAAGAATCAA
GCAAGCAGAC CATATAACAT CTACCCTCAC GGAATCACTG ATGTCCGTCC TTTGTATTCA
AGGAGATTAC CAAAAGGTGT AAAACATTTG AAGGATTTTC CAATTCTGCC AGGAGAAATA
TTCAAATATA AATGGACAGT GACTGTAGAA GATGGGCCAA CTAAATCAGA TCCTCGGTGC
CTGACCCGCT ATTACTCTAG TTTCGTTAAT ATGGAGAGAG ATCTAGCTTC AGGACTCATT
GGCCCTCTCC TCATCTGCTA CAAAGAATCT GTAGATCAAA GAGGAAACCA GATAATGTCA
GACAAGAGGA ATGTCATCCT GTTTTCTGTA TTTGATGAGA ACCGAAGCTG GTACCTCACA
GAGAATATAC AACGCTTTCT CCCCAATCCA GCTGGAGTGC AGCTTGAGGA TCCAGAGTTC
CAAGCCTCCA ACATCATGCA CAGCATCAAT GGCTATGTTT TTGATAGTTT GCAGTTGTCA
GTTTGTTTGC ATGAGGTGGC ATACTGGTAC ATTCTAAGCA TTGGAGCACA GACTGACTTC
CTTTCTGTCT TCTTCTCTGG ATATACCTTC AAACACAAAA TGGTCTATGA AGACACACTC
ACCCTATTCC CATTCTCAGG AGAAACTGTC TTCATGTCGA TGGAAAACCC AGGTCTATGG
ATTCTGGGGT GCCACAACTC AGACTTTCGG AACAGAGGCA TGACCGCCTT ACTGAAGGTT
TCTAGTTGTG ACAAGAACAC TGGTGATTAT TACGAGGACA GTTATGAAGA TATTTCAGCA
TACTTGCTGA GTAAAAACAA TGCCATTGAA CCAAGAAGCT TCTCTCAAAA CCCACCAGTC
TTGAAACGCC ATCAACGGGA AATAACTCGT ACTACTCTTC AGTCAGATCA AGAGGAAATT
GACTATGATG ATACCATATC AGTTGAAATG AAGAAGGAAG ATTTTGACAT TTATGATGAG
GATGAAAATC AGAGCCCCCG CAGCTTTCAA AAGAAAACAC GACACTATTT TATTGCTGCA
GTGGAGAGGC TCTGGGATTA TGGGATGAGT AGCTCCCCAC ATGTTCTAAG AAACAGGGCT
CAGAGTGGCA GTGTCCCTCA GTTCAAGAAA GTTGTTTTCC AGGAATTTAC TGATGGCTCC
TTTACTCAGC CCTTATACCG TGGAGAACTA AATGAACATT TGGGACTCCT GGGGCCATAT
ATAAGAGCAG AAGTTGAAGA TAATATCATG GTAACTTTCA GAAATCAGGC CTCTCGTCCC
TATTCCTTCT ATTCTAGCCT TATTTCTTAT GAGGAAGATC AGAGGCAAGG AGCAGAACCT
AGAAAAAACT TTGTCAAGCC TAATGAAACC AAAACTTACT TTTGGAAAGT GCAACATCAT
ATGGCACCCA CTAAAGATGA GTTTGACTGC AAAGCCTGGG CTTATTTCTC TGATGTTGAC
CTGGAAAAAG ATGTGCACTC AGGCCTGATT GGACCCCTTC TGGTCTGCCA CACTAACACA
CTGAACCCTG CTCATGGGAG ACAAGTGACA GTACAGGAAT TTGCTCTGTT TTTCACCATC
TTTGATGAGA CCAAAAGCTG GTACTTCACT GAAAATATGG AAAGAAACTG CAGGGCTCCC
TGCAATATCC AGATGGAAGA TCCCACTTTT AAAGAGAATT ATCGCTTCCA TGCAATCAAT
GGCTACATAA TGGATACACT ACCTGGCTTA GTAATGGCTC AGGATCAAAG GATTCGATGG
TATCTGCTCA GCATGGGCAG CAATGAAAAC ATCCATTCTA TTCATTTCAG TGGACATGTG
TTCACTGTAC GAAAAAAAGA GGAGTATAAA ATGGCACTGT ACAATCTCTA TCCAGGTGTT
TTTGAGACAG TGGAAATGTT ACCATCCAAA GCTGGAATTT GGCGGGTGGA ATGCCTTATT
GGCGAGCATC TACATGCTGG GATGAGCACA CTTTTTCTGG TGTACAGCAA TAAGTGTCAG
ACTCCCCTGG GAATGGCTTC TGGACACATT AGAGATTTTC AGATTACAGC TTCAGGACAA
TATGGACAGT GGGCCCCAAA GCTGGCCAGA CTTCATTATT CCGGATCAAT CAATGCCTGG
AGCACCAAGG AGCCCTTTTC TTGGATCAAG GTGGATCTGT TGGCACCAAT GATTATTCAC
GGCATCAAGA CCCAGGGTGC CCGTCAGAAG TTCTCCAGCC TCTACATCTC TCAGTTTATC
ATCATGTATA GTCTTGATGG GAAGAAGTGG CAGACTTATC GAGGAAATTC CACTGGAACC
TTAATGGTCT TCTTTGGCAA TGTGGATTCA TCTGGGATAA AACACAATAT TTTTAACCCT
CCAATTATTG CTCGATACAT CCGTTTGCAC CCAACTCATT ATAGCATTCG CAGCACTCTT
CGCATGGAGT TGATGGGCTG TGATTTAAAT AGTTGCAGCA TGCCATTGGG AATGGAGAGT
AAAGCAATAT CAGATGCACA GATTACTGCT TCATCCTACT TTACCAATAT GTTTGCCACC
TGGTCTCCTT CAAAAGCTCG ACTTCACCTC CAAGGGAGGA GTAATGCCTG GAGACCTCAG
GTGAATAATC CAAAAGAGTG GCTGCAAGTG GACTTCCAGA AGACAATGAA AGTCACAGGA
GTAACTACTC AGGGAGTAAA ATCTCTGCTT ACCAGCATGT ATGTGAAGGA GTTCCTCATC
TCCAGCAGTC AAGATGGCCA TCAGTGGACT CTCTTTTTTC AGAATGGCAA AGTAAAGGTT
TTTCAGGGAA ATCAAGACTC CTTCACACCT GTGGTGAACT CTCTAGACCC ACCGTTACTG
ACTCGCTACC TTCGAATTCA CCCCCAGAGT TGGGTGCACC AGATTGCCCT GAGGATGGAG
GTTCTGGGCT GCGAGGCACA GGACCTCTAC GACAAAACTC ACACATGCCC ACCGTGCCCA
GCTCCAGAAC TCCTGGGCGG ACCGTCAGTC TTCCTCTTCC CCCCAAAACC CAAGGACACC
CTCATGATCT CCCGGACCCC TGAGGTCACA TGCGTGGTGG TGGACGTGAG CCACGAAGAC
CCTGAGGTCA AGTTCAACTG GTACGTGGAC GGCGTGGAGG TGCATAATGC CAAGACAAAG
CCGCGGGAGG AGCAGTACAA CAGCACGTAC CGTGTGGTCA GCGTCCTCAC CGTCCTGCAC
CAGGACTGGC TGAATGGCAA GGAGTACAAG TGCAAGGTCT CCAACAAAGC CCTCCCAGCC
CCCATCGAGA AAACCATCTC CAAAGCCAAA GGGCAGCCCC GAGAACCACA GGTGTACACC
CTGCCCCCAT CCCGGGATGA GCTGACCAAG AACCAGGTCA GCCTGACCTG CCTGGTCAAA
GGCTTCTATC CCAGCGACAT CGCCGTGGAG TGGGAGAGCA ATGGGCAGCC GGAGAACAAC
TACAAGACCA CGCCTCCCGT GTTGGACTCC GACGGCTCCT TCTTCCTCTA CAGCAAGCTC
ACCGTGGACA AGAGCAGGTG GCAGCAGGGG AACGTCTTCT CATGCTCCGT GATGCATGAG
GCTCTGCACA ACCACTACAC GCAGAAGAGC CTCTCCCTGT CTCCGGGTAA A (ii) Fc
DNA sequence (mouse IgK signal peptide underlined) (SEQ ID NO: 7,
which encodes SEQ ID NO: 8) ATGGA GACAGACACA CTCCTGCTAT GGGTACTGCT
GCTCTGGGTT CCAGGTTCCA CTGGTGACAA AACTCACACA TGCCCACCGT GCCCAGCACC
TGAACTCCTG GGAGGACCGT CAGTCTTCCT CTTCCCCCCA AAACCCAAGG ACACCCTCAT
GATCTCCCGG ACCCCTGAGG TCACATGCGT GGTGGTGGAC GTGAGCCACG AAGACCCTGA
GGTCAAGTTC AACTGGTACG TGGACGGCGT GGAGGTGCAT AATGCCAAGA CAAAGCCGCG
GGAGGAGCAG TACAACAGCA CGTACCGTGT GGTCAGCGTC CTCACCGTCC TGCACCAGGA
CTGGCTGAAT GGCAAGGAGT ACAAGTGCAA GGTCTCCAAC AAAGCCCTCC CAGCCCCCAT
CGAGAAAACC ATCTCCAAAG CCAAAGGGCA GCCCCGAGAA CCACAGGTGT ACACCCTGCC
CCCATCCCGC GATGAGCTGA CCAAGAACCA GGTCAGCCTG ACCTGCCTGG TCAAAGGCTT
CTATCCCAGC GACATCGCCG TGGAGTGGGA GAGCAATGGG CAGCCGGAGA ACAACTACAA
GACCACGCCT CCCGTGTTGG ACTCCGACGG CTCCTTCTTC CTCTACAGCA AGCTCACCGT
GGACAAGAGC AGGTGGCAGC AGGGGAACGT CTTCTCATGC TCCGTGATGC ATGAGGCTCT
GCACAACCAC TACACGCAGA AGAGCCTCTC CCTGTCTCCG GGTAAA B. Full Length
FVIIIFc (i) Full Length FVIIIFc DNA Sequence (FVIII signal peptide
underlined, Fc region in bold) (SEQ ID NO: 9, which encodes SEQ ID
NO: 10) ATG CAAATAGAGC TCTCCACCTG CTTCTTTCTG TGCCTTTTGC GATTCTGCTT
TAGTGCCACC AGAAGATACT ACCTGGGTGC AGTGGAACTG TCATGGGACT ATATGCAAAG
TGATCTCGGT GAGCTGCCTG TGGACGCAAG ATTTCCTCCT AGAGTGCCAA AATCTTTTCC
ATTCAACACC TCAGTCGTGT ACAAAAAGAC TCTGTTTGTA GAATTCACGG ATCACCTTTT
CAACATCGCT AAGCCAAGGC CACCCTGGAT GGGTCTGCTA GGTCCTACCA TCCAGGCTGA
GGTTTATGAT ACAGTGGTCA TTACACTTAA GAACATGGCT TCCCATCCTG TCAGTCTTCA
TGCTGTTGGT GTATCCTACT GGAAAGCTTC TGAGGGAGCT GAATATGATG ATCAGACCAG
TCAAAGGGAG AAAGAAGATG ATAAAGTCTT CCCTGGTGGA AGCCATACAT ATGTCTGGCA
GGTCCTGAAA GAGAATGGTC CAATGGCCTC TGACCCACTG TGCCTTACCT ACTCATATCT
TTCTCATGTG GACCTGGTAA AAGACTTGAA TTCAGGCCTC ATTGGAGCCC TACTAGTATG
TAGAGAAGGG AGTCTGGCCA AGGAAAAGAC ACAGACCTTG CACAAATTTA TACTACTTTT
TGCTGTATTT GATGAAGGGA AAAGTTGGCA CTCAGAAACA AAGAACTCCT TGATGCAGGA
TAGGGATGCT GCATCTGCTC GGGCCTGGCC TAAAATGCAC ACAGTCAATG GTTATGTAAA
CAGGTCTCTG CCAGGTCTGA TTGGATGCCA CAGGAAATCA GTCTATTGGC ATGTGATTGG
AATGGGCACC ACTCCTGAAG TGCACTCAAT ATTCCTCGAA GGTCACACAT TTCTTGTGAG
GAACCATCGC CAGGCGTCCT TGGAAATCTC GCCAATAACT TTCCTTACTG CTCAAACACT
CTTGATGGAC CTTGGACAGT TTCTACTGTT TTGTCATATC TCTTCCCACC AACATGATGG
CATGGAAGCT TATGTCAAAG TAGACAGCTG TCCAGAGGAA CCCCAACTAC GAATGAAAAA
TAATGAAGAA GCGGAAGACT ATGATGATGA TCTTACTGAT TCTGAAATGG ATGTGGTCAG
GTTTGATGAT GACAACTCTC CTTCCTTTAT CCAAATTCGC TCAGTTGCCA AGAAGCATCC
TAAAACTTGG GTACATTACA TTGCTGCTGA AGAGGAGGAC TGGGACTATG CTCCCTTAGT
CCTCGCCCCC GATGACAGAA GTTATAAAAG TCAATATTTG AACAATGGCC CTCAGCGGAT
TGGTAGGAAG TACAAAAAAG TCCGATTTAT GGCATACACA GATGAAACCT TTAAGACTCG
TGAAGCTATT CAGCATGAAT CAGGAATCTT GGGACCTTTA CTTTATGGGG AAGTTGGAGA
CACACTGTTG ATTATATTTA AGAATCAAGC AAGCAGACCA TATAACATCT ACCCTCACGG
AATCACTGAT GTCCGTCCTT TGTATTCAAG GAGATTACCA AAAGGTGTAA AACATTTGAA
GGATTTTCCA ATTCTGCCAG GAGAAATATT CAAATATAAA TGGACAGTGA CTGTAGAAGA
TGGGCCAACT AAATCAGATC CTCGGTGCCT GACCCGCTAT TACTCTAGTT TCGTTAATAT
GGAGAGAGAT CTAGCTTCAG GACTCATTGG CCCTCTCCTC ATCTGCTACA AAGAATCTGT
AGATCAAAGA GGAAACCAGA TAATGTCAGA CAAGAGGAAT GTCATCCTGT TTTCTGTATT
TGATGAGAAC CGAAGCTGGT ACCTCACAGA GAATATACAA CGCTTTCTCC CCAATCCAGC
TGGAGTGCAG CTTGAGGATC CAGAGTTCCA AGCCTCCAAC ATCATGCACA GCATCAATGG
CTATGTTTTT GATAGTTTGC AGTTGTCAGT TTGTTTGCAT GAGGTGGCAT ACTGGTACAT
TCTAAGCATT GGAGCACAGA CTGACTTCCT TTCTGTCTTC TTCTCTGGAT ATACCTTCAA
ACACAAAATG GTCTATGAAG ACACACTCAC CCTATTCCCA TTCTCAGGAG AAACTGTCTT
CATGTCGATG GAAAACCCAG GTCTATGGAT TCTGGGGTGC CACAACTCAG ACTTTCGGAA
CAGAGGCATG ACCGCCTTAC TGAAGGTTTC TAGTTGTGAC AAGAACACTG GTGATTATTA
CGAGGACAGT TATGAAGATA TTTCAGCATA CTTGCTGAGT AAAAACAATG CCATTGAACC
AAGAAGCTTC TCCCAGAATT CAAGACACCC TAGCACTAGG CAAAAGCAAT TTAATGCCAC
CACAATTCCA GAAAATGACA TAGAGAAGAC TGACCCTTGG TTTGCACACA GAACACCTAT
GCCTAAAATA CAAAATGTCT CCTCTAGTGA TTTGTTGATG CTCTTGCGAC AGAGTCCTAC
TCCACATGGG CTATCCTTAT CTGATCTCCA AGAAGCCAAA TATGAGACTT TTTCTGATGA
TCCATCACCT GGAGCAATAG ACAGTAATAA CAGCCTGTCT GAAATGACAC ACTTCAGGCC
ACAGCTCCAT CACAGTGGGG ACATGGTATT TACCCCTGAG TCAGGCCTCC AATTAAGATT
AAATGAGAAA CTGGGGACAA CTGCAGCAAC AGAGTTGAAG AAACTTGATT TCAAAGTTTC
TAGTACATCA AATAATCTGA TTTCAACAAT TCCATCAGAC AATTTGGCAG CAGGTACTGA
TAATACAAGT TCCTTAGGAC CCCCAAGTAT GCCAGTTCAT TATGATAGTC AATTAGATAC
CACTCTATTT GGCAAAAAGT CATCTCCCCT TACTGAGTCT GGTGGACCTC TGAGCTTGAG
TGAAGAAAAT AATGATTCAA AGTTGTTAGA ATCAGGTTTA ATGAATAGCC AAGAAAGTTC
ATGGGGAAAA AATGTATCGT CAACAGAGAG TGGTAGGTTA TTTAAAGGGA AAAGAGCTCA
TGGACCTGCT TTGTTGACTA AAGATAATGC CTTATTCAAA GTTAGCATCT CTTTGTTAAA
GACAAACAAA ACTTCCAATA ATTCAGCAAC TAATAGAAAG ACTCACATTG ATGGCCCATC
ATTATTAATT GAGAATAGTC CATCAGTCTG GCAAAATATA TTAGAAAGTG ACACTGAGTT
TAAAAAAGTG ACACCTTTGA TTCATGACAG AATGCTTATG GACAAAAATG CTACAGCTTT
GAGGCTAAAT CATATGTCAA ATAAAACTAC TTCATCAAAA AACATGGAAA TGGTCCAACA
GAAAAAAGAG GGCCCCATTC CACCAGATGC ACAAAATCCA GATATGTCGT TCTTTAAGAT
GCTATTCTTG CCAGAATCAG CAAGGTGGAT ACAAAGGACT CATGGAAAGA ACTCTCTGAA
CTCTGGGCAA GGCCCCAGTC CAAAGCAATT AGTATCCTTA GGACCAGAAA AATCTGTGGA
AGGTCAGAAT TTCTTGTCTG AGAAAAACAA AGTGGTAGTA GGAAAGGGTG AATTTACAAA
GGACGTAGGA CTCAAAGAGA TGGTTTTTCC AAGCAGCAGA AACCTATTTC TTACTAACTT
GGATAATTTA CATGAAAATA ATACACACAA TCAAGAAAAA AAAATTCAGG AAGAAATAGA
AAAGAAGGAA ACATTAATCC AAGAGAATGT AGTTTTGCCT CAGATACATA CAGTGACTGG
CACTAAGAAT TTCATGAAGA ACCTTTTCTT ACTGAGCACT AGGCAAAATG TAGAAGGTTC
ATATGACGGG GCATATGCTC CAGTACTTCA AGATTTTAGG TCATTAAATG ATTCAACAAA
TAGAACAAAG AAACACACAG CTCATTTCTC AAAAAAAGGG GAGGAAGAAA ACTTGGAAGG
CTTGGGAAAT CAAACCAAGC AAATTGTAGA GAAATATGCA TGCACCACAA GGATATCTCC
TAATACAAGC CAGCAGAATT TTGTCACGCA ACGTAGTAAG AGAGCTTTGA AACAATTCAG
ACTCCCACTA GAAGAAACAG AACTTGAAAA AAGGATAATT GTGGATGACA CCTCAACCCA
GTGGTCCAAA AACATGAAAC ATTTGACCCC GAGCACCCTC ACACAGATAG ACTACAATGA
GAAGGAGAAA GGGGCCATTA CTCAGTCTCC CTTATCAGAT TGCCTTACGA GGAGTCATAG
CATCCCTCAA GCAAATAGAT CTCCATTACC CATTGCAAAG GTATCATCAT TTCCATCTAT
TAGACCTATA TATCTGACCA GGGTCCTATT CCAAGACAAC TCTTCTCATC TTCCAGCAGC
ATCTTATAGA AAGAAAGATT CTGGGGTCCA AGAAAGCAGT CATTTCTTAC AAGGAGCCAA
AAAAAATAAC CTTTCTTTAG CCATTCTAAC CTTGGAGATG ACTGGTGATC AAAGAGAGGT
TGGCTCCCTG GGGACAAGTG CCACAAATTC AGTCACATAC AAGAAAGTTG AGAACACTGT
TCTCCCGAAA CCAGACTTGC CCAAAACATC TGGCAAAGTT GAATTGCTTC CAAAAGTTCA
CATTTATCAG AAGGACCTAT TCCCTACGGA AACTAGCAAT GGGTCTCCTG GCCATCTGGA
TCTCGTGGAA GGGAGCCTTC TTCAGGGAAC AGAGGGAGCG ATTAAGTGGA ATGAAGCAAA
CAGACCTGGA AAAGTTCCCT TTCTGAGAGT AGCAACAGAA AGCTCTGCAA AGACTCCCTC
CAAGCTATTG GATCCTCTTG CTTGGGATAA CCACTATGGT ACTCAGATAC CAAAAGAAGA
GTGGAAATCC CAAGAGAAGT CACCAGAAAA AACAGCTTTT AAGAAAAAGG ATACCATTTT
GTCCCTGAAC GCTTGTGAAA GCAATCATGC AATAGCAGCA ATAAATGAGG GACAAAATAA
GCCCGAAATA GAAGTCACCT GGGCAAAGCA AGGTAGGACT GAAAGGCTGT GCTCTCAAAA
CCCACCAGTC TTGAAACGCC ATCAACGGGA AATAACTCGT ACTACTCTTC AGTCAGATCA
AGAGGAAATT GACTATGATG ATACCATATC AGTTGAAATG AAGAAGGAAG ATTTTGACAT
TTATGATGAG GATGAAAATC AGAGCCCCCG CAGCTTTCAA AAGAAAACAC GACACTATTT
TATTGCTGCA GTGGAGAGGC TCTGGGATTA TGGGATGAGT AGCTCCCCAC ATGTTCTAAG
AAACAGGGCT CAGAGTGGCA GTGTCCCTCA GTTCAAGAAA GTTGTTTTCC AGGAATTTAC
TGATGGCTCC TTTACTCAGC CCTTATACCG TGGAGAACTA AATGAACATT TGGGACTCCT
GGGGCCATAT ATAAGAGCAG AAGTTGAAGA TAATATCATG GTAACTTTCA GAAATCAGGC
CTCTCGTCCC TATTCCTTCT ATTCTAGCCT TATTTCTTAT GAGGAAGATC AGAGGCAAGG
AGCAGAACCT AGAAAAAACT TTGTCAAGCC TAATGAAACC AAAACTTACT TTTGGAAAGT
GCAACATCAT ATGGCACCCA CTAAAGATGA GTTTGACTGC AAAGCCTGGG CTTATTTCTC
TGATGTTGAC CTGGAAAAAG ATGTGCACTC AGGCCTGATT GGACCCCTTC TGGTCTGCCA
CACTAACACA CTGAACCCTG CTCATGGGAG ACAAGTGACA GTACAGGAAT TTGCTCTGTT
TTTCACCATC TTTGATGAGA CCAAAAGCTG GTACTTCACT GAAAATATGG AAAGAAACTG
CAGGGCTCCC TGCAATATCC AGATGGAAGA TCCCACTTTT AAAGAGAATT ATCGCTTCCA
TGCAATCAAT GGCTACATAA TGGATACACT ACCTGGCTTA GTAATGGCTC AGGATCAAAG
GATTCGATGG TATCTGCTCA GCATGGGCAG CAATGAAAAC ATCCATTCTA TTCATTTCAG
TGGACATGTG TTCACTGTAC GAAAAAAAGA GGAGTATAAA ATGGCACTGT ACAATCTCTA
TCCAGGTGTT TTTGAGACAG TGGAAATGTT ACCATCCAAA GCTGGAATTT GGCGGGTGGA
ATGCCTTATT GGCGAGCATC TACATGCTGG GATGAGCACA CTTTTTCTGG TGTACAGCAA
TAAGTGTCAG ACTCCCCTGG GAATGGCTTC TGGACACATT AGAGATTTTC AGATTACAGC
TTCAGGACAA TATGGACAGT GGGCCCCAAA GCTGGCCAGA CTTCATTATT CCGGATCAAT
CAATGCCTGG AGCACCAAGG AGCCCTTTTC TTGGATCAAG GTGGATCTGT TGGCACCAAT
GATTATTCAC GGCATCAAGA CCCAGGGTGC CCGTCAGAAG TTCTCCAGCC TCTACATCTC
TCAGTTTATC ATCATGTATA GTCTTGATGG GAAGAAGTGG CAGACTTATC GAGGAAATTC
CACTGGAACC TTAATGGTCT TCTTTGGCAA TGTGGATTCA TCTGGGATAA AACACAATAT
TTTTAACCCT CCAATTATTG CTCGATACAT CCGTTTGCAC CCAACTCATT ATAGCATTCG
CAGCACTCTT CGCATGGAGT TGATGGGCTG TGATTTAAAT AGTTGCAGCA TGCCATTGGG
AATGGAGAGT AAAGCAATAT CAGATGCACA GATTACTGCT TCATCCTACT TTACCAATAT
GTTTGCCACC TGGTCTCCTT CAAAAGCTCG ACTTCACCTC CAAGGGAGGA GTAATGCCTG
GAGACCTCAG GTGAATAATC CAAAAGAGTG GCTGCAAGTG GACTTCCAGA AGACAATGAA
AGTCACAGGA GTAACTACTC AGGGAGTAAA ATCTCTGCTT ACCAGCATGT ATGTGAAGGA
GTTCCTCATC TCCAGCAGTC AAGATGGCCA TCAGTGGACT CTCTTTTTTC AGAATGGCAA
AGTAAAGGTT TTTCAGGGAA ATCAAGACTC CTTCACACCT GTGGTGAACT CTCTAGACCC
ACCGTTACTG ACTCGCTACC TTCGAATTCA CCCCCAGAGT TGGGTGCACC AGATTGCCCT
GAGGATGGAG GTTCTGGGCT GCGAGGCACA GGACCTCTAC GACAAAACTC ACACATGCCC
ACCGTGCCCA GCTCCAGAAC TCCTGGGCGG ACCGTCAGTC TTCCTCTTCC CCCCAAAACC
CAAGGACACC CTCATGATCT CCCGGACCCC TGAGGTCACA TGCGTGGTGG TGGACGTGAG
CCACGAAGAC CCTGAGGTCA AGTTCAACTG GTACGTGGAC GGCGTGGAGG TGCATAATGC
CAAGACAAAG CCGCGGGAGG AGCAGTACAA CAGCACGTAC CGTGTGGTCA GCGTCCTCAC
CGTCCTGCAC CAGGACTGGC TGAATGGCAA GGAGTACAAG TGCAAGGTCT CCAACAAAGC
CCTCCCAGCC CCCATCGAGA AAACCATCTC CAAAGCCAAA GGGCAGCCCC GAGAACCACA
GGTGTACACC CTGCCCCCAT CCCGGGATGA GCTGACCAAG AACCAGGTCA GCCTGACCTG
CCTGGTCAAA GGCTTCTATC CCAGCGACAT CGCCGTGGAG TGGGAGAGCA ATGGGCAGCC
GGAGAACAAC TACAAGACCA CGCCTCCCGT GTTGGACTCC GACGGCTCCT TCTTCCTCTA
CAGCAAGCTC ACCGTGGACA AGAGCAGGTG GCAGCAGGGG AACGTCTTCT CATGCTCCGT
GATGCATGAG GCTCTGCACA ACCACTACAC GCAGAAGAGC CTCTCCCTGT CTCCGGGTAA A
(ii) Fc (same sequence as A (ii) (SEQ ID NO: 7))]
TABLE-US-00040 TABLE 40 FVIII Polypeptide Sequences A. B-Domain
Deleted FVIII-Fc Monomer Hybrid (BDD FVIIIFc monomer dimer):
created by coexpressing BDD FVIIIFc and Fc chains. Construct =
HC-LC-Fc fusion. An Fc expression cassette is cotransfected with
BDDFVIII-Fc to generate the BDD FVIIIFc monomer-. For the BDD
FVIIIFc chain, the Fc sequence is shown in bold; HC sequence is
shown in double underline; remaining B domain sequence is shown in
italics. Signal peptides are underlined. i) B domain deleted
FVIII-Fc chain (19 amino acid signal sequence underlined) (SEQ ID
NO: 6) MQIELSTCFFLCLLRFCFS
ATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFTDHLF
NIAKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKASEGAEYDDQ
TSQREKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDLVKDLNSGLIGA
LLVCREGSLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASARAWPKMHT
VNGYVNRSLPGLIGCHRKSVYWHVIGMGTTPEVHSIFLEGHTFLVRNHRQASLEISPITFL
TAQTLLMDLGQFLLFCHISSHQHDGMEAYVKVDSCPEEPQLRMKNNEEAEDYDDDLTD
SEMDVVRFDDDNSPSFIQIRSVAKKHPKTWVHYIAAEEEDWDYAPLVLAPDDRSYKSQY
LNNGPQRIGRKYKKVRFMAYTDETFKTREAIQHESGILGPLLYGEVGDTLLIIFKNQASRP
YNIYPHGITDVRPLYSRRLPKGVKHLKDFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRY
YSSFVNMERDLASGLIGPLLICYKESVDQRGNQIMSDKRNVILFSVFDENRSWYLTENIQ
RFLPNPAGVQLEDPEFQASNIMHSINGYVFDSLQLSVCLHEVAYWYILSIGAQTDFLSVFF
SGYTFKHKMVYEDTLTLFPFSGETVFMSMENPGLWILGCHNSDFRNRGMTALLKVSSC
DKNTGDYYEDSYEDISAYLLSKNNAIEPRSFSQNPPVLKRHQREITRTTLQSDQEEIDYDD
TISVEMKKEDFDIYDEDENQSPRSFQKKTRHYFIAAVERLWDYGMSSSPHVLRNRAQSG
SVPQFKKVVFQEFTDGSFTQPLYRGELNEHLGLLGPYIRAEVEDNIMVTFRNQASRPYSF
YSSLISYEEDQRQGAEPRKNFVKPNETKTYFWKVQHHMAPTKDEFDCKAWAYFSDVDL
EKDVHSGLIGPLLVCHTNTLNPAHGRQVTVQEFALFFTIFDETKSWYFTENMERNCRAP
CNIQMEDPTFKENYRFHAINGYIMDTLPGLVMAQDQRIRWYLLSMGSNENIHSIHFSGH
VFTVRKKEEYKMALYNLYPGVFETVEMLPSKAGIWRVECLIGEHLHAGMSTLFLVYSN
KCQTPLGMASGHIRDFQITASGQYGQWAPKLARLHYSGSINAWSTKEPFSWIKVDLLAP
MIIHGIKTQGARQKFSSLYISQFIIMYSLDGKKWQTYRGNSTGTLMVFFGNVDSSGIKHNI
FNPPIIARYIRLHPTHYSIRSTLRMELMGCDLNSCSMPLGMESKAISDAQITASSYFTNMF
ATWSPSKARLHLQGRSNAWRPQVNNPKEWLQVDFQKTMKVTGVTTQGVKSLLTSMY
VKEFLISSSQDGHQWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQSWVH
QIALRMEVLGCEAQDLYDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTC
VVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRYVSVLTVLHQDWLN
GKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKG
FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV
MHEALHNHYTQKSLSLSPGK ii) Fc chain (20 amino acid heterologous
signal peptide from mouse IgK.kappa. chain underlined) (SEQ ID NO:
8) METDTLLLWVLLLWVPGSTG
DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD
GVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISK
AKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPV
LDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK B. Full length
FVIIIFc monomer hybrid (Full length FVIIIFc monomer dimer): created
by coexpressing FVIIIFc and Fc chains. Construct = HC-B-LC-Fc
fusion. An Fc expression cassette is cotransfected with full length
FVIII-Fc to generate the full length FVIIIFc monomer. For the
FVIIIFc chain, the Fc sequence is shown in bold; HC sequence is
shown in double underline; B domain sequence is shown in italics.
Signal peptides are underlined. i) Full length FVIIIFc chain (FVIII
signal peptide underlined (SEQ ID NO: 10) MQIELSTCFFLCLLRFCFS
ATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFTDHLF
NIAKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKASEGAEYDDQ
TSQREKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDLVKDLNSGLIGA
LLVCREGSLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASARAWPKMHT
VNGYVNRSLPGLIGCHRKSVYWHVIGMGTTPEVHSIFLEGHTFLVRNHRQASLEISPITFL
TAQTLLMDLGQFLLFCHISSHQHDGMEAYVKVDSCPEEPQLRMKNNEEAEDYDDDLTD
SEMDVVRFDDDNSPSFIQIRSVAKKHPKTWVHYIAAEEEDWDYAPLVLAPDDRSYKSQY
LNNGPQRIGRKYKKVRFMAYTDETFKTREAIQHESGILGPLLYGEVGDTLLIIFKNQASRP
YNIYPHGITDVRPLYSRRLPKGVKHLKDFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRY
YSSFVNMERDLASGLIGPLLICYKESVDQRGNQIMSDKRNVILFSVFDENRSWYLTENIQ
RFLPNPAGVQLEDPEFQASNIMHSINGYVFDSLQLSVCLHEVAYWYILSIGAQTDFLSVFF
SGYTFKHKMVYEDTLTLFPFSGETVFMSMENPGLWILGCHNSDFRNRGMTALLKVSSC
DKNTGDYYEDSYEDISAYLLSKNNAIEPRSFSQNSRHPSTRQKQFNATTIPENDIEKTDPWF
AHRTPMPKIQNVSSSDLLMLLRQSPTPHGLSLSDLQEAKYETESDDPSPGAIDSNNSLSEMTHE
RPQLHHSGDMVETPESGLQLRLNEKLGTTAATELKKLDEKVSSTSNNLISTIPSDNLAAGTDNT
SSLGPPSMPVHYDSQLDTTLFGKKSSPLTESGGPLSLSEENNDSKLLESGLMNSQESSWGKNV
SSTESGRLFKGKRAHGPALLTKDNALFKVSISLLKTNKTSNNSATNRKTHIDGPSLLIENSPSVW
QNILESDTEFKKVTPLIHDRAILMDKNATALRLNHMSNKTTSSKNMEMYQQKKEGPIPPDAQN
PDMSFFICMLFLPESARWIQRTHGKNSLNSGQGPSPKQLVSLGPEKSVEGQNFLSEKNKVVVG
KGEFTKDVGLKEIVIVEPSSRNLFLTNLDNLHENNTHNQEKKIQEETEKKETLIQENVVLPQIHT
VTGTKNFMKNLELLSTRQNVEGSYDGAYAPVLQDFRSLNDSTNRTKKHTAHFSKKGEEENLE
GLGNQTKQIVEKYACTTRISPNTSQQNFVTQRSKRALKQERLPLEETELEKRIIVDDTSTQWSK
NMKHLTPSTLTQIDYNEKEKGAITQSPLSDCLTRSHSIPQANRSPLPIAKVSSEPSIRPTYLTRVLF
QDNSSHLPAASYRKKDSGVQESSHFLQGAKKNNLSLAILTLEMTGDQREVGSLGISATNSVTY
KKVENTVLPKPDLPKTSGKVELLPKVHIYQKDLEPTETSNGSPGHLDLVEGSLLQGTEGAIKW
NEANRPGKVPFLRVATESSAKTPSKLLDPLAWDNHYGTQIPKEEWKSQEKSPEKTAFKKKDTI
LSLNACESNHAMAINEGQNKPEIEVTWAKQGRTERLCSQNPPVLKRHQREITRTTLQSDQEEI
DYDDTISVEMKKEDFDIYDEDENQSPRSFQKKTRHYFIAAVERLWDYGMSSSPHVLRNR
AQSGSVPQFKKVVFQEFTDGSFTQPLYRGELNEHLGLLGPYIRAEVEDNIMVTFRNQASR
PYSFYSSLISYEEDQRQGAEPRKNFVKPNETKTYFWKVQHHMAPTKDEFDCKAWAYFS
DVDLEKDVHSGLIGPLLVCHTNTLNPAHGRQVTVQEFALFFTIFDETKSWYFTENMERN
CRAPCNIQMEDPTFKENYRFHAINGYIMDTLPGLVMAQDQRIRWYLLSMGSNENIHSIHF
SGHVFTVRKKEEYKMALYNLYPGVFETVEMLPSKAGIWRVECLIGEHLHAGMSTLFLV
YSNKCQTPLGMASGHIRDFQITASGQYGQWAPKLARLHYSGSINAWSTKEPFSWIKVDL
LAPMIIHGIKTQGARQKFSSLYISQFIIMYSLDGKKWQTYRGNSTGTLMVFFGNVDSSGIK
HNIFNPPIIARYIRLHPTHYSIRSTLRMELMGCDLNSCSMPLGMESKAISDAQITASSYFTN
MFATWSPSKARLHLQGRSNAWRPQVNNPKEWLQVDFQKTMKVTGVTTQGVKSLLTS
MYVKEFLISSSQDGHQWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQSW
VHQIALRMEVLGCEAQDLYDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEV
TCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDW
LNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLV
KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSC
SVMHEALHNHYTQKSLSLSPGK ii) Fc chain (20 amino acid heterologous
signal peptide from mouse ID (chain underlined) (SEQ ID NO: 8)
METDTLLLWVLLLWVPGSTG
DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD
GVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISK
AKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPV
LDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
Sequence CWU 1 SEQUENCE LISTING <160> NUMBER OF SEQ ID
NOS: 21 <210> SEQ ID NO 1 <211> LENGTH: 7583
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: pSYN-FIX-030
<400> SEQUENCE: 1 gcgcgcgttg acattgatta ttgactagtt attaatagta
atcaattacg gggtcattag 60 ttcatagccc atatatggag ttccgcgtta
cataacttac ggtaaatggc ccgcctggct 120 gaccgcccaa cgacccccgc
ccattgacgt caataatgac gtatgttccc atagtaacgc 180 caatagggac
tttccattga cgtcaatggg tggagtattt acggtaaact gcccacttgg 240
cagtacatca agtgtatcat atgccaagta cgccccctat tgacgtcaat gacggtaaat
300 ggcccgcctg gcattatgcc cagtacatga ccttatggga ctttcctact
tggcagtaca 360 tctacgtatt agtcatcgct attaccatgg tgatgcggtt
ttggcagtac atcaatgggc 420 gtggatagcg gtttgactca cggggatttc
caagtctcca ccccattgac gtcaatggga 480 gtttgttttg gcaccaaaat
caacgggact ttccaaaatg tcgtaacaac tccgccccat 540 tgacgcaaat
gggcggtagg cgtgtacggt gggaggtcta tataagcaga gctctctggc 600
taactagaga acccactgct tactggctta tcgaaattaa tacgactcac tatagggaga
660 cccaagcttc gcgacgtacg gccgccacca tgcagcgcgt gaacatgatc
atggcagaat 720 caccaggcct catcaccatc tgccttttag gatatctact
cagtgctgaa tgtacaggtt 780 tgtttccttt tttaaaatac attgagtatg
cttgcctttt agatatagaa atatctgatg 840 ctgtcttctt cactaaattt
tgattacatg atttgacagc aatattgaag agtctaacag 900 ccagcacgca
ggttggtaag tactgtggga acatcacaga ttttggctcc atgccctaaa 960
gagaaattgg ctttcagatt atttggatta aaaacaaaga ctttcttaag agatgtaaaa
1020 ttttcatgat gttttctttt ttgctaaaac taaagaatta ttcttttaca
tttcagtttt 1080 tcttgatcat gaaaacgcca acaaaattct gaatcggcca
aagaggtata attcaggtaa 1140 attggaagag tttgttcaag ggaatctaga
gagagaatgt atggaagaaa agtgtagttt 1200 tgaagaagca cgagaagttt
ttgaaaacac tgaaagaaca actgaatttt ggaagcagta 1260 tgttgatgga
gatcagtgtg agtccaatcc atgtttaaat ggcggcagtt gcaaggatga 1320
cattaattcc tatgaatgtt ggtgtccctt tggatttgaa ggaaagaact gtgaattaga
1380 tgtaacatgt aacattaaga atggcagatg cgagcagttt tgtaaaaata
gtgctgataa 1440 caaggtggtt tgctcctgta ctgagggata tcgacttgca
gaaaaccaga agtcctgtga 1500 accagcagtg ccatttccat gtggaagagt
ttctgtttca caaacttcta agctcacccg 1560 tgctgagact gtttttcctg
atgtggacta tgtaaattct actgaagctg aaaccatttt 1620 ggataacatc
actcaaagca cccaatcatt taatgacttc actcgggttg ttggtggaga 1680
agatgccaaa ccaggtcaat tcccttggca ggttgttttg aatggtaaag ttgatgcatt
1740 ctgtggaggc tctatcgtta atgaaaaatg gattgtaact gctgcccact
gtgttgaaac 1800 tggtgttaaa attacagttg tcgcaggtga acataatatt
gaggagacag aacatacaga 1860 gcaaaagcga aatgtgattc gaattattcc
tcaccacaac tacaatgcag ctattaataa 1920 gtacaaccat gacattgccc
ttctggaact ggacgaaccc ttagtgctaa acagctacgt 1980 tacacctatt
tgcattgctg acaaggaata cacgaacatc ttcctcaaat ttggatctgg 2040
ctatgtaagt ggctggggaa gagtcttcca caaagggaga tcagctttag ttcttcagta
2100 ccttagagtt ccacttgttg accgagccac atgtcttcga tctacaaagt
tcaccatcta 2160 taacaacatg ttctgtgctg gcttccatga aggaggtaga
gattcatgtc aaggagatag 2220 tgggggaccc catgttactg aagtggaagg
gaccagtttc ttaactggaa ttattagctg 2280 gggtgaagag tgtgcaatga
aaggcaaata tggaatatat accaaggtgt cccggtatgt 2340 caactggatt
aaggaaaaaa caaagctcac tgacaaaact cacacatgcc caccgtgccc 2400
agctccggaa ctcctgggcg gaccgtcagt cttcctcttc cccccaaaac ccaaggacac
2460 cctcatgatc tcccggaccc ctgaggtcac atgcgtggtg gtggacgtga
gccacgaaga 2520 ccctgaggtc aagttcaact ggtacgtgga cggcgtggag
gtgcataatg ccaagacaaa 2580 gccgcgggag gagcagtaca acagcacgta
ccgtgtggtc agcgtcctca ccgtcctgca 2640 ccaggactgg ctgaatggca
aggagtacaa gtgcaaggtc tccaacaaag ccctcccagc 2700 ccccatcgag
aaaaccatct ccaaagccaa agggcagccc cgagaaccac aggtgtacac 2760
cctgccccca tcccgggatg agctgaccaa gaaccaggtc agcctgacct gcctggtcaa
2820 aggcttctat cccagcgaca tcgccgtgga gtgggagagc aatgggcagc
cggagaacaa 2880 ctacaagacc acgcctcccg tgttggactc cgacggctcc
ttcttcctct acagcaagct 2940 caccgtggac aagagcaggt ggcagcaggg
gaacgtcttc tcatgctccg tgatgcatga 3000 ggctctgcac aaccactaca
cgcagaagag cctctccctg tctccgggta aatgagaatt 3060 cagacatgat
aagatacatt gatgagtttg gacaaaccac aactagaatg cagtgaaaaa 3120
aatgctttat ttgtgaaatt tgtgatgcta ttgctttatt tgtaaccatt ataagctgca
3180 ataaacaagt tggggtgggc gaagaactcc agcatgagat ccccgcgctg
gaggatcatc 3240 cagccggcgt cccggaaaac gattccgaag cccaaccttt
catagaaggc ggcggtggaa 3300 tcgaaatctc gtagcacgtg tcagtcctgc
tcctcggcca cgaagtgcac gcagttgccg 3360 gccgggtcgc gcagggcgaa
ctcccgcccc cacggctgct cgccgatctc ggtcatggcc 3420 ggcccggagg
cgtcccggaa gttcgtggac acgacctccg accactcggc gtacagctcg 3480
tccaggccgc gcacccacac ccaggccagg gtgttgtccg gcaccacctg gtcctggacc
3540 gcgctgatga acagggtcac gtcgtcccgg accacaccgg cgaagtcgtc
ctccacgaag 3600 tcccgggaga acccgagccg gtcggtccag aactcgaccg
ctccggcgac gtcgcgcgcg 3660 gtgagcaccg gaacggcact ggtcaacttg
gccatggttt agttcctcac cttgtcgtat 3720 tatactatgc cgatatacta
tgccgatgat taattgtcaa cacgtgctga tcagatccga 3780 aaatggatat
acaagctccc gggagctttt tgcaaaagcc taggcctcca aaaaagcctc 3840
ctcactactt ctggaatagc tcagaggcag aggcggcctc ggcctctgca taaataaaaa
3900 aaattagtca gccatggggc ggagaatggg cggaactggg cggagttagg
ggcgggatgg 3960 gcggagttag gggcgggact atggttgctg actaattgag
atgcatgctt tgcatacttc 4020 tgcctgctgg ggagcctggg gactttccac
acctggttgc tgactaattg agatgcatgc 4080 tttgcatact tctgcctgct
ggggagcctg gggactttcc acaccctcgt cgagctagct 4140 tcgtgaggct
ccggtgcccg tcagtgggca gagcgcacat cgcccacagt ccccgagaag 4200
ttggggggag gggtcggcaa ttgaaccggt gcctagagaa ggtggcgcgg ggtaaactgg
4260 gaaagtgatg tcgtgtactg gctccgcctt tttcccgagg gtgggggaga
accgtatata 4320 agtgcagtag tcgccgtgaa cgttcttttt cgcaacgggt
ttgccgccag aacacaggta 4380 agtgccgtgt gtggttcccg cgggcctggc
ctctttacgg gttatggccc ttgcgtgcct 4440 tgaattactt ccacctggct
ccagtacgtg attcttgatc ccgagctgga gccaggggcg 4500 ggccttgcgc
tttaggagcc ccttcgcctc gtgcttgagt tgaggcctgg cctgggcgct 4560
ggggccgccg cgtgcgaatc tggtggcacc ttcgcgcctg tctcgctgct ttcgataagt
4620 ctctagccat ttaaaatttt tgatgacctg ctgcgacgct ttttttctgg
caagatagtc 4680 ttgtaaatgc gggccaggat ctgcacactg gtatttcggt
ttttggggcc gcgggcggcg 4740 acggggcccg tgcgtcccag cgcacatgtt
cggcgaggcg gggcctgcga gcgcggccac 4800 cgagaatcgg acgggggtag
tctcaagctg gccggcctgc tctggtgcct ggcctcgcgc 4860 cgccgtgtat
cgccccgccc tgggcggcaa ggctggcccg gtcggcacca gttgcgtgag 4920
cggaaagatg gccgcttccc ggccctgctc cagggggctc aaaatggagg acgcggcgct
4980 cgggagagcg ggcgggtgag tcacccacac aaaggaaagg ggcctttccg
tcctcagccg 5040 tcgcttcatg tgactccacg gagtaccggg cgccgtccag
gcacctcgat tagttctgga 5100 gcttttggag tacgtcgtct ttaggttggg
gggaggggtt ttatgcgatg gagtttcccc 5160 acactgagtg ggtggagact
gaagttaggc cagcttggca cttgatgtaa ttctccttgg 5220 aatttgccct
ttttgagttt ggatcttggt tcattctcaa gcctcagaca gtggttcaaa 5280
gtttttttct tccatttcag gtgtcgtgaa cacgtggtcg cggccgcgcc gccaccatgg
5340 agacagacac actcctgcta tgggtactgc tgctctgggt tccaggttcc
actggtgaca 5400 aaactcacac atgcccaccg tgcccagcac ctgaactcct
gggaggaccg tcagtcttcc 5460 tcttcccccc aaaacccaag gacaccctca
tgatctcccg gacccctgag gtcacatgcg 5520 tggtggtgga cgtgagccac
gaagaccctg aggtcaagtt caactggtac gtggacggcg 5580 tggaggtgca
taatgccaag acaaagccgc gggaggagca gtacaacagc acgtaccgtg 5640
tggtcagcgt cctcaccgtc ctgcaccagg actggctgaa tggcaaggag tacaagtgca
5700 aggtctccaa caaagccctc ccagccccca tcgagaaaac catctccaaa
gccaaagggc 5760 agccccgaga accacaggtg tacaccctgc ccccatcccg
cgatgagctg accaagaacc 5820 aggtcagcct gacctgcctg gtcaaaggct
tctatcccag cgacatcgcc gtggagtggg 5880 agagcaatgg gcagccggag
aacaactaca agaccacgcc tcccgtgttg gactccgacg 5940 gctccttctt
cctctacagc aagctcaccg tggacaagag caggtggcag caggggaacg 6000
tcttctcatg ctccgtgatg catgaggctc tgcacaacca ctacacgcag aagagcctct
6060 ccctgtctcc gggtaaatga ctcgagagat ctggccggct gggcccgttt
cgaaggtaag 6120 cctatcccta accctctcct cggtctcgat tctacgcgta
ccggtcatca tcaccatcac 6180 cattgagttt aaacccgctg atcagcctcg
actgtgcctt ctagttgcca gccatctgtt 6240 gtttgcccct cccccgtgcc
ttccttgacc ctggaaggtg ccactcccac tgtcctttcc 6300 taataaaatg
aggaaattgc atcgcattgt ctgagtaggt gtcattctat tctggggggt 6360
ggggtggggc aggacagcaa gggggaggat tgggaagaca atagcaggca tgctggggat
6420 gcggtgggct ctatggcttc tgaggcggaa agaaccagtg gcggtaatac
ggttatccac 6480 agaatcaggg gataacgcag gaaagaacat gtgagcaaaa
ggccagcaaa aggccaggaa 6540 ccgtaaaaag gccgcgttgc tggcgttttt
ccataggctc cgcccccctg acgagcatca 6600 caaaaatcga cgctcaagtc
agaggtggcg aaacccgaca ggactataaa gataccaggc 6660 gtttccccct
agaagctccc tcgtgcgctc tcctgttccg accctgccgc ttaccggata 6720
cctgtccgcc tttctccctt cgggaagcgt ggcgctttct catagctcac gctgtaggta
6780 tctcagttcg gtgtaggtcg ttcgctccaa gctgggctgt gtgcacgaac
cccccgttca 6840 gcccgaccgc tgcgccttat ccggtaacta tcgtcttgag
tccaacccgg taagacacga 6900 cttatcgcca ctggcagcag ccactggtaa
caggattagc agagcgaggt atgtaggcgg 6960 tgctacagag ttcttgaagt
ggtggcctaa ctacggctac actagaagaa cagtatttgg 7020 tatctgcgct
ctgctgaagc cagttacctt cggaaaaaga gttggtagct cttgatccgg 7080
caaacaaacc accgctggta gcggtggttt ttttgtttgc aagcagcaga ttacgcgcag
7140 aaaaaaagga tctcaagaag atcctttgat cttttctacg gggtctgacg
ctcagtggaa 7200 cgaaaactca cgttaaggga ttttggtcat gacattaacc
tataaaaata ggcgtatcac 7260 gaggcccttt cgtctcgcgc gtttcggtga
tgacggtgaa aacctctgac acatgcagct 7320 cccggagacg gtcacagctt
gtctgtaagc ggatgccggg agcagacaag cccgtcaggg 7380 cgcgtcagcg
ggtgttggcg ggtgtcgggg ctggcttaac tatgcggcat cagagcagat 7440
tgtactgaga gtgcaccata tatgcggtgt gaaataccgc acagatgcgt aaggagaaaa
7500 taccgcatca ggcgccattc gccattcagg ctgcgcaact gttgggaagg
gcgatcggtg 7560 cgggcctctt cgctattacg cca 7583 <210> SEQ ID
NO 2 <211> LENGTH: 688 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: pSYN-FIX-030 <220> FEATURE: <221>
NAME/KEY: SIGNAL <222> LOCATION: (-46)..(-19) 220>
<221> NAME/KEY: SIGNAL <222> LOCATION: (-18)..(-1)
<220> FEATURE: <221> NAME/KEY: mat_peptide <222>
LOCATION: (1)..(642) <400> SEQUENCE: 2 Met Gln Arg Val Asn
Met Ile Met Ala Glu Ser Pro Gly Leu Ile Thr -45 -40 -35 Ile Cys Leu
Leu Gly Tyr Leu Leu Ser Ala Glu Cys Thr Val Phe Leu -30 -25 -20 -15
Asp His Glu Asn Ala Asn Lys Ile Leu Asn Arg Pro Lys Arg Tyr Asn -10
-5 -1 1 Ser Gly Lys Leu Glu Glu Phe Val Gln Gly Asn Leu Glu Arg Glu
Cys 5 10 15 Met Glu Glu Lys Cys Ser Phe Glu Glu Ala Arg Glu Val Phe
Glu Asn 20 25 30 Thr Glu Arg Thr Thr Glu Phe Trp Lys Gln Tyr Val
Asp Gly Asp Gln 35 40 45 50 Cys Glu Ser Asn Pro Cys Leu Asn Gly Gly
Ser Cys Lys Asp Asp Ile 55 60 65 Asn Ser Tyr Glu Cys Trp Cys Pro
Phe Gly Phe Glu Gly Lys Asn Cys 70 75 80 Glu Leu Asp Val Thr Cys
Asn Ile Lys Asn Gly Arg Cys Glu Gln Phe 85 90 95 Cys Lys Asn Ser
Ala Asp Asn Lys Val Val Cys Ser Cys Thr Glu Gly 100 105 110 Tyr Arg
Leu Ala Glu Asn Gln Lys Ser Cys Glu Pro Ala Val Pro Phe 115 120 125
130 Pro Cys Gly Arg Val Ser Val Ser Gln Thr Ser Lys Leu Thr Arg Ala
135 140 145 Glu Thr Val Phe Pro Asp Val Asp Tyr Val Asn Ser Thr Glu
Ala Glu 150 155 160 Thr Ile Leu Asp Asn Ile Thr Gln Ser Thr Gln Ser
Phe Asn Asp Phe 165 170 175 Thr Arg Val Val Gly Gly Glu Asp Ala Lys
Pro Gly Gln Phe Pro Trp 180 185 190 Gln Val Val Leu Asn Gly Lys Val
Asp Ala Phe Cys Gly Gly Ser Ile 195 200 205 210 Val Asn Glu Lys Trp
Ile Val Thr Ala Ala His Cys Val Glu Thr Gly 215 220 225 Val Lys Ile
Thr Val Val Ala Gly Glu His Asn Ile Glu Glu Thr Glu 230 235 240 His
Thr Glu Gln Lys Arg Asn Val Ile Arg Ile Ile Pro His His Asn 245 250
255 Tyr Asn Ala Ala Ile Asn Lys Tyr Asn His Asp Ile Ala Leu Leu Glu
260 265 270 Leu Asp Glu Pro Leu Val Leu Asn Ser Tyr Val Thr Pro Ile
Cys Ile 275 280 285 290 Ala Asp Lys Glu Tyr Thr Asn Ile Phe Leu Lys
Phe Gly Ser Gly Tyr 295 300 305 Val Ser Gly Trp Gly Arg Val Phe His
Lys Gly Arg Ser Ala Leu Val 310 315 320 Leu Gln Tyr Leu Arg Val Pro
Leu Val Asp Arg Ala Thr Cys Leu Arg 325 330 335 Ser Thr Lys Phe Thr
Ile Tyr Asn Asn Met Phe Cys Ala Gly Phe His 340 345 350 Glu Gly Gly
Arg Asp Ser Cys Gln Gly Asp Ser Gly Gly Pro His Val 355 360 365 370
Thr Glu Val Glu Gly Thr Ser Phe Leu Thr Gly Ile Ile Ser Trp Gly 375
380 385 Glu Glu Cys Ala Met Lys Gly Lys Tyr Gly Ile Tyr Thr Lys Val
Ser 390 395 400 Arg Tyr Val Asn Trp Ile Lys Glu Lys Thr Lys Leu Thr
Asp Lys Thr 405 410 415 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu
Leu Gly Gly Pro Ser 420 425 430 Val Phe Leu Phe Pro Pro Lys Pro Lys
Asp Thr Leu Met Ile Ser Arg 435 440 445 450 Thr Pro Glu Val Thr Cys
Val Val Val Asp Val Ser His Glu Asp Pro 455 460 465 Glu Val Lys Phe
Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 470 475 480 Lys Thr
Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val 485 490 495
Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 500
505 510 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys
Thr 515 520 525 530 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
Val Tyr Thr Leu 535 540 545 Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn
Gln Val Ser Leu Thr Cys 550 555 560 Leu Val Lys Gly Phe Tyr Pro Ser
Asp Ile Ala Val Glu Trp Glu Ser 565 570 575 Asn Gly Gln Pro Glu Asn
Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 580 585 590 Ser Asp Gly Ser
Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 595 600 605 610 Arg
Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 615 620
625 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
630 635 640 <210> SEQ ID NO 3 <211> LENGTH: 741
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Fc cassette
from pSYN-FIX-030 <400> SEQUENCE: 3 atggagacag acacactcct
gctatgggta ctgctgctct gggttccagg ttccactggt 60 gacaaaactc
acacatgccc accgtgccca gcacctgaac tcctgggagg accgtcagtc 120
ttcctcttcc ccccaaaacc caaggacacc ctcatgatct cccggacccc tgaggtcaca
180 tgcgtggtgg tggacgtgag ccacgaagac cctgaggtca agttcaactg
gtacgtggac 240 ggcgtggagg tgcataatgc caagacaaag ccgcgggagg
agcagtacaa cagcacgtac 300 cgtgtggtca gcgtcctcac cgtcctgcac
caggactggc tgaatggcaa ggagtacaag 360 tgcaaggtct ccaacaaagc
cctcccagcc cccatcgaga aaaccatctc caaagccaaa 420 gggcagcccc
gagaaccaca ggtgtacacc ctgcccccat cccgcgatga gctgaccaag 480
aaccaggtca gcctgacctg cctggtcaaa ggcttctatc ccagcgacat cgccgtggag
540 tgggagagca atgggcagcc ggagaacaac tacaagacca cgcctcccgt
gttggactcc 600 gacggctcct tcttcctcta cagcaagctc accgtggaca
agagcaggtg gcagcagggg 660 aacgtcttct catgctccgt gatgcatgag
gctctgcaca accactacac gcagaagagc 720 ctctccctgt ctccgggtaa a 741
<210> SEQ ID NO 4 <211> LENGTH: 247 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Fc cassette from pSYN-FIX-030
<220> FEATURE: <221> NAME/KEY: SIGNAL <222>
LOCATION: (-20)..(-1) <220> FEATURE: <221> NAME/KEY:
mat_peptide <222> LOCATION: (1)..(227) <400> SEQUENCE:
4 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro
-20 -15 -10 -5 Gly Ser Thr Gly Asp Lys Thr His Thr Cys Pro Pro Cys
Pro Ala Pro -1 1 5 10 Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe
Pro Pro Lys Pro Lys 15 20 25 Asp Thr Leu Met Ile Ser Arg Thr Pro
Glu Val Thr Cys Val Val Val 30 35 40 Asp Val Ser His Glu Asp Pro
Glu Val Lys Phe Asn Trp Tyr Val Asp 45 50 55 60 Gly Val Glu Val His
Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr 65 70 75 Asn Ser Thr
Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp 80 85 90 Trp
Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu 95 100
105 Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
110 115 120 Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu
Thr Lys 125 130 135 140 Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly
Phe Tyr Pro Ser Asp 145 150 155 Ile Ala Val Glu Trp Glu Ser Asn Gly
Gln Pro Glu Asn Asn Tyr Lys 160 165 170 Thr Thr Pro Pro Val Leu Asp
Ser Asp Gly Ser Phe Phe Leu Tyr Ser 175 180 185 Lys Leu Thr Val Asp
Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser 190 195 200 Cys Ser Val
Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser 205 210 215 220
Leu Ser Leu Ser Pro Gly Lys 225 <210> SEQ ID NO 5 <211>
LENGTH: 5052 <212> TYPE: DNA <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
B-Domain Deleted FVIIIFc <400> SEQUENCE: 5 atgcaaatag
agctctccac ctgcttcttt ctgtgccttt tgcgattctg ctttagtgcc 60
accagaagat actacctggg tgcagtggaa ctgtcatggg actatatgca aagtgatctc
120 ggtgagctgc ctgtggacgc aagatttcct cctagagtgc caaaatcttt
tccattcaac 180 acctcagtcg tgtacaaaaa gactctgttt gtagaattca
cggatcacct tttcaacatc 240 gctaagccaa ggccaccctg gatgggtctg
ctaggtccta ccatccaggc tgaggtttat 300 gatacagtgg tcattacact
taagaacatg gcttcccatc ctgtcagtct tcatgctgtt 360 ggtgtatcct
actggaaagc ttctgaggga gctgaatatg atgatcagac cagtcaaagg 420
gagaaagaag atgataaagt cttccctggt ggaagccata catatgtctg gcaggtcctg
480 aaagagaatg gtccaatggc ctctgaccca ctgtgcctta cctactcata
tctttctcat 540 gtggacctgg taaaagactt gaattcaggc ctcattggag
ccctactagt atgtagagaa 600 gggagtctgg ccaaggaaaa gacacagacc
ttgcacaaat ttatactact ttttgctgta 660 tttgatgaag ggaaaagttg
gcactcagaa acaaagaact ccttgatgca ggatagggat 720 gctgcatctg
ctcgggcctg gcctaaaatg cacacagtca atggttatgt aaacaggtct 780
ctgccaggtc tgattggatg ccacaggaaa tcagtctatt ggcatgtgat tggaatgggc
840 accactcctg aagtgcactc aatattcctc gaaggtcaca catttcttgt
gaggaaccat 900 cgccaggcgt ccttggaaat ctcgccaata actttcctta
ctgctcaaac actcttgatg 960 gaccttggac agtttctact gttttgtcat
atctcttccc accaacatga tggcatggaa 1020 gcttatgtca aagtagacag
ctgtccagag gaaccccaac tacgaatgaa aaataatgaa 1080 gaagcggaag
actatgatga tgatcttact gattctgaaa tggatgtggt caggtttgat 1140
gatgacaact ctccttcctt tatccaaatt cgctcagttg ccaagaagca tcctaaaact
1200 tgggtacatt acattgctgc tgaagaggag gactgggact atgctccctt
agtcctcgcc 1260 cccgatgaca gaagttataa aagtcaatat ttgaacaatg
gccctcagcg gattggtagg 1320 aagtacaaaa aagtccgatt tatggcatac
acagatgaaa cctttaagac tcgtgaagct 1380 attcagcatg aatcaggaat
cttgggacct ttactttatg gggaagttgg agacacactg 1440 ttgattatat
ttaagaatca agcaagcaga ccatataaca tctaccctca cggaatcact 1500
gatgtccgtc ctttgtattc aaggagatta ccaaaaggtg taaaacattt gaaggatttt
1560 ccaattctgc caggagaaat attcaaatat aaatggacag tgactgtaga
agatgggcca 1620 actaaatcag atcctcggtg cctgacccgc tattactcta
gtttcgttaa tatggagaga 1680 gatctagctt caggactcat tggccctctc
ctcatctgct acaaagaatc tgtagatcaa 1740 agaggaaacc agataatgtc
agacaagagg aatgtcatcc tgttttctgt atttgatgag 1800 aaccgaagct
ggtacctcac agagaatata caacgctttc tccccaatcc agctggagtg 1860
cagcttgagg atccagagtt ccaagcctcc aacatcatgc acagcatcaa tggctatgtt
1920 tttgatagtt tgcagttgtc agtttgtttg catgaggtgg catactggta
cattctaagc 1980 attggagcac agactgactt cctttctgtc ttcttctctg
gatatacctt caaacacaaa 2040 atggtctatg aagacacact caccctattc
ccattctcag gagaaactgt cttcatgtcg 2100 atggaaaacc caggtctatg
gattctgggg tgccacaact cagactttcg gaacagaggc 2160 atgaccgcct
tactgaaggt ttctagttgt gacaagaaca ctggtgatta ttacgaggac 2220
agttatgaag atatttcagc atacttgctg agtaaaaaca atgccattga accaagaagc
2280 ttctctcaaa acccaccagt cttgaaacgc catcaacggg aaataactcg
tactactctt 2340 cagtcagatc aagaggaaat tgactatgat gataccatat
cagttgaaat gaagaaggaa 2400 gattttgaca tttatgatga ggatgaaaat
cagagccccc gcagctttca aaagaaaaca 2460 cgacactatt ttattgctgc
agtggagagg ctctgggatt atgggatgag tagctcccca 2520 catgttctaa
gaaacagggc tcagagtggc agtgtccctc agttcaagaa agttgttttc 2580
caggaattta ctgatggctc ctttactcag cccttatacc gtggagaact aaatgaacat
2640 ttgggactcc tggggccata tataagagca gaagttgaag ataatatcat
ggtaactttc 2700 agaaatcagg cctctcgtcc ctattccttc tattctagcc
ttatttctta tgaggaagat 2760 cagaggcaag gagcagaacc tagaaaaaac
tttgtcaagc ctaatgaaac caaaacttac 2820 ttttggaaag tgcaacatca
tatggcaccc actaaagatg agtttgactg caaagcctgg 2880 gcttatttct
ctgatgttga cctggaaaaa gatgtgcact caggcctgat tggacccctt 2940
ctggtctgcc acactaacac actgaaccct gctcatggga gacaagtgac agtacaggaa
3000 tttgctctgt ttttcaccat ctttgatgag accaaaagct ggtacttcac
tgaaaatatg 3060 gaaagaaact gcagggctcc ctgcaatatc cagatggaag
atcccacttt taaagagaat 3120 tatcgcttcc atgcaatcaa tggctacata
atggatacac tacctggctt agtaatggct 3180 caggatcaaa ggattcgatg
gtatctgctc agcatgggca gcaatgaaaa catccattct 3240 attcatttca
gtggacatgt gttcactgta cgaaaaaaag aggagtataa aatggcactg 3300
tacaatctct atccaggtgt ttttgagaca gtggaaatgt taccatccaa agctggaatt
3360 tggcgggtgg aatgccttat tggcgagcat ctacatgctg ggatgagcac
actttttctg 3420 gtgtacagca ataagtgtca gactcccctg ggaatggctt
ctggacacat tagagatttt 3480 cagattacag cttcaggaca atatggacag
tgggccccaa agctggccag acttcattat 3540 tccggatcaa tcaatgcctg
gagcaccaag gagccctttt cttggatcaa ggtggatctg 3600 ttggcaccaa
tgattattca cggcatcaag acccagggtg cccgtcagaa gttctccagc 3660
ctctacatct ctcagtttat catcatgtat agtcttgatg ggaagaagtg gcagacttat
3720 cgaggaaatt ccactggaac cttaatggtc ttctttggca atgtggattc
atctgggata 3780 aaacacaata tttttaaccc tccaattatt gctcgataca
tccgtttgca cccaactcat 3840 tatagcattc gcagcactct tcgcatggag
ttgatgggct gtgatttaaa tagttgcagc 3900 atgccattgg gaatggagag
taaagcaata tcagatgcac agattactgc ttcatcctac 3960 tttaccaata
tgtttgccac ctggtctcct tcaaaagctc gacttcacct ccaagggagg 4020
agtaatgcct ggagacctca ggtgaataat ccaaaagagt ggctgcaagt ggacttccag
4080 aagacaatga aagtcacagg agtaactact cagggagtaa aatctctgct
taccagcatg 4140 tatgtgaagg agttcctcat ctccagcagt caagatggcc
atcagtggac tctctttttt 4200 cagaatggca aagtaaaggt ttttcaggga
aatcaagact ccttcacacc tgtggtgaac 4260 tctctagacc caccgttact
gactcgctac cttcgaattc acccccagag ttgggtgcac 4320 cagattgccc
tgaggatgga ggttctgggc tgcgaggcac aggacctcta cgacaaaact 4380
cacacatgcc caccgtgccc agctccagaa ctcctgggcg gaccgtcagt cttcctcttc
4440 cccccaaaac ccaaggacac cctcatgatc tcccggaccc ctgaggtcac
atgcgtggtg 4500 gtggacgtga gccacgaaga ccctgaggtc aagttcaact
ggtacgtgga cggcgtggag 4560 gtgcataatg ccaagacaaa gccgcgggag
gagcagtaca acagcacgta ccgtgtggtc 4620 agcgtcctca ccgtcctgca
ccaggactgg ctgaatggca aggagtacaa gtgcaaggtc 4680 tccaacaaag
ccctcccagc ccccatcgag aaaaccatct ccaaagccaa agggcagccc 4740
cgagaaccac aggtgtacac cctgccccca tcccgggatg agctgaccaa gaaccaggtc
4800 agcctgacct gcctggtcaa aggcttctat cccagcgaca tcgccgtgga
gtgggagagc 4860 aatgggcagc cggagaacaa ctacaagacc acgcctcccg
tgttggactc cgacggctcc 4920 ttcttcctct acagcaagct caccgtggac
aagagcaggt ggcagcaggg gaacgtcttc 4980 tcatgctccg tgatgcatga
ggctctgcac aaccactaca cgcagaagag cctctccctg 5040 tctccgggta aa 5052
<210> SEQ ID NO 6 <211> LENGTH: 1684 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: B-Domain Deleted FVIIIFc <220>
FEATURE: <221> NAME/KEY: SIGNAL <222> LOCATION:
(-19)..(-1) <220> FEATURE: <221> NAME/KEY: mat_peptide
<222> LOCATION: (1)..(1665) <400> SEQUENCE: 6 Met Gln
Ile Glu Leu Ser Thr Cys Phe Phe Leu Cys Leu Leu Arg Phe -15 -10 -5
Cys Phe Ser Ala Thr Arg Arg Tyr Tyr Leu Gly Ala Val Glu Leu Ser -1
1 5 10 Trp Asp Tyr Met Gln Ser Asp Leu Gly Glu Leu Pro Val Asp Ala
Arg 15 20 25 Phe Pro Pro Arg Val Pro Lys Ser Phe Pro Phe Asn Thr
Ser Val Val 30 35 40 45 Tyr Lys Lys Thr Leu Phe Val Glu Phe Thr Asp
His Leu Phe Asn Ile 50 55 60 Ala Lys Pro Arg Pro Pro Trp Met Gly
Leu Leu Gly Pro Thr Ile Gln 65 70 75 Ala Glu Val Tyr Asp Thr Val
Val Ile Thr Leu Lys Asn Met Ala Ser 80 85 90 His Pro Val Ser Leu
His Ala Val Gly Val Ser Tyr Trp Lys Ala Ser 95 100 105 Glu Gly Ala
Glu Tyr Asp Asp Gln Thr Ser Gln Arg Glu Lys Glu Asp 110 115 120 125
Asp Lys Val Phe Pro Gly Gly Ser His Thr Tyr Val Trp Gln Val Leu 130
135 140 Lys Glu Asn Gly Pro Met Ala Ser Asp Pro Leu Cys Leu Thr Tyr
Ser 145 150 155 Tyr Leu Ser His Val Asp Leu Val Lys Asp Leu Asn Ser
Gly Leu Ile 160 165 170 Gly Ala Leu Leu Val Cys Arg Glu Gly Ser Leu
Ala Lys Glu Lys Thr 175 180 185 Gln Thr Leu His Lys Phe Ile Leu Leu
Phe Ala Val Phe Asp Glu Gly 190 195 200 205 Lys Ser Trp His Ser Glu
Thr Lys Asn Ser Leu Met Gln Asp Arg Asp 210 215 220 Ala Ala Ser Ala
Arg Ala Trp Pro Lys Met His Thr Val Asn Gly Tyr 225 230 235 Val Asn
Arg Ser Leu Pro Gly Leu Ile Gly Cys His Arg Lys Ser Val 240 245 250
Tyr Trp His Val Ile Gly Met Gly Thr Thr Pro Glu Val His Ser Ile 255
260 265 Phe Leu Glu Gly His Thr Phe Leu Val Arg Asn His Arg Gln Ala
Ser 270 275 280 285 Leu Glu Ile Ser Pro Ile Thr Phe Leu Thr Ala Gln
Thr Leu Leu Met 290 295 300 Asp Leu Gly Gln Phe Leu Leu Phe Cys His
Ile Ser Ser His Gln His 305 310 315 Asp Gly Met Glu Ala Tyr Val Lys
Val Asp Ser Cys Pro Glu Glu Pro 320 325 330 Gln Leu Arg Met Lys Asn
Asn Glu Glu Ala Glu Asp Tyr Asp Asp Asp 335 340 345 Leu Thr Asp Ser
Glu Met Asp Val Val Arg Phe Asp Asp Asp Asn Ser 350 355 360 365 Pro
Ser Phe Ile Gln Ile Arg Ser Val Ala Lys Lys His Pro Lys Thr 370 375
380 Trp Val His Tyr Ile Ala Ala Glu Glu Glu Asp Trp Asp Tyr Ala Pro
385 390 395 Leu Val Leu Ala Pro Asp Asp Arg Ser Tyr Lys Ser Gln Tyr
Leu Asn 400 405 410 Asn Gly Pro Gln Arg Ile Gly Arg Lys Tyr Lys Lys
Val Arg Phe Met 415 420 425 Ala Tyr Thr Asp Glu Thr Phe Lys Thr Arg
Glu Ala Ile Gln His Glu 430 435 440 445 Ser Gly Ile Leu Gly Pro Leu
Leu Tyr Gly Glu Val Gly Asp Thr Leu 450 455 460 Leu Ile Ile Phe Lys
Asn Gln Ala Ser Arg Pro Tyr Asn Ile Tyr Pro 465 470 475 His Gly Ile
Thr Asp Val Arg Pro Leu Tyr Ser Arg Arg Leu Pro Lys 480 485 490 Gly
Val Lys His Leu Lys Asp Phe Pro Ile Leu Pro Gly Glu Ile Phe 495 500
505 Lys Tyr Lys Trp Thr Val Thr Val Glu Asp Gly Pro Thr Lys Ser Asp
510 515 520 525 Pro Arg Cys Leu Thr Arg Tyr Tyr Ser Ser Phe Val Asn
Met Glu Arg 530 535 540 Asp Leu Ala Ser Gly Leu Ile Gly Pro Leu Leu
Ile Cys Tyr Lys Glu 545 550 555 Ser Val Asp Gln Arg Gly Asn Gln Ile
Met Ser Asp Lys Arg Asn Val 560 565 570 Ile Leu Phe Ser Val Phe Asp
Glu Asn Arg Ser Trp Tyr Leu Thr Glu 575 580 585 Asn Ile Gln Arg Phe
Leu Pro Asn Pro Ala Gly Val Gln Leu Glu Asp 590 595 600 605 Pro Glu
Phe Gln Ala Ser Asn Ile Met His Ser Ile Asn Gly Tyr Val 610 615 620
Phe Asp Ser Leu Gln Leu Ser Val Cys Leu His Glu Val Ala Tyr Trp 625
630 635 Tyr Ile Leu Ser Ile Gly Ala Gln Thr Asp Phe Leu Ser Val Phe
Phe 640 645 650 Ser Gly Tyr Thr Phe Lys His Lys Met Val Tyr Glu Asp
Thr Leu Thr 655 660 665 Leu Phe Pro Phe Ser Gly Glu Thr Val Phe Met
Ser Met Glu Asn Pro 670 675 680 685 Gly Leu Trp Ile Leu Gly Cys His
Asn Ser Asp Phe Arg Asn Arg Gly 690 695 700 Met Thr Ala Leu Leu Lys
Val Ser Ser Cys Asp Lys Asn Thr Gly Asp 705 710 715 Tyr Tyr Glu Asp
Ser Tyr Glu Asp Ile Ser Ala Tyr Leu Leu Ser Lys 720 725 730 Asn Asn
Ala Ile Glu Pro Arg Ser Phe Ser Gln Asn Pro Pro Val Leu 735 740 745
Lys Arg His Gln Arg Glu Ile Thr Arg Thr Thr Leu Gln Ser Asp Gln 750
755 760 765 Glu Glu Ile Asp Tyr Asp Asp Thr Ile Ser Val Glu Met Lys
Lys Glu 770 775 780 Asp Phe Asp Ile Tyr Asp Glu Asp Glu Asn Gln Ser
Pro Arg Ser Phe 785 790 795 Gln Lys Lys Thr Arg His Tyr Phe Ile Ala
Ala Val Glu Arg Leu Trp 800 805 810 Asp Tyr Gly Met Ser Ser Ser Pro
His Val Leu Arg Asn Arg Ala Gln 815 820 825 Ser Gly Ser Val Pro Gln
Phe Lys Lys Val Val Phe Gln Glu Phe Thr 830 835 840 845 Asp Gly Ser
Phe Thr Gln Pro Leu Tyr Arg Gly Glu Leu Asn Glu His 850 855 860 Leu
Gly Leu Leu Gly Pro Tyr Ile Arg Ala Glu Val Glu Asp Asn Ile 865 870
875 Met Val Thr Phe Arg Asn Gln Ala Ser Arg Pro Tyr Ser Phe Tyr Ser
880 885 890 Ser Leu Ile Ser Tyr Glu Glu Asp Gln Arg Gln Gly Ala Glu
Pro Arg 895 900 905 Lys Asn Phe Val Lys Pro Asn Glu Thr Lys Thr Tyr
Phe Trp Lys Val 910 915 920 925 Gln His His Met Ala Pro Thr Lys Asp
Glu Phe Asp Cys Lys Ala Trp 930 935 940 Ala Tyr Phe Ser Asp Val Asp
Leu Glu Lys Asp Val His Ser Gly Leu 945 950 955 Ile Gly Pro Leu Leu
Val Cys His Thr Asn Thr Leu Asn Pro Ala His 960 965 970 Gly Arg Gln
Val Thr Val Gln Glu Phe Ala Leu Phe Phe Thr Ile Phe 975 980 985 Asp
Glu Thr Lys Ser Trp Tyr Phe Thr Glu Asn Met Glu Arg Asn Cys 990 995
1000 1005 Arg Ala Pro Cys Asn Ile Gln Met Glu Asp Pro Thr Phe Lys
Glu 1010 1015 1020 Asn Tyr Arg Phe His Ala Ile Asn Gly Tyr Ile Met
Asp Thr Leu 1025 1030 1035 Pro Gly Leu Val Met Ala Gln Asp Gln Arg
Ile Arg Trp Tyr Leu 1040 1045 1050 Leu Ser Met Gly Ser Asn Glu Asn
Ile His Ser Ile His Phe Ser 1055 1060 1065 Gly His Val Phe Thr Val
Arg Lys Lys Glu Glu Tyr Lys Met Ala 1070 1075 1080 Leu Tyr Asn Leu
Tyr Pro Gly Val Phe Glu Thr Val Glu Met Leu 1085 1090 1095 Pro Ser
Lys Ala Gly Ile Trp Arg Val Glu Cys Leu Ile Gly Glu 1100 1105 1110
His Leu His Ala Gly Met Ser Thr Leu Phe Leu Val Tyr Ser Asn 1115
1120 1125 Lys Cys Gln Thr Pro Leu Gly Met Ala Ser Gly His Ile Arg
Asp 1130 1135 1140 Phe Gln Ile Thr Ala Ser Gly Gln Tyr Gly Gln Trp
Ala Pro Lys 1145 1150 1155 Leu Ala Arg Leu His Tyr Ser Gly Ser Ile
Asn Ala Trp Ser Thr 1160 1165 1170 Lys Glu Pro Phe Ser Trp Ile Lys
Val Asp Leu Leu Ala Pro Met 1175 1180 1185 Ile Ile His Gly Ile Lys
Thr Gln Gly Ala Arg Gln Lys Phe Ser 1190 1195 1200 Ser Leu Tyr Ile
Ser Gln Phe Ile Ile Met Tyr Ser Leu Asp Gly 1205 1210 1215 Lys Lys
Trp Gln Thr Tyr Arg Gly Asn Ser Thr Gly Thr Leu Met 1220 1225 1230
Val Phe Phe Gly Asn Val Asp Ser Ser Gly Ile Lys His Asn Ile 1235
1240 1245 Phe Asn Pro Pro Ile Ile Ala Arg Tyr Ile Arg Leu His Pro
Thr 1250 1255 1260 His Tyr Ser Ile Arg Ser Thr Leu Arg Met Glu Leu
Met Gly Cys 1265 1270 1275 Asp Leu Asn Ser Cys Ser Met Pro Leu Gly
Met Glu Ser Lys Ala 1280 1285 1290 Ile Ser Asp Ala Gln Ile Thr Ala
Ser Ser Tyr Phe Thr Asn Met 1295 1300 1305 Phe Ala Thr Trp Ser Pro
Ser Lys Ala Arg Leu His Leu Gln Gly 1310 1315 1320 Arg Ser Asn Ala
Trp Arg Pro Gln Val Asn Asn Pro Lys Glu Trp 1325 1330 1335 Leu Gln
Val Asp Phe Gln Lys Thr Met Lys Val Thr Gly Val Thr 1340 1345 1350
Thr Gln Gly Val Lys Ser Leu Leu Thr Ser Met Tyr Val Lys Glu 1355
1360 1365 Phe Leu Ile Ser Ser Ser Gln Asp Gly His Gln Trp Thr Leu
Phe 1370 1375 1380 Phe Gln Asn Gly Lys Val Lys Val Phe Gln Gly Asn
Gln Asp Ser 1385 1390 1395 Phe Thr Pro Val Val Asn Ser Leu Asp Pro
Pro Leu Leu Thr Arg 1400 1405 1410 Tyr Leu Arg Ile His Pro Gln Ser
Trp Val His Gln Ile Ala Leu 1415 1420 1425 Arg Met Glu Val Leu Gly
Cys Glu Ala Gln Asp Leu Tyr Asp Lys 1430 1435 1440 Thr His Thr Cys
Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 1445 1450 1455 Pro Ser
Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 1460 1465 1470
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser 1475
1480 1485 His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly
Val 1490 1495 1500 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu
Gln Tyr Asn 1505 1510 1515 Ser Thr Tyr Arg Val Val Ser Val Leu Thr
Val Leu His Gln Asp 1520 1525 1530 Trp Leu Asn Gly Lys Glu Tyr Lys
Cys Lys Val Ser Asn Lys Ala 1535 1540 1545 Leu Pro Ala Pro Ile Glu
Lys Thr Ile Ser Lys Ala Lys Gly Gln 1550 1555 1560 Pro Arg Glu Pro
Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu 1565 1570 1575 Leu Thr
Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe 1580 1585 1590
Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro 1595
1600 1605 Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp
Gly 1610 1615 1620 Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys
Ser Arg Trp 1625 1630 1635 Gln Gln Gly Asn Val Phe Ser Cys Ser Val
Met His Glu Ala Leu 1640 1645 1650 His Asn His Tyr Thr Gln Lys Ser
Leu Ser Leu Ser Pro Gly Lys 1655 1660 1665 <210> SEQ ID NO 7
<211> LENGTH: 741 <212> TYPE: DNA <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Fc Sequence <400> SEQUENCE: 7 atggagacag
acacactcct gctatgggta ctgctgctct gggttccagg ttccactggt 60
gacaaaactc acacatgccc accgtgccca gcacctgaac tcctgggagg accgtcagtc
120 ttcctcttcc ccccaaaacc caaggacacc ctcatgatct cccggacccc
tgaggtcaca 180 tgcgtggtgg tggacgtgag ccacgaagac cctgaggtca
agttcaactg gtacgtggac 240 ggcgtggagg tgcataatgc caagacaaag
ccgcgggagg agcagtacaa cagcacgtac 300 cgtgtggtca gcgtcctcac
cgtcctgcac caggactggc tgaatggcaa ggagtacaag 360 tgcaaggtct
ccaacaaagc cctcccagcc cccatcgaga aaaccatctc caaagccaaa 420
gggcagcccc gagaaccaca ggtgtacacc ctgcccccat cccgcgatga gctgaccaag
480 aaccaggtca gcctgacctg cctggtcaaa ggcttctatc ccagcgacat
cgccgtggag 540 tgggagagca atgggcagcc ggagaacaac tacaagacca
cgcctcccgt gttggactcc 600 gacggctcct tcttcctcta cagcaagctc
accgtggaca agagcaggtg gcagcagggg 660 aacgtcttct catgctccgt
gatgcatgag gctctgcaca accactacac gcagaagagc 720 ctctccctgt
ctccgggtaa a 741 <210> SEQ ID NO 8 <211> LENGTH: 247
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Fc chain
<220> FEATURE: <221> NAME/KEY: SIGNAL <222>
LOCATION: (-20)..(-1) <220> FEATURE: <221> NAME/KEY:
mat_peptide <222> LOCATION: (-1)..(227) <400> SEQUENCE:
8 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro
-20 -15 -10 -5 Gly Ser Thr Gly Asp Lys Thr His Thr Cys Pro Pro Cys
Pro Ala Pro -1 1 5 10 Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe
Pro Pro Lys Pro Lys 15 20 25 Asp Thr Leu Met Ile Ser Arg Thr Pro
Glu Val Thr Cys Val Val Val 30 35 40 Asp Val Ser His Glu Asp Pro
Glu Val Lys Phe Asn Trp Tyr Val Asp 45 50 55 60 Gly Val Glu Val His
Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr 65 70 75 Asn Ser Thr
Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp 80 85 90 Trp
Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu 95 100
105 Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
110 115 120 Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu
Thr Lys 125 130 135 140 Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly
Phe Tyr Pro Ser Asp 145 150 155 Ile Ala Val Glu Trp Glu Ser Asn Gly
Gln Pro Glu Asn Asn Tyr Lys 160 165 170 Thr Thr Pro Pro Val Leu Asp
Ser Asp Gly Ser Phe Phe Leu Tyr Ser 175 180 185 Lys Leu Thr Val Asp
Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser 190 195 200 Cys Ser Val
Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser 205 210 215 220
Leu Ser Leu Ser Pro Gly Lys 225 <210> SEQ ID NO 9 <211>
LENGTH: 7734 <212> TYPE: DNA <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION: Full
Length FVIIIFc <400> SEQUENCE: 9 atgcaaatag agctctccac
ctgcttcttt ctgtgccttt tgcgattctg ctttagtgcc 60 accagaagat
actacctggg tgcagtggaa ctgtcatggg actatatgca aagtgatctc 120
ggtgagctgc ctgtggacgc aagatttcct cctagagtgc caaaatcttt tccattcaac
180 acctcagtcg tgtacaaaaa gactctgttt gtagaattca cggatcacct
tttcaacatc 240 gctaagccaa ggccaccctg gatgggtctg ctaggtccta
ccatccaggc tgaggtttat 300 gatacagtgg tcattacact taagaacatg
gcttcccatc ctgtcagtct tcatgctgtt 360 ggtgtatcct actggaaagc
ttctgaggga gctgaatatg atgatcagac cagtcaaagg 420 gagaaagaag
atgataaagt cttccctggt ggaagccata catatgtctg gcaggtcctg 480
aaagagaatg gtccaatggc ctctgaccca ctgtgcctta cctactcata tctttctcat
540 gtggacctgg taaaagactt gaattcaggc ctcattggag ccctactagt
atgtagagaa 600 gggagtctgg ccaaggaaaa gacacagacc ttgcacaaat
ttatactact ttttgctgta 660 tttgatgaag ggaaaagttg gcactcagaa
acaaagaact ccttgatgca ggatagggat 720 gctgcatctg ctcgggcctg
gcctaaaatg cacacagtca atggttatgt aaacaggtct 780 ctgccaggtc
tgattggatg ccacaggaaa tcagtctatt ggcatgtgat tggaatgggc 840
accactcctg aagtgcactc aatattcctc gaaggtcaca catttcttgt gaggaaccat
900 cgccaggcgt ccttggaaat ctcgccaata actttcctta ctgctcaaac
actcttgatg 960 gaccttggac agtttctact gttttgtcat atctcttccc
accaacatga tggcatggaa 1020 gcttatgtca aagtagacag ctgtccagag
gaaccccaac tacgaatgaa aaataatgaa 1080 gaagcggaag actatgatga
tgatcttact gattctgaaa tggatgtggt caggtttgat 1140 gatgacaact
ctccttcctt tatccaaatt cgctcagttg ccaagaagca tcctaaaact 1200
tgggtacatt acattgctgc tgaagaggag gactgggact atgctccctt agtcctcgcc
1260 cccgatgaca gaagttataa aagtcaatat ttgaacaatg gccctcagcg
gattggtagg 1320 aagtacaaaa aagtccgatt tatggcatac acagatgaaa
cctttaagac tcgtgaagct 1380 attcagcatg aatcaggaat cttgggacct
ttactttatg gggaagttgg agacacactg 1440 ttgattatat ttaagaatca
agcaagcaga ccatataaca tctaccctca cggaatcact 1500 gatgtccgtc
ctttgtattc aaggagatta ccaaaaggtg taaaacattt gaaggatttt 1560
ccaattctgc caggagaaat attcaaatat aaatggacag tgactgtaga agatgggcca
1620 actaaatcag atcctcggtg cctgacccgc tattactcta gtttcgttaa
tatggagaga 1680 gatctagctt caggactcat tggccctctc ctcatctgct
acaaagaatc tgtagatcaa 1740 agaggaaacc agataatgtc agacaagagg
aatgtcatcc tgttttctgt atttgatgag 1800 aaccgaagct ggtacctcac
agagaatata caacgctttc tccccaatcc agctggagtg 1860 cagcttgagg
atccagagtt ccaagcctcc aacatcatgc acagcatcaa tggctatgtt 1920
tttgatagtt tgcagttgtc agtttgtttg catgaggtgg catactggta cattctaagc
1980 attggagcac agactgactt cctttctgtc ttcttctctg gatatacctt
caaacacaaa 2040 atggtctatg aagacacact caccctattc ccattctcag
gagaaactgt cttcatgtcg 2100 atggaaaacc caggtctatg gattctgggg
tgccacaact cagactttcg gaacagaggc 2160 atgaccgcct tactgaaggt
ttctagttgt gacaagaaca ctggtgatta ttacgaggac 2220 agttatgaag
atatttcagc atacttgctg agtaaaaaca atgccattga accaagaagc 2280
ttctcccaga attcaagaca ccctagcact aggcaaaagc aatttaatgc caccacaatt
2340 ccagaaaatg acatagagaa gactgaccct tggtttgcac acagaacacc
tatgcctaaa 2400 atacaaaatg tctcctctag tgatttgttg atgctcttgc
gacagagtcc tactccacat 2460 gggctatcct tatctgatct ccaagaagcc
aaatatgaga ctttttctga tgatccatca 2520 cctggagcaa tagacagtaa
taacagcctg tctgaaatga cacacttcag gccacagctc 2580 catcacagtg
gggacatggt atttacccct gagtcaggcc tccaattaag attaaatgag 2640
aaactgggga caactgcagc aacagagttg aagaaacttg atttcaaagt ttctagtaca
2700 tcaaataatc tgatttcaac aattccatca gacaatttgg cagcaggtac
tgataataca 2760 agttccttag gacccccaag tatgccagtt cattatgata
gtcaattaga taccactcta 2820 tttggcaaaa agtcatctcc ccttactgag
tctggtggac ctctgagctt gagtgaagaa 2880 aataatgatt caaagttgtt
agaatcaggt ttaatgaata gccaagaaag ttcatgggga 2940 aaaaatgtat
cgtcaacaga gagtggtagg ttatttaaag ggaaaagagc tcatggacct 3000
gctttgttga ctaaagataa tgccttattc aaagttagca tctctttgtt aaagacaaac
3060 aaaacttcca ataattcagc aactaataga aagactcaca ttgatggccc
atcattatta 3120 attgagaata gtccatcagt ctggcaaaat atattagaaa
gtgacactga gtttaaaaaa 3180 gtgacacctt tgattcatga cagaatgctt
atggacaaaa atgctacagc tttgaggcta 3240 aatcatatgt caaataaaac
tacttcatca aaaaacatgg aaatggtcca acagaaaaaa 3300 gagggcccca
ttccaccaga tgcacaaaat ccagatatgt cgttctttaa gatgctattc 3360
ttgccagaat cagcaaggtg gatacaaagg actcatggaa agaactctct gaactctggg
3420 caaggcccca gtccaaagca attagtatcc ttaggaccag aaaaatctgt
ggaaggtcag 3480 aatttcttgt ctgagaaaaa caaagtggta gtaggaaagg
gtgaatttac aaaggacgta 3540 ggactcaaag agatggtttt tccaagcagc
agaaacctat ttcttactaa cttggataat 3600 ttacatgaaa ataatacaca
caatcaagaa aaaaaaattc aggaagaaat agaaaagaag 3660 gaaacattaa
tccaagagaa tgtagttttg cctcagatac atacagtgac tggcactaag 3720
aatttcatga agaacctttt cttactgagc actaggcaaa atgtagaagg ttcatatgac
3780 ggggcatatg ctccagtact tcaagatttt aggtcattaa atgattcaac
aaatagaaca 3840 aagaaacaca cagctcattt ctcaaaaaaa ggggaggaag
aaaacttgga aggcttggga 3900 aatcaaacca agcaaattgt agagaaatat
gcatgcacca caaggatatc tcctaataca 3960 agccagcaga attttgtcac
gcaacgtagt aagagagctt tgaaacaatt cagactccca 4020 ctagaagaaa
cagaacttga aaaaaggata attgtggatg acacctcaac ccagtggtcc 4080
aaaaacatga aacatttgac cccgagcacc ctcacacaga tagactacaa tgagaaggag
4140 aaaggggcca ttactcagtc tcccttatca gattgcctta cgaggagtca
tagcatccct 4200 caagcaaata gatctccatt acccattgca aaggtatcat
catttccatc tattagacct 4260 atatatctga ccagggtcct attccaagac
aactcttctc atcttccagc agcatcttat 4320 agaaagaaag attctggggt
ccaagaaagc agtcatttct tacaaggagc caaaaaaaat 4380 aacctttctt
tagccattct aaccttggag atgactggtg atcaaagaga ggttggctcc 4440
ctggggacaa gtgccacaaa ttcagtcaca tacaagaaag ttgagaacac tgttctcccg
4500 aaaccagact tgcccaaaac atctggcaaa gttgaattgc ttccaaaagt
tcacatttat 4560 cagaaggacc tattccctac ggaaactagc aatgggtctc
ctggccatct ggatctcgtg 4620 gaagggagcc ttcttcaggg aacagaggga
gcgattaagt ggaatgaagc aaacagacct 4680 ggaaaagttc cctttctgag
agtagcaaca gaaagctctg caaagactcc ctccaagcta 4740 ttggatcctc
ttgcttggga taaccactat ggtactcaga taccaaaaga agagtggaaa 4800
tcccaagaga agtcaccaga aaaaacagct tttaagaaaa aggataccat tttgtccctg
4860 aacgcttgtg aaagcaatca tgcaatagca gcaataaatg agggacaaaa
taagcccgaa 4920 atagaagtca cctgggcaaa gcaaggtagg actgaaaggc
tgtgctctca aaacccacca 4980 gtcttgaaac gccatcaacg ggaaataact
cgtactactc ttcagtcaga tcaagaggaa 5040 attgactatg atgataccat
atcagttgaa atgaagaagg aagattttga catttatgat 5100 gaggatgaaa
atcagagccc ccgcagcttt caaaagaaaa cacgacacta ttttattgct 5160
gcagtggaga ggctctggga ttatgggatg agtagctccc cacatgttct aagaaacagg
5220 gctcagagtg gcagtgtccc tcagttcaag aaagttgttt tccaggaatt
tactgatggc 5280 tcctttactc agcccttata ccgtggagaa ctaaatgaac
atttgggact cctggggcca 5340 tatataagag cagaagttga agataatatc
atggtaactt tcagaaatca ggcctctcgt 5400 ccctattcct tctattctag
ccttatttct tatgaggaag atcagaggca aggagcagaa 5460 cctagaaaaa
actttgtcaa gcctaatgaa accaaaactt acttttggaa agtgcaacat 5520
catatggcac ccactaaaga tgagtttgac tgcaaagcct gggcttattt ctctgatgtt
5580 gacctggaaa aagatgtgca ctcaggcctg attggacccc ttctggtctg
ccacactaac 5640 acactgaacc ctgctcatgg gagacaagtg acagtacagg
aatttgctct gtttttcacc 5700 atctttgatg agaccaaaag ctggtacttc
actgaaaata tggaaagaaa ctgcagggct 5760 ccctgcaata tccagatgga
agatcccact tttaaagaga attatcgctt ccatgcaatc 5820 aatggctaca
taatggatac actacctggc ttagtaatgg ctcaggatca aaggattcga 5880
tggtatctgc tcagcatggg cagcaatgaa aacatccatt ctattcattt cagtggacat
5940 gtgttcactg tacgaaaaaa agaggagtat aaaatggcac tgtacaatct
ctatccaggt 6000 gtttttgaga cagtggaaat gttaccatcc aaagctggaa
tttggcgggt ggaatgcctt 6060 attggcgagc atctacatgc tgggatgagc
acactttttc tggtgtacag caataagtgt 6120 cagactcccc tgggaatggc
ttctggacac attagagatt ttcagattac agcttcagga 6180 caatatggac
agtgggcccc aaagctggcc agacttcatt attccggatc aatcaatgcc 6240
tggagcacca aggagccctt ttcttggatc aaggtggatc tgttggcacc aatgattatt
6300 cacggcatca agacccaggg tgcccgtcag aagttctcca gcctctacat
ctctcagttt 6360 atcatcatgt atagtcttga tgggaagaag tggcagactt
atcgaggaaa ttccactgga 6420 accttaatgg tcttctttgg caatgtggat
tcatctggga taaaacacaa tatttttaac 6480 cctccaatta ttgctcgata
catccgtttg cacccaactc attatagcat tcgcagcact 6540 cttcgcatgg
agttgatggg ctgtgattta aatagttgca gcatgccatt gggaatggag 6600
agtaaagcaa tatcagatgc acagattact gcttcatcct actttaccaa tatgtttgcc
6660 acctggtctc cttcaaaagc tcgacttcac ctccaaggga ggagtaatgc
ctggagacct 6720 caggtgaata atccaaaaga gtggctgcaa gtggacttcc
agaagacaat gaaagtcaca 6780 ggagtaacta ctcagggagt aaaatctctg
cttaccagca tgtatgtgaa ggagttcctc 6840 atctccagca gtcaagatgg
ccatcagtgg actctctttt ttcagaatgg caaagtaaag 6900 gtttttcagg
gaaatcaaga ctccttcaca cctgtggtga actctctaga cccaccgtta 6960
ctgactcgct accttcgaat tcacccccag agttgggtgc accagattgc cctgaggatg
7020 gaggttctgg gctgcgaggc acaggacctc tacgacaaaa ctcacacatg
cccaccgtgc 7080 ccagctccag aactcctggg cggaccgtca gtcttcctct
tccccccaaa acccaaggac 7140 accctcatga tctcccggac ccctgaggtc
acatgcgtgg tggtggacgt gagccacgaa 7200 gaccctgagg tcaagttcaa
ctggtacgtg gacggcgtgg aggtgcataa tgccaagaca 7260 aagccgcggg
aggagcagta caacagcacg taccgtgtgg tcagcgtcct caccgtcctg 7320
caccaggact ggctgaatgg caaggagtac aagtgcaagg tctccaacaa agccctccca
7380 gcccccatcg agaaaaccat ctccaaagcc aaagggcagc cccgagaacc
acaggtgtac 7440 accctgcccc catcccggga tgagctgacc aagaaccagg
tcagcctgac ctgcctggtc 7500 aaaggcttct atcccagcga catcgccgtg
gagtgggaga gcaatgggca gccggagaac 7560 aactacaaga ccacgcctcc
cgtgttggac tccgacggct ccttcttcct ctacagcaag 7620 ctcaccgtgg
acaagagcag gtggcagcag gggaacgtct tctcatgctc cgtgatgcat 7680
gaggctctgc acaaccacta cacgcagaag agcctctccc tgtctccggg taaa 7734
<210> SEQ ID NO 10 <211> LENGTH: 2578 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Full Length FVIIIFc <220>
FEATURE: <221> NAME/KEY: SIGNAL <222> LOCATION:
(-19)..(-1) <220> FEATURE: <221> NAME/KEY: mat_peptide
<222> LOCATION: (1)..(2559) <400> SEQUENCE: 10 Met Gln
Ile Glu Leu Ser Thr Cys Phe Phe Leu Cys Leu Leu Arg Phe -15 -10 -5
Cys Phe Ser Ala Thr Arg Arg Tyr Tyr Leu Gly Ala Val Glu Leu Ser -1
1 5 10 Trp Asp Tyr Met Gln Ser Asp Leu Gly Glu Leu Pro Val Asp Ala
Arg 15 20 25 Phe Pro Pro Arg Val Pro Lys Ser Phe Pro Phe Asn Thr
Ser Val Val 30 35 40 45 Tyr Lys Lys Thr Leu Phe Val Glu Phe Thr Asp
His Leu Phe Asn Ile 50 55 60 Ala Lys Pro Arg Pro Pro Trp Met Gly
Leu Leu Gly Pro Thr Ile Gln 65 70 75 Ala Glu Val Tyr Asp Thr Val
Val Ile Thr Leu Lys Asn Met Ala Ser 80 85 90 His Pro Val Ser Leu
His Ala Val Gly Val Ser Tyr Trp Lys Ala Ser 95 100 105 Glu Gly Ala
Glu Tyr Asp Asp Gln Thr Ser Gln Arg Glu Lys Glu Asp 110 115 120 125
Asp Lys Val Phe Pro Gly Gly Ser His Thr Tyr Val Trp Gln Val Leu 130
135 140 Lys Glu Asn Gly Pro Met Ala Ser Asp Pro Leu Cys Leu Thr Tyr
Ser 145 150 155 Tyr Leu Ser His Val Asp Leu Val Lys Asp Leu Asn Ser
Gly Leu Ile 160 165 170 Gly Ala Leu Leu Val Cys Arg Glu Gly Ser Leu
Ala Lys Glu Lys Thr 175 180 185 Gln Thr Leu His Lys Phe Ile Leu Leu
Phe Ala Val Phe Asp Glu Gly 190 195 200 205 Lys Ser Trp His Ser Glu
Thr Lys Asn Ser Leu Met Gln Asp Arg Asp 210 215 220 Ala Ala Ser Ala
Arg Ala Trp Pro Lys Met His Thr Val Asn Gly Tyr 225 230 235 Val Asn
Arg Ser Leu Pro Gly Leu Ile Gly Cys His Arg Lys Ser Val 240 245 250
Tyr Trp His Val Ile Gly Met Gly Thr Thr Pro Glu Val His Ser Ile 255
260 265 Phe Leu Glu Gly His Thr Phe Leu Val Arg Asn His Arg Gln Ala
Ser 270 275 280 285 Leu Glu Ile Ser Pro Ile Thr Phe Leu Thr Ala Gln
Thr Leu Leu Met 290 295 300 Asp Leu Gly Gln Phe Leu Leu Phe Cys His
Ile Ser Ser His Gln His 305 310 315 Asp Gly Met Glu Ala Tyr Val Lys
Val Asp Ser Cys Pro Glu Glu Pro 320 325 330 Gln Leu Arg Met Lys Asn
Asn Glu Glu Ala Glu Asp Tyr Asp Asp Asp 335 340 345 Leu Thr Asp Ser
Glu Met Asp Val Val Arg Phe Asp Asp Asp Asn Ser 350 355 360 365 Pro
Ser Phe Ile Gln Ile Arg Ser Val Ala Lys Lys His Pro Lys Thr 370 375
380 Trp Val His Tyr Ile Ala Ala Glu Glu Glu Asp Trp Asp Tyr Ala Pro
385 390 395 Leu Val Leu Ala Pro Asp Asp Arg Ser Tyr Lys Ser Gln Tyr
Leu Asn 400 405 410 Asn Gly Pro Gln Arg Ile Gly Arg Lys Tyr Lys Lys
Val Arg Phe Met 415 420 425 Ala Tyr Thr Asp Glu Thr Phe Lys Thr Arg
Glu Ala Ile Gln His Glu 430 435 440 445 Ser Gly Ile Leu Gly Pro Leu
Leu Tyr Gly Glu Val Gly Asp Thr Leu 450 455 460 Leu Ile Ile Phe Lys
Asn Gln Ala Ser Arg Pro Tyr Asn Ile Tyr Pro 465 470 475 His Gly Ile
Thr Asp Val Arg Pro Leu Tyr Ser Arg Arg Leu Pro Lys 480 485 490 Gly
Val Lys His Leu Lys Asp Phe Pro Ile Leu Pro Gly Glu Ile Phe 495 500
505 Lys Tyr Lys Trp Thr Val Thr Val Glu Asp Gly Pro Thr Lys Ser Asp
510 515 520 525 Pro Arg Cys Leu Thr Arg Tyr Tyr Ser Ser Phe Val Asn
Met Glu Arg 530 535 540 Asp Leu Ala Ser Gly Leu Ile Gly Pro Leu Leu
Ile Cys Tyr Lys Glu 545 550 555 Ser Val Asp Gln Arg Gly Asn Gln Ile
Met Ser Asp Lys Arg Asn Val 560 565 570 Ile Leu Phe Ser Val Phe Asp
Glu Asn Arg Ser Trp Tyr Leu Thr Glu 575 580 585 Asn Ile Gln Arg Phe
Leu Pro Asn Pro Ala Gly Val Gln Leu Glu Asp 590 595 600 605 Pro Glu
Phe Gln Ala Ser Asn Ile Met His Ser Ile Asn Gly Tyr Val 610 615 620
Phe Asp Ser Leu Gln Leu Ser Val Cys Leu His Glu Val Ala Tyr Trp 625
630 635 Tyr Ile Leu Ser Ile Gly Ala Gln Thr Asp Phe Leu Ser Val Phe
Phe 640 645 650 Ser Gly Tyr Thr Phe Lys His Lys Met Val Tyr Glu Asp
Thr Leu Thr 655 660 665 Leu Phe Pro Phe Ser Gly Glu Thr Val Phe Met
Ser Met Glu Asn Pro 670 675 680 685 Gly Leu Trp Ile Leu Gly Cys His
Asn Ser Asp Phe Arg Asn Arg Gly 690 695 700 Met Thr Ala Leu Leu Lys
Val Ser Ser Cys Asp Lys Asn Thr Gly Asp 705 710 715 Tyr Tyr Glu Asp
Ser Tyr Glu Asp Ile Ser Ala Tyr Leu Leu Ser Lys 720 725 730 Asn Asn
Ala Ile Glu Pro Arg Ser Phe Ser Gln Asn Ser Arg His Pro 735 740 745
Ser Thr Arg Gln Lys Gln Phe Asn Ala Thr Thr Ile Pro Glu Asn Asp 750
755 760 765 Ile Glu Lys Thr Asp Pro Trp Phe Ala His Arg Thr Pro Met
Pro Lys 770 775 780 Ile Gln Asn Val Ser Ser Ser Asp Leu Leu Met Leu
Leu Arg Gln Ser 785 790 795 Pro Thr Pro His Gly Leu Ser Leu Ser Asp
Leu Gln Glu Ala Lys Tyr 800 805 810 Glu Thr Phe Ser Asp Asp Pro Ser
Pro Gly Ala Ile Asp Ser Asn Asn 815 820 825 Ser Leu Ser Glu Met Thr
His Phe Arg Pro Gln Leu His His Ser Gly 830 835 840 845 Asp Met Val
Phe Thr Pro Glu Ser Gly Leu Gln Leu Arg Leu Asn Glu 850 855 860 Lys
Leu Gly Thr Thr Ala Ala Thr Glu Leu Lys Lys Leu Asp Phe Lys 865 870
875 Val Ser Ser Thr Ser Asn Asn Leu Ile Ser Thr Ile Pro Ser Asp Asn
880 885 890 Leu Ala Ala Gly Thr Asp Asn Thr Ser Ser Leu Gly Pro Pro
Ser Met 895 900 905 Pro Val His Tyr Asp Ser Gln Leu Asp Thr Thr Leu
Phe Gly Lys Lys 910 915 920 925 Ser Ser Pro Leu Thr Glu Ser Gly Gly
Pro Leu Ser Leu Ser Glu Glu 930 935 940 Asn Asn Asp Ser Lys Leu Leu
Glu Ser Gly Leu Met Asn Ser Gln Glu 945 950 955 Ser Ser Trp Gly Lys
Asn Val Ser Ser Thr Glu Ser Gly Arg Leu Phe 960 965 970 Lys Gly Lys
Arg Ala His Gly Pro Ala Leu Leu Thr Lys Asp Asn Ala 975 980 985 Leu
Phe Lys Val Ser Ile Ser Leu Leu Lys Thr Asn Lys Thr Ser Asn 990 995
1000 1005 Asn Ser Ala Thr Asn Arg Lys Thr His Ile Asp Gly Pro Ser
Leu 1010 1015 1020 Leu Ile Glu Asn Ser Pro Ser Val Trp Gln Asn Ile
Leu Glu Ser 1025 1030 1035 Asp Thr Glu Phe Lys Lys Val Thr Pro Leu
Ile His Asp Arg Met 1040 1045 1050 Leu Met Asp Lys Asn Ala Thr Ala
Leu Arg Leu Asn His Met Ser 1055 1060 1065 Asn Lys Thr Thr Ser Ser
Lys Asn Met Glu Met Val Gln Gln Lys 1070 1075 1080 Lys Glu Gly Pro
Ile Pro Pro Asp Ala Gln Asn Pro Asp Met Ser 1085 1090 1095 Phe Phe
Lys Met Leu Phe Leu Pro Glu Ser Ala Arg Trp Ile Gln 1100 1105 1110
Arg Thr His Gly Lys Asn Ser Leu Asn Ser Gly Gln Gly Pro Ser 1115
1120 1125 Pro Lys Gln Leu Val Ser Leu Gly Pro Glu Lys Ser Val Glu
Gly 1130 1135 1140 Gln Asn Phe Leu Ser Glu Lys Asn Lys Val Val Val
Gly Lys Gly 1145 1150 1155 Glu Phe Thr Lys Asp Val Gly Leu Lys Glu
Met Val Phe Pro Ser 1160 1165 1170 Ser Arg Asn Leu Phe Leu Thr Asn
Leu Asp Asn Leu His Glu Asn 1175 1180 1185 Asn Thr His Asn Gln Glu
Lys Lys Ile Gln Glu Glu Ile Glu Lys 1190 1195 1200 Lys Glu Thr Leu
Ile Gln Glu Asn Val Val Leu Pro Gln Ile His 1205 1210 1215 Thr Val
Thr Gly Thr Lys Asn Phe Met Lys Asn Leu Phe Leu Leu 1220 1225 1230
Ser Thr Arg Gln Asn Val Glu Gly Ser Tyr Asp Gly Ala Tyr Ala 1235
1240 1245 Pro Val Leu Gln Asp Phe Arg Ser Leu Asn Asp Ser Thr Asn
Arg 1250 1255 1260 Thr Lys Lys His Thr Ala His Phe Ser Lys Lys Gly
Glu Glu Glu 1265 1270 1275 Asn Leu Glu Gly Leu Gly Asn Gln Thr Lys
Gln Ile Val Glu Lys 1280 1285 1290 Tyr Ala Cys Thr Thr Arg Ile Ser
Pro Asn Thr Ser Gln Gln Asn 1295 1300 1305 Phe Val Thr Gln Arg Ser
Lys Arg Ala Leu Lys Gln Phe Arg Leu 1310 1315 1320 Pro Leu Glu Glu
Thr Glu Leu Glu Lys Arg Ile Ile Val Asp Asp 1325 1330 1335 Thr Ser
Thr Gln Trp Ser Lys Asn Met Lys His Leu Thr Pro Ser 1340 1345 1350
Thr Leu Thr Gln Ile Asp Tyr Asn Glu Lys Glu Lys Gly Ala Ile 1355
1360 1365 Thr Gln Ser Pro Leu Ser Asp Cys Leu Thr Arg Ser His Ser
Ile 1370 1375 1380 Pro Gln Ala Asn Arg Ser Pro Leu Pro Ile Ala Lys
Val Ser Ser 1385 1390 1395 Phe Pro Ser Ile Arg Pro Ile Tyr Leu Thr
Arg Val Leu Phe Gln 1400 1405 1410 Asp Asn Ser Ser His Leu Pro Ala
Ala Ser Tyr Arg Lys Lys Asp 1415 1420 1425 Ser Gly Val Gln Glu Ser
Ser His Phe Leu Gln Gly Ala Lys Lys 1430 1435 1440 Asn Asn Leu Ser
Leu Ala Ile Leu Thr Leu Glu Met Thr Gly Asp 1445 1450 1455 Gln Arg
Glu Val Gly Ser Leu Gly Thr Ser Ala Thr Asn Ser Val 1460 1465 1470
Thr Tyr Lys Lys Val Glu Asn Thr Val Leu Pro Lys Pro Asp Leu 1475
1480 1485 Pro Lys Thr Ser Gly Lys Val Glu Leu Leu Pro Lys Val His
Ile 1490 1495 1500 Tyr Gln Lys Asp Leu Phe Pro Thr Glu Thr Ser Asn
Gly Ser Pro 1505 1510 1515 Gly His Leu Asp Leu Val Glu Gly Ser Leu
Leu Gln Gly Thr Glu 1520 1525 1530 Gly Ala Ile Lys Trp Asn Glu Ala
Asn Arg Pro Gly Lys Val Pro 1535 1540 1545 Phe Leu Arg Val Ala Thr
Glu Ser Ser Ala Lys Thr Pro Ser Lys 1550 1555 1560 Leu Leu Asp Pro
Leu Ala Trp Asp Asn His Tyr Gly Thr Gln Ile 1565 1570 1575 Pro Lys
Glu Glu Trp Lys Ser Gln Glu Lys Ser Pro Glu Lys Thr 1580 1585 1590
Ala Phe Lys Lys Lys Asp Thr Ile Leu Ser Leu Asn Ala Cys Glu 1595
1600 1605 Ser Asn His Ala Ile Ala Ala Ile Asn Glu Gly Gln Asn Lys
Pro 1610 1615 1620 Glu Ile Glu Val Thr Trp Ala Lys Gln Gly Arg Thr
Glu Arg Leu 1625 1630 1635 Cys Ser Gln Asn Pro Pro Val Leu Lys Arg
His Gln Arg Glu Ile 1640 1645 1650 Thr Arg Thr Thr Leu Gln Ser Asp
Gln Glu Glu Ile Asp Tyr Asp 1655 1660 1665 Asp Thr Ile Ser Val Glu
Met Lys Lys Glu Asp Phe Asp Ile Tyr 1670 1675 1680 Asp Glu Asp Glu
Asn Gln Ser Pro Arg Ser Phe Gln Lys Lys Thr 1685 1690 1695 Arg His
Tyr Phe Ile Ala Ala Val Glu Arg Leu Trp Asp Tyr Gly 1700 1705 1710
Met Ser Ser Ser Pro His Val Leu Arg Asn Arg Ala Gln Ser Gly 1715
1720 1725 Ser Val Pro Gln Phe Lys Lys Val Val Phe Gln Glu Phe Thr
Asp 1730 1735 1740 Gly Ser Phe Thr Gln Pro Leu Tyr Arg Gly Glu Leu
Asn Glu His 1745 1750 1755 Leu Gly Leu Leu Gly Pro Tyr Ile Arg Ala
Glu Val Glu Asp Asn 1760 1765 1770 Ile Met Val Thr Phe Arg Asn Gln
Ala Ser Arg Pro Tyr Ser Phe 1775 1780 1785 Tyr Ser Ser Leu Ile Ser
Tyr Glu Glu Asp Gln Arg Gln Gly Ala 1790 1795 1800 Glu Pro Arg Lys
Asn Phe Val Lys Pro Asn Glu Thr Lys Thr Tyr 1805 1810 1815 Phe Trp
Lys Val Gln His His Met Ala Pro Thr Lys Asp Glu Phe 1820 1825 1830
Asp Cys Lys Ala Trp Ala Tyr Phe Ser Asp Val Asp Leu Glu Lys 1835
1840 1845 Asp Val His Ser Gly Leu Ile Gly Pro Leu Leu Val Cys His
Thr 1850 1855 1860 Asn Thr Leu Asn Pro Ala His Gly Arg Gln Val Thr
Val Gln Glu 1865 1870 1875 Phe Ala Leu Phe Phe Thr Ile Phe Asp Glu
Thr Lys Ser Trp Tyr 1880 1885 1890 Phe Thr Glu Asn Met Glu Arg Asn
Cys Arg Ala Pro Cys Asn Ile 1895 1900 1905 Gln Met Glu Asp Pro Thr
Phe Lys Glu Asn Tyr Arg Phe His Ala 1910 1915 1920 Ile Asn Gly Tyr
Ile Met Asp Thr Leu Pro Gly Leu Val Met Ala 1925 1930 1935 Gln Asp
Gln Arg Ile Arg Trp Tyr Leu Leu Ser Met Gly Ser Asn 1940 1945 1950
Glu Asn Ile His Ser Ile His Phe Ser Gly His Val Phe Thr Val 1955
1960 1965 Arg Lys Lys Glu Glu Tyr Lys Met Ala Leu Tyr Asn Leu Tyr
Pro 1970 1975 1980 Gly Val Phe Glu Thr Val Glu Met Leu Pro Ser Lys
Ala Gly Ile 1985 1990 1995 Trp Arg Val Glu Cys Leu Ile Gly Glu His
Leu His Ala Gly Met 2000 2005 2010 Ser Thr Leu Phe Leu Val Tyr Ser
Asn Lys Cys Gln Thr Pro Leu 2015 2020 2025 Gly Met Ala Ser Gly His
Ile Arg Asp Phe Gln Ile Thr Ala Ser 2030 2035 2040 Gly Gln Tyr Gly
Gln Trp Ala Pro Lys Leu Ala Arg Leu His Tyr 2045 2050 2055 Ser Gly
Ser Ile Asn Ala Trp Ser Thr Lys Glu Pro Phe Ser Trp 2060 2065 2070
Ile Lys Val Asp Leu Leu Ala Pro Met Ile Ile His Gly Ile Lys 2075
2080 2085 Thr Gln Gly Ala Arg Gln Lys Phe Ser Ser Leu Tyr Ile Ser
Gln 2090 2095 2100 Phe Ile Ile Met Tyr Ser Leu Asp Gly Lys Lys Trp
Gln Thr Tyr 2105 2110 2115 Arg Gly Asn Ser Thr Gly Thr Leu Met Val
Phe Phe Gly Asn Val 2120 2125 2130 Asp Ser Ser Gly Ile Lys His Asn
Ile Phe Asn Pro Pro Ile Ile 2135 2140 2145 Ala Arg Tyr Ile Arg Leu
His Pro Thr His Tyr Ser Ile Arg Ser 2150 2155 2160 Thr Leu Arg Met
Glu Leu Met Gly Cys Asp Leu Asn Ser Cys Ser 2165 2170 2175 Met Pro
Leu Gly Met Glu Ser Lys Ala Ile Ser Asp Ala Gln Ile 2180 2185 2190
Thr Ala Ser Ser Tyr Phe Thr Asn Met Phe Ala Thr Trp Ser Pro 2195
2200 2205 Ser Lys Ala Arg Leu His Leu Gln Gly Arg Ser Asn Ala Trp
Arg 2210 2215 2220 Pro Gln Val Asn Asn Pro Lys Glu Trp Leu Gln Val
Asp Phe Gln 2225 2230 2235 Lys Thr Met Lys Val Thr Gly Val Thr Thr
Gln Gly Val Lys Ser 2240 2245 2250 Leu Leu Thr Ser Met Tyr Val Lys
Glu Phe Leu Ile Ser Ser Ser 2255 2260 2265 Gln Asp Gly His Gln Trp
Thr Leu Phe Phe Gln Asn Gly Lys Val 2270 2275 2280 Lys Val Phe Gln
Gly Asn Gln Asp Ser Phe Thr Pro Val Val Asn 2285 2290 2295 Ser Leu
Asp Pro Pro Leu Leu Thr Arg Tyr Leu Arg Ile His Pro 2300 2305 2310
Gln Ser Trp Val His Gln Ile Ala Leu Arg Met Glu Val Leu Gly 2315
2320 2325 Cys Glu Ala Gln Asp Leu Tyr Asp Lys Thr His Thr Cys Pro
Pro 2330 2335 2340 Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val
Phe Leu Phe 2345 2350 2355 Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
Ser Arg Thr Pro Glu 2360 2365 2370 Val Thr Cys Val Val Val Asp Val
Ser His Glu Asp Pro Glu Val 2375 2380 2385 Lys Phe Asn Trp Tyr Val
Asp Gly Val Glu Val His Asn Ala Lys 2390 2395 2400 Thr Lys Pro Arg
Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val 2405 2410 2415 Ser Val
Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu 2420 2425 2430
Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 2435
2440 2445 Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
Val 2450 2455 2460 Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys
Asn Gln Val 2465 2470 2475 Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
Pro Ser Asp Ile Ala 2480 2485 2490 Val Glu Trp Glu Ser Asn Gly Gln
Pro Glu Asn Asn Tyr Lys Thr 2495 2500 2505 Thr Pro Pro Val Leu Asp
Ser Asp Gly Ser Phe Phe Leu Tyr Ser 2510 2515 2520 Lys Leu Thr Val
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe 2525 2530 2535 Ser Cys
Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln 2540 2545 2550
Lys Ser Leu Ser Leu Ser Pro Gly Lys 2555 <210> SEQ ID NO 11
<211> LENGTH: 21 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Partial B domain <400> SEQUENCE: 11 Ser Phe Ser
Gln Asn Ser Arg His Pro Ser Gln Asn Pro Pro Val Leu 1 5 10 15 Lys
Arg His Gln Arg 20 <210> SEQ ID NO 12 <211> LENGTH: 11
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: albumin-binding
peptide <400> SEQUENCE: 12 Asp Ile Cys Leu Pro Arg Trp Gly
Cys Leu Trp 1 5 10 <210> SEQ ID NO 13 <211> LENGTH: 32
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: CTP peptide
<400> SEQUENCE: 13 Asp Pro Arg Phe Gln Asp Ser Ser Ser Ser
Lys Ala Pro Pro Pro Ser 1 5 10 15 Leu Pro Ser Pro Ser Arg Leu Pro
Gly Pro Ser Asp Thr Pro Ile Leu 20 25 30 <210> SEQ ID NO 14
<211> LENGTH: 28 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: CTP peptide <400> SEQUENCE: 14 Ser Ser Ser Ser
Lys Ala Pro Pro Pro Ser Leu Pro Ser Pro Ser Arg 1 5 10 15 Leu Pro
Gly Pro Ser Asp Thr Pro Ile Leu Pro Gln 20 25 <210> SEQ ID NO
15 <211> LENGTH: 20 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: PAS peptide <400> SEQUENCE: 15 Ala Ser Pro
Ala Ala Pro Ala Pro Ala Ser Pro Ala Ala Pro Ala Pro 1 5 10 15 Ser
Ala Pro Ala 20 <210> SEQ ID NO 16 <211> LENGTH: 20
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: PAS peptide
<400> SEQUENCE: 16 Ala Ala Pro Ala Ser Pro Ala Pro Ala Ala
Pro Ser Ala Pro Ala Pro 1 5 10 15 Ala Ala Pro Ser 20 <210>
SEQ ID NO 17 <211> LENGTH: 20 <212> TYPE: PRT
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: PAS peptide <400> SEQUENCE: 17
Ala Pro Ser Ser Pro Ser Pro Ser Ala Pro Ser Ser Pro Ser Pro Ala 1 5
10 15 Ser Pro Ser Ser 20 <210> SEQ ID NO 18 <211>
LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION: PAS
peptide <400> SEQUENCE: 18 Ala Pro Ser Ser Pro Ser Pro Ser
Ala Pro Ser Ser Pro Ser Pro Ala 1 5 10 15 Ser Pro Ser <210>
SEQ ID NO 19 <211> LENGTH: 20 <212> TYPE: PRT
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: PAS peptide <400> SEQUENCE: 19
Ser Ser Pro Ser Ala Pro Ser Pro Ser Ser Pro Ala Ser Pro Ser Pro 1 5
10 15 Ser Ser Pro Ala 20 <210> SEQ ID NO 20 <211>
LENGTH: 24 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION: PAS
peptide <400> SEQUENCE: 20 Ala Ala Ser Pro Ala Ala Pro Ser
Ala Pro Pro Ala Ala Ala Ser Pro 1 5 10 15 Ala Ala Pro Ser Ala Pro
Pro Ala 20 <210> SEQ ID NO 21 <211> LENGTH: 20
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: PAS peptide
<400> SEQUENCE: 21 Ala Ser Ala Ala Ala Pro Ala Ala Ala Ser
Ala Ala Ala Ser Ala Pro 1 5 10 15 Ser Ala Ala Ala 20
1 SEQUENCE LISTING <160> NUMBER OF SEQ ID NOS: 21 <210>
SEQ ID NO 1 <211> LENGTH: 7583 <212> TYPE: DNA
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: pSYN-FIX-030 <400> SEQUENCE: 1
gcgcgcgttg acattgatta ttgactagtt attaatagta atcaattacg gggtcattag
60 ttcatagccc atatatggag ttccgcgtta cataacttac ggtaaatggc
ccgcctggct 120 gaccgcccaa cgacccccgc ccattgacgt caataatgac
gtatgttccc atagtaacgc 180 caatagggac tttccattga cgtcaatggg
tggagtattt acggtaaact gcccacttgg 240 cagtacatca agtgtatcat
atgccaagta cgccccctat tgacgtcaat gacggtaaat 300 ggcccgcctg
gcattatgcc cagtacatga ccttatggga ctttcctact tggcagtaca 360
tctacgtatt agtcatcgct attaccatgg tgatgcggtt ttggcagtac atcaatgggc
420 gtggatagcg gtttgactca cggggatttc caagtctcca ccccattgac
gtcaatggga 480 gtttgttttg gcaccaaaat caacgggact ttccaaaatg
tcgtaacaac tccgccccat 540 tgacgcaaat gggcggtagg cgtgtacggt
gggaggtcta tataagcaga gctctctggc 600 taactagaga acccactgct
tactggctta tcgaaattaa tacgactcac tatagggaga 660 cccaagcttc
gcgacgtacg gccgccacca tgcagcgcgt gaacatgatc atggcagaat 720
caccaggcct catcaccatc tgccttttag gatatctact cagtgctgaa tgtacaggtt
780 tgtttccttt tttaaaatac attgagtatg cttgcctttt agatatagaa
atatctgatg 840 ctgtcttctt cactaaattt tgattacatg atttgacagc
aatattgaag agtctaacag 900 ccagcacgca ggttggtaag tactgtggga
acatcacaga ttttggctcc atgccctaaa 960 gagaaattgg ctttcagatt
atttggatta aaaacaaaga ctttcttaag agatgtaaaa 1020 ttttcatgat
gttttctttt ttgctaaaac taaagaatta ttcttttaca tttcagtttt 1080
tcttgatcat gaaaacgcca acaaaattct gaatcggcca aagaggtata attcaggtaa
1140 attggaagag tttgttcaag ggaatctaga gagagaatgt atggaagaaa
agtgtagttt 1200 tgaagaagca cgagaagttt ttgaaaacac tgaaagaaca
actgaatttt ggaagcagta 1260 tgttgatgga gatcagtgtg agtccaatcc
atgtttaaat ggcggcagtt gcaaggatga 1320 cattaattcc tatgaatgtt
ggtgtccctt tggatttgaa ggaaagaact gtgaattaga 1380 tgtaacatgt
aacattaaga atggcagatg cgagcagttt tgtaaaaata gtgctgataa 1440
caaggtggtt tgctcctgta ctgagggata tcgacttgca gaaaaccaga agtcctgtga
1500 accagcagtg ccatttccat gtggaagagt ttctgtttca caaacttcta
agctcacccg 1560 tgctgagact gtttttcctg atgtggacta tgtaaattct
actgaagctg aaaccatttt 1620 ggataacatc actcaaagca cccaatcatt
taatgacttc actcgggttg ttggtggaga 1680 agatgccaaa ccaggtcaat
tcccttggca ggttgttttg aatggtaaag ttgatgcatt 1740 ctgtggaggc
tctatcgtta atgaaaaatg gattgtaact gctgcccact gtgttgaaac 1800
tggtgttaaa attacagttg tcgcaggtga acataatatt gaggagacag aacatacaga
1860 gcaaaagcga aatgtgattc gaattattcc tcaccacaac tacaatgcag
ctattaataa 1920 gtacaaccat gacattgccc ttctggaact ggacgaaccc
ttagtgctaa acagctacgt 1980 tacacctatt tgcattgctg acaaggaata
cacgaacatc ttcctcaaat ttggatctgg 2040 ctatgtaagt ggctggggaa
gagtcttcca caaagggaga tcagctttag ttcttcagta 2100 ccttagagtt
ccacttgttg accgagccac atgtcttcga tctacaaagt tcaccatcta 2160
taacaacatg ttctgtgctg gcttccatga aggaggtaga gattcatgtc aaggagatag
2220 tgggggaccc catgttactg aagtggaagg gaccagtttc ttaactggaa
ttattagctg 2280 gggtgaagag tgtgcaatga aaggcaaata tggaatatat
accaaggtgt cccggtatgt 2340 caactggatt aaggaaaaaa caaagctcac
tgacaaaact cacacatgcc caccgtgccc 2400 agctccggaa ctcctgggcg
gaccgtcagt cttcctcttc cccccaaaac ccaaggacac 2460 cctcatgatc
tcccggaccc ctgaggtcac atgcgtggtg gtggacgtga gccacgaaga 2520
ccctgaggtc aagttcaact ggtacgtgga cggcgtggag gtgcataatg ccaagacaaa
2580 gccgcgggag gagcagtaca acagcacgta ccgtgtggtc agcgtcctca
ccgtcctgca 2640 ccaggactgg ctgaatggca aggagtacaa gtgcaaggtc
tccaacaaag ccctcccagc 2700 ccccatcgag aaaaccatct ccaaagccaa
agggcagccc cgagaaccac aggtgtacac 2760 cctgccccca tcccgggatg
agctgaccaa gaaccaggtc agcctgacct gcctggtcaa 2820 aggcttctat
cccagcgaca tcgccgtgga gtgggagagc aatgggcagc cggagaacaa 2880
ctacaagacc acgcctcccg tgttggactc cgacggctcc ttcttcctct acagcaagct
2940 caccgtggac aagagcaggt ggcagcaggg gaacgtcttc tcatgctccg
tgatgcatga 3000 ggctctgcac aaccactaca cgcagaagag cctctccctg
tctccgggta aatgagaatt 3060 cagacatgat aagatacatt gatgagtttg
gacaaaccac aactagaatg cagtgaaaaa 3120 aatgctttat ttgtgaaatt
tgtgatgcta ttgctttatt tgtaaccatt ataagctgca 3180 ataaacaagt
tggggtgggc gaagaactcc agcatgagat ccccgcgctg gaggatcatc 3240
cagccggcgt cccggaaaac gattccgaag cccaaccttt catagaaggc ggcggtggaa
3300 tcgaaatctc gtagcacgtg tcagtcctgc tcctcggcca cgaagtgcac
gcagttgccg 3360 gccgggtcgc gcagggcgaa ctcccgcccc cacggctgct
cgccgatctc ggtcatggcc 3420 ggcccggagg cgtcccggaa gttcgtggac
acgacctccg accactcggc gtacagctcg 3480 tccaggccgc gcacccacac
ccaggccagg gtgttgtccg gcaccacctg gtcctggacc 3540 gcgctgatga
acagggtcac gtcgtcccgg accacaccgg cgaagtcgtc ctccacgaag 3600
tcccgggaga acccgagccg gtcggtccag aactcgaccg ctccggcgac gtcgcgcgcg
3660 gtgagcaccg gaacggcact ggtcaacttg gccatggttt agttcctcac
cttgtcgtat 3720 tatactatgc cgatatacta tgccgatgat taattgtcaa
cacgtgctga tcagatccga 3780 aaatggatat acaagctccc gggagctttt
tgcaaaagcc taggcctcca aaaaagcctc 3840 ctcactactt ctggaatagc
tcagaggcag aggcggcctc ggcctctgca taaataaaaa 3900 aaattagtca
gccatggggc ggagaatggg cggaactggg cggagttagg ggcgggatgg 3960
gcggagttag gggcgggact atggttgctg actaattgag atgcatgctt tgcatacttc
4020 tgcctgctgg ggagcctggg gactttccac acctggttgc tgactaattg
agatgcatgc 4080 tttgcatact tctgcctgct ggggagcctg gggactttcc
acaccctcgt cgagctagct 4140 tcgtgaggct ccggtgcccg tcagtgggca
gagcgcacat cgcccacagt ccccgagaag 4200 ttggggggag gggtcggcaa
ttgaaccggt gcctagagaa ggtggcgcgg ggtaaactgg 4260 gaaagtgatg
tcgtgtactg gctccgcctt tttcccgagg gtgggggaga accgtatata 4320
agtgcagtag tcgccgtgaa cgttcttttt cgcaacgggt ttgccgccag aacacaggta
4380 agtgccgtgt gtggttcccg cgggcctggc ctctttacgg gttatggccc
ttgcgtgcct 4440 tgaattactt ccacctggct ccagtacgtg attcttgatc
ccgagctgga gccaggggcg 4500 ggccttgcgc tttaggagcc ccttcgcctc
gtgcttgagt tgaggcctgg cctgggcgct 4560 ggggccgccg cgtgcgaatc
tggtggcacc ttcgcgcctg tctcgctgct ttcgataagt 4620 ctctagccat
ttaaaatttt tgatgacctg ctgcgacgct ttttttctgg caagatagtc 4680
ttgtaaatgc gggccaggat ctgcacactg gtatttcggt ttttggggcc gcgggcggcg
4740 acggggcccg tgcgtcccag cgcacatgtt cggcgaggcg gggcctgcga
gcgcggccac 4800 cgagaatcgg acgggggtag tctcaagctg gccggcctgc
tctggtgcct ggcctcgcgc 4860 cgccgtgtat cgccccgccc tgggcggcaa
ggctggcccg gtcggcacca gttgcgtgag 4920 cggaaagatg gccgcttccc
ggccctgctc cagggggctc aaaatggagg acgcggcgct 4980 cgggagagcg
ggcgggtgag tcacccacac aaaggaaagg ggcctttccg tcctcagccg 5040
tcgcttcatg tgactccacg gagtaccggg cgccgtccag gcacctcgat tagttctgga
5100 gcttttggag tacgtcgtct ttaggttggg gggaggggtt ttatgcgatg
gagtttcccc 5160 acactgagtg ggtggagact gaagttaggc cagcttggca
cttgatgtaa ttctccttgg 5220 aatttgccct ttttgagttt ggatcttggt
tcattctcaa gcctcagaca gtggttcaaa 5280 gtttttttct tccatttcag
gtgtcgtgaa cacgtggtcg cggccgcgcc gccaccatgg 5340 agacagacac
actcctgcta tgggtactgc tgctctgggt tccaggttcc actggtgaca 5400
aaactcacac atgcccaccg tgcccagcac ctgaactcct gggaggaccg tcagtcttcc
5460 tcttcccccc aaaacccaag gacaccctca tgatctcccg gacccctgag
gtcacatgcg 5520 tggtggtgga cgtgagccac gaagaccctg aggtcaagtt
caactggtac gtggacggcg 5580 tggaggtgca taatgccaag acaaagccgc
gggaggagca gtacaacagc acgtaccgtg 5640 tggtcagcgt cctcaccgtc
ctgcaccagg actggctgaa tggcaaggag tacaagtgca 5700 aggtctccaa
caaagccctc ccagccccca tcgagaaaac catctccaaa gccaaagggc 5760
agccccgaga accacaggtg tacaccctgc ccccatcccg cgatgagctg accaagaacc
5820 aggtcagcct gacctgcctg gtcaaaggct tctatcccag cgacatcgcc
gtggagtggg 5880 agagcaatgg gcagccggag aacaactaca agaccacgcc
tcccgtgttg gactccgacg 5940 gctccttctt cctctacagc aagctcaccg
tggacaagag caggtggcag caggggaacg 6000 tcttctcatg ctccgtgatg
catgaggctc tgcacaacca ctacacgcag aagagcctct 6060 ccctgtctcc
gggtaaatga ctcgagagat ctggccggct gggcccgttt cgaaggtaag 6120
cctatcccta accctctcct cggtctcgat tctacgcgta ccggtcatca tcaccatcac
6180 cattgagttt aaacccgctg atcagcctcg actgtgcctt ctagttgcca
gccatctgtt 6240 gtttgcccct cccccgtgcc ttccttgacc ctggaaggtg
ccactcccac tgtcctttcc 6300 taataaaatg aggaaattgc atcgcattgt
ctgagtaggt gtcattctat tctggggggt 6360 ggggtggggc aggacagcaa
gggggaggat tgggaagaca atagcaggca tgctggggat 6420 gcggtgggct
ctatggcttc tgaggcggaa agaaccagtg gcggtaatac ggttatccac 6480
agaatcaggg gataacgcag gaaagaacat gtgagcaaaa ggccagcaaa aggccaggaa
6540 ccgtaaaaag gccgcgttgc tggcgttttt ccataggctc cgcccccctg
acgagcatca 6600 caaaaatcga cgctcaagtc agaggtggcg aaacccgaca
ggactataaa gataccaggc 6660 gtttccccct agaagctccc tcgtgcgctc
tcctgttccg accctgccgc ttaccggata 6720 cctgtccgcc tttctccctt
cgggaagcgt ggcgctttct catagctcac gctgtaggta 6780 tctcagttcg
gtgtaggtcg ttcgctccaa gctgggctgt gtgcacgaac cccccgttca 6840
gcccgaccgc tgcgccttat ccggtaacta tcgtcttgag tccaacccgg taagacacga
6900 cttatcgcca ctggcagcag ccactggtaa caggattagc agagcgaggt
atgtaggcgg 6960 tgctacagag ttcttgaagt ggtggcctaa ctacggctac
actagaagaa cagtatttgg 7020 tatctgcgct ctgctgaagc cagttacctt
cggaaaaaga gttggtagct cttgatccgg 7080
caaacaaacc accgctggta gcggtggttt ttttgtttgc aagcagcaga ttacgcgcag
7140 aaaaaaagga tctcaagaag atcctttgat cttttctacg gggtctgacg
ctcagtggaa 7200 cgaaaactca cgttaaggga ttttggtcat gacattaacc
tataaaaata ggcgtatcac 7260 gaggcccttt cgtctcgcgc gtttcggtga
tgacggtgaa aacctctgac acatgcagct 7320 cccggagacg gtcacagctt
gtctgtaagc ggatgccggg agcagacaag cccgtcaggg 7380 cgcgtcagcg
ggtgttggcg ggtgtcgggg ctggcttaac tatgcggcat cagagcagat 7440
tgtactgaga gtgcaccata tatgcggtgt gaaataccgc acagatgcgt aaggagaaaa
7500 taccgcatca ggcgccattc gccattcagg ctgcgcaact gttgggaagg
gcgatcggtg 7560 cgggcctctt cgctattacg cca 7583 <210> SEQ ID
NO 2 <211> LENGTH: 688 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: pSYN-FIX-030 <220> FEATURE: <221>
NAME/KEY: SIGNAL <222> LOCATION: (-46)..(-19) 220>
<221> NAME/KEY: SIGNAL <222> LOCATION: (-18)..(-1)
<220> FEATURE: <221> NAME/KEY: mat_peptide <222>
LOCATION: (1)..(642) <400> SEQUENCE: 2 Met Gln Arg Val Asn
Met Ile Met Ala Glu Ser Pro Gly Leu Ile Thr -45 -40 -35 Ile Cys Leu
Leu Gly Tyr Leu Leu Ser Ala Glu Cys Thr Val Phe Leu -30 -25 -20 -15
Asp His Glu Asn Ala Asn Lys Ile Leu Asn Arg Pro Lys Arg Tyr Asn -10
-5 -1 1 Ser Gly Lys Leu Glu Glu Phe Val Gln Gly Asn Leu Glu Arg Glu
Cys 5 10 15 Met Glu Glu Lys Cys Ser Phe Glu Glu Ala Arg Glu Val Phe
Glu Asn 20 25 30 Thr Glu Arg Thr Thr Glu Phe Trp Lys Gln Tyr Val
Asp Gly Asp Gln 35 40 45 50 Cys Glu Ser Asn Pro Cys Leu Asn Gly Gly
Ser Cys Lys Asp Asp Ile 55 60 65 Asn Ser Tyr Glu Cys Trp Cys Pro
Phe Gly Phe Glu Gly Lys Asn Cys 70 75 80 Glu Leu Asp Val Thr Cys
Asn Ile Lys Asn Gly Arg Cys Glu Gln Phe 85 90 95 Cys Lys Asn Ser
Ala Asp Asn Lys Val Val Cys Ser Cys Thr Glu Gly 100 105 110 Tyr Arg
Leu Ala Glu Asn Gln Lys Ser Cys Glu Pro Ala Val Pro Phe 115 120 125
130 Pro Cys Gly Arg Val Ser Val Ser Gln Thr Ser Lys Leu Thr Arg Ala
135 140 145 Glu Thr Val Phe Pro Asp Val Asp Tyr Val Asn Ser Thr Glu
Ala Glu 150 155 160 Thr Ile Leu Asp Asn Ile Thr Gln Ser Thr Gln Ser
Phe Asn Asp Phe 165 170 175 Thr Arg Val Val Gly Gly Glu Asp Ala Lys
Pro Gly Gln Phe Pro Trp 180 185 190 Gln Val Val Leu Asn Gly Lys Val
Asp Ala Phe Cys Gly Gly Ser Ile 195 200 205 210 Val Asn Glu Lys Trp
Ile Val Thr Ala Ala His Cys Val Glu Thr Gly 215 220 225 Val Lys Ile
Thr Val Val Ala Gly Glu His Asn Ile Glu Glu Thr Glu 230 235 240 His
Thr Glu Gln Lys Arg Asn Val Ile Arg Ile Ile Pro His His Asn 245 250
255 Tyr Asn Ala Ala Ile Asn Lys Tyr Asn His Asp Ile Ala Leu Leu Glu
260 265 270 Leu Asp Glu Pro Leu Val Leu Asn Ser Tyr Val Thr Pro Ile
Cys Ile 275 280 285 290 Ala Asp Lys Glu Tyr Thr Asn Ile Phe Leu Lys
Phe Gly Ser Gly Tyr 295 300 305 Val Ser Gly Trp Gly Arg Val Phe His
Lys Gly Arg Ser Ala Leu Val 310 315 320 Leu Gln Tyr Leu Arg Val Pro
Leu Val Asp Arg Ala Thr Cys Leu Arg 325 330 335 Ser Thr Lys Phe Thr
Ile Tyr Asn Asn Met Phe Cys Ala Gly Phe His 340 345 350 Glu Gly Gly
Arg Asp Ser Cys Gln Gly Asp Ser Gly Gly Pro His Val 355 360 365 370
Thr Glu Val Glu Gly Thr Ser Phe Leu Thr Gly Ile Ile Ser Trp Gly 375
380 385 Glu Glu Cys Ala Met Lys Gly Lys Tyr Gly Ile Tyr Thr Lys Val
Ser 390 395 400 Arg Tyr Val Asn Trp Ile Lys Glu Lys Thr Lys Leu Thr
Asp Lys Thr 405 410 415 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu
Leu Gly Gly Pro Ser 420 425 430 Val Phe Leu Phe Pro Pro Lys Pro Lys
Asp Thr Leu Met Ile Ser Arg 435 440 445 450 Thr Pro Glu Val Thr Cys
Val Val Val Asp Val Ser His Glu Asp Pro 455 460 465 Glu Val Lys Phe
Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 470 475 480 Lys Thr
Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val 485 490 495
Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 500
505 510 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys
Thr 515 520 525 530 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln
Val Tyr Thr Leu 535 540 545 Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn
Gln Val Ser Leu Thr Cys 550 555 560 Leu Val Lys Gly Phe Tyr Pro Ser
Asp Ile Ala Val Glu Trp Glu Ser 565 570 575 Asn Gly Gln Pro Glu Asn
Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 580 585 590 Ser Asp Gly Ser
Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 595 600 605 610 Arg
Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 615 620
625 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
630 635 640 <210> SEQ ID NO 3 <211> LENGTH: 741
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Fc cassette
from pSYN-FIX-030 <400> SEQUENCE: 3 atggagacag acacactcct
gctatgggta ctgctgctct gggttccagg ttccactggt 60 gacaaaactc
acacatgccc accgtgccca gcacctgaac tcctgggagg accgtcagtc 120
ttcctcttcc ccccaaaacc caaggacacc ctcatgatct cccggacccc tgaggtcaca
180 tgcgtggtgg tggacgtgag ccacgaagac cctgaggtca agttcaactg
gtacgtggac 240 ggcgtggagg tgcataatgc caagacaaag ccgcgggagg
agcagtacaa cagcacgtac 300 cgtgtggtca gcgtcctcac cgtcctgcac
caggactggc tgaatggcaa ggagtacaag 360 tgcaaggtct ccaacaaagc
cctcccagcc cccatcgaga aaaccatctc caaagccaaa 420 gggcagcccc
gagaaccaca ggtgtacacc ctgcccccat cccgcgatga gctgaccaag 480
aaccaggtca gcctgacctg cctggtcaaa ggcttctatc ccagcgacat cgccgtggag
540 tgggagagca atgggcagcc ggagaacaac tacaagacca cgcctcccgt
gttggactcc 600 gacggctcct tcttcctcta cagcaagctc accgtggaca
agagcaggtg gcagcagggg 660 aacgtcttct catgctccgt gatgcatgag
gctctgcaca accactacac gcagaagagc 720 ctctccctgt ctccgggtaa a 741
<210> SEQ ID NO 4 <211> LENGTH: 247 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Fc cassette from pSYN-FIX-030
<220> FEATURE: <221> NAME/KEY: SIGNAL <222>
LOCATION: (-20)..(-1) <220> FEATURE: <221> NAME/KEY:
mat_peptide <222> LOCATION: (1)..(227) <400> SEQUENCE:
4 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro
-20 -15 -10 -5 Gly Ser Thr Gly Asp Lys Thr His Thr Cys Pro Pro Cys
Pro Ala Pro -1 1 5 10 Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe
Pro Pro Lys Pro Lys 15 20 25 Asp Thr Leu Met Ile Ser Arg Thr Pro
Glu Val Thr Cys Val Val Val 30 35 40 Asp Val Ser His Glu Asp Pro
Glu Val Lys Phe Asn Trp Tyr Val Asp 45 50 55 60 Gly Val Glu Val His
Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr 65 70 75 Asn Ser Thr
Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp 80 85 90 Trp
Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu 95 100
105 Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
110 115 120 Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu
Thr Lys 125 130 135 140 Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly
Phe Tyr Pro Ser Asp 145 150 155
Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys 160
165 170 Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr
Ser 175 180 185 Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
Val Phe Ser 190 195 200 Cys Ser Val Met His Glu Ala Leu His Asn His
Tyr Thr Gln Lys Ser 205 210 215 220 Leu Ser Leu Ser Pro Gly Lys 225
<210> SEQ ID NO 5 <211> LENGTH: 5052 <212> TYPE:
DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: B-Domain Deleted FVIIIFc <400>
SEQUENCE: 5 atgcaaatag agctctccac ctgcttcttt ctgtgccttt tgcgattctg
ctttagtgcc 60 accagaagat actacctggg tgcagtggaa ctgtcatggg
actatatgca aagtgatctc 120 ggtgagctgc ctgtggacgc aagatttcct
cctagagtgc caaaatcttt tccattcaac 180 acctcagtcg tgtacaaaaa
gactctgttt gtagaattca cggatcacct tttcaacatc 240 gctaagccaa
ggccaccctg gatgggtctg ctaggtccta ccatccaggc tgaggtttat 300
gatacagtgg tcattacact taagaacatg gcttcccatc ctgtcagtct tcatgctgtt
360 ggtgtatcct actggaaagc ttctgaggga gctgaatatg atgatcagac
cagtcaaagg 420 gagaaagaag atgataaagt cttccctggt ggaagccata
catatgtctg gcaggtcctg 480 aaagagaatg gtccaatggc ctctgaccca
ctgtgcctta cctactcata tctttctcat 540 gtggacctgg taaaagactt
gaattcaggc ctcattggag ccctactagt atgtagagaa 600 gggagtctgg
ccaaggaaaa gacacagacc ttgcacaaat ttatactact ttttgctgta 660
tttgatgaag ggaaaagttg gcactcagaa acaaagaact ccttgatgca ggatagggat
720 gctgcatctg ctcgggcctg gcctaaaatg cacacagtca atggttatgt
aaacaggtct 780 ctgccaggtc tgattggatg ccacaggaaa tcagtctatt
ggcatgtgat tggaatgggc 840 accactcctg aagtgcactc aatattcctc
gaaggtcaca catttcttgt gaggaaccat 900 cgccaggcgt ccttggaaat
ctcgccaata actttcctta ctgctcaaac actcttgatg 960 gaccttggac
agtttctact gttttgtcat atctcttccc accaacatga tggcatggaa 1020
gcttatgtca aagtagacag ctgtccagag gaaccccaac tacgaatgaa aaataatgaa
1080 gaagcggaag actatgatga tgatcttact gattctgaaa tggatgtggt
caggtttgat 1140 gatgacaact ctccttcctt tatccaaatt cgctcagttg
ccaagaagca tcctaaaact 1200 tgggtacatt acattgctgc tgaagaggag
gactgggact atgctccctt agtcctcgcc 1260 cccgatgaca gaagttataa
aagtcaatat ttgaacaatg gccctcagcg gattggtagg 1320 aagtacaaaa
aagtccgatt tatggcatac acagatgaaa cctttaagac tcgtgaagct 1380
attcagcatg aatcaggaat cttgggacct ttactttatg gggaagttgg agacacactg
1440 ttgattatat ttaagaatca agcaagcaga ccatataaca tctaccctca
cggaatcact 1500 gatgtccgtc ctttgtattc aaggagatta ccaaaaggtg
taaaacattt gaaggatttt 1560 ccaattctgc caggagaaat attcaaatat
aaatggacag tgactgtaga agatgggcca 1620 actaaatcag atcctcggtg
cctgacccgc tattactcta gtttcgttaa tatggagaga 1680 gatctagctt
caggactcat tggccctctc ctcatctgct acaaagaatc tgtagatcaa 1740
agaggaaacc agataatgtc agacaagagg aatgtcatcc tgttttctgt atttgatgag
1800 aaccgaagct ggtacctcac agagaatata caacgctttc tccccaatcc
agctggagtg 1860 cagcttgagg atccagagtt ccaagcctcc aacatcatgc
acagcatcaa tggctatgtt 1920 tttgatagtt tgcagttgtc agtttgtttg
catgaggtgg catactggta cattctaagc 1980 attggagcac agactgactt
cctttctgtc ttcttctctg gatatacctt caaacacaaa 2040 atggtctatg
aagacacact caccctattc ccattctcag gagaaactgt cttcatgtcg 2100
atggaaaacc caggtctatg gattctgggg tgccacaact cagactttcg gaacagaggc
2160 atgaccgcct tactgaaggt ttctagttgt gacaagaaca ctggtgatta
ttacgaggac 2220 agttatgaag atatttcagc atacttgctg agtaaaaaca
atgccattga accaagaagc 2280 ttctctcaaa acccaccagt cttgaaacgc
catcaacggg aaataactcg tactactctt 2340 cagtcagatc aagaggaaat
tgactatgat gataccatat cagttgaaat gaagaaggaa 2400 gattttgaca
tttatgatga ggatgaaaat cagagccccc gcagctttca aaagaaaaca 2460
cgacactatt ttattgctgc agtggagagg ctctgggatt atgggatgag tagctcccca
2520 catgttctaa gaaacagggc tcagagtggc agtgtccctc agttcaagaa
agttgttttc 2580 caggaattta ctgatggctc ctttactcag cccttatacc
gtggagaact aaatgaacat 2640 ttgggactcc tggggccata tataagagca
gaagttgaag ataatatcat ggtaactttc 2700 agaaatcagg cctctcgtcc
ctattccttc tattctagcc ttatttctta tgaggaagat 2760 cagaggcaag
gagcagaacc tagaaaaaac tttgtcaagc ctaatgaaac caaaacttac 2820
ttttggaaag tgcaacatca tatggcaccc actaaagatg agtttgactg caaagcctgg
2880 gcttatttct ctgatgttga cctggaaaaa gatgtgcact caggcctgat
tggacccctt 2940 ctggtctgcc acactaacac actgaaccct gctcatggga
gacaagtgac agtacaggaa 3000 tttgctctgt ttttcaccat ctttgatgag
accaaaagct ggtacttcac tgaaaatatg 3060 gaaagaaact gcagggctcc
ctgcaatatc cagatggaag atcccacttt taaagagaat 3120 tatcgcttcc
atgcaatcaa tggctacata atggatacac tacctggctt agtaatggct 3180
caggatcaaa ggattcgatg gtatctgctc agcatgggca gcaatgaaaa catccattct
3240 attcatttca gtggacatgt gttcactgta cgaaaaaaag aggagtataa
aatggcactg 3300 tacaatctct atccaggtgt ttttgagaca gtggaaatgt
taccatccaa agctggaatt 3360 tggcgggtgg aatgccttat tggcgagcat
ctacatgctg ggatgagcac actttttctg 3420 gtgtacagca ataagtgtca
gactcccctg ggaatggctt ctggacacat tagagatttt 3480 cagattacag
cttcaggaca atatggacag tgggccccaa agctggccag acttcattat 3540
tccggatcaa tcaatgcctg gagcaccaag gagccctttt cttggatcaa ggtggatctg
3600 ttggcaccaa tgattattca cggcatcaag acccagggtg cccgtcagaa
gttctccagc 3660 ctctacatct ctcagtttat catcatgtat agtcttgatg
ggaagaagtg gcagacttat 3720 cgaggaaatt ccactggaac cttaatggtc
ttctttggca atgtggattc atctgggata 3780 aaacacaata tttttaaccc
tccaattatt gctcgataca tccgtttgca cccaactcat 3840 tatagcattc
gcagcactct tcgcatggag ttgatgggct gtgatttaaa tagttgcagc 3900
atgccattgg gaatggagag taaagcaata tcagatgcac agattactgc ttcatcctac
3960 tttaccaata tgtttgccac ctggtctcct tcaaaagctc gacttcacct
ccaagggagg 4020 agtaatgcct ggagacctca ggtgaataat ccaaaagagt
ggctgcaagt ggacttccag 4080 aagacaatga aagtcacagg agtaactact
cagggagtaa aatctctgct taccagcatg 4140 tatgtgaagg agttcctcat
ctccagcagt caagatggcc atcagtggac tctctttttt 4200 cagaatggca
aagtaaaggt ttttcaggga aatcaagact ccttcacacc tgtggtgaac 4260
tctctagacc caccgttact gactcgctac cttcgaattc acccccagag ttgggtgcac
4320 cagattgccc tgaggatgga ggttctgggc tgcgaggcac aggacctcta
cgacaaaact 4380 cacacatgcc caccgtgccc agctccagaa ctcctgggcg
gaccgtcagt cttcctcttc 4440 cccccaaaac ccaaggacac cctcatgatc
tcccggaccc ctgaggtcac atgcgtggtg 4500 gtggacgtga gccacgaaga
ccctgaggtc aagttcaact ggtacgtgga cggcgtggag 4560 gtgcataatg
ccaagacaaa gccgcgggag gagcagtaca acagcacgta ccgtgtggtc 4620
agcgtcctca ccgtcctgca ccaggactgg ctgaatggca aggagtacaa gtgcaaggtc
4680 tccaacaaag ccctcccagc ccccatcgag aaaaccatct ccaaagccaa
agggcagccc 4740 cgagaaccac aggtgtacac cctgccccca tcccgggatg
agctgaccaa gaaccaggtc 4800 agcctgacct gcctggtcaa aggcttctat
cccagcgaca tcgccgtgga gtgggagagc 4860 aatgggcagc cggagaacaa
ctacaagacc acgcctcccg tgttggactc cgacggctcc 4920 ttcttcctct
acagcaagct caccgtggac aagagcaggt ggcagcaggg gaacgtcttc 4980
tcatgctccg tgatgcatga ggctctgcac aaccactaca cgcagaagag cctctccctg
5040 tctccgggta aa 5052 <210> SEQ ID NO 6 <211> LENGTH:
1684 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
B-Domain Deleted FVIIIFc <220> FEATURE: <221> NAME/KEY:
SIGNAL <222> LOCATION: (-19)..(-1) <220> FEATURE:
<221> NAME/KEY: mat_peptide <222> LOCATION: (1)..(1665)
<400> SEQUENCE: 6 Met Gln Ile Glu Leu Ser Thr Cys Phe Phe Leu
Cys Leu Leu Arg Phe -15 -10 -5 Cys Phe Ser Ala Thr Arg Arg Tyr Tyr
Leu Gly Ala Val Glu Leu Ser -1 1 5 10 Trp Asp Tyr Met Gln Ser Asp
Leu Gly Glu Leu Pro Val Asp Ala Arg 15 20 25 Phe Pro Pro Arg Val
Pro Lys Ser Phe Pro Phe Asn Thr Ser Val Val 30 35 40 45 Tyr Lys Lys
Thr Leu Phe Val Glu Phe Thr Asp His Leu Phe Asn Ile 50 55 60 Ala
Lys Pro Arg Pro Pro Trp Met Gly Leu Leu Gly Pro Thr Ile Gln 65 70
75 Ala Glu Val Tyr Asp Thr Val Val Ile Thr Leu Lys Asn Met Ala Ser
80 85 90 His Pro Val Ser Leu His Ala Val Gly Val Ser Tyr Trp Lys
Ala Ser 95 100 105 Glu Gly Ala Glu Tyr Asp Asp Gln Thr Ser Gln Arg
Glu Lys Glu Asp 110 115 120 125 Asp Lys Val Phe Pro Gly Gly Ser His
Thr Tyr Val Trp Gln Val Leu 130 135 140 Lys Glu Asn Gly Pro Met Ala
Ser Asp Pro Leu Cys Leu Thr Tyr Ser 145 150 155 Tyr Leu Ser His Val
Asp Leu Val Lys Asp Leu Asn Ser Gly Leu Ile 160 165 170 Gly Ala Leu
Leu Val Cys Arg Glu Gly Ser Leu Ala Lys Glu Lys Thr 175 180 185
Gln Thr Leu His Lys Phe Ile Leu Leu Phe Ala Val Phe Asp Glu Gly 190
195 200 205 Lys Ser Trp His Ser Glu Thr Lys Asn Ser Leu Met Gln Asp
Arg Asp 210 215 220 Ala Ala Ser Ala Arg Ala Trp Pro Lys Met His Thr
Val Asn Gly Tyr 225 230 235 Val Asn Arg Ser Leu Pro Gly Leu Ile Gly
Cys His Arg Lys Ser Val 240 245 250 Tyr Trp His Val Ile Gly Met Gly
Thr Thr Pro Glu Val His Ser Ile 255 260 265 Phe Leu Glu Gly His Thr
Phe Leu Val Arg Asn His Arg Gln Ala Ser 270 275 280 285 Leu Glu Ile
Ser Pro Ile Thr Phe Leu Thr Ala Gln Thr Leu Leu Met 290 295 300 Asp
Leu Gly Gln Phe Leu Leu Phe Cys His Ile Ser Ser His Gln His 305 310
315 Asp Gly Met Glu Ala Tyr Val Lys Val Asp Ser Cys Pro Glu Glu Pro
320 325 330 Gln Leu Arg Met Lys Asn Asn Glu Glu Ala Glu Asp Tyr Asp
Asp Asp 335 340 345 Leu Thr Asp Ser Glu Met Asp Val Val Arg Phe Asp
Asp Asp Asn Ser 350 355 360 365 Pro Ser Phe Ile Gln Ile Arg Ser Val
Ala Lys Lys His Pro Lys Thr 370 375 380 Trp Val His Tyr Ile Ala Ala
Glu Glu Glu Asp Trp Asp Tyr Ala Pro 385 390 395 Leu Val Leu Ala Pro
Asp Asp Arg Ser Tyr Lys Ser Gln Tyr Leu Asn 400 405 410 Asn Gly Pro
Gln Arg Ile Gly Arg Lys Tyr Lys Lys Val Arg Phe Met 415 420 425 Ala
Tyr Thr Asp Glu Thr Phe Lys Thr Arg Glu Ala Ile Gln His Glu 430 435
440 445 Ser Gly Ile Leu Gly Pro Leu Leu Tyr Gly Glu Val Gly Asp Thr
Leu 450 455 460 Leu Ile Ile Phe Lys Asn Gln Ala Ser Arg Pro Tyr Asn
Ile Tyr Pro 465 470 475 His Gly Ile Thr Asp Val Arg Pro Leu Tyr Ser
Arg Arg Leu Pro Lys 480 485 490 Gly Val Lys His Leu Lys Asp Phe Pro
Ile Leu Pro Gly Glu Ile Phe 495 500 505 Lys Tyr Lys Trp Thr Val Thr
Val Glu Asp Gly Pro Thr Lys Ser Asp 510 515 520 525 Pro Arg Cys Leu
Thr Arg Tyr Tyr Ser Ser Phe Val Asn Met Glu Arg 530 535 540 Asp Leu
Ala Ser Gly Leu Ile Gly Pro Leu Leu Ile Cys Tyr Lys Glu 545 550 555
Ser Val Asp Gln Arg Gly Asn Gln Ile Met Ser Asp Lys Arg Asn Val 560
565 570 Ile Leu Phe Ser Val Phe Asp Glu Asn Arg Ser Trp Tyr Leu Thr
Glu 575 580 585 Asn Ile Gln Arg Phe Leu Pro Asn Pro Ala Gly Val Gln
Leu Glu Asp 590 595 600 605 Pro Glu Phe Gln Ala Ser Asn Ile Met His
Ser Ile Asn Gly Tyr Val 610 615 620 Phe Asp Ser Leu Gln Leu Ser Val
Cys Leu His Glu Val Ala Tyr Trp 625 630 635 Tyr Ile Leu Ser Ile Gly
Ala Gln Thr Asp Phe Leu Ser Val Phe Phe 640 645 650 Ser Gly Tyr Thr
Phe Lys His Lys Met Val Tyr Glu Asp Thr Leu Thr 655 660 665 Leu Phe
Pro Phe Ser Gly Glu Thr Val Phe Met Ser Met Glu Asn Pro 670 675 680
685 Gly Leu Trp Ile Leu Gly Cys His Asn Ser Asp Phe Arg Asn Arg Gly
690 695 700 Met Thr Ala Leu Leu Lys Val Ser Ser Cys Asp Lys Asn Thr
Gly Asp 705 710 715 Tyr Tyr Glu Asp Ser Tyr Glu Asp Ile Ser Ala Tyr
Leu Leu Ser Lys 720 725 730 Asn Asn Ala Ile Glu Pro Arg Ser Phe Ser
Gln Asn Pro Pro Val Leu 735 740 745 Lys Arg His Gln Arg Glu Ile Thr
Arg Thr Thr Leu Gln Ser Asp Gln 750 755 760 765 Glu Glu Ile Asp Tyr
Asp Asp Thr Ile Ser Val Glu Met Lys Lys Glu 770 775 780 Asp Phe Asp
Ile Tyr Asp Glu Asp Glu Asn Gln Ser Pro Arg Ser Phe 785 790 795 Gln
Lys Lys Thr Arg His Tyr Phe Ile Ala Ala Val Glu Arg Leu Trp 800 805
810 Asp Tyr Gly Met Ser Ser Ser Pro His Val Leu Arg Asn Arg Ala Gln
815 820 825 Ser Gly Ser Val Pro Gln Phe Lys Lys Val Val Phe Gln Glu
Phe Thr 830 835 840 845 Asp Gly Ser Phe Thr Gln Pro Leu Tyr Arg Gly
Glu Leu Asn Glu His 850 855 860 Leu Gly Leu Leu Gly Pro Tyr Ile Arg
Ala Glu Val Glu Asp Asn Ile 865 870 875 Met Val Thr Phe Arg Asn Gln
Ala Ser Arg Pro Tyr Ser Phe Tyr Ser 880 885 890 Ser Leu Ile Ser Tyr
Glu Glu Asp Gln Arg Gln Gly Ala Glu Pro Arg 895 900 905 Lys Asn Phe
Val Lys Pro Asn Glu Thr Lys Thr Tyr Phe Trp Lys Val 910 915 920 925
Gln His His Met Ala Pro Thr Lys Asp Glu Phe Asp Cys Lys Ala Trp 930
935 940 Ala Tyr Phe Ser Asp Val Asp Leu Glu Lys Asp Val His Ser Gly
Leu 945 950 955 Ile Gly Pro Leu Leu Val Cys His Thr Asn Thr Leu Asn
Pro Ala His 960 965 970 Gly Arg Gln Val Thr Val Gln Glu Phe Ala Leu
Phe Phe Thr Ile Phe 975 980 985 Asp Glu Thr Lys Ser Trp Tyr Phe Thr
Glu Asn Met Glu Arg Asn Cys 990 995 1000 1005 Arg Ala Pro Cys Asn
Ile Gln Met Glu Asp Pro Thr Phe Lys Glu 1010 1015 1020 Asn Tyr Arg
Phe His Ala Ile Asn Gly Tyr Ile Met Asp Thr Leu 1025 1030 1035 Pro
Gly Leu Val Met Ala Gln Asp Gln Arg Ile Arg Trp Tyr Leu 1040 1045
1050 Leu Ser Met Gly Ser Asn Glu Asn Ile His Ser Ile His Phe Ser
1055 1060 1065 Gly His Val Phe Thr Val Arg Lys Lys Glu Glu Tyr Lys
Met Ala 1070 1075 1080 Leu Tyr Asn Leu Tyr Pro Gly Val Phe Glu Thr
Val Glu Met Leu 1085 1090 1095 Pro Ser Lys Ala Gly Ile Trp Arg Val
Glu Cys Leu Ile Gly Glu 1100 1105 1110 His Leu His Ala Gly Met Ser
Thr Leu Phe Leu Val Tyr Ser Asn 1115 1120 1125 Lys Cys Gln Thr Pro
Leu Gly Met Ala Ser Gly His Ile Arg Asp 1130 1135 1140 Phe Gln Ile
Thr Ala Ser Gly Gln Tyr Gly Gln Trp Ala Pro Lys 1145 1150 1155 Leu
Ala Arg Leu His Tyr Ser Gly Ser Ile Asn Ala Trp Ser Thr 1160 1165
1170 Lys Glu Pro Phe Ser Trp Ile Lys Val Asp Leu Leu Ala Pro Met
1175 1180 1185 Ile Ile His Gly Ile Lys Thr Gln Gly Ala Arg Gln Lys
Phe Ser 1190 1195 1200 Ser Leu Tyr Ile Ser Gln Phe Ile Ile Met Tyr
Ser Leu Asp Gly 1205 1210 1215 Lys Lys Trp Gln Thr Tyr Arg Gly Asn
Ser Thr Gly Thr Leu Met 1220 1225 1230 Val Phe Phe Gly Asn Val Asp
Ser Ser Gly Ile Lys His Asn Ile 1235 1240 1245 Phe Asn Pro Pro Ile
Ile Ala Arg Tyr Ile Arg Leu His Pro Thr 1250 1255 1260 His Tyr Ser
Ile Arg Ser Thr Leu Arg Met Glu Leu Met Gly Cys 1265 1270 1275 Asp
Leu Asn Ser Cys Ser Met Pro Leu Gly Met Glu Ser Lys Ala 1280 1285
1290 Ile Ser Asp Ala Gln Ile Thr Ala Ser Ser Tyr Phe Thr Asn Met
1295 1300 1305 Phe Ala Thr Trp Ser Pro Ser Lys Ala Arg Leu His Leu
Gln Gly 1310 1315 1320 Arg Ser Asn Ala Trp Arg Pro Gln Val Asn Asn
Pro Lys Glu Trp 1325 1330 1335 Leu Gln Val Asp Phe Gln Lys Thr Met
Lys Val Thr Gly Val Thr 1340 1345 1350 Thr Gln Gly Val Lys Ser Leu
Leu Thr Ser Met Tyr Val Lys Glu 1355 1360 1365 Phe Leu Ile Ser Ser
Ser Gln Asp Gly His Gln Trp Thr Leu Phe 1370 1375 1380 Phe Gln Asn
Gly Lys Val Lys Val Phe Gln Gly Asn Gln Asp Ser 1385 1390 1395 Phe
Thr Pro Val Val Asn Ser Leu Asp Pro Pro Leu Leu Thr Arg 1400 1405
1410 Tyr Leu Arg Ile His Pro Gln Ser Trp Val His Gln Ile Ala Leu
1415 1420 1425 Arg Met Glu Val Leu Gly Cys Glu Ala Gln Asp Leu Tyr
Asp Lys 1430 1435 1440 Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu
Leu Leu Gly Gly 1445 1450 1455 Pro Ser Val Phe Leu Phe Pro Pro Lys
Pro Lys Asp Thr Leu Met 1460 1465 1470 Ile Ser Arg Thr Pro Glu Val
Thr Cys Val Val Val Asp Val Ser 1475 1480 1485 His Glu Asp Pro Glu
Val Lys Phe Asn Trp Tyr Val Asp Gly Val 1490 1495 1500
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn 1505
1510 1515 Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln
Asp 1520 1525 1530 Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser
Asn Lys Ala 1535 1540 1545 Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser
Lys Ala Lys Gly Gln 1550 1555 1560 Pro Arg Glu Pro Gln Val Tyr Thr
Leu Pro Pro Ser Arg Asp Glu 1565 1570 1575 Leu Thr Lys Asn Gln Val
Ser Leu Thr Cys Leu Val Lys Gly Phe 1580 1585 1590 Tyr Pro Ser Asp
Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro 1595 1600 1605 Glu Asn
Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly 1610 1615 1620
Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp 1625
1630 1635 Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala
Leu 1640 1645 1650 His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
Pro Gly Lys 1655 1660 1665 <210> SEQ ID NO 7 <211>
LENGTH: 741 <212> TYPE: DNA <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION: Fc
Sequence <400> SEQUENCE: 7 atggagacag acacactcct gctatgggta
ctgctgctct gggttccagg ttccactggt 60 gacaaaactc acacatgccc
accgtgccca gcacctgaac tcctgggagg accgtcagtc 120 ttcctcttcc
ccccaaaacc caaggacacc ctcatgatct cccggacccc tgaggtcaca 180
tgcgtggtgg tggacgtgag ccacgaagac cctgaggtca agttcaactg gtacgtggac
240 ggcgtggagg tgcataatgc caagacaaag ccgcgggagg agcagtacaa
cagcacgtac 300 cgtgtggtca gcgtcctcac cgtcctgcac caggactggc
tgaatggcaa ggagtacaag 360 tgcaaggtct ccaacaaagc cctcccagcc
cccatcgaga aaaccatctc caaagccaaa 420 gggcagcccc gagaaccaca
ggtgtacacc ctgcccccat cccgcgatga gctgaccaag 480 aaccaggtca
gcctgacctg cctggtcaaa ggcttctatc ccagcgacat cgccgtggag 540
tgggagagca atgggcagcc ggagaacaac tacaagacca cgcctcccgt gttggactcc
600 gacggctcct tcttcctcta cagcaagctc accgtggaca agagcaggtg
gcagcagggg 660 aacgtcttct catgctccgt gatgcatgag gctctgcaca
accactacac gcagaagagc 720 ctctccctgt ctccgggtaa a 741 <210>
SEQ ID NO 8 <211> LENGTH: 247 <212> TYPE: PRT
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Fc chain <220> FEATURE:
<221> NAME/KEY: SIGNAL <222> LOCATION: (-20)..(-1)
<220> FEATURE: <221> NAME/KEY: mat_peptide <222>
LOCATION: (-1)..(227) <400> SEQUENCE: 8 Met Glu Thr Asp Thr
Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro -20 -15 -10 -5 Gly Ser
Thr Gly Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro -1 1 5 10
Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys 15
20 25 Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val
Val 30 35 40 Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
Tyr Val Asp 45 50 55 60 Gly Val Glu Val His Asn Ala Lys Thr Lys Pro
Arg Glu Glu Gln Tyr 65 70 75 Asn Ser Thr Tyr Arg Val Val Ser Val
Leu Thr Val Leu His Gln Asp 80 85 90 Trp Leu Asn Gly Lys Glu Tyr
Lys Cys Lys Val Ser Asn Lys Ala Leu 95 100 105 Pro Ala Pro Ile Glu
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg 110 115 120 Glu Pro Gln
Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys 125 130 135 140
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp 145
150 155 Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr
Lys 160 165 170 Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
Leu Tyr Ser 175 180 185 Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln
Gly Asn Val Phe Ser 190 195 200 Cys Ser Val Met His Glu Ala Leu His
Asn His Tyr Thr Gln Lys Ser 205 210 215 220 Leu Ser Leu Ser Pro Gly
Lys 225 <210> SEQ ID NO 9 <211> LENGTH: 7734
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Full Length
FVIIIFc <400> SEQUENCE: 9 atgcaaatag agctctccac ctgcttcttt
ctgtgccttt tgcgattctg ctttagtgcc 60 accagaagat actacctggg
tgcagtggaa ctgtcatggg actatatgca aagtgatctc 120 ggtgagctgc
ctgtggacgc aagatttcct cctagagtgc caaaatcttt tccattcaac 180
acctcagtcg tgtacaaaaa gactctgttt gtagaattca cggatcacct tttcaacatc
240 gctaagccaa ggccaccctg gatgggtctg ctaggtccta ccatccaggc
tgaggtttat 300 gatacagtgg tcattacact taagaacatg gcttcccatc
ctgtcagtct tcatgctgtt 360 ggtgtatcct actggaaagc ttctgaggga
gctgaatatg atgatcagac cagtcaaagg 420 gagaaagaag atgataaagt
cttccctggt ggaagccata catatgtctg gcaggtcctg 480 aaagagaatg
gtccaatggc ctctgaccca ctgtgcctta cctactcata tctttctcat 540
gtggacctgg taaaagactt gaattcaggc ctcattggag ccctactagt atgtagagaa
600 gggagtctgg ccaaggaaaa gacacagacc ttgcacaaat ttatactact
ttttgctgta 660 tttgatgaag ggaaaagttg gcactcagaa acaaagaact
ccttgatgca ggatagggat 720 gctgcatctg ctcgggcctg gcctaaaatg
cacacagtca atggttatgt aaacaggtct 780 ctgccaggtc tgattggatg
ccacaggaaa tcagtctatt ggcatgtgat tggaatgggc 840 accactcctg
aagtgcactc aatattcctc gaaggtcaca catttcttgt gaggaaccat 900
cgccaggcgt ccttggaaat ctcgccaata actttcctta ctgctcaaac actcttgatg
960 gaccttggac agtttctact gttttgtcat atctcttccc accaacatga
tggcatggaa 1020 gcttatgtca aagtagacag ctgtccagag gaaccccaac
tacgaatgaa aaataatgaa 1080 gaagcggaag actatgatga tgatcttact
gattctgaaa tggatgtggt caggtttgat 1140 gatgacaact ctccttcctt
tatccaaatt cgctcagttg ccaagaagca tcctaaaact 1200 tgggtacatt
acattgctgc tgaagaggag gactgggact atgctccctt agtcctcgcc 1260
cccgatgaca gaagttataa aagtcaatat ttgaacaatg gccctcagcg gattggtagg
1320 aagtacaaaa aagtccgatt tatggcatac acagatgaaa cctttaagac
tcgtgaagct 1380 attcagcatg aatcaggaat cttgggacct ttactttatg
gggaagttgg agacacactg 1440 ttgattatat ttaagaatca agcaagcaga
ccatataaca tctaccctca cggaatcact 1500 gatgtccgtc ctttgtattc
aaggagatta ccaaaaggtg taaaacattt gaaggatttt 1560 ccaattctgc
caggagaaat attcaaatat aaatggacag tgactgtaga agatgggcca 1620
actaaatcag atcctcggtg cctgacccgc tattactcta gtttcgttaa tatggagaga
1680 gatctagctt caggactcat tggccctctc ctcatctgct acaaagaatc
tgtagatcaa 1740 agaggaaacc agataatgtc agacaagagg aatgtcatcc
tgttttctgt atttgatgag 1800 aaccgaagct ggtacctcac agagaatata
caacgctttc tccccaatcc agctggagtg 1860 cagcttgagg atccagagtt
ccaagcctcc aacatcatgc acagcatcaa tggctatgtt 1920 tttgatagtt
tgcagttgtc agtttgtttg catgaggtgg catactggta cattctaagc 1980
attggagcac agactgactt cctttctgtc ttcttctctg gatatacctt caaacacaaa
2040 atggtctatg aagacacact caccctattc ccattctcag gagaaactgt
cttcatgtcg 2100 atggaaaacc caggtctatg gattctgggg tgccacaact
cagactttcg gaacagaggc 2160 atgaccgcct tactgaaggt ttctagttgt
gacaagaaca ctggtgatta ttacgaggac 2220 agttatgaag atatttcagc
atacttgctg agtaaaaaca atgccattga accaagaagc 2280 ttctcccaga
attcaagaca ccctagcact aggcaaaagc aatttaatgc caccacaatt 2340
ccagaaaatg acatagagaa gactgaccct tggtttgcac acagaacacc tatgcctaaa
2400 atacaaaatg tctcctctag tgatttgttg atgctcttgc gacagagtcc
tactccacat 2460 gggctatcct tatctgatct ccaagaagcc aaatatgaga
ctttttctga tgatccatca 2520 cctggagcaa tagacagtaa taacagcctg
tctgaaatga cacacttcag gccacagctc 2580 catcacagtg gggacatggt
atttacccct gagtcaggcc tccaattaag attaaatgag 2640 aaactgggga
caactgcagc aacagagttg aagaaacttg atttcaaagt ttctagtaca 2700
tcaaataatc tgatttcaac aattccatca gacaatttgg cagcaggtac tgataataca
2760 agttccttag gacccccaag tatgccagtt cattatgata gtcaattaga
taccactcta 2820 tttggcaaaa agtcatctcc ccttactgag tctggtggac
ctctgagctt gagtgaagaa 2880 aataatgatt caaagttgtt agaatcaggt
ttaatgaata gccaagaaag ttcatgggga 2940 aaaaatgtat cgtcaacaga
gagtggtagg ttatttaaag ggaaaagagc tcatggacct 3000 gctttgttga
ctaaagataa tgccttattc aaagttagca tctctttgtt aaagacaaac 3060
aaaacttcca ataattcagc aactaataga aagactcaca ttgatggccc atcattatta
3120 attgagaata gtccatcagt ctggcaaaat atattagaaa gtgacactga
gtttaaaaaa 3180 gtgacacctt tgattcatga cagaatgctt atggacaaaa
atgctacagc tttgaggcta 3240
aatcatatgt caaataaaac tacttcatca aaaaacatgg aaatggtcca acagaaaaaa
3300 gagggcccca ttccaccaga tgcacaaaat ccagatatgt cgttctttaa
gatgctattc 3360 ttgccagaat cagcaaggtg gatacaaagg actcatggaa
agaactctct gaactctggg 3420 caaggcccca gtccaaagca attagtatcc
ttaggaccag aaaaatctgt ggaaggtcag 3480 aatttcttgt ctgagaaaaa
caaagtggta gtaggaaagg gtgaatttac aaaggacgta 3540 ggactcaaag
agatggtttt tccaagcagc agaaacctat ttcttactaa cttggataat 3600
ttacatgaaa ataatacaca caatcaagaa aaaaaaattc aggaagaaat agaaaagaag
3660 gaaacattaa tccaagagaa tgtagttttg cctcagatac atacagtgac
tggcactaag 3720 aatttcatga agaacctttt cttactgagc actaggcaaa
atgtagaagg ttcatatgac 3780 ggggcatatg ctccagtact tcaagatttt
aggtcattaa atgattcaac aaatagaaca 3840 aagaaacaca cagctcattt
ctcaaaaaaa ggggaggaag aaaacttgga aggcttggga 3900 aatcaaacca
agcaaattgt agagaaatat gcatgcacca caaggatatc tcctaataca 3960
agccagcaga attttgtcac gcaacgtagt aagagagctt tgaaacaatt cagactccca
4020 ctagaagaaa cagaacttga aaaaaggata attgtggatg acacctcaac
ccagtggtcc 4080 aaaaacatga aacatttgac cccgagcacc ctcacacaga
tagactacaa tgagaaggag 4140 aaaggggcca ttactcagtc tcccttatca
gattgcctta cgaggagtca tagcatccct 4200 caagcaaata gatctccatt
acccattgca aaggtatcat catttccatc tattagacct 4260 atatatctga
ccagggtcct attccaagac aactcttctc atcttccagc agcatcttat 4320
agaaagaaag attctggggt ccaagaaagc agtcatttct tacaaggagc caaaaaaaat
4380 aacctttctt tagccattct aaccttggag atgactggtg atcaaagaga
ggttggctcc 4440 ctggggacaa gtgccacaaa ttcagtcaca tacaagaaag
ttgagaacac tgttctcccg 4500 aaaccagact tgcccaaaac atctggcaaa
gttgaattgc ttccaaaagt tcacatttat 4560 cagaaggacc tattccctac
ggaaactagc aatgggtctc ctggccatct ggatctcgtg 4620 gaagggagcc
ttcttcaggg aacagaggga gcgattaagt ggaatgaagc aaacagacct 4680
ggaaaagttc cctttctgag agtagcaaca gaaagctctg caaagactcc ctccaagcta
4740 ttggatcctc ttgcttggga taaccactat ggtactcaga taccaaaaga
agagtggaaa 4800 tcccaagaga agtcaccaga aaaaacagct tttaagaaaa
aggataccat tttgtccctg 4860 aacgcttgtg aaagcaatca tgcaatagca
gcaataaatg agggacaaaa taagcccgaa 4920 atagaagtca cctgggcaaa
gcaaggtagg actgaaaggc tgtgctctca aaacccacca 4980 gtcttgaaac
gccatcaacg ggaaataact cgtactactc ttcagtcaga tcaagaggaa 5040
attgactatg atgataccat atcagttgaa atgaagaagg aagattttga catttatgat
5100 gaggatgaaa atcagagccc ccgcagcttt caaaagaaaa cacgacacta
ttttattgct 5160 gcagtggaga ggctctggga ttatgggatg agtagctccc
cacatgttct aagaaacagg 5220 gctcagagtg gcagtgtccc tcagttcaag
aaagttgttt tccaggaatt tactgatggc 5280 tcctttactc agcccttata
ccgtggagaa ctaaatgaac atttgggact cctggggcca 5340 tatataagag
cagaagttga agataatatc atggtaactt tcagaaatca ggcctctcgt 5400
ccctattcct tctattctag ccttatttct tatgaggaag atcagaggca aggagcagaa
5460 cctagaaaaa actttgtcaa gcctaatgaa accaaaactt acttttggaa
agtgcaacat 5520 catatggcac ccactaaaga tgagtttgac tgcaaagcct
gggcttattt ctctgatgtt 5580 gacctggaaa aagatgtgca ctcaggcctg
attggacccc ttctggtctg ccacactaac 5640 acactgaacc ctgctcatgg
gagacaagtg acagtacagg aatttgctct gtttttcacc 5700 atctttgatg
agaccaaaag ctggtacttc actgaaaata tggaaagaaa ctgcagggct 5760
ccctgcaata tccagatgga agatcccact tttaaagaga attatcgctt ccatgcaatc
5820 aatggctaca taatggatac actacctggc ttagtaatgg ctcaggatca
aaggattcga 5880 tggtatctgc tcagcatggg cagcaatgaa aacatccatt
ctattcattt cagtggacat 5940 gtgttcactg tacgaaaaaa agaggagtat
aaaatggcac tgtacaatct ctatccaggt 6000 gtttttgaga cagtggaaat
gttaccatcc aaagctggaa tttggcgggt ggaatgcctt 6060 attggcgagc
atctacatgc tgggatgagc acactttttc tggtgtacag caataagtgt 6120
cagactcccc tgggaatggc ttctggacac attagagatt ttcagattac agcttcagga
6180 caatatggac agtgggcccc aaagctggcc agacttcatt attccggatc
aatcaatgcc 6240 tggagcacca aggagccctt ttcttggatc aaggtggatc
tgttggcacc aatgattatt 6300 cacggcatca agacccaggg tgcccgtcag
aagttctcca gcctctacat ctctcagttt 6360 atcatcatgt atagtcttga
tgggaagaag tggcagactt atcgaggaaa ttccactgga 6420 accttaatgg
tcttctttgg caatgtggat tcatctggga taaaacacaa tatttttaac 6480
cctccaatta ttgctcgata catccgtttg cacccaactc attatagcat tcgcagcact
6540 cttcgcatgg agttgatggg ctgtgattta aatagttgca gcatgccatt
gggaatggag 6600 agtaaagcaa tatcagatgc acagattact gcttcatcct
actttaccaa tatgtttgcc 6660 acctggtctc cttcaaaagc tcgacttcac
ctccaaggga ggagtaatgc ctggagacct 6720 caggtgaata atccaaaaga
gtggctgcaa gtggacttcc agaagacaat gaaagtcaca 6780 ggagtaacta
ctcagggagt aaaatctctg cttaccagca tgtatgtgaa ggagttcctc 6840
atctccagca gtcaagatgg ccatcagtgg actctctttt ttcagaatgg caaagtaaag
6900 gtttttcagg gaaatcaaga ctccttcaca cctgtggtga actctctaga
cccaccgtta 6960 ctgactcgct accttcgaat tcacccccag agttgggtgc
accagattgc cctgaggatg 7020 gaggttctgg gctgcgaggc acaggacctc
tacgacaaaa ctcacacatg cccaccgtgc 7080 ccagctccag aactcctggg
cggaccgtca gtcttcctct tccccccaaa acccaaggac 7140 accctcatga
tctcccggac ccctgaggtc acatgcgtgg tggtggacgt gagccacgaa 7200
gaccctgagg tcaagttcaa ctggtacgtg gacggcgtgg aggtgcataa tgccaagaca
7260 aagccgcggg aggagcagta caacagcacg taccgtgtgg tcagcgtcct
caccgtcctg 7320 caccaggact ggctgaatgg caaggagtac aagtgcaagg
tctccaacaa agccctccca 7380 gcccccatcg agaaaaccat ctccaaagcc
aaagggcagc cccgagaacc acaggtgtac 7440 accctgcccc catcccggga
tgagctgacc aagaaccagg tcagcctgac ctgcctggtc 7500 aaaggcttct
atcccagcga catcgccgtg gagtgggaga gcaatgggca gccggagaac 7560
aactacaaga ccacgcctcc cgtgttggac tccgacggct ccttcttcct ctacagcaag
7620 ctcaccgtgg acaagagcag gtggcagcag gggaacgtct tctcatgctc
cgtgatgcat 7680 gaggctctgc acaaccacta cacgcagaag agcctctccc
tgtctccggg taaa 7734 <210> SEQ ID NO 10 <211> LENGTH:
2578 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION: Full
Length FVIIIFc <220> FEATURE: <221> NAME/KEY: SIGNAL
<222> LOCATION: (-19)..(-1) <220> FEATURE: <221>
NAME/KEY: mat_peptide <222> LOCATION: (1)..(2559) <400>
SEQUENCE: 10 Met Gln Ile Glu Leu Ser Thr Cys Phe Phe Leu Cys Leu
Leu Arg Phe -15 -10 -5 Cys Phe Ser Ala Thr Arg Arg Tyr Tyr Leu Gly
Ala Val Glu Leu Ser -1 1 5 10 Trp Asp Tyr Met Gln Ser Asp Leu Gly
Glu Leu Pro Val Asp Ala Arg 15 20 25 Phe Pro Pro Arg Val Pro Lys
Ser Phe Pro Phe Asn Thr Ser Val Val 30 35 40 45 Tyr Lys Lys Thr Leu
Phe Val Glu Phe Thr Asp His Leu Phe Asn Ile 50 55 60 Ala Lys Pro
Arg Pro Pro Trp Met Gly Leu Leu Gly Pro Thr Ile Gln 65 70 75 Ala
Glu Val Tyr Asp Thr Val Val Ile Thr Leu Lys Asn Met Ala Ser 80 85
90 His Pro Val Ser Leu His Ala Val Gly Val Ser Tyr Trp Lys Ala Ser
95 100 105 Glu Gly Ala Glu Tyr Asp Asp Gln Thr Ser Gln Arg Glu Lys
Glu Asp 110 115 120 125 Asp Lys Val Phe Pro Gly Gly Ser His Thr Tyr
Val Trp Gln Val Leu 130 135 140 Lys Glu Asn Gly Pro Met Ala Ser Asp
Pro Leu Cys Leu Thr Tyr Ser 145 150 155 Tyr Leu Ser His Val Asp Leu
Val Lys Asp Leu Asn Ser Gly Leu Ile 160 165 170 Gly Ala Leu Leu Val
Cys Arg Glu Gly Ser Leu Ala Lys Glu Lys Thr 175 180 185 Gln Thr Leu
His Lys Phe Ile Leu Leu Phe Ala Val Phe Asp Glu Gly 190 195 200 205
Lys Ser Trp His Ser Glu Thr Lys Asn Ser Leu Met Gln Asp Arg Asp 210
215 220 Ala Ala Ser Ala Arg Ala Trp Pro Lys Met His Thr Val Asn Gly
Tyr 225 230 235 Val Asn Arg Ser Leu Pro Gly Leu Ile Gly Cys His Arg
Lys Ser Val 240 245 250 Tyr Trp His Val Ile Gly Met Gly Thr Thr Pro
Glu Val His Ser Ile 255 260 265 Phe Leu Glu Gly His Thr Phe Leu Val
Arg Asn His Arg Gln Ala Ser 270 275 280 285 Leu Glu Ile Ser Pro Ile
Thr Phe Leu Thr Ala Gln Thr Leu Leu Met 290 295 300 Asp Leu Gly Gln
Phe Leu Leu Phe Cys His Ile Ser Ser His Gln His 305 310 315 Asp Gly
Met Glu Ala Tyr Val Lys Val Asp Ser Cys Pro Glu Glu Pro 320 325 330
Gln Leu Arg Met Lys Asn Asn Glu Glu Ala Glu Asp Tyr Asp Asp Asp 335
340 345 Leu Thr Asp Ser Glu Met Asp Val Val Arg Phe Asp Asp Asp Asn
Ser 350 355 360 365 Pro Ser Phe Ile Gln Ile Arg Ser Val Ala Lys Lys
His Pro Lys Thr 370 375 380 Trp Val His Tyr Ile Ala Ala Glu Glu Glu
Asp Trp Asp Tyr Ala Pro 385 390 395 Leu Val Leu Ala Pro Asp Asp Arg
Ser Tyr Lys Ser Gln Tyr Leu Asn 400 405 410 Asn Gly Pro Gln Arg Ile
Gly Arg Lys Tyr Lys Lys Val Arg Phe Met 415 420 425
Ala Tyr Thr Asp Glu Thr Phe Lys Thr Arg Glu Ala Ile Gln His Glu 430
435 440 445 Ser Gly Ile Leu Gly Pro Leu Leu Tyr Gly Glu Val Gly Asp
Thr Leu 450 455 460 Leu Ile Ile Phe Lys Asn Gln Ala Ser Arg Pro Tyr
Asn Ile Tyr Pro 465 470 475 His Gly Ile Thr Asp Val Arg Pro Leu Tyr
Ser Arg Arg Leu Pro Lys 480 485 490 Gly Val Lys His Leu Lys Asp Phe
Pro Ile Leu Pro Gly Glu Ile Phe 495 500 505 Lys Tyr Lys Trp Thr Val
Thr Val Glu Asp Gly Pro Thr Lys Ser Asp 510 515 520 525 Pro Arg Cys
Leu Thr Arg Tyr Tyr Ser Ser Phe Val Asn Met Glu Arg 530 535 540 Asp
Leu Ala Ser Gly Leu Ile Gly Pro Leu Leu Ile Cys Tyr Lys Glu 545 550
555 Ser Val Asp Gln Arg Gly Asn Gln Ile Met Ser Asp Lys Arg Asn Val
560 565 570 Ile Leu Phe Ser Val Phe Asp Glu Asn Arg Ser Trp Tyr Leu
Thr Glu 575 580 585 Asn Ile Gln Arg Phe Leu Pro Asn Pro Ala Gly Val
Gln Leu Glu Asp 590 595 600 605 Pro Glu Phe Gln Ala Ser Asn Ile Met
His Ser Ile Asn Gly Tyr Val 610 615 620 Phe Asp Ser Leu Gln Leu Ser
Val Cys Leu His Glu Val Ala Tyr Trp 625 630 635 Tyr Ile Leu Ser Ile
Gly Ala Gln Thr Asp Phe Leu Ser Val Phe Phe 640 645 650 Ser Gly Tyr
Thr Phe Lys His Lys Met Val Tyr Glu Asp Thr Leu Thr 655 660 665 Leu
Phe Pro Phe Ser Gly Glu Thr Val Phe Met Ser Met Glu Asn Pro 670 675
680 685 Gly Leu Trp Ile Leu Gly Cys His Asn Ser Asp Phe Arg Asn Arg
Gly 690 695 700 Met Thr Ala Leu Leu Lys Val Ser Ser Cys Asp Lys Asn
Thr Gly Asp 705 710 715 Tyr Tyr Glu Asp Ser Tyr Glu Asp Ile Ser Ala
Tyr Leu Leu Ser Lys 720 725 730 Asn Asn Ala Ile Glu Pro Arg Ser Phe
Ser Gln Asn Ser Arg His Pro 735 740 745 Ser Thr Arg Gln Lys Gln Phe
Asn Ala Thr Thr Ile Pro Glu Asn Asp 750 755 760 765 Ile Glu Lys Thr
Asp Pro Trp Phe Ala His Arg Thr Pro Met Pro Lys 770 775 780 Ile Gln
Asn Val Ser Ser Ser Asp Leu Leu Met Leu Leu Arg Gln Ser 785 790 795
Pro Thr Pro His Gly Leu Ser Leu Ser Asp Leu Gln Glu Ala Lys Tyr 800
805 810 Glu Thr Phe Ser Asp Asp Pro Ser Pro Gly Ala Ile Asp Ser Asn
Asn 815 820 825 Ser Leu Ser Glu Met Thr His Phe Arg Pro Gln Leu His
His Ser Gly 830 835 840 845 Asp Met Val Phe Thr Pro Glu Ser Gly Leu
Gln Leu Arg Leu Asn Glu 850 855 860 Lys Leu Gly Thr Thr Ala Ala Thr
Glu Leu Lys Lys Leu Asp Phe Lys 865 870 875 Val Ser Ser Thr Ser Asn
Asn Leu Ile Ser Thr Ile Pro Ser Asp Asn 880 885 890 Leu Ala Ala Gly
Thr Asp Asn Thr Ser Ser Leu Gly Pro Pro Ser Met 895 900 905 Pro Val
His Tyr Asp Ser Gln Leu Asp Thr Thr Leu Phe Gly Lys Lys 910 915 920
925 Ser Ser Pro Leu Thr Glu Ser Gly Gly Pro Leu Ser Leu Ser Glu Glu
930 935 940 Asn Asn Asp Ser Lys Leu Leu Glu Ser Gly Leu Met Asn Ser
Gln Glu 945 950 955 Ser Ser Trp Gly Lys Asn Val Ser Ser Thr Glu Ser
Gly Arg Leu Phe 960 965 970 Lys Gly Lys Arg Ala His Gly Pro Ala Leu
Leu Thr Lys Asp Asn Ala 975 980 985 Leu Phe Lys Val Ser Ile Ser Leu
Leu Lys Thr Asn Lys Thr Ser Asn 990 995 1000 1005 Asn Ser Ala Thr
Asn Arg Lys Thr His Ile Asp Gly Pro Ser Leu 1010 1015 1020 Leu Ile
Glu Asn Ser Pro Ser Val Trp Gln Asn Ile Leu Glu Ser 1025 1030 1035
Asp Thr Glu Phe Lys Lys Val Thr Pro Leu Ile His Asp Arg Met 1040
1045 1050 Leu Met Asp Lys Asn Ala Thr Ala Leu Arg Leu Asn His Met
Ser 1055 1060 1065 Asn Lys Thr Thr Ser Ser Lys Asn Met Glu Met Val
Gln Gln Lys 1070 1075 1080 Lys Glu Gly Pro Ile Pro Pro Asp Ala Gln
Asn Pro Asp Met Ser 1085 1090 1095 Phe Phe Lys Met Leu Phe Leu Pro
Glu Ser Ala Arg Trp Ile Gln 1100 1105 1110 Arg Thr His Gly Lys Asn
Ser Leu Asn Ser Gly Gln Gly Pro Ser 1115 1120 1125 Pro Lys Gln Leu
Val Ser Leu Gly Pro Glu Lys Ser Val Glu Gly 1130 1135 1140 Gln Asn
Phe Leu Ser Glu Lys Asn Lys Val Val Val Gly Lys Gly 1145 1150 1155
Glu Phe Thr Lys Asp Val Gly Leu Lys Glu Met Val Phe Pro Ser 1160
1165 1170 Ser Arg Asn Leu Phe Leu Thr Asn Leu Asp Asn Leu His Glu
Asn 1175 1180 1185 Asn Thr His Asn Gln Glu Lys Lys Ile Gln Glu Glu
Ile Glu Lys 1190 1195 1200 Lys Glu Thr Leu Ile Gln Glu Asn Val Val
Leu Pro Gln Ile His 1205 1210 1215 Thr Val Thr Gly Thr Lys Asn Phe
Met Lys Asn Leu Phe Leu Leu 1220 1225 1230 Ser Thr Arg Gln Asn Val
Glu Gly Ser Tyr Asp Gly Ala Tyr Ala 1235 1240 1245 Pro Val Leu Gln
Asp Phe Arg Ser Leu Asn Asp Ser Thr Asn Arg 1250 1255 1260 Thr Lys
Lys His Thr Ala His Phe Ser Lys Lys Gly Glu Glu Glu 1265 1270 1275
Asn Leu Glu Gly Leu Gly Asn Gln Thr Lys Gln Ile Val Glu Lys 1280
1285 1290 Tyr Ala Cys Thr Thr Arg Ile Ser Pro Asn Thr Ser Gln Gln
Asn 1295 1300 1305 Phe Val Thr Gln Arg Ser Lys Arg Ala Leu Lys Gln
Phe Arg Leu 1310 1315 1320 Pro Leu Glu Glu Thr Glu Leu Glu Lys Arg
Ile Ile Val Asp Asp 1325 1330 1335 Thr Ser Thr Gln Trp Ser Lys Asn
Met Lys His Leu Thr Pro Ser 1340 1345 1350 Thr Leu Thr Gln Ile Asp
Tyr Asn Glu Lys Glu Lys Gly Ala Ile 1355 1360 1365 Thr Gln Ser Pro
Leu Ser Asp Cys Leu Thr Arg Ser His Ser Ile 1370 1375 1380 Pro Gln
Ala Asn Arg Ser Pro Leu Pro Ile Ala Lys Val Ser Ser 1385 1390 1395
Phe Pro Ser Ile Arg Pro Ile Tyr Leu Thr Arg Val Leu Phe Gln 1400
1405 1410 Asp Asn Ser Ser His Leu Pro Ala Ala Ser Tyr Arg Lys Lys
Asp 1415 1420 1425 Ser Gly Val Gln Glu Ser Ser His Phe Leu Gln Gly
Ala Lys Lys 1430 1435 1440 Asn Asn Leu Ser Leu Ala Ile Leu Thr Leu
Glu Met Thr Gly Asp 1445 1450 1455 Gln Arg Glu Val Gly Ser Leu Gly
Thr Ser Ala Thr Asn Ser Val 1460 1465 1470 Thr Tyr Lys Lys Val Glu
Asn Thr Val Leu Pro Lys Pro Asp Leu 1475 1480 1485 Pro Lys Thr Ser
Gly Lys Val Glu Leu Leu Pro Lys Val His Ile 1490 1495 1500 Tyr Gln
Lys Asp Leu Phe Pro Thr Glu Thr Ser Asn Gly Ser Pro 1505 1510 1515
Gly His Leu Asp Leu Val Glu Gly Ser Leu Leu Gln Gly Thr Glu 1520
1525 1530 Gly Ala Ile Lys Trp Asn Glu Ala Asn Arg Pro Gly Lys Val
Pro 1535 1540 1545 Phe Leu Arg Val Ala Thr Glu Ser Ser Ala Lys Thr
Pro Ser Lys 1550 1555 1560 Leu Leu Asp Pro Leu Ala Trp Asp Asn His
Tyr Gly Thr Gln Ile 1565 1570 1575 Pro Lys Glu Glu Trp Lys Ser Gln
Glu Lys Ser Pro Glu Lys Thr 1580 1585 1590 Ala Phe Lys Lys Lys Asp
Thr Ile Leu Ser Leu Asn Ala Cys Glu 1595 1600 1605 Ser Asn His Ala
Ile Ala Ala Ile Asn Glu Gly Gln Asn Lys Pro 1610 1615 1620 Glu Ile
Glu Val Thr Trp Ala Lys Gln Gly Arg Thr Glu Arg Leu 1625 1630 1635
Cys Ser Gln Asn Pro Pro Val Leu Lys Arg His Gln Arg Glu Ile 1640
1645 1650 Thr Arg Thr Thr Leu Gln Ser Asp Gln Glu Glu Ile Asp Tyr
Asp 1655 1660 1665 Asp Thr Ile Ser Val Glu Met Lys Lys Glu Asp Phe
Asp Ile Tyr 1670 1675 1680 Asp Glu Asp Glu Asn Gln Ser Pro Arg Ser
Phe Gln Lys Lys Thr 1685 1690 1695 Arg His Tyr Phe Ile Ala Ala Val
Glu Arg Leu Trp Asp Tyr Gly 1700 1705 1710 Met Ser Ser Ser Pro His
Val Leu Arg Asn Arg Ala Gln Ser Gly 1715 1720 1725
Ser Val Pro Gln Phe Lys Lys Val Val Phe Gln Glu Phe Thr Asp 1730
1735 1740 Gly Ser Phe Thr Gln Pro Leu Tyr Arg Gly Glu Leu Asn Glu
His 1745 1750 1755 Leu Gly Leu Leu Gly Pro Tyr Ile Arg Ala Glu Val
Glu Asp Asn 1760 1765 1770 Ile Met Val Thr Phe Arg Asn Gln Ala Ser
Arg Pro Tyr Ser Phe 1775 1780 1785 Tyr Ser Ser Leu Ile Ser Tyr Glu
Glu Asp Gln Arg Gln Gly Ala 1790 1795 1800 Glu Pro Arg Lys Asn Phe
Val Lys Pro Asn Glu Thr Lys Thr Tyr 1805 1810 1815 Phe Trp Lys Val
Gln His His Met Ala Pro Thr Lys Asp Glu Phe 1820 1825 1830 Asp Cys
Lys Ala Trp Ala Tyr Phe Ser Asp Val Asp Leu Glu Lys 1835 1840 1845
Asp Val His Ser Gly Leu Ile Gly Pro Leu Leu Val Cys His Thr 1850
1855 1860 Asn Thr Leu Asn Pro Ala His Gly Arg Gln Val Thr Val Gln
Glu 1865 1870 1875 Phe Ala Leu Phe Phe Thr Ile Phe Asp Glu Thr Lys
Ser Trp Tyr 1880 1885 1890 Phe Thr Glu Asn Met Glu Arg Asn Cys Arg
Ala Pro Cys Asn Ile 1895 1900 1905 Gln Met Glu Asp Pro Thr Phe Lys
Glu Asn Tyr Arg Phe His Ala 1910 1915 1920 Ile Asn Gly Tyr Ile Met
Asp Thr Leu Pro Gly Leu Val Met Ala 1925 1930 1935 Gln Asp Gln Arg
Ile Arg Trp Tyr Leu Leu Ser Met Gly Ser Asn 1940 1945 1950 Glu Asn
Ile His Ser Ile His Phe Ser Gly His Val Phe Thr Val 1955 1960 1965
Arg Lys Lys Glu Glu Tyr Lys Met Ala Leu Tyr Asn Leu Tyr Pro 1970
1975 1980 Gly Val Phe Glu Thr Val Glu Met Leu Pro Ser Lys Ala Gly
Ile 1985 1990 1995 Trp Arg Val Glu Cys Leu Ile Gly Glu His Leu His
Ala Gly Met 2000 2005 2010 Ser Thr Leu Phe Leu Val Tyr Ser Asn Lys
Cys Gln Thr Pro Leu 2015 2020 2025 Gly Met Ala Ser Gly His Ile Arg
Asp Phe Gln Ile Thr Ala Ser 2030 2035 2040 Gly Gln Tyr Gly Gln Trp
Ala Pro Lys Leu Ala Arg Leu His Tyr 2045 2050 2055 Ser Gly Ser Ile
Asn Ala Trp Ser Thr Lys Glu Pro Phe Ser Trp 2060 2065 2070 Ile Lys
Val Asp Leu Leu Ala Pro Met Ile Ile His Gly Ile Lys 2075 2080 2085
Thr Gln Gly Ala Arg Gln Lys Phe Ser Ser Leu Tyr Ile Ser Gln 2090
2095 2100 Phe Ile Ile Met Tyr Ser Leu Asp Gly Lys Lys Trp Gln Thr
Tyr 2105 2110 2115 Arg Gly Asn Ser Thr Gly Thr Leu Met Val Phe Phe
Gly Asn Val 2120 2125 2130 Asp Ser Ser Gly Ile Lys His Asn Ile Phe
Asn Pro Pro Ile Ile 2135 2140 2145 Ala Arg Tyr Ile Arg Leu His Pro
Thr His Tyr Ser Ile Arg Ser 2150 2155 2160 Thr Leu Arg Met Glu Leu
Met Gly Cys Asp Leu Asn Ser Cys Ser 2165 2170 2175 Met Pro Leu Gly
Met Glu Ser Lys Ala Ile Ser Asp Ala Gln Ile 2180 2185 2190 Thr Ala
Ser Ser Tyr Phe Thr Asn Met Phe Ala Thr Trp Ser Pro 2195 2200 2205
Ser Lys Ala Arg Leu His Leu Gln Gly Arg Ser Asn Ala Trp Arg 2210
2215 2220 Pro Gln Val Asn Asn Pro Lys Glu Trp Leu Gln Val Asp Phe
Gln 2225 2230 2235 Lys Thr Met Lys Val Thr Gly Val Thr Thr Gln Gly
Val Lys Ser 2240 2245 2250 Leu Leu Thr Ser Met Tyr Val Lys Glu Phe
Leu Ile Ser Ser Ser 2255 2260 2265 Gln Asp Gly His Gln Trp Thr Leu
Phe Phe Gln Asn Gly Lys Val 2270 2275 2280 Lys Val Phe Gln Gly Asn
Gln Asp Ser Phe Thr Pro Val Val Asn 2285 2290 2295 Ser Leu Asp Pro
Pro Leu Leu Thr Arg Tyr Leu Arg Ile His Pro 2300 2305 2310 Gln Ser
Trp Val His Gln Ile Ala Leu Arg Met Glu Val Leu Gly 2315 2320 2325
Cys Glu Ala Gln Asp Leu Tyr Asp Lys Thr His Thr Cys Pro Pro 2330
2335 2340 Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu
Phe 2345 2350 2355 Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg
Thr Pro Glu 2360 2365 2370 Val Thr Cys Val Val Val Asp Val Ser His
Glu Asp Pro Glu Val 2375 2380 2385 Lys Phe Asn Trp Tyr Val Asp Gly
Val Glu Val His Asn Ala Lys 2390 2395 2400 Thr Lys Pro Arg Glu Glu
Gln Tyr Asn Ser Thr Tyr Arg Val Val 2405 2410 2415 Ser Val Leu Thr
Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu 2420 2425 2430 Tyr Lys
Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 2435 2440 2445
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 2450
2455 2460 Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln
Val 2465 2470 2475 Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser
Asp Ile Ala 2480 2485 2490 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu
Asn Asn Tyr Lys Thr 2495 2500 2505 Thr Pro Pro Val Leu Asp Ser Asp
Gly Ser Phe Phe Leu Tyr Ser 2510 2515 2520 Lys Leu Thr Val Asp Lys
Ser Arg Trp Gln Gln Gly Asn Val Phe 2525 2530 2535 Ser Cys Ser Val
Met His Glu Ala Leu His Asn His Tyr Thr Gln 2540 2545 2550 Lys Ser
Leu Ser Leu Ser Pro Gly Lys 2555 <210> SEQ ID NO 11
<211> LENGTH: 21 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Partial B domain <400> SEQUENCE: 11 Ser Phe Ser
Gln Asn Ser Arg His Pro Ser Gln Asn Pro Pro Val Leu 1 5 10 15 Lys
Arg His Gln Arg 20 <210> SEQ ID NO 12 <211> LENGTH: 11
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: albumin-binding
peptide <400> SEQUENCE: 12 Asp Ile Cys Leu Pro Arg Trp Gly
Cys Leu Trp 1 5 10 <210> SEQ ID NO 13 <211> LENGTH: 32
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: CTP peptide
<400> SEQUENCE: 13 Asp Pro Arg Phe Gln Asp Ser Ser Ser Ser
Lys Ala Pro Pro Pro Ser 1 5 10 15 Leu Pro Ser Pro Ser Arg Leu Pro
Gly Pro Ser Asp Thr Pro Ile Leu 20 25 30 <210> SEQ ID NO 14
<211> LENGTH: 28 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: CTP peptide <400> SEQUENCE: 14 Ser Ser Ser Ser
Lys Ala Pro Pro Pro Ser Leu Pro Ser Pro Ser Arg 1 5 10 15 Leu Pro
Gly Pro Ser Asp Thr Pro Ile Leu Pro Gln 20 25 <210> SEQ ID NO
15 <211> LENGTH: 20 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: PAS peptide <400> SEQUENCE: 15 Ala Ser Pro
Ala Ala Pro Ala Pro Ala Ser Pro Ala Ala Pro Ala Pro 1 5 10 15 Ser
Ala Pro Ala 20 <210> SEQ ID NO 16 <211> LENGTH: 20
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: PAS peptide
<400> SEQUENCE: 16 Ala Ala Pro Ala Ser Pro Ala Pro Ala Ala
Pro Ser Ala Pro Ala Pro 1 5 10 15 Ala Ala Pro Ser 20 <210>
SEQ ID NO 17 <211> LENGTH: 20 <212> TYPE: PRT
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: PAS peptide <400> SEQUENCE: 17
Ala Pro Ser Ser Pro Ser Pro Ser Ala Pro Ser Ser Pro Ser Pro Ala 1 5
10 15 Ser Pro Ser Ser 20 <210> SEQ ID NO 18 <211>
LENGTH: 19 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION: PAS
peptide <400> SEQUENCE: 18 Ala Pro Ser Ser Pro Ser Pro Ser
Ala Pro Ser Ser Pro Ser Pro Ala 1 5 10 15 Ser Pro Ser <210>
SEQ ID NO 19 <211> LENGTH: 20 <212> TYPE: PRT
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: PAS peptide <400> SEQUENCE: 19
Ser Ser Pro Ser Ala Pro Ser Pro Ser Ser Pro Ala Ser Pro Ser Pro 1 5
10 15 Ser Ser Pro Ala 20 <210> SEQ ID NO 20 <211>
LENGTH: 24 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION: PAS
peptide <400> SEQUENCE: 20 Ala Ala Ser Pro Ala Ala Pro Ser
Ala Pro Pro Ala Ala Ala Ser Pro 1 5 10 15 Ala Ala Pro Ser Ala Pro
Pro Ala 20 <210> SEQ ID NO 21 <211> LENGTH: 20
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: PAS peptide
<400> SEQUENCE: 21 Ala Ser Ala Ala Ala Pro Ala Ala Ala Ser
Ala Ala Ala Ser Ala Pro 1 5 10 15 Ser Ala Ala Ala 20
* * * * *